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Summary 
Fasciola cause considerable monetary loss in the agriculture industry, primarily through 
infection of sheep and cattle, while parasitism of humans is an emerging disease.  The 
cathepsin L-like proteases of Fasciola are important proteins believed to aid parasite invasion 
and survival through a range of functions including feeding, immune evasion and modulation, 
tissue migration and possibly egg production and excystment.  As such these proteases are 
considered good targets for chemotherapies and vaccine development. 
Fasciola cathepsins are evolutionarily divided into clades that reflect function and life stage 
of expression.  Analysis of relative mRNA transcript levels shows that the predominant 
cathepsins expressed in adult fluke belong to clades A and B.  Analysis of F. gigantica 
genomic DNA and mRNA has also identified a novel group of cathepsin L-like sequences 
which are incorporated into a phylogenetic analysis of the complete Fasciola cathepsin L-like 
protease family, which to date comprises over 40 sequences.  This updates previous 
phylogenetic analysis conducted with this family of proteases and identifies new clades that 
may represent functionally unique proteases. 
Analysis of mRNA transcripts isolated in this study also points to trans-splicing occurring 
amongst cathepsin transcripts, the first time this has been identified in Fasciola species.  This 
mechanism provides a further means of introducing variability to this already large family.   
The S2 subsite specificity is important in determining substrate interactions with cathepsin L-
like proteases.  Previous work has shown that amino acid substitutions at this site can 
dramatically influence substrate specificity.  A number of substitutions, specifically those that 
have been observed, or predicted to occur during the evolution of Fasciola cathepsins L-like 
proteases, were introduced into the S2 subsite of FhCatL5 at aa69 to determine their influence.   
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The introduction of L69C and L69S substitutions resulted in low overall activity indicating 
their expression provides no functional advantage, thus explaining the absence of such 
variants amongst fluke.  The L69F variant showed an increase in the ability to cleave 
substrates with P2 proline, indicating F69 variants expressed by fluke would have this ability, 
similar to that previously shown in FhCatL5 L69Y and with FhCatL2. 
The introduction of a L69W substitution also leads to increased cleavage of substrates with P2 
proline, along with a decrease in cleavage of substrates with P2 phenylalanine.  These results 
allowed comparison with recombinant expressed FgCatL1G. 
FgCatL1G transcripts were isolated from F.gigantica metacercariae.  This contrasts with 
FhCatL5 and FhCatL2 which have been isolated in adult F. hepatica.  Each of these 
cathepsins differ at aa69, possessing tryptophan, leucine and tyrosine respectively.  The 
processing and substrate specificity of FgCatL1G was analysed and compared with FhCatL5 
and FhCatL2.  While FhCatL5 and FhCatL2 process in vitro in a manner similar to that 
reported for FhCatL1, FgCatL1G requires different processing conditions, including neutral 
pH.  Combined with FgCatL1G possessing increased stability at acidic pH, this reflects the 
different environment into which FgCatL1G is expressed by immature compared to the adult 
flukes. 
The substrate specificity of FgCatL1G also differed from previously reported cathepsins, with 
a preference for P2 proline and low activity against substrates with P2 phenylalanine.  This is 
the first time recombinant expression and purification of a cathepsin L-like protease specific 
to the immature life stages of Fasciola has been undertaken and had enzyme specificity 
analysed.   
This work has expanded knowledge of the repertoire of cathepsin proteases expressed at 
various life-stages of the liver fluke. Vaccination and/or drug inhibition studies may in the 
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future be targeted towards cathepsins that are expressed in either the adult or immature stage, 
or perhaps both in a multi-targeted approach. The knowledge gained in this study may allow 
such targets to be chosen. 
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1.1 Fasciola 
1.1.1 Fasciola general 
The flatworms Fasciola hepatica and F. gigantica are commonly known as liver flukes and 
belong to the trematode subclass known as digenea.  The two species are proposed to have 
diverged approximately 19 million years ago (Irving et al., 2003). 
Fasciola parasitize sheep and other ruminants, as well as a wider range of mammalian hosts, 
including humans.  In addition to F. hepatica and F. gigantica, other minor species of the 
Fasciola have been reported, including F. tragelaphi, F. jacksoni, and F. nyanzae which are 
found in sitatunga-antelope, elephants and hippopotamus respectively.   
1.1.2 Life cycle and infection 
The life cycle of F. hepatica was among the first digenetic trematodes to be completely 
elucidated, and represents a typical example of a Digenean lifecycle, with miracidial and 
cercarial stages.  The life cycle is complex involving several phases and two hosts; a 
mammalian primary host, with certain genera of amphibious snails acting as the intermediate 
host (reviewed in Andrews, 1999; Kumar, 1999). 
Like all trematodes, with the exception of the blood flukes, Fasciola are hermaphrodites.  
Sexual reproduction is the most common form of procreation, however self-fertilisation can 
occur, and facultative gynogenesis may be widespread in this parasite (Fletcher et al., 2004) 
with asexually reproducing diploid and triploid Fasciola present, particularly in Asia 
(Terasaki et al., 1998; Terasaki et al., 2000).   
There are several stages in the Fasciola life cycle (Figure 1.1), these include (1) egg, (2) 
miracidium, (3) sporocyst, (4) redia, (5) cercaria, (6) metaceraria, (7) juvenile and (8) adult.  
Each will be discussed briefly.  
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Figure 1.1:  Lifecycle of Fasciola.  
Reproduced from http:www.dpd.cdc.gov/dpdx 
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1. Thin-shelled, unembryonated ovoid eggs are laid by the adult parasite in the bile duct 
system of the primary host.  The eggs pass with bile, via the common bile duct into the host 
alimentary tract, specifically the duodenum.  The eggs are then passed in faeces from the 
definitive host.  The eggs must encounter fresh water for the fluke lifecycle to continue.  
Embryonic development occurs in water, and is regulated by temperature and moisture.  In 
laboratory conditions, the optimum temperature for egg development is 30ºC, and it generally 
takes one to two weeks before the operculum opens and the fully developed miracidium 
escapes (Torgerson and Claxton, 1999).  Light also facilitates the hatching process (Erasmus, 
1972).   
2. The motile miracidium must locate and actively penetrate a suitable snail host within 
24 hours.  The miracidium penetrates the snail using a retractile papilliform process, possibly 
facilitated by the secretion of proteolytic enzymes (Smythe and Halton, 1983).   
3. The miracidium then metamorphoses into a rounded sporocyst, which migrates to the 
snail’s digestive gland.   
4. The sporocyst gives rise to 5-8 motile rediae.  Germ balls in the brood chamber of the 
rediae develop into cercariae, or under certain conditions give rise to a second generation of 
rediae (Andrews, 1999).   
5. The cercariae actively emerge from the snail and become free swimming.  A single 
miracidium is able to produce 4000 metacercariae (Krull, 1941).  The whole process, from 
snail infection to cercariae emergence usually lasts five to seven weeks. 
6. Within two hours of leaving the snail, the cercariae attach to various objects such as 
submerged aquatic vegetation, and encyst as metacercariae.  The cyst, almost immediately 
infective, will darken and harden over a few days.  Metacercariae are able to survive for 6 
months or more in appropriate conditions, but show reduced survivability at increased 
temperature and in dry conditions (Boray and Enigk, 1964a; Suhardono et al., 2006).   
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7. Upon being swallowed by the definitive host they are stimulated to excyst in the 
duodenum.  Excystment in vitro is stimulated by high carbon dioxide concentrations, reducing 
conditions and temperature at 39°C (reviewed in Andrews, 1999).  The emergence of the 
parasite is also stimulated by the presence of bile, bile salts and gastric juices (Dixon, 1966; 
Sukhdeo and Mettrick, 1986; Mulcahy et al., 1999a).  Newly excysted juveniles (NEJ) 
penetrate the intestinal wall, and enter the peritoneal cavity within 24 hours.  In sheep, the 
liver is penetrated four to six days post infection.  The immature or juvenile flukes then 
migrate through the liver parenchyma, consuming liver cells and blood for a few weeks.   
8. Seven to eight weeks post infection they reach the bile ducts where they attain sexual 
maturity, generally within 12 weeks of the initial infection (Boray, 1969).  Flukes attach to the 
bile duct wall using their suckers, with their spines securing them in place.  This abrades the 
host epithelia and ruptures blood vessels, providing the parasite with additional nutrition 
(Dawes, 1963).  Adult F. hepatica can live for up to 13 years (Chatterjee, 1975; Dan et al., 
1981; Harinasuta et al., 1993) and have been estimated to produce 20,000-50,000 eggs per 
day (Boray, 1969; Happich and Boray, 1969). 
There may be some variation with the Fasciola lifecycle, particularly within different primary 
hosts.  Occasionally ectopic infections can occur, with immature flukes observed migrating to 
almost any organ (Harinasuta et al., 1993; Rim et al., 1994; Mas-Coma et al., 1999b; 
Nithiuthai et al., 2004; Saba, 2005).  The main factors affecting the life cycle however tend to 
be the requirement of suitable temperature and sufficient moisture. 
F. gigantica are present in tropical areas where temperature and moisture are not generally 
limiting factors, and their life cycle is essentially identical to that of F. hepatica (Kumar, 
1999).  However, immature F. gigantica take longer to migrate through the host liver and are 
slower to develop to sexual maturity compared to F. hepatica.  The periods of F. gigantica 
egg embryonation and intramolluscan larval development are also slightly longer (Kumar, 
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1999).  The eggs of F. gigantica are also generally larger in size than those of F. hepatica.  
Lastly, in some cases the miracidium of F. gigantica, unlike that of F. hepatica, are actively 
repelled by light (Taylor, 1964). 
1.1.2.1 Fasciola intermediate hosts 
The intermediate hosts of Fasciola are the amphibious freshwater snails of the family 
Lymnaeidae.  Fasciola species have different affinities for different snail species, suggesting 
an old parasite-host relationship; F. hepatica with Galba (Fossaria) and F. gigantica with 
Radix (Bargues and Mas-Coma, 1997).  This suggests a parallel evolution of each liver fluke 
species with different lymnaeid branches towards an increasing specificity (Bargues et al., 
2001).  
The intermediate snail hosts of F. hepatica and F. gigantica differ in their environmental 
preferences, thus affecting their distribution and ultimately the distribution of the Fasciola 
parasites.   
1.1.2.2 Fasciola primary hosts 
Fasciola has a wide range of primary hosts.  The primary hosts of Fasciola are generally 
ruminants such as cows, sheep and goats, however Fasciola have shown an ability to expand 
from infecting important European livestock to parasitising many animals indigenous to other 
continents.  Primary hosts can also include various wild and domestic animals, including 
various marsupials, and humans (reviewed in Harinasuta et al., 1993; Mas-Coma, 1998; 
Spithill et al., 1999a; Torgerson and Claxton, 1999; Hurtrez-Bousses et al., 2001; Mas-Coma, 
2004).  F. hepatica have also been discovered in emus and rheas (Vaughan et al., 1997; 
Soares et al., 2007).  Infestation levels of primary hosts vary among sites and among host 
species, as does the range and level of infection of host species in different regions.   
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1.1.3 F. hepatica and F. gigantica 
1.1.3.1 Adult morphology and identification 
There are many references describing the morphology of Fasciola flukes (recent reviews 
include Fairweather et al., 1999; Kumar, 1999; Lotfy et al., 2002; Valero et al., 2005; Ashrafi 
et al., 2006).  
Adult F. hepatica are similar to other flukes in that they possess a flat leaf-like body, however 
they are one of the larger digeneans to parasitise humans.  They generally measure 20-30 mm 
long by 8-13 mm wide and possess a tegument with backwardly directed spines.  Flukes 
possess oral and ventral suckers of approximately equal size, located on an anterior elongation 
known as a cephalic cone (Figure 1.2).  The adult intestine is very highly branched, with 
numerous diverticulae extending from the extreme anterior to the extreme posterior of the 
parasite’s body.  Another distinguishing feature is their highly branched testes, located 
posteriorly and occupying almost the whole middle region of the body.  The ovary, located 
above the testes, opens to a genital pore via a link to a short convoluted uterus.  The genital 
pore is found above the ventral sucker.  F. hepatica also possess well developed vitellaria, 
highly diffuse glands that are branched in the lateral and posterior region of the body. 
F. hepatica and F. gigantica are morphologically distinct, with F. hepatica having a much 
broader body (length to width ratio), while F. gigantica can be much larger, reaching 25-75 
mm by 15 mm.  The cephalic cone of F. gigantica is also proportionally shorter and their 
body is more leaf-like in shape.  Despite these morphological differences, the flukes show 
considerable overlap between species, while the likely presence of hybrid parasites in 
environments where both parasites co-exist has led to some confusion. 
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Figure 1.2:  Adult Fasciola hepatica (Katz et al., 1988). 
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Fasciola are polymorphic and can vary morphologically depending on the host they parasitise 
(Stunkard, 1957; Lee and Zimmerman, 1993; Lofty and Hillyer, 2003).  Therefore 
morphology and phenotypic analysis cannot always be used to reliably distinguish between 
the two species. 
1.1.3.2 Differentiation between species 
There have been some taxonomical uncertainties regarding Fasciola species, particularly in 
Asia due to a range of morphological types (Kendall, 1965).  Interspecific cross-hybridisation 
has been found within Korean (Agatsuma et al., 2000) and Japanese (Kendall, 1965) flukes, 
and molecular evidence of natural hybridisation between F. hepatica and F. gigantica has 
been reported (Agatsuma et al., 2000).  This, along with the different intermediate and 
definitive hosts that Fasciola parasitise has led some researchers to suggest the possibility that 
subspecific or distinct evolutionary lineages may exist (Dosay-Akbulut et al., 2005) and has 
lead to certain species being described that are probably synonyms of F. hepatica and F. 
gigantica. 
As a result of problems associated with differentiation between Fasciola species using 
morphological, chromosomal and biochemical techniques a large component of the molecular 
research conducted on Fasciola has been applied to the problem of identification.  
Isoelectric focusing electrophoresis (IEF) and polyacrylamide gel electrophoresis (PAGE) 
have been used to differentiate between F. hepatica and F. gigantica (Lee et al., 1992a; Lee et 
al., 1992b; Lee et al., 1992c; Lee and Zimmerman, 1993; Allam et al., 2002; Lotfy et al., 
2002).  Species identification using F. hepatica and F. gigantica antigens on cases of human 
acute fasciolosis have also been reported (Allam et al., 2002).   
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Different DNA regions have been sequenced to determine diversity and differentiate among 
Fasciola species from separate locations.  The DNA regions amplified include cytochrome c-
oxidase subunit 1 (CO1) and the NADH dehydrogenase subunit 1 (ND1), from mitochondrial 
DNA; and internal-transcribed spacer 1 (ITS1) and 2 (ITS2), and 28S rDNA (28S) from 
nuclear DNA (Adlard et al., 1993; Hashimoto et al., 1997; Itagaki and Tsutsumi, 1998; 
Itagaki et al., 1998; Abdel Tawab et al., 2000; Agatsuma et al., 2000; Marcilla et al., 2002; 
Huang et al., 2004; Morozova et al., 2004; Dosay-Akbulut et al., 2005; Itagaki et al., 2005a; 
Itagaki et al., 2005b; Abdel Tawab et al., 2006; Semyenova et al., 2006; Lin et al., 2007; 
reviewed in Nolan and Cribb, 2005). 
1.1.4 Fasciolosis 
1.1.4.1 Introduction 
Infection by the parasites F. hepatica or F. gigantica causes the disease known as fasciolosis, 
characterised among other things by extensive liver damage.  Direct evidence for Fasciola 
infection and an existing infection cycle involving both human and domesticated animals has 
been recorded from as far back as ca. 3000 BC (Dittmar and Teegen, 2003).   
Fasciolosis has traditionally been considered an important veterinary disease because of the 
substantial production and economic losses it causes in livestock, particularly sheep and cattle 
(Boray and Enigk, 1964b; Mas-Coma et al., 1999a; Mas-Coma et al., 1999b), and is probably 
the most common helminth infection of cattle (Torgerson and Claxton, 1999). 
In contrast, human fasciolosis has always been viewed as a secondary disease (Boray and 
Enigk, 1964b; Mas-Coma et al., 1999a; Mas-Coma et al., 1999b).  However, with the 
significant increase in reported clinical cases and number of infected persons identified during 
epidemiological surveys over the last 25 years, the public health importance of human 
fasciolosis has increased (Esteban et al., 1998) and in recent years several reviews have 
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focused on human fasciolosis (Mas-Coma and Bargues, 1997; Mas-Coma et al., 1999b; Mas-
Coma, 2005).  It is emerging or re-emerging in many areas and is now considered an 
important human parasitic disease with cases reported in 61 countries over five continents 
(Haseeb et al., 2002).  An estimated 2.4 million (Rim et al., 1994) to 17 million people 
(Hopkins, 1992) are infected and another 180 million are at risk (WHO, 1995).   
1.1.4.2 Distribution 
Fasciola are dependant on a consistent set of suitable environmental conditions to survive.  
They require acceptable moisture and temperature conditions both for the intermediate host 
and for their own growth and development.  F. hepatica has a cosmopolitan distribution, 
while F. gigantica is largely confined to the tropics (Figure 1.3).  While both species are 
endemic to many countries, F. hepatica often predominates at higher altitudes, due to its 
lower temperature requirements.   
Fasciolosis has a great capacity to spread to new areas, due to the colonising ability and 
introduction of intermediate-host snail species, and the parasites’ ability to infect a large range 
of primary hosts.  Changes in climate can also introduce Fasciola to new areas (Fairweather 
and Boray, 1999). 
There are human endemic areas where Fasciola infection is regarded as a serious health 
problem, particularly in South America (Mas-Coma et al., 1999a; Nithiuthai et al., 2004).  
Ecologically, human infection occurs most frequently in sheep- and cattle-raising regions 
(Bogitsh et al., 2005).  However, there is only a very basic correlation between human and 
livestock infection, and high or low prevalence do not seem to be related between humans and 
animals (Esteban et al., 1998; Mas-Coma et al., 1999a; Mas-Coma et al., 1999b; Mas-Coma, 
2004).   
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Figure 1.3:  Fasciola worldwide distribution (Torgerson and Claxton, 1999). 
F. hepatica is widely distributed in Europe, the Americas, Asia, Australia, New Zealand and 
some North African countries, as well as highlands and cooler zones of Pakistan, Kenya and 
South Africa.  F. gigantica is present in southern Europe, south and south-east Asia, South 
America and wide-spread in most of Africa, except for some arid zones. 
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1.1.4.3 Transmission 
In many areas of the world there are yearly cycles of livestock infection, with disease 
outbreaks usually relating to peak pasture contamination by metacercariae.  This is not always 
the case however, and continuous contamination of pastures can occur, as seen in Australia.   
Both domestic and wild animals act as reservoir hosts, with the range of hosts infected 
differing strongly among regions.  Sheep, cattle and goats are generally the predominant 
animal reservoirs.  Humans can also play an important role in transmission of the parasite, at 
least in hyperendemic areas (Mas-Coma et al., 2005). 
Human infections occur through ingestion of contaminated watercress and other plants 
associated with water and eaten raw in salads.  Water has also been cited as a source of human 
infection through direct drinking or contamination of food or utensils (Mas-Coma et al., 
2005).  Experimental evidence in mice and pigs also suggests that people who consume raw 
dishes prepared from fresh livers infected with immature flukes can also become infected 
(Taira et al., 1997).   
1.1.4.4 Disease development 
In animals, fasciolosis occurs in two phases, known as parenchymal and biliary (reviewed in 
Behm and Sangster, 1999; Kumar, 1999; Nithiuthai et al., 2004).  During the parenchymal 
phase, pathology is caused by damage to tissues during migration, and can include severe 
liver damage and even result in death.  The biliary stage coincides with fluke residence in the 
bile ducts, with symptoms resulting from the feeding action of the parasites.  Symptoms can 
also occur as a result of biliary obstruction and inflammation.  In hosts such as cattle and 
humans, few fluke survive to maturity and biliary disease is rare.  However, the biliary stage 
of disease is more common in sheep, rabbits, rats and mice.   
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Disease severity can be classified as acute or chronic.  The pathology of acute fasciolosis 
occurs when large numbers of metacercariae are ingested in a short amount of time.  It does 
not usually occur, except in sheep and goats.  The chronic form of the disease is more 
common in all hosts, though considerable variation exists between animals.  Though rarely 
fatal, it is of considerable economic importance.   
In general the level of infection affects pathology however; disease severity also depends on 
the nutritional status of the animals.  There is also considerable variation in susceptibility to 
infection and in immune responses against liver fluke (Mulcahy et al., 1999a), with certain 
hosts possessing innate resistance against one or both Fasciola species.  Host immunity is 
discussed in section 1.1.6. 
Whether the variability seen in fluke development is due to genetic differences among the 
liver fluke infecting different hosts, or results from phenotypic plasticity is unknown.  Fluke 
growth, fecundity, metacercariae infectivity, egg numbers and developmental mortality of 
flukes have all been shown to be affected by the fluke’s choice of definitive host (Dixon, 
1964; Rondelaud and Dreyfuss, 1995; reviewed in Hurtrez-Bousses et al., 2001). 
Human fasciolosis is reviewed by Mas-Coma et al. (1999b), and follows a similar course to 
that in animals as described above.  The two stages of human infection are termed acute and 
chronic, which are associated with fluke migration and fluke residence in bile ducts 
respectively.  Fasciola does not appear to have fully adapted to human hosts, with most 
migrating flukes trapped in the liver parenchyma and perishing before reaching the bile ducts 
(Mas-Coma et al., 1999b).   
An often fatal complication of fasciolosis, known as black disease, is caused by secondary 
infection with Clostridium oedematiens or C. novyi.  The bacteria proliferate in necrotic 
lesions, and cause hepatitis.  Additionally, in some regions, particularly the Middle East, 
Chapter 1: Introduction 
18 
Fasciola can cause a condition known as halzoun.  Young worms, ingested with raw liver, 
attach to buccal or pharyngeal membranes, causing pain, irritation, hoarseness, and coughing 
(Bogitsh et al., 2005). 
1.1.4.5 Economic impact and damage  
Human fasciolosis leads to significant economic costs that can be estimated in terms of 
absenteeism, hospitalisation, treatments and disability (Rim et al., 1994). 
As liver flukes infect a wide range of domestic animals worldwide, the disease causes 
considerable impact on the economy of the livestock industry.  Clinical fasciolosis effects can 
range from sudden death to chronic underperformance, while subclinical infections often go 
unnoticed, yet also produce marked economic effects.  Infected sheep show impaired live 
weight gain and wool production and infection of cattle leads to weight gain reductions.  Milk 
quality and yields are also affected by fluke infection and fertility rates have also been 
reported to be lower. 
Economic losses include costs of treatment, labour, liver condemnation; and losses in 
production.  This, along with the public health significance of human fasciolosis means that 
even if a majority of animals infected have modest burdens, worldwide economic losses are in 
the billions of dollars (reviewed in Spithill et al., 1999a; Torgerson and Claxton, 1999; Saba, 
2005). 
1.1.5 Excretory/secretory material (ES) and the tegument 
The ES of many digenetic trematodes play vital roles in host-parasite interactions including 
digestion, invasion and immune evasion.  Fasciola ES is composed of products secreted into 
the gut and expelled via the mouth, material excreted through the median pore, and 
components of the tegument which are actively shed.  The composition and role of Fasciola 
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ES is varied, with different life stages secreting distinct sets of proteins (Carmona et al., 1993; 
McGinty et al., 1993; Tkalcevic et al., 1995).  ES is also shown to vary among flukes 
developing in different hosts (Lee et al., 1992a). 
At least 60 prominent ES proteins have been found, with a high number and abundance of 
protective enzymes, pointing to the central role of ES protecting Fasciola from host immune 
responses (Jefferies et al., 2001).  Such proteins include oxidant scavenger enzymes, 
glutathione S-transferase (GST) and fatty acid binding proteins (FABPs) (Das et al., 1991; 
Campos et al., 1999; Cervi et al., 1999; Piedrafita et al., 2000; Jefferies et al., 2001; Salazar-
Calderon et al., 2003). 
Fluke tegument is believed to play an important role in evasion of the host immune system.  
Migrating flukes make alterations to the outer tegument, secrete granules and are constantly 
shedding the tegument, only slowing down these processes once in the relative safety of the 
bile duct (reviewed in Reddington et al., 1984; Sobhon et al., 1998).  The constant sloughing 
of the tegument may help protect against specific antibodies and eosinophil attachment, or act 
as a decoy (Hanna, 1980; Keegan and Trudgett, 1992).  Secreted granules have been proposed 
to promote production of irrelevant antibody (Hughes, 1985; reviewed in Piedrafita et al., 
2004). 
Immune evasion and modulation is also assisted by ES (Zimmerman et al., 1983; Jefferies et 
al., 1996; Jefferies et al., 2001).  ES has been shown to play a role in modulating host 
immunity towards a Th2 response through induction of IL-4 and IL-10 cytokine production 
(Brady et al., 1999b; Cervi et al., 2001; O'Neill et al., 2001; reviewed in Mulcahy et al., 
1999a; Piedrafita et al., 2004).  This can facilitate the chronic disease state.  ES is capable of 
digesting host immunoglobulin, aiding evasion of antibody-dependant cell cytotoxicity, as 
well as causing downstream release of cytokines, modulating the immune response (Chapman 
and Mitchell, 1982; Heffernan et al., 1991; Carmona et al., 1993; Smith et al., 1993a; 
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Berasain et al., 2000).  ES has been shown to kill lymphocytes in vitro (Goose, 1978), 
decrease nitrite production and the phagocytic ability of rat peritoneal cells (Cervi et al., 
1996; Masih et al., 1996; Cervi et al., 1998), and suppress delayed-type hypersensitivity 
(Cervi et al., 1996).  ES can also modulate lymphocyte proliferation (Cervi et al., 1996; 
Jefferies et al., 1996; Cervi and Masih, 1997; Cervi et al., 1998; Prowse et al., 2002), reduce 
CD4+ surface expression (Prowse et al., 2002), prevent peritoneal inflammatory cells killing 
NEJ in vitro (Goose, 1978) and may prevent antibody-mediated eosinophil attachment to 
juvenile flukes (Carmona et al., 1992; Carmona et al., 1993).  Secreted material from the 
tegument may also modulate the immune response towards Th2 by activating mast cells 
(Trudgett et al., 2000; Trudgett et al., 2003).  Further, a Kunitz-type molecule isolated from 
F. hepatica has been proposed to play a role in immune evasion (Bozas et al., 1995), similar 
to that performed by protease inhibitors in other parasite species (Leid et al., 1987; Ghendler 
et al., 1994).   
Adult Fasciola residing in the bile duct are primarily blood-feeders, though they also ingest 
hyper-plastic bile duct epithelium (Fairweather et al., 1999).  Fasciola absorb nutrients 
through the tegument and intestinal epithelium of the gut (Tielens, 1999).  Digestion is mainly 
an extracellular process that is completed intracellularly.  A number of potential digestive 
enzymes have been recognised in ES that can degrade a large range of host substrates such as 
collagen, haemoglobin, albumin and immunoglobulin (Chapman and Mitchell, 1982; 
Yamasaki et al., 1992; Smith et al., 1993a; Carmona et al., 1994; Creaney et al., 1996; 
Berasain et al., 1997; Acosta et al., 1998; Piacenza et al., 1999; Berasain et al., 2000).  
Enzymes recovered from regurgitant are expected to play a role in feeding and nutrition, and 
the variety of enzymes present may reflect the range of food available or alternatively, 
different suites of enzymes may be expressed in different hosts. 
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Many of the proteolytic properties associated with ES have been attributed to cysteine 
proteases, specifically cathepsin L-like and B-like proteases, with cathepsin L-like proteases 
accounting for a large proportion of the ES from adult fluke (Jefferies et al., 2001; Morphew 
et al., 2007; Robinson et al., 2008b).  Fasciola cysteine proteases are discussed in further 
detail in section 1.2.4. 
Work on other helminth parasites suggest that proteases in ES from these parasites are 
involved in migration (McKerrow et al., 1990; Dalton et al., 1997; Na et al., 2006; 
Williamson et al., 2006), and it has been proposed that several Fasciola ES enzymes, 
including cysteine proteases are involved in tissue migration (Dalton and Heffernan, 1989; 
Berasain et al., 1997; Law et al., 2003; Alcala-Canto et al., 2005).  ES possesses glycosidase 
activity (Irwin et al., 2004) and enolase, which can support plasmin-mediated proteolysis 
including degradation of host extracellular matrix (Bernal et al., 2004; Dzik, 2006).   
Many ES products are immunogenic and can be used in diagnosis.  A monoclonal antibody 
directed against ES and used for diagnosis in human fasciolosis (Espino et al., 1990; Espino 
and Finlay, 1994) also confers passive protection to mice against F. hepatica (Marcet et al., 
2002), while several ES products have been characterised for use as vaccines or proposed 
drug targets (Wijffels et al., 1994b; Dalton et al., 1996a; Hawthorne et al., 2000; Dalton and 
Mulcahy, 2001). 
1.1.6 Host immunology 
Fasciola are able to survive for long periods inside hosts, and are relatively safe from the host 
immune system while residing in bile ducts.  However, during migration juvenile or immature 
flukes encounter various host immune responses and utilise a variety of molecules to help 
penetrate defensive barriers and avoid and modulate the host immune system (see Roitt, 1997; 
O'Garra and Arai, 2000; Parkin and Cohen, 2001 for reviews on the immune system).   
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Parasite infection is frequently accompanied with down-regulated cell-mediated immunity 
(Cervi et al., 1996; Allan and MacDonald, 1998; Dzik, 2006), and it is well documented that 
helminth infections induce a Th2 immune response (Kamal and El Sayed Khalifa, 2006), 
which is generally considered more important than a Th1 response in ridding the host of the 
parasite (Mulcahy et al., 1999a).  However, with Fasciola infections there is evidence that a 
Th1 response is associated with protection and Th2 with chronic disease (Scott et al., 1989; 
Spithill et al., 1997; O'Neill et al., 2000; Cervi et al., 2004). 
Fasciola modulates host immunity towards a Th2 type response by down-regulating the Th1 
response (O'Neill et al., 2000; O'Neill et al., 2001).  The immunomodulatory molecules 
secreted are effective at down-regulating both the induction and effector stages of the Th1 
response (Brady et al., 1999b).  Multiple ES components contribute directly and indirectly to 
effective immune modulation and evasion (see section 1.1.5).   
The immune mechanisms employed by various hosts differ, as does fluke susceptibility to the 
different killing mechanisms (reviewed by Perez et al., 1998; Mulcahy et al., 1999a; Spithill 
et al., 1999a; Piedrafita et al., 2004).  While Fasciola species possess a large range of immune 
evasion and modulation techniques, there are differences between the two species regarding 
their effectiveness in different hosts, as seen by the different susceptibility observed in certain 
hosts.  The relative resistance of Indonesian thin tailed sheep against F. gigantica compared to 
F. hepatica is an example (Roberts et al., 1996; Roberts et al., 1997a; Piedrafita et al., 2007).   
1.1.7 Detection and diagnosis 
Diagnosis of fasciolosis has traditionally been determined through coproparasitological 
examination (Happich and Boray, 1969).  However, weak infections can pass undetected, and 
identification requires the fluke to reach sexual maturity and release eggs.  By this stage, liver 
damage due to fluke migration has occurred.  An array of serological and immunological 
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detection methods including ELISA and western blots have been developed in search of a 
reliable, cost-effective diagnostic tool.  Routine diagnosis for humans is based on egg 
detection or a serological test (Rim et al., 1994). 
The large variety of antigens secreted and excreted by the parasites that are present in blood, 
faeces and other fluids of infected hosts has lead to a range of possible antigens for potential 
use in immunodiagnosis.  Several purified or recombinant antigens have been utilised for 
antibody detection (O'Neill et al., 1999; Neyra et al., 2002; Rokni et al., 2002; Sirisriro et al., 
2002; Ruiz et al., 2003; Raina et al., 2004; Intapan et al., 2005; Yadav et al., 2005; Raina et 
al., 2006; Arias et al., 2007).  Antibody and antigen detection assays have been shown to 
detect infection far earlier than traditional methods and are sensitive, but specificity is 
sometimes a problem (Itagaki et al., 1989; Espino et al., 1990; Guobadia and Fagbemi, 1997; 
Viyanant et al., 1997; Dumenigo et al., 2000; Almazan et al., 2001; Estuningsih et al., 2004).  
Antigen levels can also correlate to worm burden and may lead to the development of a semi-
quantitative assay (Espino and Finlay, 1994; Rodriguez and Hillyer, 1995; Dumenigo et al., 
1996; Abdel-Rahman et al., 1998; Dumenigo et al., 2000). 
Early detection of Fasciola infection is required for timely chemotherapeutic intervention and 
greatly facilitates epidemiological studies (Spithill et al., 1999a; Raina et al., 2006).  As such, 
serodiagnosis is crucial to control fasciolosis, but as yet no test has 100% sensitivity and 
specificity (Rapsch et al., 2006).  For a more thorough overview of Fasciola 
immunodiagnosis than discussed here, several reviews have been written, including those of 
Pfister, 1990; Sobhon et al., 1998; Hillyer, 1999; Dixit et al., 2008). 
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1.1.8 Control measures 
1.1.8.1 Chemotherapy 
Administration of anthelmintics is the main method used to control F. hepatica in livestock.  
Anthelmintic drugs differ in availability, price, efficacy and safety, however most products 
are efficacious against both F. hepatica and F. gigantica (Torgerson and Claxton, 1999). 
Triclabendazole has been the drug of choice for treating fluke infections in livestock for over 
20 years and has more recently been used successfully to treat human cases (Fairweather, 
2005).  Triclabendazole disrupts microtubule-based processes (Fairweather and Boray, 1999) 
and inhibits fluke mobility and secretory functions (Stitt and Fairweather, 1994; Stitt et al., 
1995).  
Drug resistance to a number of fasciolicides has been identified (reviewed in Fairweather and 
Boray, 1999) and while it is not yet a major problem, it may pose a serious problem for 
fasciolosis control in the future (Fairweather and Boray, 1999; Coles, 2005).  Resistance to 
triclabendazole in livestock was first reported in Australia (Overend and Bowen, 1995), with 
subsequent resistance observed in other countries (WHO, 1995; Lane, 1998; Mitchell et al., 
1998; O'Brien, 1998; Moll et al., 2000; Thomas et al., 2000; Mansour-Ghanaei et al., 2003; 
Keiser and Utzinger, 2004; Fairweather, 2005; Keiser and Utzinger, 2005; Alvarez-Sanchez et 
al., 2006).  Synergistic drug combinations are being used to prevent development of 
resistance and to treat resistant strains (Fairweather and Boray, 1999). 
Several novel chemotherapeutic agents are also being trialled.  These include 
chemotherapeutics directed against cysteine proteases (Engel et al., 1998; Alcala-Canto et al., 
2006, 2007), free radical protective enzymes (Piedrafita et al., 2000; Keiser et al., 2006b) or 
drugs effective by other mechanisms (Keiser et al., 2006a; Hegazi et al., 2007).  However, 
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research and development of these compounds is generally at a preliminary stage (reviewed in 
Bennet-Jenkins and Bryant, 1996). 
1.1.8.2 Alternate control methods 
Control and prevention of fasciolosis is likely to involve a range of methods.  The type of 
control program will depend on local husbandry and climatic conditions, together with socio-
economic factors (reviewed in Barger, 1996; Roberts and Suhardono, 1996; Torgerson and 
Claxton, 1999). 
The control of snails has been shown to be able to minimise Fasciola infections.  The broad 
range of control methods focusing on the intermediate snail host include management 
regimes, the use of organic, inorganic or plant-derived molluscicides and biological control 
using competitor snails, predators, snail parasites and commensals.  Despite the range of snail 
control strategies, it is often not practical or sufficient to eliminate liver fluke disease using 
these means (reviewed by Haroun and Hillyer, 1986; Graczyk and Fried, 1999; Spithill et al., 
1999a; Torgerson and Claxton, 1999). 
The use of resistant livestock has been reported as another option (Roberts and Suhardono, 
1996; Roberts et al., 1997b; Torgerson and Claxton, 1999).  While the large host range 
available to Fasciola limits this to some degree, a number of resistant animal breeds have 
been identified and breeding of relatively resistant livestock, especially in developing 
countries where Fasciola is endemic may be a viable means to reduce the impact of Fasciola 
infections. 
Despite the varied options and their reported successes, none have been widely adopted.  
Anthelmintic treatment continues to be favoured means of control, and looks set to remain so, 
at least until a commercial vaccine becomes a reality.  
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1.1.8.3 Vaccines  
To date no commercial vaccine is available for treatment of either F. hepatica or F. gigantica 
infection.  However, several promising vaccine candidates have been identified and several 
detailed reviews discuss vaccine development in far more detail than is covered in this section 
(Spithill et al., 1997; Spithill and Dalton, 1998; Smith, 1999; Spithill et al., 1999a; Spithill et 
al., 1999b; Dalton and Mulcahy, 2001; Hillyer, 2005; McManus and Dalton, 2006). 
Promising vaccine candidates identified include FABP, cathepsin L-like proteases (1.2.4.2.1), 
GST, leucine amino peptidase (LAP) and haemoglobin. 
In cattle, the protective response to Fasciola appears to correlate with a Th1 or Th1/Th2 
mixed immune response (Dalton and Mulcahy, 2001).  Vaccination can induce this type of 
protective immune response (Mulcahy et al., 1998; Mulcahy et al., 1999a; Mulcahy et al., 
1999b; Mulcahy and Dalton, 2001; Bentancor et al., 2002), which is qualitatively different 
from the non-protective response typically seen in natural infection (Clery et al., 1996; 
Bossaert et al., 2000a; Bossaert et al., 2000b; Zhang et al., 2005).  However, the choice of 
adjuvant appears important in developing a protective immune response, with Freund’s 
adjuvant seeming essential for generating a protective immune response with certain antigens, 
thus limiting commercial applications. 
Although hurdles still exist, the future for Fasciola vaccines looks promising.  A commercial 
trematode vaccine need not be 100% protective to be commercially viable (Williams et al., 
2002; McManus and Dalton, 2006).  Apart from reducing fluke burdens, the anti-fecundity 
aspect observed with some vaccines would be expected to reduce transmission rates 
(McManus and Dalton, 2006).  
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1.2 Proteases 
1.2.1 Introduction 
Proteases are enzymes that cleave or degrade peptides by catalysing the hydrolysis of peptide 
bonds (refer to Figure 1.4). 
 
 
 
Figure 1.4:  Hydrolysis of peptide bond. 
Proteases are also known as peptidases, proteinases and proteolytic enzymes.  For clarity, the 
term protease will be used throughout this work.  Proteases that cause cleavage of internal 
peptide bonds are known as endopeptidases, or historically proteinases.  Those that function 
on or near the end of polypeptides are called exopeptidases, or more specifically, 
aminopeptidases and carboxypeptidases, depending on whether they cleave at the N- or C-
terminus respectively (Barrett and McDonald, 1986). 
Proteases are involved in almost all physiological processes, and are important commercial 
enzymes.  Genome analysis has shown that about 2% of proteins from all organisms are 
proteases or non-proteolytic homologues (Rawlings and Barrett, 1999), while 18% of 
SwissProt sequences are annotated as undergoing proteolytic cleavage (Rawlings et al., 
2006).  This large group of proteins is proving very important to a wide range of fields 
including biotechnology and medicine.  Proteases have been implicated in immunity as well 
as parasite invasion and sustenance and are potential drug or vaccine targets as well as 
diagnostic tools. 
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There are currently six major classes of proteases, based on important chemical groups in 
their active site.  The six catalytic types are the aspartyl (carboxyl), cysteine (thiol), glutamic, 
metallo-, serine and threonine proteases.  Despite the different chemical groups, in each case 
they generate a nucleophile that attacks the peptide’s carbonyl group, either through the use of 
side chains or water molecules.  
However, grouping enzymes based on catalytic chemical groups can be misleading.  While 
each class contains the same residue in the active site, the mode of catalysis can vary greatly.  
This convergent evolution means that enzymes within the same class are not necessarily more 
closely related, and as such a system of classification using homology and molecular structure 
has also been developed.  These classification systems are utilised by the MEROPS database 
(Rawlings et al., 2008; http://merops.sanger.ac.uk), and will be referred to throughout this 
thesis.   
The MEROPS database provides a more detailed review of the classification system but 
briefly, proteases are divided into homologous families based on amino acid sequence 
similarity.  Families can then be grouped into clans. This reflects the fact that while proteases 
between families may not contain amino acid similarity, the families are ultimately related as 
revealed by the conservation of three-dimensional structures, as well as the arrangement of 
catalytic residues.  Clans and families can also be further subdivided.  For example, cathepsin-
L like proteases from Fasciola species belong to the C1 family, subfamily A, within the clan 
CA.  Other proteases in this subfamily include papain and human cathepsin L (HuCatL). 
The cysteine proteases are of interest in this review.  For a detailed explanation of the other 
proteases, their catalytic activities and functions, the MEROPS database is a structure-based 
catalogue of proteases, while many reviews on proteases have also been published, including 
McDonald, 1985; Barrett and Rawlings, 1991; Rawlings and Barrett, 1993, 1994; Barrett and 
Rawlings, 2001; Hooper, 2002; Barrett et al., 2004). 
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1.2.2 Cysteine Proteases 
Cysteine proteases possess a cysteine residue in the active site that acts as a nucleophile in the 
cleavage of peptide bonds.  The nucleophilic cysteine is present with a histidine residue which 
acts as a proton donor/general base.  In some cysteine protease families the cysteine is present 
as part of a catalytic dyad, however a third residue forming a catalytic triad is required in 
others.  Thus, the active site of cysteine proteases often involves three key residues, namely 
asparagine (or aspartate), histidine and cysteine, with the active site believed to exist as a 
zwitterion (Beveridge, 1996).  Refer to Figure 1.5 
Cysteine proteases are found in organisms from all kingdoms, and are currently divided into 
seven clans, reflecting the fact they have diverged from at least seven different evolutionary 
origins (Barrett and Rawlings, 2001).  While almost all cysteine proteases rely on catalytic 
dyads of cysteine and histidine for activity, they possess a range of catalytic mechanisms, 
residues and activities that have been inherited from different ancestral proteins (Barrett and 
Rawlings, 2001). 
Clan CA is the largest of the cysteine protease clans and at the time of writing contained 25 
families, accounting for almost half of the cysteine protease families.  The clan contains endo- 
and exopeptidases and along with the nucleophilic cysteine and histidine catalytic residues, a 
glutamine residue and an asparagine residue are commonly conserved among proteases of this 
clan.  Papain is the archetypal CA protease; however the clan also contains calpains, 
cathepsins and several important viral proteases.   
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Figure 1.5:  Common catalytic mechanism of cysteine proteases. 
(1) The thiol anion of the cysteine residue attacks the scissile carbon of the substrate.  (2) The 
imidazole ring of the histidine residue then transfers a proton to the substrates scissile 
nitrogen, initiating cleavage.  (3) A water molecule then hydrolyses the intermediate and (4) 
the enzyme returns to its original state. An asparagine or aspartate residue is also often 
important in the catalytic process, as it helps orientate the histidine residue (Berg et al., 2002). 
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1.2.3 Papain superfamily 
Evolutionary analysis of family C1 proteases enabled further division of the family into C1A, 
known as the papain subfamily and C1B, the bleomycin hydrolase subfamily.  It has been 
hypothesised that a family C1 protease was present in the universal ancestor of all organisms, 
and that this evolved into a subfamily C1A-type protein in early archaea and a subfamily 
C1B-type protein in early bacteria (Barrett et al., 2004).  Further divergence and horizontal 
transfer has led to the two subfamilies we recognise today.  
Subfamily C1A is the larger of the two subfamilies (see Figure 1.6).  It contains mainly 
endopeptidases from viruses, protozoa, plants and animals.  Besides papain, the family also 
includes cathepsins B, H and L, and a clear division is evident between the cathepsin B-like 
enzymes and papain-like enzymes (Barrett et al., 2004).   
The functions of C1A proteases differ in various organisms.  Plant proteases are mainly used 
to immobilise storage proteins in seeds.  Most parasitic proteases act extracellularly, while 
mammalian C1A cysteine proteases are considered primarily lysosomal enzymes. 
Papain is a single-chain nonglycosylated proteolytic enzyme, containing three disulphide 
bonds.  Like all papain-like enzymes, its tertiary structure is characterised by two domains 
separated by an active site cleft (Figure 1.7).  The active site contains Cys25 and His159 
(papain numbering).  Gln19 and Asn175 are also important for catalysis.  Some papain-like 
enzymes possess Asn19, or Asp175 (Barrett et al., 2004). 
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Subfamily C1A 
Subfamily C1B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  Evolutionary tree of family C1 proteases. 
Phylogenetic tree of family C1 proteases (http://merops.sanger.ac.uk/; 27/06/08).  It shows the 
separation between subfamily C1A and C1B proteases, with certain characteristic proteases 
and protease groups identified. 
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Figure 1.7:  Cartoon structure of papain.  
Transparent molecular surface mapped onto the ribbon structure of papain (9PAP), showing 
the secondary structure elements.  Papain possesses comparable domains on each side of the 
active site cleft.  The catalytic triad residues are identified as blue stick structures and 
labelled. 
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All papain-like proteases consist of an N-terminal propeptide and a catalytic domain that 
represents the mature active enzyme.  A signal, or pre-peptide, is also present for those 
enzymes that enter the secretory pathway (Figure 1.8).  The propeptides of the cathepsin B- 
and papain-like enzymes differ in length and sequence, but are believed to act in similar ways.   
1.2.3.1 Proregion and processing 
As proteases are involved in most vital cell processes, their activities must be carefully 
controlled.  To prevent inappropriate or premature proteolysis, proteases are typically 
synthesised as inactive precursors known as zymogens or proenzymes (Erickson, 1989; 
Neurath, 1989).   
The papain-like enzymes typically consist of three regions, an N-terminal prepeptide, a 
propeptide, and the mature enzyme (Figure 1.8).  The prepeptide (or signal sequence) initiates 
post-translational transport of the protein and upon reaching its destination the prepeptide is 
proteolytically cleaved off.  The propeptide affects post-translational modifications, mediates 
interaction with other molecules, is involved in targeting, and acts as an intra-molecular 
chaperone, facilitating correct folding, and stability of the catalytic domain (reviewed by 
Anfinsen, 1972; Erickson, 1989; Baker et al., 1993; Eder and Fersht, 1995; Wiederanders, 
2000; Cappetta et al., 2002; Lecaille et al., 2002b; Wiederanders, 2003; Wiederanders et al., 
2003; Bromme et al., 2004).  The proregion can also act as an intrinsic inhibitor of the 
enzyme (Baker et al., 1992; Fox et al., 1992; Mach et al., 1994a; Taylor et al., 1995; 
Carmona et al., 1996b; Coulombe et al., 1996; Groves et al., 1998; Quraishi et al., 1999; 
Roche et al., 1999; Billington et al., 2000; Cappetta et al., 2002; Bromme et al., 2004; Silva 
et al., 2004). 
Chapter 1: Introduction 
35 
A) 
 
B) 
 
 
 
 
 
 
Figure 1.8:  A representation of the preproenzyme. 
(A) A schematic representation of a polypeptide with the pre- and pro-N-terminal extensions.  
The arrows indicate putative cleavage sites. (B) Structure of HuCatL proenzyme (1cjl) with 
the surface structure of the mature region coloured red, and the proregion ribbon coloured 
blue.  The active site cysteine is highlighted light grey.  Three conserved regions within the 
proregion are also highlighted; the tripartite tryptophan motif (green), ERFNIN motif (purple) 
and GNFD motif (yellow).   
The N-terminal portion of the proregion is globular and contains three α-helices with a small 
hydrophobic core built around aromatic side chains.  The C-terminal portion of the proregion 
assumes an extended conformation and follows along the substrate binding cleft toward the 
N-terminus of the mature enzyme.  The direction of the proregion in the substrate binding 
cleft is opposite to that of substrates (Coulombe et al., 1996).   
NH2-    Pre           Pro    Mature        -COOH 
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While C1A proregions tend to show more amino acid sequence divergence than the mature 
region of proteases, they contain some highly conserved regions (Karrer et al., 1993).  One 
such region is known as the ERFNIN motif, found in the cathepsin L, K and S-like proteases, 
but not in the cathepsin B proteases (Karrer et al., 1993).  It is present as an ERFNAQ motif 
in cathepsin F and W (Wiederanders, 2003; Wiederanders et al., 2003) and as a DRWNIN 
motif in Fasciola cathepsin L like proteases.  The residues in this region are important in 
stabilising the globular structure of the proregion (reviewed in Coulombe et al., 1996; Groves 
et al., 1996; Groves et al., 1998).  Another conserved region is the GNFD motif (Ishidoh et 
al., 1987), with residues believed to be essential for correct folding and processing of the 
propeptide (Vernet et al., 1995; Collins et al., 2004).  A conserved tripartite tryptophan motif 
may play a role in maintenance of the prodomain structure (Kreusch et al., 2000). 
The proteolytic cleavage and subsequent removal of the pro-peptide yields an active protease.  
Different enzymes are processed and activated in different ways, although they typically 
generate intermediates in a multistep process (Vernet et al., 1991; Ishidoh and Kominami, 
1994, 2002; Yamasaki et al., 2002; Collins et al., 2004; Beckham et al., 2006). 
The proregion can be cleaved by self processing, (known as autoprocessing, or autocatalytic 
processing), or alternatively by other proteases.  When autoprocessing occurs by one 
molecule cleaving another, it is known as inter- or bi-molecular processing.  Alternatively, 
when a molecule removes its own pro-peptide, it is known as uni- or intra-molecular 
processing (Rowan et al., 1992).  Recombinant HuCatL autoprocessing has been shown to 
involve both uni- and bimolecular processes (Menard et al., 1998). 
Activation processes are strongly affected by the environment, with a variety of factors 
influencing protease activations in vivo, including pH, inhibitors, macromolecular 
components and clusters of negative charges (Wiederanders, 2003).  Change of pH is a 
common trigger for activation (Mason and Massey, 1992; Coulombe et al., 1996; Ishidoh and 
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Kominami, 2002), and lysosomal papain-like cysteine proteases are often susceptible to 
autoprocessing at low pH (Smith and Gottesman, 1989; Vernet et al., 1991; Rowan et al., 
1992; Mach et al., 1994a, 1994b; Menard et al., 1998; Yamasaki et al., 2002; reviewed in 
Bromme et al., 2004).  The stability of the propeptide-mature enzyme complex is believed to 
rely on electrostatic interactions (Quraishi and Storer, 2001).  For HuCatL, disruption of the 
salt bridges involved in the interaction between the proregion and mature enzyme at low pH is 
believed to trigger the processing event (Coulombe et al., 1996), causing the proregion to 
bind less strongly to the active site and making it more susceptible to proteolysis (Jerala et al., 
1998; Rozman et al., 1999).  For Fasciola cathepsin L (FhCatL), binding between the 
proregion and the enzyme is weaker at low pH (Roche et al., 1999) with activation 
progressing fastest below pH 5 (Stack et al., 2007).   
1.2.3.2 Propeptide inhibition 
The propeptides of C1A enzymes have been shown to be potent and selective inhibitors of 
cysteine proteases (Fox et al., 1992; Carmona et al., 1996a; Roche et al., 1999; Billington et 
al., 2000; Wiederanders, 2003; Wiederanders et al., 2003).  The inhibition mechanism is 
common to all C1A proteases (Cygler and Mort, 1997).  The propeptide runs down the groove 
between the two domains of the mature enzyme, interacting in a non-covalent manner (Mach 
et al., 1994a), covering and binding tightly to the active site.  However, its orientation is 
opposite that of a substrate.  This reverse orientation ensures that hydrolysis of the peptide 
bond cannot occur (Coulombe et al., 1996).  Thus the proregion sits in the active site, denying 
access to substrates (Figure 1.8).   
The N-terminal region of the propeptide has been found to be more important for inhibition 
than the C-terminal region (Carmona et al., 1996b).  The N-terminal α-helices determine, at 
least in part, the inhibition specificity of the propeptides (Guo et al., 2000), while propeptide 
residues interacting directly with the active site may also play a role (Lalmanach et al., 1998).  
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Like activation, propeptide inhibitory activity is strongly pH-dependent (Carmona et al., 
1996b; Roche et al., 1999; Billington et al., 2000; Guay et al., 2000).  The pH effect on 
inhibition constants, dissociation rates and the activation mechanisms for cathepsin L is 
believed to be due to conformational changes in the proregion.  At neutral pH the proregion 
has a defined structure.  However, as the pH drops conformational changes occur, eventually 
resulting in the propeptide adopting a molten globule conformation (Jerala et al., 1998).   
As inhibition by propeptides is potent and specific to the parent enzyme (Roche et al., 1999; 
Guay et al., 2000) it has been suggested that mimicking the sequence of residues found in the 
pro-peptide may lead to potential therapeutic agents (Carmona et al., 1996a; Lalmanach et al., 
1998; Roche et al., 1999; Yamamoto et al., 2002; Godat et al., 2005).   
1.2.3.3 Mammalian cathepsins 
All mammalian lysosomal cysteine proteases are known as cathepsins.  Some cathepsins 
however are not cysteine proteases, an example being cathepsins D and A, which are aspartyl 
and serine proteases respectively.  Only the cysteine cathepsins will be discussed here. 
There are 11 cysteine cathepsins encoded in the human genome, known as cathepsins B, H, L, 
S, C, K, O, F, V, X and W (Turk et al., 2000; Rossi et al., 2004).  Some human cathepsins are 
expressed ubiquitously (eg. cathepsins B, H and L), while others show tissue or cell 
specificity (eg. cathepsins S and K).  Cathepsin L and B are the major mammalian lysosomal 
cysteine proteases (Alves et al., 2001a).  The lysosomal cysteine proteases are involved in an 
array of functions including antigen presentation (reviewed in Chapman et al., 1997; Hsing 
and Rudensky, 2005; Rudensky and Beers, 2006; Zavasnik-Bergant and Turk, 2006), 
apoptosis (reviewed in Stoka et al., 2005; Chwieralski et al., 2006), bone resorption (reviewed 
in Vaes et al., 1992; Chapman et al., 1997), proenzyme and hormone processing (Samarel et 
al., 1989; Tepel et al., 2000), sperm maturation (Okamura et al., 1995), as well as general 
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protein degradation and turnover (reviewed in Bond and Butler, 1987; Kirschke and 
Wiederanders, 1987; McGrath, 1999; Lecaille et al., 2002b; Nagler and Menard, 2003).   
The cysteine cathepsins have also been implicated in human pathology, generally due to over-
expression or ‘out of place’ activities.  Disease states that cysteine cathepsins are believed to 
play a role in include bone resorption related diseases such as osteoporosis, atherosclerosis 
(Liu et al., 2004), and pycnodysostosis (Fratzl-Zelman et al., 2004), also immune system-
related diseases such as cancer (tumour invasion and metastasis) (Jedinak and Maliar, 2005; 
Nomura and Katunuma, 2005; Mohamed and Sloane, 2006), allergic inflammation and 
asthma (Hamaguchi et al., 1990; Layton et al., 2001), as well as a range of other pathological 
or disease states including rheumatoid arthritis (Yasuda et al., 2005), Alzheimer’s disease 
(neurodegeneration) (Lemere et al., 1995; Hook, 2006), muscular dystrophy (Katunuma and 
Kominami, 1987), vascular diseases (Sukhova and Shi, 2006), gingivitis (Trabandt et al., 
1995) and emphysema (Zheng et al., 2005).  Due to their association with the aforementioned 
pathological disease states, the lysosomal cysteine proteases are looked at as promising 
therapeutic targets (reviewed in McGrath, 1999; Lecaille et al., 2002b; Turk and Guncar, 
2003; Turk et al., 2003; Vasiljeva et al., 2007). 
1.2.3.4 Parasite cysteine cathepsins 
Papain-like cysteine proteases are also utilised by a wide variety of parasites.  They are 
especially ubiquitous in protozoan parasites and helminths, performing key roles.  Helminth 
parasites that utilise cysteine proteases include those belonging to the trematode, nematode 
and cestode families.  Trematodes tend to express predominantly cathepsin L-like proteases, 
while nematodes tend to express cathepsin B-like proteases in greater amounts (reviewed in 
Tort et al., 1999). 
Chapter 1: Introduction 
40 
Cysteine proteases have been shown to be important virulence factors, but are also involved in 
non-pathological roles.  Cysteine protease have important roles in reproduction, and have 
been implicated in other vital processes including nutrition and feeding, tissue and cell 
invasion, life cycle differentiation and transition including ex- and encystment, hatching, 
moulting, and also immune evasion and modulation.  Reviews on helminths parasites in 
relation to cysteine proteases include McKerrow, 1989; McKerrow et al., 1993; Tort et al., 
1999; Que and Reed, 2000; Trap and Boireau, 2000; Lecaille et al., 2002b; Sajid and 
McKerrow, 2002; Dalton et al., 2006; Kasny et al., 2007; Robinson et al., 2008a).   
1.2.4 Fasciola cathepsins 
Proteolytic enzymes were detected from F. hepatica about 40 years ago (Thorsell and 
Bjorkman, 1965; Howell, 1966; Halton, 1967; Locatelli and Paoletti, 1969).  These 
proteolytic enzymes were shown to be able to degrade a variety of substrates including 
immunoglobulins, gelatin, collagen, albumin and haemoglobin (Thorsell and Bjorkman, 1965; 
Howell, 1966; Locatelli and Paoletti, 1969; Simpkin et al., 1980; Chapman and Mitchell, 
1982; Aoki et al., 1983; Dalton and Heffernan, 1989; Fagbemi and Hillyer, 1991; Heffernan 
et al., 1991; Smith et al., 1993a). 
Studies attributed the proteolytic activity to cysteine proteases (Chapman and Mitchell, 1982; 
Dalton and Heffernan, 1989; Rege et al., 1989; Yamasaki et al., 1989; Fagbemi and Hillyer, 
1992; Smith et al., 1993a; Smith et al., 1993b) with dominant activity ascribed to cathepsin L-
like proteases (Dalton and Heffernan, 1989; Dowd et al., 1992; Dalton et al., 1996a; Brady et 
al., 1999a; Tort et al., 1999).  Since then, several cysteine proteases have been found to be 
expressed by Fasciola (reviewed in Tort et al., 1999; Dalton et al., 2003a; Irving et al., 2003).  
Proteases expressed by adult fluke include a variety of cathepsin L-like and B-like proteases, 
as well as a serine protease (Carmona et al., 1994; Mohamed et al., 2005) and leucine 
aminopeptidase (Acosta et al., 1998). 
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Cathepsin B-like and L-like proteases have also been found to be expressed by metacerceriae 
and NEJ fluke (Carmona et al., 1993; McGinty et al., 1993; Heussler and Dobbelaere, 1994; 
Tkalcevic et al., 1995; Wilson et al., 1998), along with other proteases (Carmona et al., 1994; 
Tkalcevic et al., 1995). 
Cathepsin L-like protease activity was found to be secreted by all fluke stages in the 
mammalian host (Carmona et al., 1993; Heussler and Dobbelaere, 1994), and is the dominant 
proteolytic enzyme in adult ES (Yamasaki and Aoki, 1993; Dowd et al., 1994; Morphew et 
al., 2007) while cathepsin B is predominantly expressed in NEJ and metacercariae (Wilson et 
al., 1998). 
Although the exact roles of these proteases are unknown, some may play roles external to the 
parasite.  While gut related proteases with acidic pH optima are expected to be inactive in the 
host, some Fasciola secreted proteases have optimum activity at physiological pH (Dalton 
and Heffernan, 1989; Fagbemi and Hillyer, 1991).  It has been suggested that secreted 
cysteine proteases play pivotal roles in migration, feeding, evasion of the host immune system 
and processing of other proteases. 
1.2.4.1 Cathepsin B-like proteases of Fasciola 
Cathepsin B-like activity in F. hepatica was first indicated by McGinty et al., 1993), and two 
partial cathepsin B-like cDNA transcripts were cloned from adult F. hepatica soon after 
(Heussler and Dobbelaere, 1994).  Since then, cathepsin B-like proteases have been shown to 
be temporally expressed in Fasciola with cathepsin B-like protease transcripts most abundant 
in metacercariae and NEJ, with progressively less abundance as the fluke mature through the 
juvenile stage, eventually being expressed the least in adults (Meemon et al., 2004).  
Cathepsin B-like proteases represent the major protein secreted by juvenile flukes (Wilson et 
al., 1998), with at least two cathepsin B-like N-terminal sequences identified from F. hepatica 
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NEJ fluke ES (Wilson et al., 1998) and NEJ somatic extracts (Tkalcevic et al., 1995).  Three 
full length cathepsin B-like cDNA sequences have been identified in F. gigantica, two 
detected only in metacercariae and NEJ flukes (FgCB2 and FgCB3), the other detected in 
metacercariae, NEJ flukes and adult parasites (FgCB1) (Meemon et al., 2004).  These results 
suggest that Fasciola express a number of cathepsin B-like proteases, comparable to the 
observed expression of cathepsin L-like proteases in Fasciola (1.2.4.2) and Schistosoma 
(Dalton et al., 1996a; Tort et al., 1999; Irving et al., 2003). 
Cathepsin B-like RNA transcripts have been localised to the gut lumen and secretory vesicles 
of the gut of NEJ and adult Fasciola (Creaney et al., 1996; Meemon et al., 2004), as well as 
to tegumental cells underlining the surface tegument (Meemon et al., 2004).  In the adult 
stage, cathepsin B-like transcripts were also detected in reproductive system tissues (Meemon 
et al., 2004).  While the functions of Fasciola cathepsin B-like proteases are unknown, their 
localisation and temporal expression provide clues to their possible functions.  Cathepsin B 
expressed in secretory cells throughout the developmental and the adult stage may act as a 
general digestive enzyme.  This is not expected to be the case in NEJ however, as the gut is 
not absorptive until fluke reach the host liver, NEJ relying on glycogen reserves in the early 
migratory phase rather than feeding (Bennett and Threadgold, 1973). 
Expression of cathepsin B during maturation, particularly release up to 5 weeks post infection 
(Wilson et al., 1998; Law et al., 2003) suggests involvement in excystment or migration 
(Wilson et al., 1998; Meemon et al., 2004).  Fasciola cathepsin B-like proteases may also be 
important virulence factors, with Creaney et al. (1996) suggesting attenuation may be 
associated with loss of cathepsin B activity, and they have been implicated in immune evasion 
due to the ability to digest immunoglobulins (Wilson et al., 1998), possibly preventing 
immune cell attachment, and aiding tegumental sloughing (Meemon et al., 2004).  Recently, 
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down-regulation of cathepsin B expression in F. hepatica NEJ using RNA interference 
(RNAi) significantly reduced fluke penetration of rat intestinal wall (McGonigle et al., 2006). 
The association of cathepsin B with reproductive tissues suggests possible roles in processing 
of eggshell precursor proteins, vitellogenic degradation or post fertilisation egg activation 
(Meemon et al., 2004). 
Due to their expression profile and possible roles in Fasciola, cathepsin B-like proteases 
represent good vaccine or chemotherapeutic targets.  Recombinant Fasciola cathepsin B or 
Fasciola cathepsin B expressed as a DNA vaccine has been shown to be able to induce an 
immune response in rats (Law et al., 2003).  There may also be a role for Fasciola cathepsin 
B-like proteases in detection and diagnosis, with the protein shown to be immunogenic in 
sheep and rats (Law et al., 2003).  
1.2.4.2 Cathepsin L-like proteases of Fasciola 
Early studies indicated that adult F. hepatica expressed a number of cathepsin L-like 
proteases (Dalton and Heffernan, 1989; Heussler and Dobbelaere, 1994).  The two major 
proteases secreted by adult F. hepatica were soon isolated and referred to as FhCL1 (Smith et 
al., 1993b; Roche et al., 1997) and FhCL2 (Dowd et al., 1994; Dowd et al., 1997).  These two 
cathepsins represent over 80% of the protein content of F. hepatica secreted material, are the 
dominant enzymatic components (Dowd et al., 1994) and are believed to be the 
immunodominant antigens of human fasciolosis (Cordova et al., 1997). 
Work by Wijffels et al. (1994a) and Jefferies et al. (2001) suggested multiple cathepsin L-like 
proteases other than FhCL1 and FhCL2 were present in adult F. hepatica ES.  Heussler and 
Dobbelaere (1994) identified five cathepsin L-like cDNA transcripts from adult F. hepatica, 
and (Grams et al., 2001) isolated several cathepsin L-like cDNA transcripts from F. gigantica 
adults.  Enzyme activity suggested cathepsin L-like proteases were secreted by F. hepatica 
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NEJ (Chapman and Mitchell, 1982; Carmona et al., 1992; Carmona et al., 1993), and 
subsequently F. gigantica and F. hepatica NEJ and metacercariae specific cathepsin L-like 
cDNA sequences were identified (Harmsen et al., 2004; Genbank accession numbers 
AF419329 and AY428949). 
There are currently over 40 partial or complete cathepsin L-like sequences from F. hepatica 
and F. gigantica deposited in public databases.  However, several transcripts differ at only a 
few nucleotides, and may represent alleles, rather than distinct genes (Dalton et al., 2003b), 
while several genes from F. hepatica and F. gigantica appear to be orthologs.   
Analysis of the gene sequences showed that Fasciola cathepsin L-like proteases belong to a 
monophyletic group (Yamasaki et al., 2002; Irving et al., 2003) within the enzyme lineage 
giving rise to mammalian cathepsin L, K and S (Tort et al., 1999).  The Fasciola cathepsin L-
like group comprises a complex gene family that can be separated into 4 clades corresponding 
to observed and predicted enzymatic activity (Irving et al., 2003) (Figure 1.9).  
Characterisation of several Fasciola cathepsin L-like proteases has shown that they differ in 
certain aspects including specificity to synthetic and host substrates, and pH and inhibition 
profiles.   
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Figure 1.9:  Fasciola cathepsin L gene family (Irving et al., 2003). 
Bootstrap neighbour-joining phylogenetic tree of Fasciola cathepsin L-like proteases.  
Fasciola cathepsins L-like proteases are divided into four distinct clades.  The residue at aa69 
is conserved within each clade. 
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Fasciola cathepsin L-like zymogen structures are similar to those of vertebrate cathepsin L, 
consisting of a hydrophobic signal peptide, prosegment and mature enzyme (Yamasaki and 
Aoki, 1993; Roche et al., 1997; Yamasaki et al., 2002).  No potential N-glycosylation sites 
are present in the mature enzymes, with the exception of some F. hepatica NEJ cathepsins L-
like proteases, and they are not glycosylated in the parasite (Dowd et al., 1994; Dalton et al., 
1996b; Dowd et al., 1997; Roche et al., 1997; Brady et al., 1999a; Van Milligen et al., 2000; 
Harmsen et al., 2004).  However, certain proline residues of F. hepatica proteins (including 
cathepsin L-like proteases) have been reported to be modified to unusual 3-hydroxyproline 
derivatives (Wijffels et al., 1994a; Bozas and Spithill, 1996). 
The temporal and spatial expression of each of the cathepsin L-like proteases in Fasciola is 
unknown (Dalton et al., 2003b), and is difficult to determine due to DNA and amino acid 
sequence similarities.  However, transcripts of certain cathepsin L-like proteases have only 
been identified in NEJ flukes or metacercariae suggesting there is some dependence on life 
stage (Cancela et al., 2008). 
Initial work demonstrated confinement of Fasciola cathepsin L to vesicles in the gut epithelial 
cells (Dowd et al., 1992; Yamasaki et al., 1992; Yamasaki and Aoki, 1993), and subsequent 
studies have shown that a vast majority of cathepsin L gene expression is carried out in 
epithelial cells lining the parasite gut (Yamasaki et al., 1992; Smith et al., 1993b; Yamasaki 
and Aoki, 1993; Grams et al., 2001; Collins et al., 2004).  Cathepsins L is synthesised and 
packaged into vesicles within epithelial cells lining the liver fluke intestine (Smith et al., 
1993b).  It is stored in these secretory vesicles as inactive proenzyme (Collins et al., 2004).  
Upon secretion into the acidic gut lumen, it is processed into active mature cathepsin L 
(Collins et al., 2004) and carries out its proposed digestive roles.  The flukes expel their 
stomach contents frequently, releasing proteases into the surrounding environment where they 
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may perform a variety of functions.  The flukes also produce endogenous inhibitors that 
suggest they can regulate protease activity (Bozas et al., 1995). 
Cathepsin L has also been immunolocalised to reproductive organs of mature Fasciola, and 
may play a pivotal role in the egg production pathway (Wijffels et al., 1994b; Dalton et al., 
1996b; Brady et al., 1999a), with vaccination studies using Fasciola cathepsin L proteases 
significantly reducing fluke egg production and egg viability (Wijffels et al., 1994b; Dalton et 
al., 1996b; Mulcahy et al., 1999b; Dalton et al., 2003b). 
Contrasting with lysosomal cathepsin L, some Fasciola cathepsin L-like proteases have been 
shown to be active and extremely stable at physiological pH (Dowd et al., 2000), while others 
have optimum activity at acidic pH. 
While the specific roles of the Fasciola cathepsin L-like proteases are unknown, several 
functions have been suggested.  Fasciola cathepsin-L like proteases can digest a range of host 
compounds (Berasain et al., 1997) and they may play a primary role in parasite nutrient 
acquisition and feeding (Yamasaki et al., 1992).  FhCL1 and FhCL2 also possess 
kininogenase activity, generating vasoactive kinins by cleavage of high molecular weight 
kininogen (Cordova et al., 2001).   
Besides their role in nutrient acquisition by protein degradation, they have been proposed to 
play roles in migration, immune modulation and evasion (reviewed in Tort et al., 1999; 
Mulcahy and Dalton, 2001; Dzik, 2006).  There is little direct evidence for cathepsins L-like 
proteases having a role in migration, with studies conducted in vitro, and protease activity 
possibly correspond to feeding, rather than migration.  However, certain cathepsin L-like 
proteases have been shown to be active at physiological pH, and FhCL1 and FhCL2 are able 
to degrade extracellular matrix and basement membrane molecules, including fibronectin, 
laminin and collagen (Berasain et al., 1997).   
Chapter 1: Introduction 
48 
Fasciola cathepsin L can cleave host immunoglobulins (Smith et al., 1993a; Roche et al., 
1997; Berasain et al., 2000), and has been shown to prevent in vitro antibody-mediated 
eosinophil attachment to NEJ (Carmona et al., 1992; Carmona et al., 1993).  Prowse and 
colleagues (2002) also showed that F. hepatica cathepsin L can suppress T-lymphocyte 
proliferation in sheep, as well as reduce CD4 expression on sheep and human T-cells.  These 
results suggest cathepsin L-like proteases may offer protection from host effector 
mechanisms.  Fasciola cathepsin L has also been implicated in immune modulation through 
suppression of the Th1-type immune response (Brady et al., 1999b; O'Neill et al., 2000; 
O'Neill et al., 2001; reviewed in Dalton and Mulcahy, 2001; Dalton et al., 2003b). 
In addition to the other functions mentioned, cathepsin L2 is able to cleave fibrinogen to 
produce a fibrin clot (Dowd et al., 1995; Dowd et al., 1997).  This may prevent excessive 
bleeding at feeding points in the bile ducts, or alternatively the clot may prevent access of 
immune effector cells to the parasites surface (Dowd et al., 1997). 
Due to Fasciola cathepsin L-like proteases suspected roles in vital parasite functions, they are 
considered important targets for vaccines (section 1.2.3.4) or chemotherapies (Hawthorne et 
al., 2000; Alcala-Canto et al., 2007).  Fasciola cathepsin L-like proteases are also seen as 
viable immunodiagnostic agents (section 1.2.4.2.2) with the use of native and recombinant 
cathepsin L protein, epitopes or anti-cathepsin L antibodies in human and animal diagnosis 
reported (Yamasaki et al., 1989; Fagbemi and Guobadia, 1995; O'Neill et al., 1998; 
Cornelissen et al., 1999; O'Neill et al., 1999; Strauss et al., 1999; Cornelissen et al., 2001). 
Recombinant FhCL1 has been used to successfully synthesise a tripeptide, the first parasite 
protease to be used for peptide synthesis, hinting there may be possible roles for Fasciola 
cathepsins in industry (Ruth et al., 2006). 
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1.2.4.2.1 Fasciola cathepsin L-like proteases as vaccine candidates 
Fasciola cysteine proteases are known to interact with the host immune system and have been 
shown to be immunogenic (Piacenza et al., 1997).  Native F. hepatica cathepsin L proteases 
have been shown to be protective in sheep and cattle, with protection ranging from 33 to 69% 
(Dalton et al., 1996b; Piacenza et al., 1999; McManus and Dalton, 2006).  Wijffels and 
colleagues (1994b) found native cathepsin L did not reduce worm burdens in sheep but 
reduced egg production and viability.  In cattle, native cathepsin L was shown to induce egg 
fecundity and an anti-worm effect (Dalton et al., 1996b).  Protection levels increased to 72% 
when cattle were vaccinated with cathepsin L in conjunction with F. hepatica haemoglobin 
(Dalton et al., 1996b), with worm burden and egg viability further reduced and up to 98% 
anti-fecundity effect observed (McManus and Dalton, 2006). 
When sheep were vaccinated with cathepsin L in combination with a F. hepatica leucine 
aminopeptidase (LAP), protection was increased from 60% to 79% (Piacenza et al., 1999), 
although LAP provided significant (89%) protection on its own.  These results suggest that if 
cathepsin L is to be used as a vaccine, a vaccine cocktail may give the greatest level of 
protection. 
Recombinant cathepsin L has also been shown to be protective (Reszka et al., 2005; 
McManus and Dalton, 2006).  A DNA vaccine encoding a F. hepatica cathepsin L was able to 
elicit an immune response (Smooker et al., 2001), and a DNA vaccine encoding a F. hepatica 
cysteine protease has been shown to confer protection in rats (Kofta et al., 2000; 
Wedrychowicz et al., 2003).  However, while a F. gigantica cathepsin L was able to induce 
an immune response in cattle, it was not significantly protective or able to reduce egg counts 
(Estuningsih et al., 1997).   
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The majority of the vaccine work undertaken with Fasciola cathepsin proteases has involved 
adult expressed cathepsin L proteases, or proteases expressed throughout development.  
Flukes are exposed to the host immune system as they develop during migration to the bile 
ducts (Van Milligen et al., 1998, 1999).  Proteases expressed during this period would be 
expected to make good vaccine targets.  Vaccine work has been undertaken with Fasciola 
hepatica cathepsin B-like (Law et al., 2003) and cathepsin L-like proteases (Van Milligen et 
al., 2000; Harmsen et al., 2004; Reszka et al., 2005) expressed predominantly in juveniles 
flukes.  Cathepsin B has been shown to be immunogenic, while the NEJ cathepsin L can 
confer protection. 
1.2.4.2.2 Fasciola cathepsins in diagnostic assays 
Some of the most promising Fasciola diagnostic antigens are the cysteine proteases, including 
cathepsin L, as they are highly antigenic in animals and humans (Cordova et al., 1997; 
Piacenza et al., 1997; Cornelissen et al., 1999; Cornelissen et al., 2001; Dalton et al., 2003b; 
Law et al., 2003).  Native, recombinant protein and epitopes of various cathepsin L proteases 
for both F. hepatica and F. gigantica have been analysed and shown to have potential for use 
in serological diagnosis (O'Neill et al., 1998; Cordova et al., 1999; Cornelissen et al., 1999; 
O'Neill et al., 1999; Strauss et al., 1999; Carnevale et al., 2001; Cornelissen et al., 2001; 
Neyra et al., 2002; Rokni et al., 2002; Ruiz et al., 2003; Intapan et al., 2005; Yadav et al., 
2005; Raina et al., 2006; Sriveny et al., 2006; Tantrawatpan et al., 2007).  Fasciola cathepsin 
L proteases are also considered useful target antigens, with monoclonal antibodies and 
defined sera directed against them studied for use in diagnostic assays (Marcet et al., 2002; 
Wongkham et al., 2005). 
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1.2.5 Active sites and substrate specificity 
When a protease cleaves a substrate, the bond that is hydrolysed is known as the scissile bond.  
In the generally accepted nomenclature, the active site consists of subsites that are numbered 
in increasing order, moving away from the scissile bond. The subsite immediately N-terminal 
to the scissile bond is known as S1, while the subsite immediately C-terminal is referred to as 
S1’.  The amino acid residues of the substrate that are accommodated in these sites are known 
as P1 and P1’ respectively, as detailed in Figure 1.10 (Schechter and Berger, 1967).   
The dominant subsite specificity in C1A proteases is at the S2 subsite (Turk et al., 1998).  The 
other subsites are not as well defined and play smaller roles in determining substrate 
preferences.  Broad specificity is generally exhibited at P1 (Fox et al., 1995), with the S1 
subsite of the cathepsin L, B, H, and S proteases accommodating basic residues with large 
side chains, namely arginine and lysine (Barrett and Kirschke, 1981).  Cathepsin L prefers 
small or long and unbranched residues at P1’ (Menard et al., 1993), and hydrophobic and 
basic residues in the P3 position (Portaro et al., 2000; Puzer et al., 2004). 
For the substrate to bind effectively to the enzyme, a favourable interaction must be present 
between residues forming the S2 site and the side chain at P2, with S2-P2 interactions largely 
determining the primary specificity of C1A proteases.  Therefore S2 is the most extensively 
studied subsite.  The S2 subsite commonly displays a preference for bulky hydrophobic 
aliphatic or aromatic amino acids, commonly leucine or phenylalanine (Bromme et al., 1994; 
Buhling et al., 2000; Turk and Guncar, 2003; Puzer et al., 2004; Choe et al., 2006).   
Several C1A proteases are capable of accommodating ‘non-typical’ residues including 
arginine or proline at P2.  It has been shown that substrate specificities between cysteine 
protease isoforms are mediated by a few amino acid changes, with the most important 
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Figure 1.10:  Protease subsite nomenclature. 
A diagrammatic example of the specificity subsites and substrate nomenclature (Schechter 
and Berger, 1967). 
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residues in defining substrate specificity situated deep in the S2 pocket (Smooker et al., 2000; 
Juliano et al., 2004).  As such, despite the high amino acid sequence identities and structural 
similarities between many C1A subfamily proteases, enzyme specificity is not necessarily 
strongly related to the enzyme family phylogeny. 
1.2.5.1 Site-directed mutagenesis 
Molecular models of cysteine proteases have enabled researchers to determine the amino 
acids that line the S2 subsite.  This in combination with site-directed mutagenesis has allowed 
researchers to determine the influence these residues can have in determining the substrate 
specificity of the enzyme.   
Several amino acids capable of influencing substrate preferences at various subsites of 
cysteine proteases have been identified by site-directed mutagenesis and X-ray 
crystallography (Khouri et al., 1991; Musil et al., 1991; Bromme et al., 1994; Fox et al., 
1995; Fujishima et al., 1997; McGrath et al., 1998; Pauly et al., 2003; Juliano et al., 2004). 
Residues lining the S2 subsite of particular interest include aa69 (Fasciola cathepsin L mature 
region numbering) which lines one wall, aa135 and aa160 which make up part of the other 
wall and aa209 which closes off the base of the pocket (Figure 1.11). 
The ability to accommodate arginine at P2 has been reported in a number of cysteine proteases 
including cruzain and cathepsin B, and is due to the presence of a glutamic acid residue lying 
at the bottom of the S2 pocket (Khouri et al., 1991; Hasnain et al., 1993; Bromme et al., 1994; 
Gillmor et al., 1997; Barlic-Maganja et al., 1998; Chan et al., 1999).  Similarly, the presence 
of alanine at aa209 appears to result in a preference for bulkier aromatic residues over 
aliphatic residues at P2 as highlighted by the specificity changes observed in FhCatL1 with the 
introduction of a Leu209Ala substitution (Stack et al., 2008).  Bromme et al. (1994) showed 
that the residue at aa135 is also capable of altering the preference for aromatic and aliphatic 
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Figure 1.11:  Amino acids lining the S2 subsite of Fasciola cathepsin L1. 
Structure of the S2 subsite of F. hepatica cathepsin L1 Cys25Gly (Stack et al., 2008).  
Important residues lining the subsite are represented as blue stick models with a P2 
phenylalanine (green) superimposed in the subsite. 
Leu 69 
Met 70 
Ala 135 
Val 160 
Asn 161 
Ala 163 
Leu 209 
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residues, a Gly135Ala substitution altering the aromatic/aliphatic P2 profile in HuCatS.   
Smooker and colleagues (2000) showed that the ability of FhCatL2 to accommodate proline 
was at least partially due to the presence of a tyrosine residue at aa69, altering the specificity 
of FhCatL5 towards FhCatL2-like with a Leu69Tyr substitution.  A Leu69Tyr substitution in 
FhCatL1 which did not result in increased proline acceptance suggests the specificity 
determining capabilities of aa69 appear to work in conjunction with aa160, with the residues 
proposed to act as ‘gatekeeping’ residues to the S2 subsite (Stack et al., 2008). 
The importance of aa69 and aa209 was further highlighted when a dual Tyr69Leu/Leu209Ala 
substitution in HuCatK resulted in a HuCatL-like specificity (Lecaille et al., 2002a).  This 
combined with the recent engineering of HuCatK-like specificity in HuCatL (Lecaille et al., 
2007) indicated key roles for aa209 and aa69 in determining the relative preferences for 
aromatic or aliphatic residues as well as the ability to accommodate proline.   
1.2.5.2 Fasciola cathepsin substrate specificity 
Parasite cathepsins usually fall into two classes when it comes to substrate specificity; the 
cathepsin B-like class of proteases, preferring dibasic amino acid motifs (i.e. P2 Arg- P1 Arg), 
and the cathepsin L-like proteases which prefer a Leu or Phe residue at the P2 position.  Some 
cathepsin proteases, including some expressed by parasites have been shown to accommodate 
Pro at P2, (Dowd et al., 1994; Choi et al., 1999; Lecaille et al., 2002a; Aoki et al., 2003; 
Berasain et al., 2003). 
Fasciola have been shown to possess cathepsin B-like and L-like proteases (1.2.4).  
Comparison of Fasciola cathepsin L-like proteases has shown there is variation in the 
substrate specificity of some of these proteases.  FhCL2 is able to accommodate Pro at P2 
(Dowd et al., 1994; Dowd et al., 1997), while FhCL1 cannot, preferring Phe and Leu (Dowd 
et al., 1994). 
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Smooker and colleagues (2000), initially through molecular modeling, and then through site-
directed mutagenesis showed that amino acid 69 (F. hepatica cathepsin L mature numbering), 
which lines the S2 subsite, significantly influences the subsite specificity of Fasciola 
cathepsin L-like proteases, and was at least partially responsible for the different substrate 
specificities observed between the Fasciola cathepsin L-like proteases.  This result, along 
with work on other cysteine proteases (Khouri et al., 1991; Bromme et al., 1994; Chan et al., 
1999; Juliano et al., 2004), showed that cysteine protease specificity can be altered by 
changing just one or two amino acids forming the S2 subsite. 
Subsequent phylogenetic analysis showed that Fasciola cathepsins L-like protease could be 
differentiated into clades (Figure 1.9; Irving et al., 2003).  These clades (A-D), where found 
to correlate with proposed differences in substrate specificities.  
Clades C and D contain cathepsins possessing Leu at amino acid residue 69, and are expected 
to exhibit typical cathepsin L-like substrate specificity, as seen with FhCL1 (Dowd et al., 
1994) and FhCL5 (Smooker et al., 2000).  Clade B cathepsins, including FhCL2, possess a 
tyrosine residue at position 69, and are expected to accommodate proline at P2 (Dowd et al., 
1994; Dowd et al., 1997; Smooker et al., 2000).  Clade A cathepsins, isolated from NEJ and 
metacercariae, are divergent from other Fasciola cathepsins.  These cathepsins possess a 
tryptophan residue at position 69, but to date have not been characterised.  However, their S2 
subsite is proposed to prefer residues with small hydrophobic sidechains such as proline 
(Irving et al., 2003). 
1.2.6 Inhibition 
With the discovery of the wide range of functions performed by parasite cysteine proteases, 
design and discovery of their inhibitors has been intensively researched.  Protease inhibitors 
are now not only being used to investigating the role of cysteine proteases, but are being 
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investigated as potential treatments of parasitic diseases as well (McKerrow, 1999; McKerrow 
et al., 1999; Lecaille et al., 2001; Lecaille et al., 2002b).  Inhibition of cysteine proteases is 
also seen as an important strategy for treatment of a variety of human pathological conditions 
(Turk et al., 2003). 
There are many cysteine protease inhibitor reviews (including Turk et al., 1985; Bode and 
Huber, 1991; Katunuma and Kominami, 1995; Turk et al., 1997; Hernandez and Roush, 2002; 
Lecaille et al., 2002b; Leung-Toung et al., 2002; Turk et al., 2003; Rawlings et al., 2004; 
Rzychon et al., 2004; Leung-Toung et al., 2006; Steverding et al., 2006).  Inhibitors are often 
based on natural cysteine protease inhibitors.  A number of inhibitors based on protease 
proregions have been developed (Carmona et al., 1996b; Cygler et al., 1996; Schaschke et al., 
1998; Alves et al., 2001b; Chowdhury et al., 2002; Yamamoto et al., 2002; Godat et al., 
2005; Korde et al., 2008), as have those based on cystatins (Grubb et al., 1990; Gauthier et 
al., 1992; Lalmanach et al., 1995; Serveau et al., 1996).   
Cysteine protease inhibitors have been developed against a number of parasitic diseases, 
reducing parasite number or symptoms (Rosenthal et al., 1991; Harth et al., 1993; Wasilewski 
et al., 1996; Scory et al., 1999; Selzer et al., 1999; Troeberg et al., 1999; Mahmoudzadeh-
Niknam and McKerrow, 2004; Rosenthal, 2004; Barr et al., 2005; Korde et al., 2008), and in 
some cases curing disease (Rosenthal et al., 1993; Engel et al., 1998; Abdulla et al., 2007). 
While a range of synthetic and natural inhibitors have been shown to inhibit cysteine 
proteases, problems can occur due to the presence of mammalian cathepsins in important 
processes and possible subsequent toxic effects on the host.  However, differences in 
inhibition efficacy have been observed between mammalian and parasite proteases, and 
development of inhibitor specificity may lead to useful inhibitor design for chemotherapeutics 
(Hawthorne et al., 2000).   
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1.3 Aims and scope of the thesis 
The S2 subsite is known to be the dominant site in determining substrate interactions with 
cathepsin L-like protease.  Previous work has shown that the Fasciola cathepsin L-like 
proteases comprise a large monophyletic family, with individual members displaying different 
specificities.  The S2 subsite of Fasciola cathepsin L-like proteases can be altered through a 
single mutation of the amino acid at residue 69 to affect the substrate specificity.  
This project, through mutagenesis of a F. hepatica cathepsin L-like protease (FhCatL5; 
AF271385) aims to introduce defined substitutions to the protease active site (S2 subsite).  
Mutations that are predicted to alter the substrate specificity, and also expected to be found in 
nature will be constructed, in an attempt to provide a better understanding of the architecture 
of the active site, and how this affects substrate specificity.  The characterisation of the active 
sites will involve the use of host substrates and synthetic substrates. 
The information from the characterisation can be correlated with evolutionary relationships of 
Fasciola cathepsins L-like proteases and molecular models of the proteases, to compare 
predicted architecture and substrate specificity with observed specificity. 
The characterisation of a cathepsin L-like protease isolated from F. gigantica metacercariae 
(FgCatL1G) will also be performed, with the results incorporated into the active site analysis.   
These results should provide a thorough characterisation of the specificity of the cathepsin L-
like proteases expressed by Fasciola, with particular focus on the role of the S2 subsite.  
These results can then be extrapolated to other parasites that utilise cysteine proteases within 
their life cycles.  Hints as to which cathepsins may provide good vaccine or therapeutic 
targets may also emerge, as may a role for Fasciola cathepsins as potential industrial 
enzymes.  
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2.1 General Procedures 
Commonly used methods are listed below, with more specific details outlined in the 
appropriate chapter.  Unless otherwise stated, all solutions were prepared with reverse 
osmosis double distilled water (referred to as mH2O) obtained from a Millipore Milli-Q® 
water system (Liquipure, Melbourne, Australia), with the exception of media, where distilled 
water (dH2O) was used.  Chemicals used were of analytical or molecular grade, and stored at 
room temperature (RT) unless otherwise stated. 
Sterilisation by autoclaving was undertaken at 121oC (15 lbs/in2) for 20 min unless otherwise 
stated.  Samples were filtered sterilised using acrodisc filters (Pall).  Degassing or filtering of 
particulate matter from volumes greater than 50 mL was undertaken with the Sterifil® aseptic 
system and filter holder (Millipore) with 47 mm, 0.45 µm filters (Whatman). 
The Finnpipette® digital pipette range (Thermo Labsystems) were used to dispense solutions.  
The range included 0.5-10 µL, 5-40 µL, 20-200 µL, 200-1000 µL, 1-5 mL, 5-10 mL digital 
pipettes and a 50-300 µL multi-channel pipette. 
Volumes less than 1.5 mL underwent centrifugation with an Eppendorf microcentrifuge.  
Volumes of up to 200 mL requiring less than 5,445 × g underwent centrifugation in the 
Beckman Allegra 21R centrifuge.  Volumes greater than 200 mL; or less than 200 mL, but 
requiring greater than 5,445 × g, underwent centrifugation in a Beckman J2-21 M/E 
centrifuge. 
Products less than 2 g were weighed on a Sartorius analytical top-loading balance.  Products 
of greater than 2 g were weighed on an ISSCO model 300 top loading balance. 
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2.2 General Equipment and suppliers 
ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit: 
 Perkin-Elmer Corp., USA. 
Balances: 
 Analytical balance:     Sartorius Gottingen, Germany 
 Balance (0.1-300 g)     U-Lab, Australia 
Biological safety cabinet class II, BH2000 series: Clyde-Apac, Australia 
Centricon ultracentrifugal devices:  Millipore, USA 
Centrifuges:  
 Eppendorf EBA 12, 5414C and 5414D bench top Centrifuges 
 Eppendorf Geratebau, Germany 
 Beckman Allegra™ 21R Centrifuge  Beckman Coulter, USA 
 Beckman J2-21 M/E Super Centrifuge  Beckman Coulter, USA 
Centrifuge tubes: 
 1.5 mL microfuge tubes    Sarstedt, Germany  
 10 mL centrifuge tubes    Sarstedt, Germany 
 15 mL centrifuge tubes    Sarstedt, Germany 
 50 mL centrifuge tubes    Greiner Labortechnik, Germany 
 200 mL autoclavable centrifuge bottles  Nalge Nunc International, USA 
Chelating sepharose™ fast flow:   GE healthcare 
Chromatography paper (0.18 mm thick):   Whatman, England. 
Columns: 
 Polypropylene gravity flow column (1 mL, 5 mL) 
 Qiagen, Australia 
 Econo-column, 0.7 cm ID,10 cm length  BioRad Laboratories, USA  
 MonoSTM HR 5/5 ion exchange column   Amersham Phamacia, Sweden. 
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Cryovials (1.8 mL):     Iwaki, Canada 
Dialysis tubing:     Viskase, USA 
 Membra-cel 14 kDa cut off, 43 mm flat width 
 Membra-cel 14 kDa cut off, 25 mm flat width 
Dialysis clamps (Cellu.Sep®, 90 mm):  Membrane filtration products, Inc., USA 
DIG DNA Labelling and Detection kit:   Boehringer Mannheim, Germany 
Dry block heaters:     Ratek, Australia 
Electrophoresis power supply: 
 EPS 3000xi     BioRad Laboratories, USA 
 EPS 1000/500     BioRad Laboratories, USA 
 PowerPac 300     Biorad Laboratories, USA 
 PowerPac Basic     Biorad Laboratories, USA 
 EPS 600      Pharmacia LKB, Sweden 
 EPS 500/400     Pharmacia LKB, Sweden 
Electrophoresis units: 
 DNA: 
 Mini gel (GNA-100)    Pharmacia LKIB, Sweden 
 Midi gel (wide mini-sub cell GT)   BioRad Laboratories, USA 
 Protein: 
 Mini-Protean II gel system    BioRad Laboratories, USA 
 Mini-Protean III gel system   BioRad Laboratories, USA 
Electroporation cuvettes (0.2 cm):    Molecular Bio Products, USA 
Filters:  
 Acrodisc® 0.2 µm and 0.45µm   Pall, USA 
 Cellulose nitrate sterile membrane filter (0.45µm, 47 mm) 
 Whatman 
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FPLC system:     Biorad, USA 
Gel Doc image system:     BioRad, USA 
Geneclean® kit:      QBIOgene USA 
Hybond™-N nylon membrane:    Amersham Biosciences 
Hybond™-C nitrocellulase membrane:   Amersham Biosciences 
Incubating shaker (Infors HT):   Infors AG, Bottmingen, Switzerland 
ImProm II™ reverse transcription system: Promega, USA 
ISCO Tris™ peristaltic pump:   Cole-Parmer, USA 
Masterflex® pump system:     Cole-Palmer, USA 
 Cole-Palmer motor drive (model 7567-80) 
 Masterflex® pump head (model 7015-20) 
 Masterflex® solid stated speed control 
 Tygon® lab tubing 
Microplate readers: 
 Spectrophotometer (96-well) MR7000  Dynatech (now Dynex), USA 
 Fluorimeter, Fluostar Galaxy   BMG Technologies, Australia 
 Fluorimeter, Polarstar    BMG Technologies, Australia 
Microtitre plates:  
 96-well, colourless, flat bottom   Nunc, Denmark 
 96-well, solid white, flat bottom   Costar, Australia 
 384-well, solid white, flat bottom   Nunc, Denmark 
Needles (25 gauge): Terumo Pty, Ltd., Australia 
Parafilm:      Pechiney Packaging, USA 
PCR machines: 
 GeneAmp2400 PCR system   Perkin-Elmer, USA 
 PCR Express gradient thermal cycler   Thermohybaid, UK 
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Petri dishes:       BioLab, Australia 
pH meter:       Hanna, U-lab, Australia 
Platform shaker:      Ratek, Australia 
Pulse controller & Gene pulser apparatus:  BioRad, USA 
QIAprep® spin miniprep kit:    Qiagen, Australia 
RNAgents® total RNA isolation system:  Promega, USA 
Sterifil® aseptic system:     Millipore 
Sterifil® 47 mm filter holder:   Millipore 
Suction pump (Compact laboratory, series 30): Clements Medical Equipment Pty. Ltd., 
 Australia 
Syringes (1, 3, 5, 10, 20, and 60 mL):  Terumo Pty, Ltd, Australia 
Trans-blot electrophoretic transfer cell (mini): BioRad Laboratories, USA 
Transilluminator (UV):     Novex, Australia 
Ultrafiltration Stirred cells:  
 Amicon series 8000    Millipore, USA 
 Vivaflow 50 filters:    Sartorius, Germany 
   10,000 MWCO PES 
   100,000 MWCO PES 
Waterbath:       Ratek, Australia. 
Wizard® PCR prep, DNA purification kit:  Promega, USA 
Wizard® genomic DNA purification kit:  Promega, USA 
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2.3 General Materials and suppliers 
2.3.1 General media 
All media were prepared using aseptic technique and stored at 4°C.  Media requiring the 
addition of supplements were autoclaved and cooled to 55°C before supplement addition.  For 
plate media, 1.5% (w/v) bacteriological agar No.1 (Oxoid, England.) was added prior to 
autoclaving. 
Expression (YPHSM) media:  1% (w/v) yeast extract (Oxoid), 8% (w/v) peptone (Oxoid), 
1% (w/v) dextrose (BDH chemical, UK), 3% (w/v) glycerol (BDH), 20 mM calcium chloride 
(BDH).  Yeast extract and peptone were autoclaved together, while other components were 
made as 20× stock solutions and autoclaved separately, before being combined prior to use 
(Nomura and Fujisawa, 1997). 
Luria-Bertani (LB) media: 0.5% (w/v) yeast extract (Oxoid), 1% (w/v) tryptone (Oxoid), 
1% (w/v) sodium chloride (BDH).  When required, ampicillin was added to a final 
concentration of 100 µg/mL. 
Minimal media + uracil + lysine (MM+UL): 0.67% (w/v) yeast nitrogen base (BD), 2% 
(w/v) dextrose (BDH), 0.002% (w/v) uracil (Sigma-Aldrich), 0.003% (w/v) lysine (BDH).  
Media was made as a 10× stock solution and filtered sterilised.  For broth media, stock was 
added to autoclaved dH2O; for plate media, bacteriological agar was autoclaved and mixed 
with the stock solution. 
S.O.C. media: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 20 mM dextrose.  Supplied by Invitrogen, USA 
Yeast extract peptone dextrose (YPD) media: 1% (w/v) yeast extract (Oxoid), 2% (w/v) 
peptone (Oxoid), 2% (w/v) dextrose (BDH). 
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2.3.2 General solutions 
100 bp DNA ladder:  250 µL (Promega) mixed with 25 µL of 11× DNA loading buffer. 
Stored at −20ºC.  Five and a half microlitres loaded per lane. See Appendix 1 for band sizes. 
5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal): 20 mg/mL X-gal (Sigma-
Aldrich) in dimethylformamide (BDH).  Stored in the dark at 4ºC. 
β-mercaptoethanol: electrophoresis purity (BDH). 
λ-DNA: 50 µg/mL (Promega) stored at −20ºC. 
Acetate-MES-Tris (AMT) buffer: 100 mM acetate (Merck), 100 mM MES (Sigma-
Aldrich), 200 mM Tris (Amresco), 1 mM EDTA (BDH).  Adjusted to the appropriate pH with 
NaOH or HCl (Ellis and Morrison, 1982). 
Acrylamide/bisacrylamide solution: 40% (w/v) prepared solution containing 38.67% (w/v) 
ultra pure acrylamide and 1.33% (w/v) bisacrylamide (Australia Scientific, Australia). 
Agarose: x% (w/v) DNA grade agarose (Progen Industries, Australia) in 1×TAE buffer, 
solubilised by heating in a microwave oven. 
Alkaline phosphatase conjugate substrate kit: Prepared according to manufacturers 
instructions (Biorad). 
Ammonium hydroxide (NH4OH): 30% (14.8 M) (Sigma-Aldrich). 
Ammonium persulphate (APS): 10% (w/v) ammonium persulphate (Sigma-Aldrich) stored 
at 4ºC. 
Ampicillin: 100 mg/mL ampicillin (CSL, Australia), filter sterilised through 0.2 µM filter. 
Stored at −20ºC. 
Anode buffer: 0.2 M Tris-HCl (Astral Scientific), pH 8.9.  Prepared with dH2O 
Anti-DIG antibody solution:  Anti-DIG-alkaline phosphatase (1:5,000) in blocking solution. 
Binding buffer: 25 mM NaH2PO4 (BDH), pH 7.6, 0.5 M NaCl (BDH), 1-10 mM imidazole 
(Sigma-Aldrich). 
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Blocking buffer: 5% (w/v) skim milk (Bonlac Foods Limited, Australia) in Tris buffered 
saline. 
Blocking reagent: (Roche Diagnostics). 
Blocking reagent stock solution (10%): 10% (w/v) Blocking Reagent (Roche Diagnostics) 
in Maleic Acid Buffer.  The Blocking Reagent was heated at 65°C with constant stirring for 1 
h or until completely dissolved.  The solution was autoclaved and stored at 4°C. 
Blocking solution: 1% Blocking reagent diluted in Maleic Acid Buffer. 
Bovine serum albumin, fraction V (BSA): 1 mg/mL (Sigma-Aldrich), stored at −20°C. 
Bradford reagent: 0.1 mg/mL Coomassie Brilliant G-250 dye (Sigma-Aldrich) dissolved in 
4.75% (v/v) ethanol and 8.5% (v/v) phosphoric acid.  Stored at 4ºC, and filtered through a 
0.45 µm filter before use. 
Bromophenol blue: 1% (w/v) bromophenol blue (Sigma-Aldrich). 
Buffer 1: 0.1% sodium citrate, pH 4.5 (BDH), 2.5% (w/v) Triton X-100 (Biorad). 
Buffer 2: 0.1% sodium citrate, pH 4.5 (BDH).  Fresh DTT added to 2 mM just before use. 
Buffer A: 25 mM acetic acid (Merck), 1 mM EDTA (BDH).  Adjust pH to 5 with NaOH. 
Buffer B: 25 mM acetic acid (Merck), 500 mM NaCl (BDH), 1 mM EDTA (BDH).  Adjust 
pH to 5 with NaOH. 
Calcium chloride (CaCl2): 1 M CaCl2 (BDH). 
Cathode buffer: 0.1 M Tris (Amresco), 0.1 M Tricine, 0.1% SDS, pH 8.25.  Prepared with 
dH2O. 
Chloroform: 100% (v/v) chloroform (BDH). 
Chloroform/Isoamyl alcohol (CI): 96% (v/v) chloroform (BDH), 4% (v/v) isoamyl alcohol 
(BDH). 
Citric acid: (BDH). 
Coomassie blue destain solution: 10% (v/v) ethanol (BDH) and 10% (v/v) glacial acetic 
acid (BDH). 
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Coomassie blue stain solution: 0.1% (w/v) Coomassie brilliant blue R-250 (Sigma-Aldrich), 
50% (v/v) methanol (BDH), 10% (v/v) glacial acetic acid (BDH). 
Dialysis buffer: 100mM NaCl (BDH), pH 7.6. 
Denaturation solution: 0.5 M NaOH, 1.5 M NaCl, 0.1% SDS. 
DEPC: 1% diethyl pyrocarbonate (Sigma-Aldrich). 
Detection buffer: 100mM Tris-HCl, 100 mM NaCl; pH 9.5. 
Dextran sulphate: 10 mg/mL stored at −20ºC (Sigma-Aldrich). 
DIG-labelled control DNA:  5 µg/mL DIG-labelled pBR328 linearised by EcoRI.  Supplied 
by Roche Diagnostics.  Stored at −20°C. 
Dimethyl sulfoxide (DMSO): 100% (w/v) (Sigma-Aldrich). 
Dithiothreitol (DTT): Freshly made 1 M dithiothreitol (Molecular Biology Grade, Progen). 
DNA dilution buffer: 10 mM Tris-HCl, pH 8, 50 µg/mL herring sperm DNA.  Supplied by 
Roche Diagnostics.  Stored at −20°C. 
DNA loading buffer (11×): 10% (w/v) ficoll®-400 (BDH), 50% (v/v) glycerol (BDH), 0.5% 
(w/v) Orange G (Sigma-Aldrich), 1% (w/v) SDS (BDH), 10 mM EDTA (BDH), 50 mM Tris 
(pH 8.0). 
dNTPs (deoxynucleoside triphosphates): 10 mM each of dATP, dGTP, dTTP and dCTP 
(Boehringer Mannheim-BM, Germany). 
dNTP labelling mixture (10×): (Roche Diagnostics). 
E-64: E-64 dissolved in 100% DMSO and diluted with mH2O to give stock concentration of 1 
mM in 10% DMSO. 
Elution Buffer: 25 mM NaH2PO4 (BDH), pH 7.6, 0.5 M NaCl (BDH), 250 mM imidazole 
(Sigma-Aldrich). 
Enzyme buffer: 100 mM acetic acid, 1 mM EDTA (BDH).  NaOH used to adjust to pH 5.5, 
then passed through 0.45 µm filter.  10 mM cysteine added immediately before use. 
Ethanol: 70% (v/v), 95% (v/v), 100% (v/v) analytic ethanol (BDH). 
Chapter 2: General materials and methods 
69 
Ethidium bromide (EtBr): 10 mg/mL stock solution (BM).  
Ethylenediaminetetra-aetate (EDTA) buffer: 0.5 M EDTA (BDH), pH 8.0.  
FITC-casein:  10 mg/ml (Molecular Probes, Australia).  Kindly supplied by Dr Simone 
Beckham and Dr Rob Pike.  Aliquotes stored at −20°C. 
Formaldehyde: 37% (w/v) (Sigma-Aldrich). 
Gelatin: Teleostean gelatin from cold water fish skin (Sigma-Aldrich). 
Gelatin gel (12%): 125 mM Tris (pH 6.8), 1% SDS, 12% bis/acrylamide, 0.1% (v/v) gelatine 
made up to volume with mH2O.  Gel was polymerised by addition of 0.05% (w/v) ammonium 
persulphate and 0.1% (v/v) TEMED. 
Glacial acetic acid: (Merck). 
Glycerol: 100%, 50% (v/v) glycerol (BDH). 
Hexanucleotide mixture (10×): (Roche Diagnostics). 
Hybridisation solution: 5× SSC, 0.1% N-lauroylsarcosine, 0.02% SDS , 1% Blocking 
reagent (from 10% stock solution) diluted in dH2O. 
Hydrochloric acid: 32% (w/v) (Ajax Chemicals Ltd., Australia). 
Hydrogen peroxide (H202): 30% (w/v) H2O2 (BDH). 
Imidazole: 5 M imidazole (Sigma-Aldrich) stock solution, pH 7.6, filtered through a 0.45 µm 
filter. 
Isopropanol: Propan-2-ol (BDH). 
Isopropyl-β-D-thiogalactopyranoside (IPTG): 1 M stock: 200 mg/mL IPTG (Astral), filter-
sterilised through 0.2 µm filter.  Aliquots stored at −20°C.  
L-Cysteine:  1 M stock (Sigma-Aldrich), made fresh.  
Maleic acid buffer: 100 mM maleic acid, 150 mM NaCl. Adjusted to pH 7.5 with NaOH.  
Autoclaved.  
Maleic acid wash buffer: 100 mM maleic acid, 150 mM NaCl, 0.3% (v/v) Tween® 20; pH 
7.5. 
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Methanol: 100% (v/v) (BDH). 
Mixing buffer: 250 mM NaH2PO4, 4 M NaCl, pH 7.6. 
Native loading buffer (5×): 60 mM Tris (pH 6.8), 25% (w/v) glycerol (BDH), 0.1% (w/v) 
bromophenol blue (Sigma-Aldrich). 
Native PAGE running buffer (10×): 250 mM Tris, 1.92 M glycine (Sigma-Aldrich). 
Native PAGE sample buffer (5×): 312.5 mM Tris (pH 6.8), 50% (v/v) glycerol (BDH), 
0.05% (w/v) bromophenol blue (Sigma-Aldrich). 
Native PAGE separating gel (x%): 375 mM Tris (pH 8.8), x% bis/acrylamide, made up to 
volume in mH2O.  Gel was set by addition of 0.05% (w/v) ammonium persulphate and 0.1% 
(v/v) TEMED. 
Native PAGE stacking gel (4%): 125 mM Tris (pH 6.8), 4% (v/v) bis/acrylamide made up 
in mH2O.  Gel was gelatinised by the addition of 0.05% (w/v) ammonium persulphate and 
0.1% (v/v) TEMED. 
NaCl-bicine (NB) buffer: 0.15 M NaCl (BDH), 10 mM Bicine, pH 8.35 (Sigma-Aldrich).  
Sterilised through 0.2 µm filter and stored at −20°C. 
NBT/BCIP solution: (Roche diagnostics). 
Neutralisation solution: 1 M Tris-HCl,pH 7.5 and 1.5 M NaCl. 
Nickel Sulphate: 0.2 M nickel sulphate (BDH) stock, filtered through a 0.45 µm filter. 
N-lauroylsarcosine stock: 10% (w/v) sterilised through 0.2 µm filter. 
Non-reducing loading buffer (5×): 60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH), 2% 
(w/v) SDS (BDH), 0.1% (w/v) bromophenol blue (Sigma-Aldrich). 
One Shot competent cells: INVαF’ and TOP10F’ chemically competent cells (Invitrogen) 
PEG-bicine: 40% (w/v) PEG 1000 (Sigma-Aldrich), 200 mM Bicine, pH 8.35 (Sigma-
Aldrich).  Sterilised through a 0.2 µm filter and stored at −20°C. 
Phenol (saturated): (Astral Scientific). 
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Phenol/chloroform-isoamyl: A ratio of 25:24:1 (BDH) of phenol, chloroform and isoamyl 
alcohol. 
Phosphate-buffered saline (PBS): 1 tablet  Dulbecco’s ‘A’ PBS (Oxoid) in 100 mL mH2O 
(sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 0.115%, 
potassium dihydrogen phosphate 0.02%, pH 7.2).  Sterilised by autoclave.   
Plasmid isolation solution I: 25 mM Tris, pH 8.0 (Amresco), 10 mM EDTA (BDH), 50 mM 
glucose (Sigma-Aldrich).  Lysozyme (BM) (4 mg/mL) was added immediately prior to use. 
Plasmid isolation solution II: 0.2 M NaOH (BDH), 1% (w/v) SDS (BDH). 
Plasmid isolation solution III: 3 M potassium acetate (BDH) combined with 2 M glacial 
acetic acid (BDH). 
Protein standards: refer to Appendix 1. 
  Mark 12™ unstained standard (Invitrogen) 
  SeeBlue® Plus2 pre-stained protein standard (Invitrogen) 
SBEG (Sorbitol bicine ethylene glycol) buffer: 1 M sorbitol (Sigma-Aldrich), 10 mM 
Bicine, pH 8.35 (Sigma-Aldrich), 3% (v/v) ethylene glycol (Sigma-Aldrich).  Sterilised 
through 0.2 µm filter and stored at −20ºC. 
SDS loading buffer (5×): 60 mM Tris (pH 6.8), 25% (v/v) glycerol (BDH), 2% (w/v) SDS 
(BDH), 14.4 mM β-mercaptoethanol (Bio-Rad, Aust.), 0.1% (w/v) bromophenol blue (Sigma-
Aldrich).  Stored at −20ºC. 
SDS-PAGE Separating gel (x%): 375 mM Tris (pH 8.8), 1% SDS, x% bis/acrylamide, 
made up to volume in mH2O.  Gel was polymerised by addition of 0.05% (w/v) ammonium 
persulphate and 0.1% (v/v) TEMED. 
SDS-PAGE stacking gel (4%): 125 mM Tris (pH 6.8), 1% SDS, 4% (v/v) bis/acrylamide 
made up in mH2O.  Gel was polymerised by the addition of 0.05% (w/v) ammonium 
persulphate and 0.1% (v/v) TEMED. 
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SDS running buffer: 25 mM Tris, 192 mM glycine (BDH), 0.1% (w/v) SDS (BDH), pH 
adjusted to 8.3. 
Silver nitrate: (Sigma-Aldrich). 
Silver stain development solution: 0.005% (w/v) citric acid (BDH), 0.019% (v/v) 
formaldehyde. Made fresh before use. 
Silver stain fixing solution: 50% (v/v) methanol (BDH), 10% (v/v) glacial acetic acid 
(BDH). 
Silver Stain Solution: 18.9 mM NaOH (BDH), 207 mM NH4OH (Sigma-Aldrich), with 
dissolved silver nitrate added to 0.8% (w/v).  Made fresh before use.  
Silver stain stop solution: 1% glacial acetic acid (BDH). 
Sodium acetate (NaOAc): 3 M (BDH), pH 4.6. 
Sodium bicarbonate: (BDH). 
Sodium citrate : 1% citric acid (BDH). Adjusted to pH 4.5 with NaOH (BDH).  
Sodium chloride (NaCl): 5 M stock solution (BDH). 
Sodium dodecyl sulphate (SDS): 10% (w/v) SDS (BDH). 
Sodium hydroxide (NaOH): 10 M stock solution (BDH). 
SSC (20×): 3 M NaCl, 300 mM sodium citrate, pH 7. Autoclaved. 
SSC (2×) wash buffer: 2× SSC, 0.1% SDS. 
SSC (0.5×) wash buffer: 0.5× SSC, 0.1% SDS. 
Substrate solution: 200 µL NBT/BCIP solution in 10 mL Detection buffer. 
TE buffer (10×): 100 mM Tris (Amresco), 10 mM EDTA (Amresco), pH 8.0. 
TEMED (N,N,N’,N’-tetramethylethylenediamine): Electrophoresis purity (Biorad). 
Transfer buffer: 25 mM Tris (Amresco), 192 mM glycine (BDH), 20% (v/v) methanol 
(BDH). 
Trichloroacetic acid (TCA): 100% (w/v) stock solution (Sigma-Aldrich). 
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Tricine SDS-PAGE separating gel buffer: 1 M Tris (pH 8.45), 0.1% SDS, 16% 
bis/acrylamide, 0.14% (w/v) glycerol made up to volume in mH2O.  Gel was polymerised by 
addition of 0.05% (w/v) ammonium persulphate and 0.1% (v/v) TEMED. 
Tricine SDS-PAGE stacking gel buffer: 745 mM Tris (pH 8.45), 0.745% SDS, 4% 
bis/acrylamide made up to volume in mH2O.  Gel was polymerised by addition of 0.05% 
(w/v) ammonium persulphate and 0.1% (v/v) TEMED. 
Tricine SDS-PAGE loading buffer (3×): 150 mM Tris (pH 6.8), 36% (v/v) glycerol (BDH), 
24% (w/v) SDS (BDH), 8.7 mM β-mercaptoethanol (BioRad), 0.3% (w/v) coomassie blue 
G-250 (Sigma-Aldrich).  Stored at −20°C. 
Tris (hydroxymethyl) aminomethane (Tris): 2 M stock solution (Amresco).  Adjusted to 
pH 8 with HCl. 
Tris-Acetate-EDTA buffer (TAE): (50×) 2 M Tris, 1 M acetic acid, 0.1 M EDTA (BDH). 
Tris buffered saline (TBS): 25 mM Tris, 180 mM sodium chloride, pH 7.4. 
Tween® 20: (Sigma-Aldrich). 
Wash Buffer: 25 mM NaH2PO4 (BDH), pH 7.6, 0.5 M NaCl (BDH), 10 mM imidazole 
(Sigma-Aldrich). 
Western blot substrate solution: 30 mg of 4-Chloro-1-naphthol (Sigma-Aldrich) dissolved 
in 10 mL methanol (BDH), brought up to 50 mL with TBS.  Immediately prior to use 30 µL 
of hydrogen peroxide (H2O2) was added.  
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2.3.3 Enzymes 
All enzymes were used with their supplied buffer according to manufacturer’s instructions, 
and were stored at −20ºC unless otherwise stated. 
Calf intestinal phosphatase (CIP): 10 U/µL (Roche, Germany), stored at 4ºC. 
DNase I bovine pancreas: Stock of 10 U/µL prepared from lyophilised DNase (Sigma-
Aldrich). 
DNA Ligase, T4: 3 U/µL (Promega). 
DNA polymerase, Expand Long Template PCR system: 5 U/µL (Roche Diagnostics). 
DNA polymerase, Pfu: 3 U/µL (Promega, USA). 
DNA polymerase, AmpliTaq: 5 U/µL (Perkin-Elmer, USA). 
DNA polymerase, Platinum® high fidelity Taq: 5 U/µL (Invitrogen). 
Klenow enzyme: 2 U/µL (Roche Diagnostics). 
Lysozyme solution 1: 20 mg/mL lysozyme (BM) in EDTA buffer, prepared fresh. 
Polynucleotide kinase (PNK): 10 U/µL (Promega). 
Proteinase K: 20 mg/mL (BM) in sterile mH2O.  
Restriction enzymes: See Table 2.4. 
RNase solution: 10 mg/mL bovine pancreas ribonuclease 1A (Pharmacia), boiled for 30 min 
to ensure DNase free. 
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2.3.4 Fluorogenic substrates 
A small amount of lyophilised substrate was accurately weighed and completely dissolved in 
an appropriate volume of 100% DMSO to give a substrate concentration of 10 mM.  This was 
diluted with mH2O to 1 mM and aliquoted for storage at −20°C.  All flourogenic substrates 
(Sigma-Aldrich) were kindly provided by Dr Rob Pike and Dr Simone Beckham.   
AGPR  Boc-b-benzyl-Ala-Gly-Pro-Arg-7-amido-4-methylcoumarin hydrochloride  
DPR  Boc-b-benzyl-Asp-Pro-Arg-7-amido-4-methylcoumarin hydrochloride  
FR  Z-Phe-Arg-7-amido-4-methylcoumarin hydrochloride. 
FVR  Bz-Phe-Val-Arg-7-amido-4-methylcoumarin hydrochloride. 
TGPR  N-p-Tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin hydrochloride . 
PFR  Pro-Phe-Arg-7-amido-4-methylcoumarin. 
VLK  Boc-Val-Leu-Lys-7-amido-4-methylcoumarin. 
VLR  D-Val-Leu-Arg-7-amido-4-methylcoumarin. 
VPR  Boc-Val-Pro-Arg-7-amido-4-methylcoumarin hydrochloride. 
2.3.5 Antibodies and sera 
Goat anti-rabbit IgG-HRP    ICN, USA 
Rabbit Anti-FhCatL5 sera    Dr Ruby Law, Monash University 
Anti-DIG-alkaline phosphatase antibody  Roche Diagnostics 
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2.4 Microbiological methods 
2.4.1 Microorganisms, plasmids and recombinant proteins 
Bacterial and yeast strains used in this work is summarised in Table 2.1.  Plasmids used, and a 
description of recombinant proteins used and developed throughout the study are listed in 
Table 2.2 and Table 2.3 respectively. 
2.4.1.1 Bacterial and yeast strains 
Gene search clones were transformed into all bacterial strains mentioned.  DH5α was used for 
construction of cathepsin L recombinant protein clones.  The yeast strain BJ3505 was used for 
recombinant protein expression.   
2.4.1.2 Plasmids 
The plasmids pBluescript and pCR®2.1 were used for the Fasciola mRNA and genomic DNA 
cathepsin L gene search.  The FgCatL1G cDNA clone in the pGEM T-easy plasmid was 
kindly supplied by Dr Rudi Grams.  Cathepsin L constructs were made using YEpFLAG, 
which acted as a shuttle vector between DH5α and BJ3505, and the expression vector in 
BJ3505. 
2.4.2 Storage conditions 
E. coli strains were stored at −80°C in 50% glycerol.  S. cerevisiae was stored at −80°C in 
20% glycerol.  Recombinant enzyme was stored at −80°C in MonoS buffer A. 
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Table 2.1:  Microorganisms used throughout this study 
Bacterial strain Genotype/Description Source 
DH5α (Escherichia coli) 
 
F’/endA1 hsdR17(rK-, mK+) 
supE44 thi-1 recA1 gyrA96 
(NalR) relA1 ∆(lacZYA-
argF)U169 Φ80d lacZ∆M15 
deoR phoA λ- 
Hanahan, 1983 
InvαF (E. coli) F´endA1 recA1 hsdR17 (rK-, 
mK
+) supE44 thi-1 gyrA96 
relA1 Φ80lacZ∆M15 
∆(lacZYA-argF)U169 λ- 
Invitrogen TA cloning manual, 
Invitrogen, USA 
TOP10F’(E. coli) F´[lacIq Tn10(TetR)] mcrA ∆ 
(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacX74 
recA1 araD139 ∆(ara-
leu)7697 galU galK rpsL 
(StrR) endA1 nupG 
Invitrogen TA cloning manual, 
Invitrogen, USA 
Yeast strain Genotype/Description Source 
BJ3505 (Saccharomyces 
cerevisea) 
MATa ura3-52 trp1-∆101 
lys2-208 gal2 can1 
pep4::HIS3 prb∆1.6R 
Eastman Kodak, NY 
 
Table 2.2:  Plasmids used throughout this study 
Plasmid Description/Genotype Diagram Source 
pBluescript 
(pBSIISK-) 
2.96 kbp phagemid: AmpR, lacZ, 
ColE1 origin of replication 
Figure 2.1 Stratagene, USA 
pCR®2.1 3.9 kbp PCR cloning plasmid, 
AmpR, KmR, lacZ, 3’ T-overhang 
Figure 2.2 Invitrogen, USA 
pGEM® T-easy 3.0 kbp, high copy number 
cloning plasmid, AmpR, lacZ, 3’ 
T-overhang 
Figure 2.3 Promega, USA 
YEpFLAG 7.2 kbp shuttle expression vector, 
AmpR, TRP1, 2µ origin of 
replication, FLAG sequences, 
ADH2 promoter and CYC 
terminator 
Figure 2.4 Eastman Kodak, 
NY 
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Table 2.3:  Expression plasmids and a description of the cathepsin L-like recombinant proteins used and developed throughout this study 
Expression plasmid Protein Description Source 
YEpFLAGFhCatL5 rFhCatL5 F. hepatica cathepsin L5 (Acc. No. AF271385) cloned into YEpFLAG 
expression vector.  Expressed as fusion preproMFα-FLAG-protein with a 
C-terminal 6 ×his-tag for purification. 
Smooker et al., 
2000 
YEpFLAGFhCatL5 L69Y rFhCatL5 L69Y rFhCatL5, with substitution to aa69 (mature enzyme numbering) changing 
leucine to tyrosine. 
Smooker et al., 
2000 
YEpFLAGFhCatL5 L69W rFhCatL5 L69W  rFhCatL5, with substitution to aa69 (mature enzyme numbering) changing 
leucine to tryptophan. 
(this study) 
YEpFLAGFhCatL5 L69C rFhCatL5 L29C  rFhCatL5, with substitution to aa69 (mature enzyme numbering) changing 
leucine to cysteine. 
(this study) 
YEpFLAGFhCatL5 L69S rFhCatL5 L69S rFhCatL5, with substitution to aa69 (mature enzyme numbering) changing 
leucine to serine. 
(this study) 
YEpFLAGFhCatL5 L69F rFhCatL5 L69F rFhCatL5, with substitution to aa69 (mature enzyme numbering) changing 
leucine to phenylalanine. 
(this study) 
YEpFLAGFhCatL2 rFhCatL2  F. hepatica cathepsin L2 (similar to Acc. No. U62289) expressed as fusion 
preproMFα-FLAG-protein with a C-terminal 6 ×his-tag for purification. 
Smooker et al., 
2000 
YEpFLAGFhCatL2 Y69L rFhCatL2 Y69L  rFhCatL2 with substitution to aa69 (mature enzyme numbering) changing 
tyrosine to leucine. 
(this study) 
YEpFLAGFgCatL1G rFgCatL1G F. gigantica cathepsin L1G (similar to Acc. No. AF419329) expressed as 
fusion preproMFα-FLAG-protein with a C-terminal 6 ×his-tag for 
purification 
(this study) 
YEpFLAGFgCatL1G C-79Y rFgCatL1G C-79Y rFgCatL1G with substitution, changing cysteine at aa-79 in proregion to 
tyrosine. 
(this study) 
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Figure 2.1:  pBluescript (pBSIISK-). 
2.96 kbp phagemid: AmpR, lacZ, ColE1 origin of replication. 
 
 
 
 
 
 
 
 
 
Figure 2.2:  pCR®2.1. 
3.9 kbp PCR cloning plasmid, AmpR, KmR, lacZ, 3’ T-overhang. 
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Figure 2.3:  pGEM® T-easy. 
3.0 kbp, high copy number cloning plasmid, AmpR, lacZ, 3’ T-
overhang. 
 
 
 
 
 
 
 
 
 
Figure 2.4:  YEpFLAG. 
7.2 kbp shuttle expression vector, AmpR, TRP1, 2µ origin of replication, 
FLAG sequences, ADH2 promoter and CYC terminator. 
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2.4.3 Culture conditions 
All E. coli strains, grown in broth or on solid microbiological media were incubated under 
aerobic conditions at 37°C for 16-20 h.  Broths were shaken at approximately 150 rotations 
per min (rpm) on a Ratek orbital shaker.  Yeast was incubated at 28°C, with broths shaking at 
160 rpm.   
2.4.4 Microorganism manipulation 
2.4.4.1 Preparation of electro-competent cells 
Bacterial cells were prepared for electro-transformation according to the Gene Pulser 
apparatus user’s manual (BioRad) with minor alterations.  All steps were performed 
aseptically.  An overnight bacterial culture was used to inoculate 200 mL of Luria-Bertani 
(LB) broth at a 1/100 volume.  The cells were incubated, shaking at 37ºC, until an OD600 of 
about 0.6 (early to mid-log phase) was obtained.  The culture was placed on ice for 30 min, 
before the bacteria were pelleted by centrifugation at 5,000 × g for 15 min at 4ºC.  The 
supernatant was removed and the pellet resuspended in 200 mL of ice-cold mH2O.  The 
centrifuge process was repeated twice, with the cells firstly resuspended in 100 mL of ice-cold 
mH2O, then 10 mL of ice-cold 10% glycerol.  The cells were pelleted by centrifugation at 
16,000 × g for 2 min then resuspended in 400 µL of ice-cold 10% glycerol.  Aliquots of 40 µL 
were stored at −80ºC immediately. 
2.4.4.2 Electro-transformation 
The method supplied in the Gene Pulser apparatus user’s manual (BioRad) was utilised for 
electro-transformation of E. coli.  Frozen electro-competent cells were thawed on ice and 
mixed with up to 10 µL of DNA.  After sitting on ice for 1 min, the mixture was placed into a 
chilled 0.2 cm electroporation cuvette.  The sample was pulsed with settings of 2.5 kV, 25 µF 
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and 200 Ω.  Cells were gently resuspended in 1 mL of LB broth and incubated at 37°C for 
1 h.  The cells were then plated onto LB agar containing the appropriate selective agents. 
2.4.4.3 Chemical (heat shock) transformation 
Chemically competent InvαF’ and TOP10F’ cells were obtained from Invitrogen and stored at 
−80ºC.  The cells were thawed on ice for 15 min, mixed with up to 10 µL of a DNA and 
incubated on ice for a further 30 min.  The cells were then heat shocked in a 42ºC water bath 
for exactly 90 s, followed by cooling on ice for 2 min.  S.O.C. broth was added to a final 
volume of 1 mL and the cells incubated, shaking at 37ºC for 1 h.  Aliquots of 10-100 µL of 
transformed cells were plated onto LB plates containing appropriate selective agents. 
2.4.4.4 PEG-Bicine yeast transformation 
A 10 mL overnight culture of BJ3505 yeast was used to inoculate 100 mL of YPD.  The cells 
were incubated, shaking at 28ºC, until the absorbance measured at 600 nm (OD600) reached 
approximately 0.6.  Aliquots of 10 mL were pelleted by centrifugation at 5,000 × g for 2 min 
at RT, and resuspended in 5 mL SBEG.  After a further 2 min centrifugation at RT, the pellet 
was resuspended in 200 µL SBEG and incubated, shaking at 28ºC for 5 min.  About 1 µg of 
DNA was mixed with the cells, which were then further incubated at 28ºC for 10 min, this 
time without shaking.  Cells were then placed at −80ºC for at least 20 min.  The cells were 
thawed with gentle agitation in a 37ºC water bath, then gently mixed with 1.5 mL PEG-bicine 
and incubated at 28ºC for 1 h without shaking.  The mixture was then combined with 2 mL 
NB buffer by inversion and the cells pelleted by centrifugation at 5,000 × g for 5 min at RT.  
Cells were resuspended in 500 µL NB buffer, with 100 µL aliquots lawn cultured onto the 
selective media, MM+UL.  Cultures were incubated at 28ºC for up to 7 days. 
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2.4.4.5 Blue-white screening 
The blue-white screening method was adapted from Sambrook and Russell (2001).  LB agar 
supplemented with 100 µg/mL ampicillin, had 40 µL of 100 mM IPTG and 40 µL of 
40 mg/mL X-gal spread onto the agar plate surface.  The plates were then left in darkness at 
room temperature for 30 min to allow the agar to absorb the liquid.   
Transformations (10 µL and 100 µL) were spread plated onto LB agar and incubated 
overnight at 37°C.  Due to the light sensitivity of X-gal, plates were incubated wrapped in 
foil.  Plates were kept at 4ºC for 2 h to allow proper colour development, before white 
colonies were selected for analysis. 
Cloning into the plasmids pBluescript and pCR®2.1 allowed for this method of screening.  
INVαF’ do not express the lac repressor, meaning IPTG was not required when plasmids 
were transformed using this strain.  IPTG was included for blue-white screening when using 
DH5α and TOP10F’ as both strains express the lac repressor. 
2.5 DNA methods 
2.5.1 Nucleic acid isolation 
2.5.1.1 RNA extraction (kit) 
Fluke RNA for reverse-transcription PCR was isolated using the RNAgents® total RNA 
isolation system (Promega) according to the manufacturer’s protocol with minor alterations.  
RNase-free molecular grade water (Sigma-Aldrich) was used and all materials and solutions 
were treated by adding DEPC to a final concentration of 0.1% and autoclaved under standard 
conditions.  All work was undertaken in a biological safety cabinet, class II.  Briefly, adult F. 
gigantica stored at −80°C, was placed in liquid nitrogen where it was pulverised using a 
mortar and pestle, then mixed with RNAgents® denaturing solution.  The sample was then 
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passed through a 25-gauge needle to break up clumps, and mixed with 2 M sodium acetate, 
pH 4.  PCI was added, and the tube chilled for 10 min, before phase separation by 
centrifugation at 10,000 × g for 20 min.  The top phase, containing RNA, was removed and 
mixed with an equal volume of isopropanol.  The RNA was then precipitated at −20°C for at 
least 30 min, before pelleting by centrifugation at 10,000 × g for 10 min.  RNA was then 
washed in ice-cold 75% (v/v) ethanol, air-dried and dissolved in molecular grade nuclease-
free water.  The RNA was treated with 10U RQ1 RNase-Free DNase (Promega) in 1× RQ1 
buffer for 30 min at 37°C.  The reaction was stopped by addition of RQ1 stop solution and 
DNase inactivated at 65°C for 20 min.  RNA was stored at −80°C. 
2.5.1.2 Chromosomal DNA extraction (kit) 
Chromosomal DNA was purified using the Wizard® genomic DNA purification kit as per the 
manufacturer’s protocol.  Briefly, adult F. gigantica stored at −80°C, was placed in liquid 
nitrogen and pulverised using a mortar and pestle.  The ground tissue was mixed with nuclei 
lysis solution/EDTA, and incubated with Proteinase K at 55oC for 3 h.  The sample was 
further incubated at 37°C in the presence of RNase.  Protein was then precipitated, and 
removed to a clean microfuge tube, where it was washed with 70% (v/v) ethanol, air-dried 
and dissolved in TE buffer overnight at room temperature.  Genomic DNA was stored at 
−20°C. 
2.5.1.3 Plasmid extraction (miniprep) 
Plasmids used in restriction digests were purified using the alkaline lysis method based on the 
protocol described in Ausubel et al., 1994) with minor alterations.  One and a half millilitres 
of an overnight culture was placed in a microfuge tube and pelleted in a centrifuge at 
16,000 × g for 2 min.  The media was removed and the bacterial pellet resuspended in 100 µL 
of plasmid isolation solution I, then left at room temperature for 5 min.  Cells were lysed by 
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the addition of 200 µL of plasmid isolation solution II.  After 5 min on ice, the addition of 150 
µL ice cold plasmid isolation solution III precipitated chromosomal DNA and protein.  The 
precipitate was pelleted by centrifugation at 16,000 × g for 10 min at 4°C and the supernatant 
transferred to a new microfuge tube.  Fifty microlitres of PCI was added to the supernatant 
and mixed by vortex.  The phases were separated by centrifugation at 16,000 × g for 2 min.  
The upper aqueous phase was collected and mixed with 50 µL of CI.  The solution was mixed 
and separated as before.  The aqueous phase was collected, with plasmid DNA precipitated by 
the addition of 900 µL of 96% ethanol.  After letting stand for 5 min, plasmid DNA was 
pelleted by centrifugation at 16,000 × g for 5 min and the supernatant decanted.  Two hundred 
microlitres of 70% (v/v) ethanol was added to the pellet, before the pellet was recovered by 
centrifugation at 16,000 × g for 5 min.  The supernatant was completely removed and the 
pellet air-dried before addition of 30 µL 10 mM Tris, pH 8.0 and stored at −20ºC. 
2.5.1.4 Plasmid extraction for sequencing 
Plasmid DNA required for sequencing was purified using the QIAprep® spin miniprep kit as 
per the manufacturer’s instructions.  Briefly, template DNA was loaded onto and bound to a 
QIAquick spin column.  The DNA was washed in the supplied wash buffer containing 
ethanol, then eluted in mH2O and stored at −20ºC. 
2.5.1.5 DNA extraction from agarose 
DNA was excised from the agarose gel and extracted using the GeneClean® kit according to 
the manufacturer’s instructions.  Briefly, 3 gel volumes of sodium iodide (6M) was added to 
the excised DNA, and the gel solubilised at 55ºC.  The sample was mixed with Glassmilk® 
and let stand for 5 min.  Glassmilk® was pelleted by centrifugation at 10,000 × g for 1 min and 
then washed in 500 µL NEW™ wash buffer.  The pellet was air-dried before resuspension in 
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sterile mH2O.  The Glassmilk® was pelleted by centrifugation and the supernatant, containing 
the DNA, was transferred to a new microfuge tube and stored at −20ºC. 
2.5.1.6 Purification of PCR product 
PCR product was directly purified using Wizard® PCR preps DNA purification kit as per the 
manufacturer’s protocol.  Briefly, PCR product was mixed with direct purification buffer and 
resin.  The mix was then passed through a minicolumn, washed in isopropanol and eluted in 
mH2O. 
2.5.1.7 Phenol extraction 
Sample was mixed with an equal volume of PCI.  The phases were then separated by 
centrifugation at 10,000 × g for 2 min and the upper aqueous phase collected.  The sample 
was then mixed with an equal volume of CI and the solution mixed and separated as before, 
with the upper phase collected.  
2.5.2 DNA Analysis 
2.5.2.1 λ-DNA marker 
A solution of 0.1 µg/µl digested λ-DNA was prepared by incubating 20 µg λ-DNA with 10 U 
PstI in 1× Buffer H and mH2O made up to 120 µL, at 37°C overnight.  Twenty microlitres of 
11× DNA loading buffer was then added to stop the digest, and mH2O was added to make the 
total volume 200 µL.  The marker was stored at 4ºC, with 10 µL used on a DNA agarose gel.  
A diagram of PstI digested λ-DNA is located in Appendix 1. 
2.5.2.2 Agarose gel electrophoresis 
Agarose gels ranging from 0.8-4.0% were used to separate and view DNA fragments.  Gel 
percentage was determined depending on the size range of the fragments.  DNA samples were 
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mixed with 11× loading buffer and underwent electrophoresis against an appropriate DNA 
marker in an adjacent lane.  Gels were run in 1× TAE electrophoresis buffer, at voltages 
ranging from 60 to 120 V.  Gels were stained with ethidium bromide (3 µg/ml) before 
destaining in running tap water.  The DNA products were visualised with an UV illuminator 
and photographed using a Biorad Geldoc imaging system running Quantity One software. 
2.5.3 Quantification of nucleic acids 
Two methods were used in the quantitation of nucleic acids.  For the exact quantitation of 
well-purified DNA or RNA, a spectrophotometer was used, and for approximate quantitation 
of DNA, DNA was separated on an agarose gel and compared to known standards of λ-PstI. 
2.5.3.1 Spectrophotometric quantitation of DNA/RNA 
DNA and RNA diluted in mH2O in quartz cuvettes had their concentration and purity 
estimated using a Varian CARY 50 Bio UV-visible spectrophotometer.  The absorbance was 
determined at wavelengths of 260 and 280 nm.  The concentration was calculated from the 
absorbance at 260 nm while the purity was checked using the absorbance ratio from 260/280 
nm.  One absorbance unit at 260 nm was considered equal to 50 µg of double-stranded DNA 
or 40 µg of single-stranded RNA.  A ratio between 1.7-2.0 was considered acceptable for 
DNA and RNA purity (Sambrook and Russell, 2001).  The purity of the DNA was also 
checked visually by electrophoresis on an agarose gel.   
2.5.3.2 DNA gel electrophoresis quantitation of DNA 
λ-DNA previously digested with PstI was separated on an agarose gel along with sample 
DNA fragments.  The quantity of DNA within each digested fragment of λ-DNA (Appendix 
1) was compared with intensities of unknown DNA samples. 
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2.5.4 DNA manipulation 
2.5.4.1 Restriction enzyme digests 
The restriction enzymes used throughout the study are listed in Table 2.4.  All restriction 
enzymes were purchased from Promega, USA or New England Biolabs, USA.  Restriction 
enzyme reaction conditions were as specified by the manufacturer.  In multi-enzyme 
reactions, buffer was chosen on the basis of maximum compatibility with all enzymes.  About 
1 µg of DNA was digested with 2 U of enzyme, in 1× buffer in a total volume of 10-20 µL at 
37°C for 1-20 h.  For reactions incubated for over 4 h, acetylated BSA was added to a 
concentration of 100 µg/mL.  When required, enzymes were heat inactivated at 65ºC for 20 
min.   
 
Table 2.4:  Restriction enzymes used throughout this study 
Restriction enzyme Restriction site 
BamHI …G▼GATCC… 
DpnI …GA▼TC… 
EcoRI …G▼AATTC… 
HincII …GTY▼RAC… 
KpnI …GGTAC▼C… 
NlaIII …CATG▼… 
Sau3AI …▼GATC… 
XhoI …C▼TCGAG… 
Where ▼ represents the point of cleave; and N = any, M =A or C, R = A or G, W = A or T, 
S = C or G, Y = C or T, K = G or T, B = not A, D = not C, H = not G, V = not T. 
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2.5.4.2 PCR .  
PCR was performed with either AmpliTaq polymerase, platinum® Taq polymerase, Pfu 
polymerase or Expand Long template PCR system, with the PCR performed according to the 
polymerase manufacturer’s instructions.   
The reagents were prepared in the sterility of a Biological Safety Cabinet, Class II.  A Perkin-
Elmer DNA Thermal Cycler or a ThermoHybaid gradient cycler was used to amplify the 
DNA.   
2.5.4.2.1 General PCR 
For general detection of fragments, PCR was prepared with platinum®- or Ampli-Taq 
polymerase, while Pfu polymerase was used for cloning.  The general reaction mix and 
programs used are listed in Table 2.5:  Standard reaction mix for PCR with Pfu polymerases 
 to Table 2.8, with specific conditions specified in the relevant chapters.  Template DNA was 
diluted in mH2O so that when 1 µL was added to a 25 µL PCR reaction mix the appropriate 
DNA concentration was obtained.  Approximately 10-100 ng of plasmid and chromosomal 
DNA were used as template DNA.  Reactions were prepared in a final volume of 25 µL, or in 
50 µL if a greater amount of amplified DNA was required. 
2.5.4.2.2 Inverse PCR 
Inverse PCR was performed with Pfu polymerase.  The general reaction mix and programs 
used are listed in Table 2.9 and Table 2.10, with specific conditions specified in the relevant 
chapters.    
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Table 2.5:  Standard reaction mix for PCR with Pfu polymerases 
PCR reagent Volume added Final concentration 
mH2O 18.8 µL N/A 
Pfu PCR reaction Buffer (10×) 2.5 µL 1× 
dNTP mix (10 mM)  0.5 µL 200 µM 
Sense primer (5 µM) 1 µL 0.2 µM 
Antisense primer (5 µM) 1 µL 0.2 µM 
DNA (variable) 1 µL 10-100 ng 
Pfu polymerase (3U/µL) 0.2 µL 0.6 U 
Total volume  25 µL 
 
Table 2.6:  Standard reaction conditions for PCR with Pfu polymerase 
Program Temperature Time cycles 
Initial denaturation 94°C 2 min 1 
Denaturation 94°C 30 s  
Annealing 45-60°C 30 s 25-35 
Extension 72°C 2 min/kbp  
Final Extension 72°C 2 min/kbp + 2 min 1 
Hold 4°C hold 1 
 
Table 2.7:  Standard reaction mix for PCR with Taq polymerases 
PCR reagent Volume added Final concentration 
mH2O 18.4 µL N/A 
Taq PCR reaction Buffer (10×) 2.5 µL 1× 
MgCl2 (50 mM) 1 µL 2 mM 
dNTP mix (10 mM)  0.5 µL 200 µM 
Sense primer (5 µM) 1 µL 0.2 µM 
Antisense primer (5 µM) 1 µL 0.2 µM 
DNA (variable) 1 µL 10-100 ng 
Taq polymerase (5U/µL) 0.1 µL 0.5 U 
Total volume  25 µL 
 
Table 2.8:  Standard reaction conditions for PCR with Taq polymerases 
Program Temperature Time cycles 
Initial denaturation 94°C 5 min 1 
Denaturation 94°C 30 s  
Annealing 45-60°C 30 s 25-35 
Extension 72°C 30 s/kbp  
Final Extension 72°C 30 s/kbp + 2 min  1 
Hold 4°C hold 1 
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Table 2.9:  Inverse PCR reaction mix 
PCR reagent Volume added Final concentration 
mH2O  34.5 µL N/A 
Pfu PCR reaction Buffer (10×) 5 µL 1× 
dNTP mix (10 mM)  2.5 µL 500 µM 
Sense primer (5 µM) 3 µL 0.3 µM 
Antisense primer (5 µM) 3 µL 0.3 µM 
DNA (variable) 1 µL  10-50 ng 
Pfu polymerase (3U/µL) 1 µL 3 U 
Total volume  50 µL 
 
Table 2.10:  Inverse PCR reaction conditions 
Program Temperature Time cycles 
Initial denaturation 94ºC 2 min 1 
Denaturation 94ºC 45 s  
Annealing 52-56ºC 45 s 30 
Extension 72ºC 17 min  
Final Extension 72ºC 20 min  1 
Hold 4ºC hold 1 
 
2.5.4.2.3 Reverse transcriptase PCR 
The ImProm II™ reverse transcription system (Promega) was used to construct cDNA from 
RNA according to the manufacturer’s protocol.  The reaction mix was made up in two parts, 
listed in Table 2.11 and Table 2.12.  The reaction conditions are stated in Table 2.13 
Table 2.11:  Reverse transcriptase PCR reaction mix part 1 
PCR reagent Volume added Final amount 
RNA (~2 µg/µL) 0.5 µL 1 µg 
PolyA-BamHI oligonucleotide (100 µM) 0.7 µL 0.5 µg 
Nuclease-free water Up to 5µL N/A 
Heat 70ºC, 5min.  Chill on ice for at least 5 min. 
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Table 2.12:  Reverse transcriptase PCR reaction mix part 2 
PCR reagent Volume added Final concentration 
Nuclease-free water 6.1 µL N/A 
ImProm-II™ 5× reaction buffer 4.0 µL 1× 
MgCl2 (25mM) 2.4 µL 3 mM 
dNTP mix (10 mM) 1.0 µL 0.5 mM 
Inhibitor 0.5 µL N/A 
ImProm-II™ reverse transcriptase 1.0 µL N/A 
Final volume  15.0 µL 
The two reaction samples were mixed giving a total volume of 20 µL. 
Table 2.13:  Reverse transcriptase PCR reaction conditions 
Program Temperature Time cycles 
Annealing 25ºC 5 min 1 
Extension 42ºC 60 min 1 
Reverse transcriptase inactivation  70ºC 15 min  1 
Hold 4ºC Hold 1 
The cDNA products were stored at −20ºC.  One microlitre of reverse transcriptase PCR 
product was used as template DNA in a 25 µL PCR reaction using Pfu polymerase.  Specific 
details are listed in the relevant chapter. 
2.5.4.2.4 Sequencing PCR 
DNA was amplified using the ABI Prism BigDye Terminator Cycle Sequencing Ready 
Reaction kit (Perkin-Elmer) using ¼ scale, with 200-300 ng of template DNA and 3 pmol of 
primer.  
Conditions for the sequencing PCR cycle run are described in Table 2.14.  The PCR product 
was cleaned according to the BigDye manufacturer’s protocol.  Briefly, the PCR product was 
transferred to a microfuge tube, and DNA precipitated by the addition of 0.1 vol of 3 M 
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sodium acetate and 2.5 vol of 95% ethanol.  The tube was vortexed briefly, then let stand for 
10 min before the DNA was pelleted by centrifugation at 16,000 × g for 20 min.  The DNA 
was washed twice in 70% ethanol with centrifugation at 16,000 × g for 5 min.  The sample 
was then air dried, with sequencing undertaken at Micromon DNA sequencing facility, 
Monash University (Clayton Campus), Victoria, Australia using the Applied Biosystems 
3730S Genetic Analyser.  Sequencing outputs were analysed using the software program 
ChromasPro (Technelysium Pty Ltd).   
Table 2.14:  Sequencing PCR reaction conditions 
Program Temperature Time Cycles 
Denaturation 96ºC 10 s  
Annealing 50ºC 5 s 25 
Extension 60ºC 4 min  
Hold 4ºC Hold 1 
 
2.5.4.2.5 Primers/oligonucleotides 
Primers were designed with the aid of Primer Designer 4, version 4.20 within the Sci Ed 
Central Program.  When possible, primers were designed to have guanine/cytosine (GC) 
content between 40-60% and a melting temperature (TmºC) greater than 50°C.  To facilitate 
cloning, restriction sites were incorporated into the design of certain primers.  When 
restriction sites were included, an additional 3 bp were added to the 5’ end of the primer to 
facilitate digestion of the resulting PCR product.  Primers were obtained as lyophilised 
samples from Invitrogen, Geneworks or Sigma.  Primers and there descriptions are found in 
the relevant chapters. 
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2.5.4.3 Alkaline phosphatase treatment of vector DNA 
Restriction-digested plasmids were treated with alkaline phosphatase to remove 5’ phosphate 
groups, minimising self-ligation.  Briefly, 0.25 U of calf-intestinal alkaline phosphatase in the 
supplied buffer was added to digested plasmid DNA, and incubated at 37°C for 45 min.  A 
phenol extraction was then undertaken as described in section 2.5.1.7. 
2.5.4.4 Kinase treatment of PCR products  
Prior to self-ligation, 150-250 ng of cleaned PCR amplified DNA was incubated with 20 U of 
T4 polynucleotide kinase (PNK), 40 µM ATP, 1× PNK buffer in a total volume of 50 µL.  
The reaction was incubated at 37°C for 4 h and then heat inactivated at 70°C for 10 min.  
2.5.4.5 Ligation 
Both sticky-end, and blunt-end ligations were undertaken on DNA using T4 DNA ligase.  The 
ligated DNA was then either purified or used directly in transformations. 
2.5.4.5.1 Sticky-end ligation 
Ligations were performed with a vector:insert ratio of 1:3 as determined using Equation 2.1.  
Ligation was undertaken in 1× ligation buffer with the addition of 2 U T4 ligase, in a total 
volume of 20 µL.  The reaction was incubated at 16°C for at least 16 h.  On occasions when 
digested DNA was ligated without initial purification, digested DNA never exceeded 40% 
(v/v) of the total reaction volume. 
Equation 2.1: ( ) ( ) ( )( ) 3  bp vector of size
bpinsert  of size
  ngDNA  vector  ngDNA insert ××=  
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2.5.4.5.2 Blunt-end ligation 
Blunt-end ligations were performed using PCR product from inverse PCR.  Cleaned (2.5.1.6) 
and kinase treated (2.5.4.4) inverse PCR product was self-ligated at room temperature 
overnight in the presence of 0.3 U/µL T4 DNA ligase in 1× ligase buffer as stated in Table 
2.15. 
Table 2.15:  Blunt end ligation reaction mix 
Reagent Volume Final amount 
Kinase treated inverse PCR product 20 µL N/A 
Ligase buffer (10×) 2.5 µL 1× 
T4 DNA ligase 2.5 µL 7.5 U 
Total volume 25 µL  
 
2.5.4.6 Purification of ligation DNA for electroporation 
DNA ligations were purified prior to electrotransformation to prevent arcing.  To the ligation 
mixture was added 0.04 vol of 10 mg/mL dextran, 0.1 vol of 3 M sodium acetate and 2.5 vol 
of 100% ethanol.  After mixing, the sample was left on ice for 15 min.  The precipitated DNA 
was then pelleted by centrifugation at 16,000 × g for 15 min at 4°C.  The sample was washed 
in 200 µL 70% ice-cold ethanol and the centrifugation process repeated.  The DNA pellet was 
air-dried then dissolved in 10 µL mH2O and transformed via electro-transformation. 
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2.6 Protein methods 
2.6.1 Protein quantitation 
2.6.1.1 Bradford Assay 
Protein determination was performed using the Bradford method (Bradford, 1976; Bollag and 
Edelstein, 1991).  One millilitre of Bradford reagent was added to 100 µL of sample, or 
standard.  This was mixed and allowed to stand for 5 min.  BSA was used as the standard 
protein solution, and where required samples and standards were diluted in 0.15 M NaCl.  
Two hundred microlitres of mixed sample was then added to the wells of a clear flat bottomed 
96-well microtitre plate.  The OD600 of the samples was determined with a Dynatech MR7000 
ELISA plate reader.  A standard curve, constructed by plotting the concentrations of the BSA 
standards (µg) versus absorbance, was used to determine the protein content of unknowns. 
2.6.2 Protein visualisation 
2.6.2.1 SDS-PAGE 
One-dimensional SDS-PAGE was performed using a discontinuous buffer system (Bollag and 
Edelstein, 1991).  The gels were prepared using SDS stacking gel buffer and SDS separating 
gel buffer.  Resolving gel percentage was determined depending on the size range of the 
protein fragments.  Proteins were mixed with SDS loading buffer and heated to 100ºC in a dry 
heating block for 10 min.  The proteins were separated in an electrophoresis unit (BioRad) 
containing SDS running buffer, by electrophoresis at 80 V for 30 min, then 180 V for 45 min 
or until the dye front reached the bottom of the gel.  Gels where then transferred onto 
nitrocellulose membranes for immunoblotting, or were stained using coomassie blue or silver 
stain.  The SeeBlue® or Mark 12™ protein standards were used to determination protein size 
(Appendix 1). 
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2.6.2.2 Native PAGE 
Native PAGE was prepared according to the methods in Bollag and Edelstein (1991).  Native 
PAGE gel stacking and separating buffers were used to prepare the polyacrylamide gel.  
Proteins were mixed with native sample buffer, loaded onto the gel and separated by 
electrophoresis for up to 2 h at 160 V at 4ºC in native PAGE running buffer.  Gels were then 
stained by coomassie blue or silver stain. 
2.6.2.3 Non-reducing SDS-PAGE 
The protocol for non-reducing page was similar to that of SDS-PAGE (2.6.2.1) with the 
exception that samples were mixed with non-reducing sample buffer and incubated 37ºC for 
15 min. 
2.6.2.4 Tris-tricine 
Tris-tricine SDS-PAGE was used to visualise proteins smaller than 15 kDa, using the method 
described by Ausubel et al. (1994) with some modification.  Gels were prepared using Tricine 
SDS-PAGE separating and stacking gel buffers.  Protein was mixed with Tris-tricine sample 
buffer and heated to 100ºC in a dry heating block for 10 min.  Proteins were separated in a 
mini gel apparatus (BioRad) with separate anode and cathode buffers at 80 V for 30 min, then 
180 V for 45 min or until the dye front reached the bottom of the gel.  Gels were stained using 
coomassie or silver stain. 
2.6.2.5 Gelatin gel 
Gelatin gels were adapted from the methods of Heussen and Dowdle, 1980) and Dalton and 
Heffernan, 1989).  Gels were made using gelatin gel buffer.  Samples were mixed with non-
reducing loading buffer and incubated at 37°C, 15 min.  Gels were run at 160 V, 2 h at 4°C in 
chilled SDS-PAGE running buffer.  After electroporesis, gels were soaked in 100 mL buffer 
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1, shaking at room temperature for 20 min.  The buffer was changed and incubation step 
repeated.  The gel was then soaked in 100mL buffer 2 for 5 min, shaking at RT.  The buffer 
was changed and the incubation repeated twice, with the final incubation step at 37°C for 12-
24 h.  Gels then underwent coomassie blue staining, with clearing indicating the presence of 
gelatinase activity. 
2.6.2.6 Coomassie staining 
PAGE gels were immersed in Coomassie blue staining solution for 30 min.  Gels were rinsed 
in mH2O, then submerged in the Coomassie destain solution until bands were appropriately 
resolved. 
2.6.2.7 Silver staining 
All silver stain steps were undertaken with gels shaking gently at room temperature, and was 
conducted according to the method of Bollag and Edelstein (1991) with slight variations.   
PAGE gels were fixed in silver stain fixing solution overnight, with a minimum of two 
solution changes.  Gels where then immersed in 50% (v/v) methanol for 30 min, followed by 
3, 10 min washes in mH2O.  The gels were transferred to a clean container and stained in 
freshly prepared silver staining reagent for 15 min.  Excess stain was removed by rinsing in 
mH2O five times over 10 min.  The gels were then developed in freshly prepared developing 
solution until desired clarity was obtained.  Development was stopped by rinsing in stop 
solution.  Gels were then washed for at least 1 h in mH2O. 
2.6.2.8 Immunotransfer 
Proteins resolved by SDS-PAGE gels were transferred by electrophoresis onto a 
nitrocellulose membrane, based on the method describe in Bollag and Edelstein (1991).  The 
gel and membrane were sandwiched between Whatman chromatography paper and scotch-
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brite pads and soaked in transfer buffer.  The proteins were then transferred onto the 
membrane at 100 V for 70 min in transfer buffer cooled with ice. 
2.6.2.9 Immunoblot  
Immunoblot was based on the method of Sambrook et al., 1989), with all incubations and 
washes performed on a shaker.  After immunotransfer, the nitrocellulose membrane was 
placed in blocking buffer for 1 h.  The membrane was washed twice in TBS, then incubated 
overnight at 4°C in rabbit anti-cathepsin L antisera diluted (1:5000) in blocking buffer.  The 
membrane was washed 2 times in TBS buffer for 10 min, then incubated with a Horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit antibody diluted 1:5000 in TBS containing 
1% skim milk for 2 h.  The membrane was washed 3 times for 5 min in TBS and the 
developed in darkness in the Western blot substrate solution for up to 30 min.  The reaction 
was stopped by washing in dH2O and the membrane then air dried.  
2.6.3 Protein Expression and Purification 
2.6.3.1 Supernatant concentration  
Culture supernatant was concentrated by passing through Vivaflow 50 filters (Sartorious), 
using the masterflex® pump system (Cole-Parmer).  Sample was passed through two 100,000 
MWCO cartridges connected in series.  The flow through was then continuously passed 
through two 10,000 MWCO cartridges connected in series until the retained sample volume 
was about 10% of the starting volume. 
2.6.3.2 Dialysis 
2.6.3.2.1 Preparation of dialysis tubing 
Dialysis tubing with a cutoff of 14 kDa was prepared according to Sambrook et al. (1989) and 
always handled with gloves.  The tubing was cut to a suitable length and boiled for 10 min in 
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2% (w/v) sodium bicarbonate, 1 mM EDTA, pH 8.0.  The tubing was rinsed in dH20, then 
boiled for 10 min in 1 mM EDTA, pH 8.0.  The tubing was stored in 1 mM EDTA, pH 8.0 at 
4°C.  Before use the tubing was washed inside and out with mH20. 
2.6.3.2.2 Dialysis procedure 
Prior to purification by IMAC the recombinant protein was extensively dialysed to remove 
any components that may have interfered with the binding of the protein to the IMAC matrix. 
The culture supernatant was placed in dialysis tubing, and the tubes sealed with clamps.  The 
tubes where then submerged in 5 L dialysis buffer for 1 L supernatant and incubated, stirring 
at 4°C.  The dialysis buffer was changed at least 4 times, a minimum of 4 h apart. 
Protein was also dialysed prior to activation.  Protein samples were dialysed against buffer A 
at 4°C, with 1L of buffer A for every 1 mL of sample.  A minimum of 4 changes were 
undertaken, at least 4 hours apart. 
2.6.3.3 Immobilised metal affinity chromatography (IMAC) 
General preparations are mentioned here, purification procedures for each protein are detailed 
in the appropriate sections. 
2.6.3.3.1 IMAC column preparation: 
Chelating sepharose fast flow was prepared according to the manufacturer’s instructions 
(Amersham Biosciences) using 1 and 5 mL gravity flow columns.  Once packed and washed 
with mH2O, the column was charged using half a column volume (CV) of 0.2 M nickel 
sulphate (NiSO4) solution.  The column was washed with at least 5 CV of 0.45 µm filtered 
mH2O and equilibrated with 5 CV of binding buffer.   
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2.6.3.3.2 IMAC purification 
Dialysed sample was made up to 25 mM NaH2PO4, 5 M NaCl, pH 7.6 using mixing buffer.  
Imidazole, pH 7.6, was added to a final concentration of 1-10 mM depending on the protein to 
be purified.  Any precipitate was removed at 15,000 × g, 10 min, then the sample was passed 
through a 0.45 µm filter to remove any particles capable of blocking the IMAC column.  Up 
to 2.5 L of dialysed sample was applied to the column using an ISCO Tris™ peristaltic pump.  
The column was washed with 10 CV of wash buffer, then the protein eluted with 10 CV of 
elution buffer.  One millilitre elution fractions were collected.  Column flow through was then 
passed through a second IMAC column and the process repeated.  Fractions were analysed 
using SDS-PAGE.  After analysis samples were pooled and mixed to 40% (v/v) glycerol.  
Samples were then dialysed immediately or stored at −20ºC. 
2.6.3.3.3 IMAC column cleaning and regeneration  
Gravity flow columns were re-used multiple times, and stripped and cleaned between each 
use to remove contaminants.  The Ni2+ was stripped with 2 CV 50 mM EDTA, 0.5 M NaCl, 
pH 7.0.  Cleaning in place involved the addition of 10 CV of 2 M NaCl, followed by 10 CV 
of 1 M NaOH, and finally 10 CV of 70% ethanol (v/v).  Columns were washed with mH2O 
between each solution   The sepharose was stored in 20% ethanol solution. 
2.6.3.4 Protein processing 
2.6.3.4.1 Buffer exchange and concentration: 
Solutions containing protein were concentrated using centricon centrifugal devices with 5 and 
10 kDa cut-off membranes, according to the manufacturer’s instructions.  Centricon devices 
were spun at 4,000 × g at 4ºC.  Buffer exchange of proteins was also done in the centricon 
devices.  Any remaining salts and metals were removed by continual concentration and 
dilution of the protein sample in the new buffer.  
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2.6.3.4.2 Processing in buffer A at various pH 
Proteins were dialysed in buffer A at pH 5.  Samples were then concentrated to less than 5% 
their initial volume, using 10 kDa MWCO centricons.  Aliquots of the concentrated proteins 
were then diluted into buffer A, with pH ranging from pH 4.0 to pH 5.5 in 0.25 increments.  A 
1 M cysteine stock, adjusted to the appropriate pH, was added to a final concentration of 10 
mM.  The total volume gave a protein concentration similar to that which was initially present 
prior to centricon concentration.  Samples were activated for 2.5 h at 37ºC.  Aliquots were 
taken prior to incubation, at 1 h and at the 2.5 h and mixed with SDS sample buffer and boiled 
for 10 min at 100ºC.  Samples were visualised on 12.5% SDS-PAGE to determine at which 
pH the protein was best processed.  
2.6.3.4.3 Activation for purification 
After dialysis and buffer exchange into buffer A at the appropriate pH, the enzyme was 
incubated at 37°C for 2.5 h in the presence of 10 mM cysteine, pH adjusted.  Processing was 
visualised on SDS-PAGE. 
2.6.3.5 Cation exchange chromatography 
Activated protein was purified by ion exchange on a Mono S HR 5/5 cation exchange column, 
running on an FPLC system (BioRad).  All buffers were degassed through 0.45 µm filters, 
and before samples were loaded onto the MonoS column they were spun at 5,000 × g for 15 
min at RT, to ensure no precipitate was loaded onto the column.  Protein in buffer A was 
passed over the column at a flow rate of 1 mL/min.  The column was washed with 5 mL 
buffer A.  Bound protein was eluted by the addition of buffer B, creating a linear gradient of 
0-500 mM NaCl over 2 mL, with a further 10 mL of buffer B run through the column to 
ensure all protein was eluted.  Five hundred microlitre fractions were collected.  The protein 
concentration of fractions coming off the MonoS column was monitored by spectroscopy. 
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Between purification of different proteins, the MonoS column was cleaned by conducting a 
wash run.  The wash run followed the same protocol as the purification run however, protein 
was replaced with buffer A, 1 M NaCl was used in buffer B, and flow through was 
immediately discarded. 
2.6.3.6 Fraction analysis 
Elution fractions from MonoS purification were analysed for activity using the synthetic 
substrates Z-FR-AMC or TGPR-AMC.  Briefly, 10 µL of fraction was mixed with 190 µL of 
20 µM substrate in enzyme buffer in a 96-well microtitre plate.  The resultant fluorescence 
was read using a Fluostar fluorometric microtitre plate reader.  Fractions were also analysed 
by electrophoresis on SDS-PAGE and visualised with coomassie blue or silver stain. 
2.6.4 Storage 
After purification, appropriate protein fractions were pooled then buffer exchanged and 
concentrated in buffer A using 5,000 MWCO Millipore centricon devices (2.6.3.4.1).  At least 
two buffer exchanges were undertaken.  Samples were kept in aliquots at −80ºC.  They were 
only thawed immediately prior to use, and kept on ice at all times.  Once thawed for enzyme 
studies, samples were only used once, any left over sample was not refrozen to be reused. 
2.6.5 Protease Assays with fluorogenic substrates  
2.6.5.1 Detection of activity against AMC fluorogenic substrates 
Buffers were pre-warmed for 5 min prior to enzymatic assays.  The release of the fluorogenic 
leaving group, 7-amino-4-methylcoumarin (AMC), was measured continuously at 37°C over 
a designated time period.  Synthetic substrate assays were performed in 200 µL or 100 µL 96 
well plates, read on a Fluostar fluorometric microtitre plate reader.  Excitation and emission 
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wavelengths were 370 nm and 460 nm, respectively.  Graphpad Prism 3 was used to analyse 
data. 
2.6.5.2 E64 active site titration 
The active site titration was based on the method of Barrett et al., 1982).  Enzymes were 
incubated in duplicate or triplicate, for 1 h at 37˚C with E-64 concentrations ranging from 0-
100 nM in enzyme buffer.  The substrates Z-FR-AMC or TGPR-AMC were then added to a 
final concentration of 10 µM.  The fluorescence was measured as stated in section 2.6.5.1.  
Graphpad Prism 3 was used to plot the activity (AFU/min) against the concentration of E-64.  
The linear portion of the plot was extrapolated to determine the x intercept, indicating enzyme 
concentration. 
2.6.5.2.1 AMC standard curve 
AMC was dissolved in DMSO and diluted to 0-10 µM in the appropriate assay buffer and 
appropriate concentration of DMSO.  Fluorescence was measured as stated in section 2.6.5.1. 
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3.1 Introduction 
Fasciola cathepsin L-like proteases have been shown through phylogenetic analysis to be 
divided into clades which are proposed to reflect their substrate specificity, most noticeably 
through the S2 subsite (Irving et al., 2003).  Amino acid residue 69 (aa69; mature cathepsin 
L5 numbering) has been shown to affect the S2 subsite architecture and influence enzyme 
specificity (Smooker et al., 2000).  While a majority of the Fasciola cathepsin L-like gene 
sequences deposited in public databases possess a leucine residue at aa69, sequences have 
also been isolated containing tyrosine and tryptophan at aa69.  
By virtue of codon usage, the presence of Fasciola cathepsin L-like proteases possessing 
other residues at aa69 would be expected to be present in Fasciola (Irving et al., 2003).  The 
generation of the Tyr69 codon requires 2 base substitutions from either the Trp69 or Leu69 
codons; other codons expected to be observed during the generation of these substitutions 
include those encoding phenylalanine (Phe, F), cysteine (Cys, C) and serine (Ser, S).  Several 
Phe69 CA1 protease sequences have been isolated from a number of organisms including the 
trematodes Paragonimus westermani and S. japonicum.  Since the start of this project 
Fasciola cathepsin L-like proteases possessing a Phe residue at aa69 have been discovered in 
both F. hepatica and F. gigantica.  A handful of cysteine proteases have been discovered that 
possess a serine residue at the equivalent to position 69, however none have been isolated 
from trematodes, while no Cys69 CA1 cysteine proteases have been isolated from any 
organism.  This has lead to the suggestion that such proteases may be structurally or 
functionally compromised. 
Mammalian lysosomal cathepsins along with several parasite cysteine proteases have been 
shown to autoprocess at low pH (reviewed in Wiederanders et al., 2003; Bromme et al., 
2004).  F. hepatica cathepsin L-like proteases appear to activate in a similar manner.  
Recombinant FhCatL1 has been shown to undergo autocatalytic processing at acidic pH in a 
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multistep process, that like recombinant human cathepsin L may involve both intra- and inter-
molecular processing (Yamasaki et al., 2002; Collins et al., 2004; Stack et al., 2007).  Like 
FhCatL1, recombinant FhCatL2, FhCatL5 and FgCatLB22 have all been shown to be able to 
autoprocess (Dowd et al., 1997; Smooker et al., 2000; Yamasaki et al., 2002), while 
recombinant FhCatL8 processes inefficiently (Harmsen et al., 2004).  While the processing 
mechanisms of FhCatL1 have been studied, little has been undertaken in regard to processing 
of other Fasciola cathepsin L-like proteases. 
Autoprocessing of recombinant cathepsin proteases has been shown to be influenced by 
glycosaminoglycans (GAGs) and polysulphated polysaccharides (PSPs).  These polyanionic 
molecules can significantly influence the autoprocessing of cathepsin proteases (Mach et al., 
1994a; Ishidoh and Kominami, 1995; Barlic-Maganja et al., 1998; Almeida et al., 1999; 
Vasiljeva et al., 2005; Beckham et al., 2006). 
The functional expression of recombinant Fasciola cathepsin L-like proteases, belonging to 
clades other than that of FhCatL1, will enable their processing mechanisms to be examined 
with specific regard to the effect of pH and dextran sulphate.  This will allow for comparison 
amongst the related proteases and provide a broader view of this divergent protein family.  In 
addition, the expression of recombinant FhCatL5 with defined substitutions at aa69 will be 
used to determine whether these substitutions result in active functional enzymes and what 
effects the substitutions have on autoprocessing.  The influence of the substitutions on 
substrate specificity of the active enzyme is discussed in chapter 4. 
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3.2 Materials and methods 
3.2.1 YEpFLAG constructs for recombinant cathepsin expression in yeast 
3.2.1.1 Supplied constructs 
Three previously constructed clones were provided for use in this study; pFLAGFhCatL5, 
pFLAGFhCatL5 L69Y and pFLAGFhCatL2 (Smooker et al., 2000).  The constructs encode 
the pro- and mature regions of Fasciola cathepsins, in addition to a polyhistidine-tag at the 
carboxy-terminus to facilitate purification.  All clones use the YEpFLAG shuttle expression 
vector; clone pFLAGFhCatL5 encodes the gene designated FhCatL5 and pFLAGFhCatL2 
encodes FhCatL2.  The construct pFLAGFhCatL5 L69Y encodes FhCatL5 in which a 
substitution at aa69 of leucine to tyrosine has been constructed (Smooker et al., 2000).   
3.2.1.2 Generating the pFLAGFgCatL1G construct 
A FgCatL1G allele was cloned from F. gigantica metacercariae into the pGEM T-easy vector 
and kindly provided by Dr Rudi Grams. 
Upon receiving the construct, it was electro-transformed into competent DH5α and the 
FgCatL1G nucleotide sequence determined with the primers M13-20 and M13 Reverse (Table 
3.1).  The gene was then amplified with the primers CatL1GF and CatL1GR (Table 3.2), to 
produce a 963 bp PCR product containing the FgCatL1G gene, flanked with XhoI restriction 
sites and containing a C-terminal His-tag and stop codon.  The PCR was undertaken using Pfu 
polymerase with an annealing temperature of 50°C, and an extension time of 3 min.  Five 
microlitres of PCR product was visualised on a 1% agarose gel, with remaining PCR product 
cleaned using the Wizard PCR prep DNA purification kit (Promega, USA).  YEpFLAG 
previously isolated from DH5α using the alkaline lysis method and the purified PCR product 
were both digested overnight with 10 U XhoI.  Both samples were heat inactivated, and the 
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Table 3.1:  Designated sequencing primers 
Name Sequence 5'-3' Description 
CatL5seq1843 CTCAACAACAGGTGCTATGG Sequencing primer for FhCatL5 gene in YEpFLAG 
CatL2seq GCATTGACTGGCGTGACTAT Sequencing primer for FhCatL2 gene in YEpFLAG 
CatL2seqRev GGCCAGAGAAGCAATTCCAC Sequencing primer for FhCatL2 gene in YEpFLAG 
FLAGseqF1431 TTGCCAGCATTGCTGCTA Sequencing from YEpFLAG 
FLAGseqR1635 ACGCGTGTACGCATGTAA Sequencing from YEpFLAG 
M13-20 GTAAAACGACGGCCAGT Sequencing from pBluescript and pCR2.1 (Stratagene) 
M13 Reverse CAGGAAACAGCTATGAC Sequencing from pBluescript and pCR2.1 (Stratagene) 
Table 3.2:  Mutagenesis and cathepsin clone construction primers 
Name Sequence 5'-3' Description 
CatL5inverse GCATACGAATATTTGAAACGATTTG Primer for inverse PCR generation of pFLAGFhCatL5 mutants 
CatL5mut L69W ATTTTCCATCCATCCACCATTAC Mutagenesis primer for inverse PCR generation of pFLAGFhCatL5 L69W 
CatL5mut L69C ATTTTCCATACATCCACCATTAC Mutagenesis primer for inverse PCR generation of pFLAGFhCatL5 L69C 
CatL5mut L69S ATTTTCCATAGATCCACCATTAC Mutagenesis primer for inverse PCR generation of pFLAGFhCatL5 L69S 
CatL5mut L69F ATTTTCCATAAATCCACCATTAC Mutagenesis primer for inverse PCR generation of pFLAGFhCatL5 L69F 
CatL2inverse GCTTATGAATATTTGAAACACAACG Primer for inverse PCR generation of pFLAGFhCatL2 Y69L 
CatL2mut Y69L GTTTTCCATCAATCCTCCACCGC Primer for inverse PCR generation of pFLAGFhCatL2 Y69L 
CatL1GF CCGCTCGAGGATTTGTGGCATGAATGG Forward primer for construction of pFLAGFgCatL1G clone 
CatL1GR CCGCTCGAGTCAATGGTGATGGTGATGGT
GCGGAAATCGTGCCACCAT 
Reverse primer for construction of pFLAGFgCatL1G clone 
CatL1GRev TTCCATTCATGCCACAAATCC Primer for inverse PCR generation of pFLAGFgCatL1G C-79Y 
CatL1GmutC-79Y GCGAAAATACAATAAAGAATACAAC Mutagenesis primer for inverse PCR generation of pFLAGFgCatL1G C-79Y 
Restriction sites incorporated into primers are underlined and nucleotides generating substitutions are shaded grey. 
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digested plasmid was dephosphorylated with alkaline phosphatase.  The PCR product was 
then ligated into YEpFLAG without further purification.  The ligation reaction was cleaned 
and electro-transformed into competent DH5α cells.  Colonies isolated on LB plates 
containing ampicillin were cultured by shaking at 37°C overnight in LB broth containing 
ampicillin.  Plasmids were isolated and digested with 2 U XhoI for 4 h.  The presence of insert 
was determined by visualisation of samples with agarose gel electrophoresis.  The DNA 
sequence of the construct was confirmed with the primers FLAGseqF1431 and 
FLAGseqR1635 (Table 3.1).  The FgCatL1G allele provided for use in this study has several 
synonymous and nonsynonymous substitutions compared to the FgCatL1G database sequence 
(GenBank Acc. No. AF419329).  These differences are discussed later.  The construct was 
then transformed into BJ3505 using the PEG-bicine method to allow for recombinant protein 
expression.   
3.2.1.3 Generating substitutions into clones using inverse PCR. 
Inverse PCR was used to introduce defined substitutions to specific codons within the 
pFLAG-cathepsin constructs.  The codon encoding amino acid residue 69 in FhCatL5 and 
FhCatL2, as well as a substitution in the proregion of FgCatL1G were created by this method.  
Pfu polymerase was used in the PCR to allow for the direct blunt-end self-ligation of the PCR 
product.  An overview of the cloning process is shown in Figure 3.1. 
FhCatL5 possesses a leucine residue at aa69.  For this study, substitutions were introduced 
using inverse PCR, changing the leucine to tryptophan (W), cysteine (C), serine (S) or 
phenylalanine (F).  The FhCatL2 gene has a tyrosine residue at aa69; in this study a 
substitutions generating a leucine residue was created.  A cysteine residue in the proregion of 
the FgCatL1G allele used in this study, situated 79 residues upstream of the pro-mature 
cleavage site was also substituted for a tyrosine residue (refer to section 3.3.1.2 for a brief 
explanation). 
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(A)           (B) 
 
 
 
 
 
 
 
Figure 3.1:  Diagrammatic representation of the introduction of defined substitutions using inverse PCR. 
(A) Diagrammatic overview of a typical YEpFLAG-cathepsin construct.  (B) The YEpFLAG constructs containing the cathepsin gene of interest were 
amplified using inverse PCR.  One of the primers possessed a mismatch which introduced specific substitutions into the amplified product.  The 
resulting PCR products which contained the defined substitution were then blunt-end ligated, and transformed into DH5α.   
Mismatch 
Amplification of 
construct by inverse PCR 
Blunt-end ligation of 
amplified construct 
possessing defined 
substitution 
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The primers used in inverse PCR (Table 3.2) were designed to introduce the specified 
substitution, allow for blunt-end ligation of the resulting PCR product and if possible 
restriction mapping identification of the mutant product.  S. cerevisiae codon usage was taken 
into account when designing primers; the most frequently used codon for the substituted 
amino acid was coded for in the primer (Table 3.3).  An exception was the tyrosine 
substitution generated in the proregion of FgCatL1G, where an alternate codon was used.  The 
codon TAC was used rather than TAT, as it was present in the FgCatL1G database sequence 
and required only one nucleotide substitution rather than two. The specific details for the 
individual inverse PCR conditions are listed in Table 3.4. 
Amplified inverse PCR product was visualised by agarose gel electrophoresis.  The remaining 
PCR product was then cleaned using the Wizard® PCR prep DNA purification kit and 
visualised on an agarose gel to determine the amount of PCR product present.  Samples were 
then treated with kinase at 37°C for 4 h to phosphorylate 5’ ends.  The kinase was heat 
inactivated at 70°C for 10 min before the sample was cooled and blunt-end ligation was 
performed without further purification.  No additional ATP was required to facilitate the 
blunt-end ligation due to its continued presence from the kinase treatment.  Ligation was 
undertaken at room temperature overnight.  The ligase was heat inactivated at 75°C for 10 
min.  Up to 25 µL of heat treated ligation product was made to 50 µL in the presence of 10 U 
of DpnI in restriction enzyme buffer B (Promega), and incubated at 37°C for 4 h.  The 
restriction enzyme DpnI recognises the nucleotide sequence GATC, but requires N6-
methylation of the adenine residue for activity.  Thus DpnI treatment cleaves any remaining 
template DNA, leaving the amplified PCR product intact.   
The self-ligated PCR product was cleaned using sodium acetate and dextran prior to electro-
transformation and subsequently transformed into electrocompetent DH5α.  Transformed 
cells were plated onto LB plates containing ampicillin as the selective agent.   
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Table 3.3:  Codon frequency in S. cerevisiae 
Amino Acid Codon Frequency 
Phenylalanine TTT 0.58 
 TTC 0.42 
Tryptophan TGG 1.00 
Cysteine TGT 0.64 
 TGC 0.36 
Serine TCG 0.09 
 TCA 0.21 
 TCT 0.27 
 TCC 0.16 
Tyrosine TAT 0.56 
 TAC 0.44 
Leucine TTG 0.30 
 TTA 0.28 
 CTG 0.11 
 CTA 0.14 
 CTT 0.12 
 CTC 0.05 
For each amino acid listed, the codon with the highest frequency is highlighted in grey. 
Note:  Data produced by J. Michael Cheery using the GCG program CodonFrequency using 
data taken from ORFs assigned a gene name within the Saccharomyces genome database 
(SGD) as of January 1999.  SGD: http://genome-www.stanford.edu/saccharomyces. 
 
Table 3.4:  Specific inverse PCR conditions 
Construct Template DNA Primers Annealing 
temp. 
Elongation
time 
pFLAGFhCatL5L69W pFLAGFhCatL5L69Y CatL5inverse and 
CatL5mutL69W 
52°C 17 min 
pFLAGFhCatL5L69C pFLAGFhCatL5L69Y CatL5inverse and 
CatL5mutL69C 
52°C 17 min 
pFLAGFhCatL5L69S pFLAGFhCatL5L69Y CatL5inverse and 
CatL5mutL69S 
52°C 17 min 
pFLAGFhCatL5L69F pFLAGFhCatL5L69Y CatL5inverse and 
CatL5mutL69F 
52°C 17 min 
pFLAGFhCatL2Y69L pFLAGFhCatL2 CatL2inverse and 
CatL2mutY69L 
56°C 18 min 
pFLAGFgCatL1GC-79Y pFLAGFgCatL1G CatL1gRev and 
CatL1gmutC-79Y 
55°C 18 min 
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Isolated colonies were incubated and shaken overnight at 37ºC in LB broth containing 
ampicillin.  Plasmids were isolated using the alkaline lysis method and digested overnight in 
the presence of either NlaIII or HincII. 
When generating FhCatL5 constructs, pFLAGFhCatL5 L69Y isolated by the alkaline lysis 
method from DH5α was used as template DNA (Table 3.4).  This allowed for screening of 
clones by restriction mapping with the restriction enzyme NlaIII, as the NlaIII restriction site 
was destroyed when the substitutions were made.  Generation of pFLAGFhCatL2 Y69L and 
pFLAGFgCatL1G C-79Y constructs did not result in the creation or removal of suitable 
restriction sites so clones could not be screened by this method.  Instead, clones were digested 
with HincII and the banding profile visualised to ensure that the complete plasmid was 
present. 
Clones with a restriction pattern suggesting the presence of the correct constructs were 
repurified using QIAprep® spin miniprep kit and had their nucleotide sequence determined by 
DNA sequencing.  The sequencing PCR used the primers listed in Table 3.1.  More 
specifically, primers CatL5seq1843, FlagKpn or CatL5Rev were used with FhCatL5 mutant 
constructs, primers CatL2seq and CatL2seqRev were used with the pFLAGFhCatL2 Y69L 
construct, and FLAGseqF1431 and FLAGseqR1635 were used with the pFLAGFgCatL1G C-
79Y construct.  Once the presence of the defined substitution was confirmed, the plasmids 
were transformed into BJ3505 using the PEG-bicine method and selected for using minimal 
media plates containing uracil and lysine (MM+UL). 
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3.2.2 Protein expression 
3.2.2.1 Small scale expression  
To confirm transformation and expression of the recombinant protein by BJ3505, as well as 
determine which clones produced the highest amount of recombinant protein, at least six 
colonies were picked from the MM+UL plates and batch screened. 
3.2.2.2 Batch screening 
Small scale cultures were screened for expressed protein by IMAC batch purification.  Fifty 
millilitres of YPHSM inoculated with 5 mL MM+UL culture (incubated at 28ºC for 72 h), 
was itself incubated at 28ºC for 72 h with vigorous shaking.  One and a half millilitres of 
culture underwent centrifugation at 16,000 × g, 2 min.  The culture supernatant was kept, with 
1.35 mL mixed with 150 µL of mixing buffer.  The preparation was then incubated with 50 
µL of charged chelating sepharose™ fast flow previously equilibrated in wash buffer.  After 
30 min shaking at RT, the mixture underwent centrifugation at 10,000 × g, 30 s.  The 
supernatant was discarded and the resin washed by resuspension in 1 mL wash buffer and 
centrifugation at 10,000 × g, 30 s.  The wash step was repeated twice.  The resin was then 
mixed with an equal volume of 100 mM EDTA and let stand for 10 min at RT.  The sample 
was spun at 10,000 × g, 30 s, and the supernatant retained for visualisation on SDS-PAGE 
and quantitation by Bradford assay.  A glycerol stock was made from the isolate with the 
highest expression level.  This stock was used for all subsequent expression and purifications 
of that particular recombinant enzyme. 
3.2.2.3 Protein induction 
An analysis was undertaken to determine optimum conditions for protein induction using 
small scale protein expression in a method similar to batch screening.  The appropriate 
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glycerol stock was used to inoculate 10 mL of MM+UL culture, which was incubated at 28ºC 
for 72 h.  Five milliltres of the MM+UL culture was used to inoculate 50 mL of expression 
media (YPHSM).  The YPHSM was then incubated at 28ºC for 120 h with vigorous shaking.  
The YPHSM media was adjusted to and maintained at a set pH, ranging from pH 4 to pH 9, 
with or without 25 mM NaH2PO4 acting as a buffer.  The pH of the media was monitored 
every 12 h and adjusted with either 10 M NaOH or concentrated HCl.  Media samples were 
collected every 24 hours, yeast separated at 16,000 × g for 2 min, and the supernatant 
aspirated and frozen at −20ºC.  At the completion of the incubation, the samples were thawed 
and 1.35 mL was mixed with 150 µL of mixing buffer.  The preparation was then incubated 
with 50 µL of charged chelating sepharose™ fast flow in a manner similar to that described 
during batch screening.  The protein stripped from the column with EDTA was retained for 
visualisation on SDS-PAGE and quantitation by Bradford assay. 
3.2.3 Large scale expression and protein purification 
3.2.3.1 Expression 
The yeast was initially grown in MM+UL to ensure only recombinant clones were present.  
The yeast was then induced to express recombinant protein through ethanol activation of the 
yeast alcohol dehydrogenase isoenzyme II (ADH2) gene promoter through incubation in 
YPHSM media.  Yeast expression in YPHSM was undertaken 2 litres at a time, as this was 
the upper level of the laboratory limits. 
3.2.3.2 Protein expression 
Recombinant yeast was inoculated into 200 mL of MM+UL.  The media was incubated by 
shaking for 72 h at 28˚C.  The yeast were pelleted at 5,000 × g, 10 min and inoculated into 
2 L of YPHSM.  The YPHSM was then incubated by shaking for 72 h at 28˚C.  The ADH2 
promoter is tightly repressed in the presence of dextrose.  The yeast cells were grown in the 
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presence of dextrose which was consumed during yeast metabolism, eventually reaching a 
level at which it no longer repressed the ADH2 promoter and the recombinant protein was 
produced. 
3.2.3.3 Protein Purification 
The cells were collected at 10,000 × g, 10 min and the supernatant removed for further 
processing.  Initially the supernatant was concentrated through Vivaflow 50 filters and then 
dialysed against 100mM NaCl (2.6.3.1).  Protein purification undertaken later in the study 
dispensed with this concentration step, proceeding directly to dialysis (2.6.3.2).  This sped up 
the purification process, leading to less protein degradation.  After dialysis, protein was 
filtered to remove any particulate matter and purified by IMAC purification (2.6.3.3).  Sample 
generally passed through the column at about 1.5 mL/min.  Samples containing recombinant 
FhCatL5, FhCatL2 and their derived mutants were loaded and washed with 10 mM imidazole.  
The recombinant proteins FgCatL1G and FgCatL1G C-79Y were loaded and washed with 1 
mM imidazole.  All proteins were eluted in 250 mM imidazole.  A significant amount of 
protein failed to bind to the column during initial purification, so flow-through from the 
column purification was passed through a second 5 mL IMAC column.  Elution fractions 
from both columns were quantified by Bradford assay and visualised by SDS-PAGE.  
Samples containing sufficient amounts of purified recombinant protein were pooled and made 
up to 40% glycerol.  Samples were then stored at −20°C until they were to be activated. 
3.2.4 Protein processing 
3.2.4.1 pH profiles of Fasciola cathepsin autoprocessing 
Proteins were dialysed in buffer A at pH 7.  Samples were then concentrated to less than 5% 
their initial volume, using 10 kDa MWCO centricons.  The proteins were incubated at a 
concentration of 200 nM at pH values between 3.1 and 9 in AMT buffers containing 10 mM 
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cysteine with and without 20 µg/mL of dextran sulphate.  Samples were taken at time points 
over 4 h and measured for activity against 10 µM Z-Phe-Arg-AMC or Tosyl-Gly-Pro-Arg-
AMC in 1× enzyme buffer at 37ºC.  Processing was also followed by SDS-PAGE, with 
samples taken at 1, 30, 60 120 and 240 min, immediately mixed with 5× SDS loading buffer 
and heated at 100ºC for 10 min.  The optimal processing conditions were determined by 
observing a decrease in the molecular weight of the enzyme to the approximate predicted size 
of the mature protease and an accompanying increase in enzymatic activity. 
3.2.4.2 Autoprocessing in the presence of dextran sulphate 
Proteins were dialysed and prepared as stated in Section 3.2.4.1.  The proteins were incubated 
at a concentration of 200 nM in 1× AMT buffer, pH 5.0 containing 10 mM cysteine with 
0-1000 ng/mL of dextran sulphate.  Five microlitre samples were taken at 30 min and diluted 
to 100 µL in 1× enzyme buffer and assayed for activity against 10 µM Z-Phe-Arg-AMC or 
Tosyl-Gly-Pro-Arg-AMC at 37ºC.  Processing was also followed by SDS-PAGE, with 
samples immediately mixed with 5× SDS loading buffer and heated at 100ºC for 10 min.  The 
optimal conditions were determined by observing a decrease in the molecular weight of the 
enzyme to the approximate predicted size and an accompanying increase in enzymatic 
activity. 
3.2.4.3 Intra- versus inter-molecular processing mechanisms of FhCatL5. 
Recombinant FhCatL5 at concentrations ranging from 20 nM to 500 nM was incubated for 0, 
20, 40, 60, 90 and 180 min at 37°C in 1× AMT buffer containing 10mM cysteine, pH 5.  
Samples were assayed simultaneously for activity against 10 µM Z-Phe-Arg-AMC in 
1× enzyme buffer with 10mM cysteine at 37°C.  Each well contained the same amount of 
enzyme. 
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3.2.5 Protease Assays  
3.2.5.1 Gelatin Assay 
Gelatinase activity of proteases was performed using gelatin gels.  Proteins were run on a 
non-reducing gel containing gelatin (2.6.2.5).  Clearing of areas after coomassie blue staining 
indicated the presence of protease activity. 
3.2.6 Bioinformatics 
Amino acid and nucleotide alignments were undertaken with the program ClustalX 
(Thompson et al., 1997) and edited by eye where necessary.   
Homology modeling of the Fasciola cathepsin L-like proteases was based on the crystal 
structures of F. hepatica procathepsin L1 (PDB accession, 2o6x) and human cathepsin L 
(1cs8) which has ~50% identity to the Fasciola sequences.  Models were constructed and 
refined using MODELLER 9v2 (Sali and Blundell, 1993). 
The structures of ginger rhizome protease GP-II (1cqd); cathepsin K (1tu6) and cathepsin V 
(1fh0) were used to infer the orientation for tryptophan, tyrosine and phenylalanine at 
residue 69 of the Fasciola cathepsins.  CHARMm minimisation of side-chain torsions was 
then performed.   
The software programs Prosa2003 and Procheck 3.4 for Windows NT were used to assess the 
accuracy of the models by ensuring psi-phi angles occurred within acceptable regions of the 
Ramachandran plot and side chain clashes were minimal.  Stereochemistry of each model was 
checked and after refinement all residues were in allowed conformations. 
The models were visualised using the program Deepview v3.7 (Guex and Peitsch, 1997; 
http://www.expasy.org/spdbv/) which was used for superposition of models, building 
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electrostatic potential surface onto models and to qualitatively identify differences between 
the proteases. 
The program Compute pI/MW (Bjellqvist et al., 1993; Bjellqvist et al., 1994; Gasteiger et al., 
2005) in the Expasy suite of programs (http://au.expasy.org/tools/) was used to compute the 
theoretical molecular weight and the isoelectric point of proteins.  The web-based program 
ProtParam (Gasteiger et al., 2005; http://ca.expasy.org/tools/protparam.html) was used to 
calculate other theoretical physical and chemical properties for the protein sequences 
including their instability index (Guruprasad et al., 1990).   
SignalP 3.0 (Dyrlov Bendtsen et al., 2004; http://www.cbs.dtu.dk/services/SignalP/) was used 
to determine theoretical signal peptide cleavage sites for the Fasciola cathepsin L-like genes, 
for comparison with published data.   
Rare codons were those that appeared at a frequency of less than 5 per 1000 in S. cerevisiae, 
and sequences were analysed with a web-based program from ‘Practical Molecular Biology’ 
(http://molbiol.edu.ru/eng/scripts/01_11.html).   
Potential PEST (P, proline; E, glutamic acid; S, serine; and T, threonine) sequences were 
searched for using the web-based program PESTfind (Rogers et al., 1986; Rechsteiner and 
Rogers, 1996; https://emb1.bcc.univie.ac.at/toolbox/pestfind/).   
Relevant tools from the Expasy suite of programs were used to determine the presence of 
possible glycosylation sites in the recombinant proteins (http://au.expasy.org/tools/). 
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3.3 Results 
3.3.1 Construct development 
3.3.1.1 FhCatL5 and FhCatL2 constructs and development of pFLAGFgCatL1G 
The pFLAGFhCatL5 and pFLAGFhCatL2 constructs were not made in this study, being 
previously constructed and used to express recombinant protein in S. cerevisiae by Smooker 
and colleagues (2000).  Both clones contain a C-terminal 6 × His-tag and are directed to be 
secreted by the alpha factor pre-pro leader (Figure 3.2).  Different methods were used to 
construct the clones; as such they differ in the length of the partial FLAG epitope situated 
between the alpha factor leader sequence and start of the cathepsin gene sequence.  After 
cleavage of the alpha factor pre-pro leader region and secretion, rFhCatL5 possesses a shorter 
FLAG epitope than rFhCatL2 (Figure 3.3), with the partial FLAG epitope composed of only 8 
residues compared to 12 for rFhCatL2.  Here, rather than for its use in immunodetection, the 
FLAG epitope acts as a spacer sequence.  Spacer sequences have been shown to be 
advantageous when using the alpha factor leader for directing secretion of recombinant 
proteins in S. cerevisiae, facilitating efficient cleavage of the alpha factor leader sequence and 
minimising hyperglycosylation (Kjeldsen et al., 1996; Kjeldsen, 2000).  The N-terminal 
FLAG extensions were not expected to affect enzyme specificity as the proregion is cleaved 
during activation of the mature enzyme.  The effect of this N-terminal extension to protein 
processing is expected to be minimal, with modeling studies suggesting there is no interaction 
or secondary structure formation with the mature or propeptide regions of the recombinant 
protein.  Similarly the C-terminal 6 × His-tag is not expected to affect either processing or 
activity of the enzymes (Figure 3.4).  While unlikely, their influence particularly in regard to 
processing cannot be completely excluded. 
Primers for the amplification of the FgCatL1G gene sequence provided by Dr Rudi Grams 
were designed to amplify a PCR product spanning the same region as the cathepsin gene in 
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Figure 3.2:  Diagrammatic representation of pFLAG constructs.   
The constructs encode the pro- and mature regions of the cathepsin L genes, in addition to a 
carboxy-terminus polyhistidine tag.  The genes are inserted within the FLAG epitope, behind 
the ADH2 promoter and the α-factor signal sequence.  Other features of YEpFLAG are: AmpR 
and TRP1, which allow for selection in E. coli and S. cerevisea respectively, CYCI 
transcription termination and also the 2µ ori which allows for the replication of the plasmid in 
S. cerevisea. 
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Figure 3.3:  Amino acid sequences of recombinant proteins and database sequences.   
Recombinant expressed proteins are represented with an ‘r’ preceding the protein name, 
database sequences have no such designation.  Regions shaded dark grey represents conserved 
residues.  Boxed regions represent; alpha-factor leader region (blue); partial FLAG epitope 
(brown); and Fasciola putative signal sequence (purple).  The 6 × His-tag is shaded green.  
Residues that are not identical between the database sequence and recombinant protein used 
in this study are shaded light grey and boxed.  An arrow (►) indicates the start of the mature 
region. 
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Figure 3.4:  Molecular models of recombinant expressed Fasciola cathepsins. 
The molecular surface is mapped onto the mature region of the protein, while the proregion is represented as a ribbon model.  Surface exposed residues 
different from database sequences are coloured turquoise and labelled by single letter code and residue number.  The 6 × His-tag is coloured green, and 
the partial FLAG epitope present after secretion is brown.   
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the pFLAGFhCatL2 clone (Smooker et al., 2000).  The resultant 963 bp PCR product 
contained the FgCatL1G gene with a C-terminal 6 × His-tag and stop codon.  The sequence 
was flanked with XhoI restriction sites, allowing insertion into the YEpFLAG plasmd.  This 
created the clone pFLAGFgCatL1G (Figure 3.5). 
Upon ligation and transformation into DH5α, nucleotide sequencing revealed the gene was 
ligated in the correct direction, in frame with the vector start codon and encoded a 411 amino 
acid product.  The recombinant protein included the alpha-factor leader and a short (12 aa) 
segment of the FLAG epitope upstream of the propeptide, which spanned residues –88 to 219.  
The C-terminal 6 × His-tag sequence required for downstream processing was also present 
directly upstream of the stop codon (Figure 3.3).   
The alpha-factor pre-pro leader, which directs secretion of the recombinant proteins from the 
BJ3505 yeast cells, is cleaved during secretion.  For rFgCatL1G the resulting 326aa protein 
had a theoretical size of 37,766 Da, which compared with a size of approximately 38.5 kDa 
when calculated from its migration on SDS-PAGE.  The mature protein (assuming cleavage 
immediately prior to the DVPA motif) is composed of 226 amino acids with a theoretical 
molecular weight of 25,773 Da.  The secreted proenzyme of rFhCatL5 was expected to be a 
322 amino acid product with a theoretical molecular weight of 37,010 Da, with the 226 aa 
mature form MW expected to be 25,291 Da.  Secreted rFhCatL2 on the other hand was 326 aa 
in length and 37,483 Da, with the mature protein 25,335 Da.  Unexpectedly, when IMAC 
purified sample was analysed on SDS-PAGE under reducing conditions rFhCatL2 migrated 
faster, suggesting it is smaller in size.  Size estimates from SDS-PAGE were approximately 
38.5 kDa and 36.5 kDa for rFhCatL5 and rFhCatL2 respectively.  Clearly visible under both 
rFhCatL5 and rFhCatL2 IMAC purified proenzymes were three distinct bands (Figure 3.6).  
These bands were assumed to be partly processed enzyme, brought about by the slightly 
acidic environment of the expression media. 
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Figure 3.5:  Construction of pFLAGFgCatL1G.   
(A) Diagrammatic representation of pFLAGFgCatL1G. The pFLAGFgCatL1G construct encodes the pro- and mature regions of FgCatL1G spanning 
residues-88 to 219, in addition to a C-terminal polyhistidine tag and stop codon.  The gene is inserted within the FLAG epitope, with expression and 
secretion under the control of the ADH2 promoter and the α-factor signal sequence.  Regions homologous to the sequencing primers are designated 
with purple arrows. (B) Cloning of FgCatL1G into YEpFLAG. Lane 1, λ-PstI; Lane 2, PCR product of FgCatL1G. (C) Clone screening.  Lane 1, λ-
PstI; Lane 2, pFLAGFgCatL1G clone digested with XhoI.  
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Figure 3.6:  IMAC purified recombinant cathepsins. 
(A) Lane 1, Mark12 standard; Lanes 2-7, rFhCatL5 and derived mutants; Lanes 8-9, 
rFhCatL2 and rFhCatL2 Y69L; Lane 10, rFgCatL1G.  (B) Lane 1, rFhCatL5; Lane 2, Mark12 
standard.  (C) Lane 1, Mark12 standard; Lane 2, rFgCatL1G. 
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For rFhCatL5 these bands were estimated to be 31.5, 29.5 and 27 kDa.  The three bands 
below the unprocessed rFhCatL2 migrated slightly differently, with estimated sizes of 31, 29 
and 27 kDa.  Only two bands were visible underneath the unprocessed rFgCatL1G after 
IMAC purification.  These bands were 30 and 28.5 kDa in size when estimated by SDS-
PAGE under reducing conditions (Figure 3.6).  These bands were very faint for rFgCatL1G 
when compared to those observed with rFhCatL2 and rFhCatL5, suggesting that during 
expression and subsequent purification less rFgCatL1G was processed compared to rFhCatL2 
and rFhCatL5. 
Alignment of the recombinant protein sequences against their database sequences revealed 
several substitutions (Figure 3.3).  Three amino acid differences were seen between our 
FhCatL2 and the database sequence; however, each of the substitutions was represented in all 
other FhCatL2-like clade B cathepsins.  One was found in the C-terminal variable region of 
the proregion, slightly removed from an important processing site (Stack et al., 2007), while 
the other two residues were found in an area of positive selection that corresponds to patch II 
(Irving et al., 2003).  While the patch itself forms on a side of the active site cleft, these 
specific residues are located away from the cleft on the proteins surface (Figure 3.4). 
The conceptual translation of our FgCatL1G clone possessed four amino acid differences with 
the database sequence (Figure 3.3).  Three of these differences were in the mature region, 
only two of which were surface exposed.  None of these residues are thought to play a role in 
determining substrate specificity, with model studies indicating they are remote from the 
active site cleft (Figure 3.4). 
Due to the presence of the 6 × His-tag, the theoretical pI values of the recombinant proteases 
are slightly higher than their native counterparts (Table 3.5).  The presence of several 
substitutions between the sequences also has some effect on the predicted pI.  The largest 
variation is seen with mature rFgCatL1G (8.43), compared to mature FgCatL1G (6.98).  
Chapter 3: Cloning, expression and processing of recombinant Fasciola cathepsin L 
129 
 
 
 
 
Table 3.5:  Isoelectric points of cathepsin L-like proteases 
Name Genbank 
protein acc. no. 
pI 
(mature) 
pI 
(pro-mature) 
rFhCatL2 - 5.17 5.52 
FhCatL2 AAC47721 4.65 5.43 
FhCatL7 CAA80446 4.54 5.33 
FhCatL29 ABN50361 4.63 5.42 
FhCatL34 ABQ95351 4.59 5.33 
    
rFhCatL5 - 5.32 5.69 
FhCatL5 AAF76330 4.75 5.44 
FhCatL4 AAA29137 4.92 5.80 
    
rFgCatL1G - 8.43 5.97 
FgCatL1G AAL23917 6.98 5.68 
Mature: 0-219; Pro-mature: S-91 to 219; recombinant proteins also incorporate the 6 × his-
tag, and the FLAG epitope where applicable. 
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The difference is due to the 6 × His-tag and the amino acid substitutions present between the 
sequences.  With all proteins the presence of the 6 × His-tag and its effect on protein pI is not 
expected to significantly influence the enzyme studies undertaken. 
3.3.1.2 Introducing defined substitutions to constructs using inverse PCR. 
A number of mutant constructs were generated using inverse PCR, where an 8.1 kbp PCR 
product (Figure 3.7) was blunt-end ligated and transformed into DH5α.  FhCatL5, which 
normally possesses a leucine residue at aa69 had previously been mutated to possess a 
tyrosine at residue aa69 (FhCatL5 L69Y).  Four other defined substitutions were introduced to 
FhCatL5 at residue 69 to determine their effect on the subsite architecture, specifically 
through assaying enzyme specificity.  The leucine residue at aa69 was replaced with 
tryptophan, cysteine, serine and phenylalanine.  These constructs were designated 
pFLAGFhCatL5 L69W, pFLAGFhCatL5 L69C, pFLAGFhCatL5 L69S and 
pFLAGFhCatL5 L69F respectively. 
The use of pFLAGFhCatL5 L69Y as template for the inverse PCR meant that generation of 
the defined substitution removed an NlaIII restriction site, enabling restriction profiles to be 
used to screen for clones containing the correct constructs (Figure 3.7). 
The cathepsin FhCatL2 possesses a tyrosine residue at aa69.  Inverse PCR was used to mutate 
the tyrosine at aa69 to leucine.  The generation of the L69Y substitution in FhCatL5 has been 
shown to enable the protein to accept and cleave peptides that possess a proline residue at P2.  
Generation of the Y69L substitution in FhCatL2 would be used to determine if the reverse 
was also true, restricting the ability of the FhCatL2 variant to accommodate peptides with Pro 
at P2.  During inverse PCR, no acceptable restriction sites were created or removed to allow 
for screening by restriction mapping.  Therefore clones were screened by digesting with 
HincII to ensure the complete construct was present with no visible deletions (Figure 3.7). 
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Figure 3.7:  Inverse PCR generation of constructs.   
(A) Inverse PCR products.  Lane 1, λ-PstI; Lane 2, Inverse PCR product with pFLAGFhCatL5 L69Y as template; Lane 3, Inverse PCR product with 
pFLAGFhCatL2 as template. (B) Inverse PCR product.  Lane 1, λ-PstI; Lane 2, Inverse PCR product with pFLAGFgCatL1G as template.  
(C) NlaIII restriction mapping of FhCatL5 derived inverse PCR clones.  Lane 1, λ-PstI; Lane 2, pFLAGFhCatL5 L69Y; Lanes 3-5, 
pFLAGFhCatL5 mutant constructs produced by inverse PCR. (D) HincII restriction mapping of FhCatL2 and FgCatL1G derived inverse PCR 
mutant clones.  Lane 1, λ-PstI; Lane 2, pFLAGFhCatL2 Y69L; Lane 3, pFLAGFgCatL1G C-79Y.   
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The DNA sequence was then determined. 
The protein expression levels from pFLAGFgCatL1G were significantly lower than the levels 
obtained for the other constructs, with processing and activation initially very inefficient, as 
discussed later in this chapter.  Initially, one of the possible reasons for this was proposed to 
be as a result of incorrect protein folding and disulphide bond formation.  As mentioned, the 
FgCatL1G gene used in this study differs at several amino acid residues when compared to 
the database sequence.  While these substitutions may simply represent natural variations 
between different fluke populations, the possibility that they resulted from errors introduced 
by Taq polymerase during the initial isolation of the gene, prior to our receiving the construct 
was also considered.  When the FgCatL1G gene used in this study was compared against an 
alignment of all known Fasciola cathepsin L-like proteases it revealed that three of its four 
substitutions were observed in other clade A cathepsins, suggesting a natural origin.  
However, the cysteine residue at aa-79 in the proregion replaced a conserved tyrosine residue 
found in all known Fasciola cathepsin L sequences.   
It was thought that the cysteine at residue -79, while not in the vicinity of any disulphide 
bonds in the established protein structure, may interfere with disulphide bond formation 
during protein folding, leading to incorrect protein structure.  Analysis of cysteine proteases 
from other species revealed that this cysteine residue is conserved as an aromatic amino acid, 
with histidine, tyrosine or phenylalanine present in almost all sequences analysed (none 
contained cysteine).  The residue may participate in a stacking interaction with the tryptophan 
at residue -83 Hunter et al., 1991, alternatively the residue is in the vicinity of the conserved 
GNFD motif, with which it may interact.  In either case, the interactions may help maintain 
proenzyme structure, with the presence of the cysteine playing a role in destabilising the 
protein.  Comparison of reducing and non-reducing migration through SDS-PAGE with 
purified rFgCatL1G, rFhCatL2 and rFhCatL5 showed that while both rFhCatL2 and rFhCatL5 
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migrated as a lower band when run on a non-reducing gel compared to a reducing gel, no such 
drop was observed with rFgCatL1G (data not shown).  This suggested that similar disulphide 
bonds were not being formed.  As such, the cysteine residue at aa-79 was assumed to be 
brought about by a cloning error rather than natural variation, and was substituted via inverse 
PCR into a tyrosine residue.  Using the pFLAGFgCatL1G construct as template, the 
substitution was introduced using the primers CatL1gRev and CatL1gmutC-79Y.  Restriction 
mapping with HincII was used to ensure the complete construct was present with no visible 
deletions (Figure 3.7), and the DNA sequence was then determined.  The new construct was 
labelled pFLAGFgCatL1G C-79Y, with the resulting recombinant protein designated 
rFgCatL1G C-79Y.   
Purification levels of rFgCatL1G C-79Y were only marginally better than for rFgCatL1G, and 
analysis indicated it also did not appear to form disulphide bonds (Figure 3.8).  However, it 
was later determined that dialysing the enzyme in an acidic buffer resulted in the generation 
of what appeared to be partially processed protein, and resulted in the pro-enzyme migrating 
in a manner similar to rFhCatL2 and rFhCatL5 under non-reducing conditions (Figure 3.8).  
The rFgCatL1G protein was also found to behave in a similar manner when exposed to the 
same dialysis conditions, suggesting that the C-79 residue was not responsible for the poor 
expression and processing observed.  The dialysed recombinant protein was then able to be 
processed (3.3.4).  This indicates that rFgCatL1G and its variant appears to require an acidic 
pH to fold into a functional conformation. 
The amino acid alignment in Figure 3.9 shows all Fasciola cathepsins expressed in this study, 
highlighting the substitutions introduced by inverse PCR. 
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Figure 3.8:  Migration comparison with reducing and non-reducing SDS-PAGE.   
(A) Reduced and (B) non-reduced samples.  Lane 1, Mark12 standard; Lane 2, rFhCatL2; 
Lane 3, rFhCatL5; Lane 4, rFgCatL1G C-79Y; Lane 5, rFgCatL1G C-79Y post dialysis prior 
to activation. 
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Figure 3.9:  Alignment of secreted recombinant proteins used in this study.   
Recombinant mutant proteins are aligned against their ‘parent’ protein, with defined 
substitutions introduced by inverse PCR boxed and coloured.  Dark grey and light grey 
shading represent levels of conservation.  The 6 × His-tag is shaded green, the partial FLAG 
epitope is shaded pink.  Amino acids encoded by rare codons in yeast are in bold type. 
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3.3.2 Recombinant protein expression and purification 
The recombinant proteins were isolated by utilising a C-terminal 6 × His-tag, allowing 
purification by affinity chromatography using nickel IMAC columns, as described in 3.2.3.3.  
All recombinant proteins were able to be expressed in yeast and purified by this method 
(Figure 3.6).  Optimum expression was found between 72 and 96 h post YPHSM inoculation, 
which was consistent with a previous report of recombinant Fasciola cathepsin expression 
using this expression system (Irving, 1997).   
A typical purification elution is shown in Figure 3.10, with confirmation of expression and 
purification of rFhCatL5 and its mutants obtained by recognition with anti-FhCatL5 rabbit 
polyclonal antisera.  Purified samples were visualised as two bands, consisting of unprocessed 
and processed enzyme. 
Typically the protein was purified in the presence of 10mM imidazole, to minimise non-
specific binding of yeast proteins.  This also caused a considerable amount of recombinant 
protein to pass through the column without binding, thus the flow through from the original 
IMAC purification was run through another IMAC column.  This resulted in a higher yield of 
protein obtained than from passing the sample through a column once.  IMAC purification of 
rFhCatL5 and rFhCatL2 resulted in yields of approximately 3.5 mg/L and 3 mg/L 
respectively.  The purification levels of the cathepsin L5 and -L2 variants were similar to that 
of their respective parent recombinant proteins. 
The differences seen with purification levels between the rFhCatL5 and rFhCatL2 proteins are 
likely due to intrinsic factors of the proteins, although codon usage may also be a factor.  
However, the effect of the difference in length of the FLAG epitope cannot be discounted, 
with Kjeldsen and colleagues (1996, 2000) showing that the spacer region between the alpha-
factor leader and the protein can influence protein expression levels.   
Chapter 3: Cloning, expression and processing of recombinant Fasciola cathepsin L 
137 
 
(A)    1    2     3     4     5     6     7     8     9                 (C)                1          2        3       4      5 
 
 
 
 
(B) 
 
 
 
Figure 3.10:  Typical IMAC elution profile of rFhCatL5. 
(A) Recombinant protein eluted from an IMAC column with 250 mM imidazole, visualised 
by SDS-PAGE and coomassie blue stain.  Lanes 1-8, elution fractions 4-11; Lane 9, Mark 12 
standard.  (B) Elution fraction concentration as determined by Bradford method (µg/ml), and 
relative activity against Z-FR-AMC (AFU/min).  (C) IMAC purification of rFhCatL5 L69Y 
as detected by immunoblot using rabbit anti-FhCatL5 sera.  Lane 1, Seeblue protein standard; 
Lane 2, flow through; Lanes 3 and 4, wash fractions; Lane 5, elution fraction. 
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The expression level of rFgCatL1G was far lower than observed for the other recombinant 
cathepsins, with only 50 µg/L able to be purified.  Unfortunately, due to the low expression 
levels, and inadequate sensitivity of the antibody, experiments were not able to be performed 
to determine if the protein was being retained within the cells, rather than secreted.  As such 
attempts were made to increase purification levels by altering the expression environment.   
The purified rFgCatL1G was not processed upon purification, so processing and degradation 
were not thought to be implicated in the low yields.  This was supported by addition of E-64 
to 10 µM in the expression media which failed to increase the purification level, however low 
stability of E-64 in the media may also explain this result.  Maintaining the expression media 
pH between 7 and 8 resulted in purification of almost twice as much protein, possibly as a 
result of increased proenzyme stability at neutral pH.  
Despite this, levels of rFgCatL1G were still about 30-fold lower than the other recombinant 
cathepsins.  A number of theoretical determinants were obtained for rFgCatL1G and 
compared with the other recombinant proteases in an attempt to determine any major 
discrepancies that may explain the differences.  Analysis of codon usage in yeast showed that 
the gene encoding the secreted rFhCatL2 possessed 11 rare codons compared to 7 for 
rFhCatL5, and 10 for rFgCatL1G.  There was however no obvious grouping of the rare 
codons (Figure 3.9).  An analysis of the instability index of the secreted proteases showed that 
all were considered stable and no potential PEST motifs (high local concentrations of proline 
(P), glutamic acid (E), serine (S) and threonine (T) that reduce the half-lives of proteins) were 
identified.  While the instability indices for the secreted proenzymes and their processed 
counterparts indicated rFhCatL5 was the most stable, and rFgCatL1G the least stable, there 
was only a very small difference between FhCatL2 and FgCatL1G, which suggests that this 
instability was not the likely cause of the lower expression levels. 
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With the C-79 residue in the recombinant protein thought to play a role in destabilising the 
protein, and the extremely low expression levels obtained with rFgCatL1G and the initial 
problems associated with activation, clone rFgCatL1G C-79Y was constructed in a hope of 
rectify these issues.  The rFgCatL1G C-79Y clone was purified at levels slightly higher than 
the original clone, at about 200 µg/mL.  While around twice as much as rFgCatL1G, it was 
still well below other protein levels.  However, as a result of higher yields, all further studies 
with FgCatL1G were undertaken with rFgCatL1G C-79Y. 
To ensure maximum levels of protein were able to bind to the column, the purification of 
rFgCatL1G and rFgCatL1G C-79Y was undertaken with the addition of only 1mM imidazole 
to the sample and wash solution.  An extra buffer change during dialysis prior to IMAC 
purification was also undertaken to further remove any remaining expression media and 
contaminants that could affect binding. 
The expression and purification of the ortholog FhCatL8 in S. cerevisiae with a different 
expression system was not reported to produce low yields (Harmsen et al., 2004).  It appears 
that the expression system used in this study was not suited to expression of this particular 
protease.  However, work in our laboratory has shown that high levels of recombinant 
FgCatL1GC-79Y can be obtained using E. coli , although the protein is in an insoluble form 
(R. Jayaraj, personal communication). 
3.3.3 Recombinant protein processing 
It appeared from SDS-PAGE analysis that each of the recombinant proteins was capable of 
processing, with all shown to have what appeared to be mature processed protein migrating 
below the unprocessed protein.  This was consistent with other reports of recombinant 
Fasciola cathepsin L-like protease maturation upon purification from yeast (Dowd et al., 
1997; Roche et al., 1997; Smooker et al., 2000; Cornelissen et al., 2001; Collins et al., 2004).  
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The only Fasciola cathepsin L protease to date to not be processed upon expression in yeast 
was FhCatL8 Harmsen et al., 2004 an ortholog of FgCatL1G.  This lessened processing upon 
purification also occurred with rFgCatL1G and rFgCatL1G C-79Y, although faint bands 
corresponding to the expected size of the mature processed protease were visible, suggesting 
some processing had taken place, albeit to a small degree. 
The recombinant proteases were assayed for gelatinase activity by running a gelatin gel.  Each 
enzyme produced clearing in the gel, showing they possessed gelatinase activity (Figure 
3.11).  This signified that proteases were correctly folded and were capable of being 
processed into functionally active mature enzymes, including rFgCatL1G and the two 
rFhCatL5 variants, -L69C and –L69S. 
3.3.4 Autoprocessing of recombinant proteases 
To assess the autoprocessing ability of the recombinant proteases, they were incubated in the 
presence of cysteine at various pH values.  The proteases were first dialysed into an acetate 
solution to remove the IMAC purification buffer, as the proteases failed to activate in its 
presence.  The rFgCatL1G protease and C-79Y variant required more stringent dialysis 
conditions than the other proteases for processing to occur. 
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Figure 3.11:  Gelatin gel of recombinant FhCatL proteases.   
Lanes 1-6, rFhCatL5 and variants; Lane 7, rFhcatL2; Lane 8, rFhCatL2 Y69L; Lane 9, Mark 
12 protein standard; Lane 10, rFgCatL1G. 
The clearing observed with rFgCatL1G is lighter than with the other cathepsins due to less 
protein loaded onto the gel due to issues with purification quantities. 
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Autoprocessing was followed by analysis on SDS-PAGE, visualised by silver staining, and 
assays of enzymatic activity against Z-Phe-Arg-AMC at pH 5.5.  The assays each contained 
unprocessed sample, with some partially processed protein already present.  For rFhCatL5, 
rFhCatL2 and their respective variants, the unprocessed sample was present with one to three 
minor bands of apparently partially processed protein as mentioned previously.  However, 
after dialysis often only a single processed band, corresponding to the middle minor band was 
present at about 29.5 kDa (Figure 3.12).  For rFhCatL5, the processing was observed with the 
band at 38.5 kDa decreasing in intensity, while the band at 29.5 kDa increased in intensity.  
The accompanying increase in proteolytic activity suggested removal of the proregion.  If the 
processing was allowed to continue, further processing to produce a band at about 28 kDa 
occurred, suggesting sequential cleavage; however this cleavage step was not necessary for 
protein activation.  A sigmoidal increase in enzyme activity was observed during processing, 
which is suggestive of a bi-molecular process.  All the FhCatL5 variants processed in the 
same manner, with similar pH profiles.  Optimum processing occurred around pH 5.0 (Figure 
3.13), with processing occurring almost immediately upon incubation in the presence of 
cysteine.  Processing occurred at a slower rate at increasing pH values, and often did not 
continue to completion, while degradation of the proenzyme at more acidic pH was also 
evident. 
Processing with rFhCatL2, occurred in a similar manner, however optimum processing and 
the resulting increase in activity occurred at a slightly higher pH (Figure 3.13), with 
processing occurring optimally between pH 5.5 and pH 6.  Processed rFhCatL2 migrated 
slightly (0.5-1 kDa) faster than processed rFhCatL5.  This is similar to their respective 
proenzymes, where despite the theoretical molecular weights of the enzymes being very 
similar, rFhCatL2 migrates faster on SDS-PAGE.  
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Figure 3.12:  Autoprocessing of rFhCatL visualised on SDS-PAGE with silver staining.   
(A) Purified rFhCatL5 and partially processed rFhCatL5.  Lane 1, Seeblue protein standard; 
Lane 2, purified rFhcatL5; Lane 3, partially processed rFhCatL5.  (B) Progress of 
autocatalytic processing of rFhCatL5 L69F and rFhCatL2.  Lane 1, Seeblue protein standard; 
Lane 2, unprocessed rFhcatL5 L69F; Lane 3, partially processed rFhCatL5 L69F; Lane 4; 
processed rFhCatL6 L69F; Lane 5, unprocessed rFhCatL2; Lane 6, processed rFhCatL2. 
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Figure 3.13:  Characteristic autoprocessing of rFhCatL5 and rFhCatL2 across a pH 
range of 3.1-8.0.  
(A) rFhCatL5, and (B) rFhCatL2 processing in AMT buffer in the presence of 10 mM 
cysteine at varying pH.  Aligned against the Mark 12 standard and visualised on SDS-PAGE 
with silver staining.   
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Ultimately both rFgCatL1G and rFgCatL1G C-79Y were able to be processed; however 
processing only occurred after specific preparation conditions.  Dialysis was required to be 
undertaken at an acidic pH, and more buffer changes were required during dialysis than for 
the other proteases in the study or no processing was seen.  If dialysis was undertaken at pH 5, 
a more distinct ‘intermediate band’ was observed by SDS-PAGE and samples could be 
activated, however if dialysed at pH 7, even in the presence of an apparent processing 
intermediate, no processing occurred during the subsequent experiment.  For FgCatL1G, 
processing occurred optimally at pH 6 and 7 (Figure 3.14).  The 38.5 kDa unprocessed 
sample, and 30 kDa partially processed samples disappeared, resulting in the generation of a 
distinct 28.5 kDa band, and an increase in proteolytic activity.  The processing decreased with 
decreasing pH, until about pH 5, below which no processing was evident, although protein 
degradation was visible at these lower pH values.  It appears the enzyme requires two 
different environmental conditions for processing to occur efficiently.  Assuming the enzyme 
activates in a similar manner to other papain-like cysteine proteases; the first step, a 
unimolecular process, requires an acidic pH like other Fasciola cathepsin L-like proteases.  
Similar to other cathepsins it appears this is the rate limiting step, but unlike other Fasciola 
cathepsins appears to require far more stringent conditions as observed by the lack of 
processed sample upon initial purification from the expression media.  The second step, 
cleavage at the C-terminal end of the prodomain then requires a more neutral pH, either due to 
conformational demands with the proregion, or alternatively the active site requires a more 
neutral pH to ensure acceptable interaction between the active site and the C-terminal 
proregion cleavage site. 
This is the first Fasciola cathepsin shown to process most efficiently at neutral pH. 
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Figure 3.14:  Characteristic autoprocessing of FgCatL1GC-79Y across a pH range of 
3.1-8.0.   
Lanes 1-8, rFgCatL1G C-79Y processed at varying pH in AMT buffer containing 10mM 
cysteine at 37°C; Lane 9, Mark 12 standard.  Visualised on SDS-PAGE with silver staining.   
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3.3.5 Autoprocessing mechanism of rFhCatL5 
To establish the mechanism of autoprocessing, rFhCatL5 was pre-incubated at different 
concentrations at pH 5 in the presence of cysteine for up to 180 minutes.  The samples were 
then assayed for activity against Z-Phe-Arg-AMC.  The longer the pre-incubation time the 
greater the initial activity and the faster linearity in the release of fluorescence was reached, 
indicating all available sample was processed.   
The results show that linearity was reached more quickly by enzyme that was incubated at 
higher concentration (Figure 3.15), this suggests the rate of autoprocessing is dependant on 
the enzyme’s concentration, which is indicative of bi-molecular processing (Beckham et al., 
2006).   
3.3.6 The effect of dextran sulphate on rFhCatL5 autoprocessing 
Glycosaminoglycans (GAGs) and polysulphated polysaccharides (PSPs) are polyanionic 
molecules consisting of a sulphated polysaccharide backbone.  Several of these molecules 
have been shown to increase the processing and activity of mammalian and parasite 
cathepsins (Ishidoh and Kominami, 1995; Barlic-Maganja et al., 1998; Almeida et al., 1999; 
Beckham et al., 2006).  The effect that one such molecule, dextran sulphate has on the pH-
activity profile of recombinant Fasciola cathepsins L processing was determined by 
processing in its presence across the pH range of 3.1 to 8.0.  Previous reports studying the 
optimal dextran sulphate concentration for processing of several cysteine proteases used a 
range between 10 and 50 µg/ml (Kopitar et al., 1996; Barlic-Maganja et al., 1998; Rozman et 
al., 1999; Quraishi and Storer, 2001; Vasiljeva et al., 2005; Beckham et al., 2006).  For this 
study, 20 µg/ml of dextran sulphate was used.   
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Figure 3.15:  Mechanism of rFhCatL5 processing.   
Unprocessed rFhCatL5 was incubated at concentrations of (A) 20 nM; (B) 100 nM and (C) 
500 nM for 0, 20, 40, 60, 90, and 180 min at pH 5.0, prior to being assayed for activity 
against Z-Phe-Arg-AMC, with each assay containing the same amount of starting material.
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The presence of the dextran accelerated the processing of the rFhCatL5 enzyme (Figure 3.16).  
This effectively lead to a slight broadening of the pH at which the enzymes processed 
efficiently, from 4.5-5.5 to 4.0-6.0.  However, the enzymes processed in the presence of 
dextran sulphate, particularly at the lower pH ranges, were generally not as stable as those 
processed in its absence as shown in Figure 3.16.  The presence of 20 µg/ml of dextran 
sulphate did not lead to any discernable differences in the processing profiles of FhCatL2 or 
FgCatL1G (data not shown).   
The dose effect of dextran sulphate on recombinant Fasciola cathepsin L processing was 
investigated by incubating unprocessed sample in the presence of 0-1000 µg/ml of dextran 
sulphate at pH 5.0 for 30 minutes.  The level of processing was estimated by determining 
activity against Z-Phe-Arg-AMC.  A pH of 5.0 was used as the presence of dextran provided 
an increase in processing for almost all proteases tested at this pH. 
The activity of the proteases increased with higher dextran sulphate concentrations.  The 
effect of dextran was more pronounced with rFhCatL5 and variants when compared to 
rFhCatL2 and –L2 Y69L, while dextran sulphate only increased the activity of rFgCatL1G 
processing at the highest concentration tested.  For rFhCatL5, the most activity was seen in 
the presence of 50 µg/ml of dextran, past this concentration, as the dextran concentration 
increased, the level of activity decreased (Figure 3.17).  These results suggest that Fasciola 
cathepsin L processing can be influenced by interactions with dextran sulphate, however the 
level of the effect depends on the dextran concentration, pH of the environment and the 
cathepsin involved. 
While only the influence of dextran sulphate was analysed, naturally occurring GAGs 
including heparin, heparin sulphate and chondroitin sulphate have been shown to behave 
similarly to dextran sulphate in regards to influencing other cysteine proteases during 
processing, (Ishidoh and Kominami, 1995; Beckham et al.
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Figure 3.16:  Influence of dextran sulphate on the time course of processing of rFhCatL5 
L69C. 
(A) Enzyme processed at 37°C for 0-120 minutes in AMT buffer, pH 5.0 containing 10mM 
cysteine.  Lanes 1-4 in the absence of dextran sulphate; Lane 5, Mark 12 standard; Lanes 6-9 
in the presence of 20µg/ml dextran sulphate. (B) Enzyme activity against Z-FR-AMC during 
processing in AMT buffer, pH 4.5 containing 10mM cysteine in the presence and absence of 
dextran. 
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Figure 3.17:  Relative activities of recombinant Fasciola cathepsins activated in the 
presence of varying amounts of dextran sulphate at pH 5.0 for 30 minutes. 
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Naturally occurring GAGs and PSPs are found in blood and extracellular matrix proteins 
(Metcalfe and Austen, 1979; Potter et al., 2001; Capila and Linhardt, 2002; Belmiro et al., 
2005), and may find their way into the fluke gut, where FhCatL1 has been shown to process 
and activate (Collins et al., 2004).  The presence of GAGs, while not necessary, may facilitate 
the processing and activation of some Fasciola cathepsins in vivo. 
3.4 Discussion 
Recombinant FhCatL1 and FhCatL2 expressed in S. cerevisiae were the first active Fasciola 
cathepsin L proteases purified (Dowd et al., 1997; Roche et al., 1997).  Similar to their 
mammalian counterparts and other members of the papain superfamily, the Fasciola 
cathepsins have been shown to require expression as zymogens, with the proregion necessary 
to produce proteins that can process into active mature enzyme (Roche et al., 1997; Cappetta 
et al., 2002).  These N-terminal proregions bind to the active site cleft in reverse orientation, 
acting as regulators of activity, and perform a number of other functions as outlined in section 
1.2.3.1 and reviewed by Wiederanders et al., 2003). 
Yeasts are among the most common hosts for the production of heterologous proteins.  They 
combine ease of genetic manipulation, established fermentation technology, and unlike 
prokaryotic systems the ability to undertake many of the post-translational folding, processing 
and modification events required to produce ‘authentic’ functional proteins (reviewed in 
Dalton et al., 2003a; Porro et al., 2005). 
S. cerevisiae was initially the system of choice when expressing active recombinant cathepsin 
L, producing correctly processed and secreted functional enzymes with biochemical and 
substrate specificities identical to the native parasite enzymes (Dowd et al., 1997; Roche et 
al., 1997).  Recombinant FhCatL5 and FhCatL2 have previously been produced by the 
expression system used in this study (Smooker et al., 2000; Prowse et al., 2002), which 
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includes expression in the protease-deficient S. cerevisiae strain BJ3505.  However, it should 
be noted that certain proline residues of F. hepatica proteins (including cathepsin L-like 
proteases) are modified to unusual 3-hydroxyproline derivatives (Wijffels et al., 1994a; Bozas 
and Spithill, 1996).  Such modifications are unlikely to be present in the recombinant versions 
of the proteins and may influence protein biochemistry. 
While adequate yields of protein were obtained for rFhCatL2, rFhCatL5 and their respective 
variants, a more efficient expression system is necessary for rFgCatL1G, especially where 
analysis of relatively larger amounts of protein is required.  While no alternate expression 
systems were evaluated in this study, Pichia pastoris has also been used to express other 
functional helminth cathepsin proteases at high yields (Park et al., 2001; Caffrey et al., 2002) 
while insect and mammalian cell-lines have been used for Fasciola cathepsin L expression in 
recent years (Collins et al., 2004; Reszka et al., 2005; Kuk et al., 2006). 
Bacterial expression systems do not produce functionally active Fasciola cathepsins due to 
the absence of eukaryotic post-translational modifications.  However, expression in E. coli, 
and refolding to produce active enzyme has been reported (Yamasaki et al., 2002; Kesik et 
al., 2007) and work undertaken in our laboratory has yielded large quantities of rFgCatL1G 
when purified from recombinant E. coli which can be refolded to active enzyme (R. Jayaraj, 
personal communication). 
An important modification which takes place during secretion is the glycosylation of proteins.  
Different types of organisms have different sets of glycan processing enzymes.  Fasciola 
possess enzymes enabling glycosylation (Casaravilla et al., 2003; Freire et al., 2003), and 
despite the presence of potential glycosylation sites in several Fasciola cathepsin L-like 
proteases, to date no native Fasciola cathepsin L has been shown to be glycosylated.  Due to 
the lack of possible glycosylation sequons, none of the cathepsins utilised in this study 
appears to be glycosylated, all migrating near their expected band size when analysed by 
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SDS-PAGE, although rFhCatL2 did migrate slightly faster than expected when compared to 
the other cathepsins.  The reason for this was unknown, but is consistent with a previous 
analysis (P. M. Smooker, personal communication).   
As discussed during the introduction to this chapter, the Fasciola cathepsin L-like protease 
gene family is composed of numerous cathepsins with the variable amino acid at position 69 
believed to significantly affect subsite architecture and subsequently enzyme specificity.  
Leucine, tyrosine, tryptophan and phenylalanine residues had been observed at aa69, with 
leucine by far the most common residue.  The identification of several F69 possessing 
Fasciola cathepsin L-like proteases in recent years, combined with phylogenetic analysis has 
provided a more complete view of the evolution of this protein family. 
The expression levels and subsequent gelatinase activity observed in all the aa69 variants 
indicated that the residue at amino acid 69 does not structurally compromise the proteases, 
which was a possible hypothesis for the absence of serine and cysteine residues at this residue 
in nature, and all proteases used in this study were able to autoprocess to mature active 
enzyme.  For FhCatL2, FhCatL5 and their respective variants, three faster migrating bands 
were observed along with the unprocessed enzyme after purification.  These three bands were 
assumed to represent processed enzyme and processing intermediates, as the presence of 
processed sample after purification of the recombinant proteins was expected, as reported 
with recombinant FhCatL1 and L2 previously (Dowd et al., 1997; Roche et al., 1997; Collins 
et al., 2004; Harmsen et al., 2004).  This is thought to be brought about by the slightly acidic 
pH of the expression media triggering autoprocessing.  Very little or no processed protein 
copurified with rFgCatL1G.  This matched the report for the expression and purification of 
recombinant FhCatL8, an ortholog which was inefficiently processed upon purification 
(Harmsen et al., 2004). 
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Acidic and reducing conditions are a common trigger of autoprocessing for papain-like 
proteases, including mammalian cathepsin L, S and K (reviewed in Wiederanders et al., 2003; 
Bromme et al., 2004).  Yamasaki et al. (2002), with a recombinant FgCatLB22-GST fusion 
protein, was the first to show that Fasciola cathepsin L process by a pH-dependent 
autocatalytic mechanism in vitro, apparently proceeding in multiple steps, with their enzyme 
processing optimally between pH 4.5 and 5.5.  The processing of FhCatL5 and FhCatL2 in 
this study occurs in a similar manner, with a comparable pH range.   
The similarities observed between the in vitro processing of FhCatL5 and FhCatL2 in this 
study, compared to FhCatL1 (Collins et al., 2004; Stack et al., 2007), combined with these 
proteases all being expressed by the adult fluke suggests they are likely to process in a similar 
manner in vivo.  To date FhCatL1 is the only Fasciola cathepsin L which has had its 
processing analysed in detail (Collins et al., 2004; Stack et al., 2007).  F. hepatica has been 
shown to synthesise FhCatL1 within the gastrodermis that lines the flukes gut (Smith et al., 
1993b; Collins et al., 2004), where the protease is retained as inactive zymogen in secretory 
vesicles (Collins et al., 2004).  Upon secretion to the gut lumen, where the pH is estimated to 
be ~5.5 or slightly lower (Halton, 1997), the zymogen is processed to active mature enzyme.  
It then presumably performs various protein degrading functions.  The regular expulsion of 
the flukes gut contents, combined with the identified stability of Fasciola cathepsin L 
proteases at physiological pH, activity over a broad pH range, and their substrate preferences 
also suggests they perform roles in the surrounding tissues.   
Unlike the cathepsin L proteases expressed by the adult fluke where only fully processed 
mature enzyme is isolated, analysis of juvenile fluke ES has identified both mature and 
unprocessed cathepsin L (Cancela et al., 2008). 
Enzyme maturation is proposed to be a two step process (Menard et al., 1998), with activation 
of the proenzyme followed by generation of the mature enzyme through cleavage of the 
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proregion.  Both uni- and bi-molecular reactions appear to be involved for processing of 
recombinant human cathepsin L (reviewed in Wiederanders et al., 2003), with in vitro 
processing of recombinant Fasciola cathepsin L1 appearing to occur in a similar manner 
(Stack et al., 2007) as did the processing observed in this study.  The exact mechanism 
required to initiate processing is unknown.  Dissociation of the proregion from the active site, 
or intramolecular cleavage to remove part of the proregion in a small proportion of molecules 
has been suggested (Menard et al., 1998; Quraishi and Storer, 2001).  These molecules which 
no longer have their active site obstructed by the proregion can then active other zymogens 
through intermolecular interactions (Menard et al., 1998; Quraishi and Storer, 2001).   
While a major conformational change to the propeptide at lower pH is not the initial step in 
processing, proregion binding to the mature region is dependant on electrostatic interaction 
and is substantially weaker at lower pH (Carmona et al., 1996b; Billington et al., 2000) 
possibly leading to a looser conformation and more susceptibility to proteolysis (Jerala et al., 
1998; Rozman et al., 1999).  Disruption of a salt bridge involving residues of the GNFD motif 
at low pH may initiate the process (Vernet et al., 1995; Coulombe et al., 1996), with removal 
of the proregion brought about by subsequent cleavage at central and C-terminal portions of 
the proregion.  Collins et al. (2004) identified a cleavage site within the GNFD motif of 
FhCatL1 with the motif proposed to play an important role in processing.  The same group 
also proposed that intermediates observed during FhCatL1 processing were generated by 
cleavage at this same site (Stack et al., 2007).  The GNFD motif is completely conserved 
within the proteases used in this study. 
Another processing intermediate cleavage site, 10 amino acid residues upstream of the mature 
region putative start site has also been identified as critical to the activation process (Collins et 
al., 2004; Stack et al., 2007).  This cleavage step is reliant on the enzyme specificity of the S2 
subsite, with the residue at -12, situated at the P2 position.  This is a conserved leucine residue 
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amongst almost all Fasciola cathepsin L-like proteases.  Stack et al. (2007) showed that 
substituting Leu-12 to an unfavourable residue in Proline, prevented trans-processing of 
rFhCatL1, significantly slowing the activation process, while trans-processing of this 
rFhCatL1 mutant with rFhCatL2 which readily accommodates Pro at P2 still proceeded.  
Synthetic substrate studies suggest leucine is one of, or even the most readily accepted residue 
at P2 among Fasciola cathepsin L-like proteases (Dowd et al., 1994; Stack et al., 2008).  This 
requirement of enzyme specificity to cleave the C-terminal portion of the proregion during 
processing has also been observed with other papain-like cysteine proteases (Ishidoh and 
Kominami, 1994; McQueney et al., 1997; Menard et al., 1998; Shenai et al., 2000; Quraishi 
and Storer, 2001).  
While N-terminal sequences of the processing intermediates observed in this study were not 
obtained to confirm exact cleavage sites, conservation of important residues in the proregion, 
including at the C-terminal processing cleavage site (Figure 3.18) combined with similar 
substrate specificities, suggests that the processing intermediates observed during purification 
and processing of enzymes in this study are produced by cleavage at similar sites to those 
identified for rFhCatL1 (Collins et al., 2004; Stack et al., 2007). 
In this study, rFhCatL5 was also shown to autoprocess in an acidic environment, with 
processing most efficient at pH 5.0, although some processing was also observed up to neutral 
pH.  Processing was dependant on the protein concentration, indicating that rFhCatL5 is able 
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Figure 3.18:  Amino acid composition around a C-terminal propeptide processing 
cleavage site amongst Fasciola cathepsin L-like proteases (organised and weighted by 
clade). 
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to undergo bi-molecular autoprocessing, while the observation of intermediate bands during 
processing, suggests it occurs in a stepwise fashion.  These results suggest that rFhCatL5 
autoprocessing proceeds in an almost identical fashion to rFhCatL1 which was also recently 
shown to be a bi-molecular multi-step process induced at acidic pH (Stack et al., 2007).  
Although the in vitro pH processing optimum of rFhCatL5 appears to be slightly more acidic, 
differences with FhCatL1 may correspond to differences in experimental protocol, most 
noticeably buffer composition.  Processing of rFhCatL2 is also similar, with the exception of 
a slightly higher pH processing optimum, of 6.0.   
The ability of dextran sulphate to influence the processing of FhCatL5 and –L2 hints at the 
possibility of physiologically relevant GAGs also playing a role in processing in vivo.  
FhCatL5, like FhCatL1 and FhCatL2 is found in the ES of adult fluke.  As such the synthesis 
and processing are expected to occur in similar environments.  All three enzymes appear to 
process in vitro optimally near the estimated pH of ES in the fluke’s gut, which results in the 
observance of only mature active enzyme in vivo.   
The processing of rFgCatL1G varies from the other Fasciola cathepsin L-like proteases, and 
other cysteine proteases in that it appears to require two distinct pH environments for efficient 
autoprocessing to occur.  It is proposed that similar to other cathepsin L-like proteases, the 
first unimolecular step requires an acidic pH.  This step appears to be quite inefficient for 
FgCatL1G when compared to other Fasciola cathepsins, apparently requiring quite stringent 
conditions as observed by the presence of very little processed sample upon purification, and 
the more thorough preparation required prior to the processing experiments.  The relative 
inefficiency at the initial processing step may be due to structural abnormalities resulting from 
the expression system used, however the lack of processing observed with the ortholog 
FhCatL8 (Harmsen et al., 2004), combined with the presence of proenzyme along with 
processed enzyme in NEJ and metacercariae extracts (Tkalcevic et al., 1995; Cancela et al., 
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2008) suggests that it is intrinsic to this class of Fasciola cathepsin L.  While an acidic pH 
appears able to initiate processing in vitro, it is possible cleavage by an asparaginyl 
endopeptidase may initiate processing in vivo, as has been proposed for cathepsin B from 
Fasciola and Schistosoma (Sajid et al., 2003; Beckham et al., 2006).  The subsequent 
processing and activation involving cleavage at the C-terminal region of the proregion then 
requires a more neutral pH to occur efficiently.  Stack et al. (2007) has shown that enzyme 
specificity plays a role in trans-processing of Fasciola cathepsin L-like proteases, and the C-
terminal portion of the proregion of clade A cathepsins differs from other Fasciola cathepsins, 
with a distinct lack of basic residues.  This lack of conservation compared to other Fasciola 
cathepsin L-like proteases is in line with the unique substrate specificity of FgCatL1G, which 
is discussed in chapter 4.  Papain-like cysteine proteases can have varying pH optima for 
cleavage of different substrates, and it may be that cleavage near the C-terminal proregion is 
only efficient at the pH values observed in this study. 
FgCatL1G has been isolated from F. gigantica metacercariae, while F. hepatica clade A 
counterparts were isolated from metacercariae and NEJ.  Unlike their adult counterparts, 
juvenile F. hepatica ES isolates tend to possess both processed and unprocessed cathepsin L-
like proteases, specifically clade A cathepsins.  This indicates that the inefficient processing at 
acidic pH observed with FgCatL1G in vitro is repeated in vivo with F. hepatica orthologs.  
This combined with the requirements listed for processing of FgCatL1G indicates a primary 
role in the external environment to metacercariae and immature flukes.  Assuming cathepsin 
L is synthesised in juvenile flukes in a similar manner to their cathepsin L counterparts in 
adult fluke, FgCatL1G would be expected to be packaged and secreted into the parasites gut 
as a zymogen.  Here, in an acidic environment, a small proportion of the FgCatL1G enzymes 
would be processed.  Upon expulsion from the gut into the surrounding environment, the less 
acidic pH would facilitate the subsequent processing of the bulk of FgCatLG into mature 
active enzyme.  
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The identification of orthologs in juvenile F. hepatica, indicates a possible role for FgCatL1G 
in F. gigantica at the same life stage.  As juvenile fluke do not possess an absorptive gut, 
FgCatL1G would not be expected to play a role in nutrient acquisition, thus roles in 
excystment, tissue invasion and possibly immune evasion are likely.   
FgCatL1G isoforms have been detected in F. gigantica metacercariae but their presence has 
not been explored.  Before emerging as a newly excysted juvenile in the small intestine 
(Andrews, 1999), the parasite convulses to break out of the cyst (Dixon, 1966), and purges the 
contents of the gut (Sukhdeo and Mettrick, 1986).  This supposedly releases substances 
(possibly FgCatL1G) that may be involved in weakening the interior of the cyst, similar to the 
role of cysteine proteases in other trematodes (Chung et al., 1995; Li et al., 2004).  A recent 
publication by Cancela et al. (2008) focusing on F. hepatica NEJ and metacercariae has 
identified clade A cathepsins in both life stages and highlighted their role in excystment. 
The processing results, combined with studies of fluke ES indicate that unprocessed 
FgCatL1G would be expelled from the flukes gut as part of ES and therefore exposed to the 
hosts immune system before complete activation.  This when combined with the knowledge 
that the proregion of a putative ortholog to FgCatL1G, FhCatL8 has been shown to be a good 
vaccine candidate against F. hepatica suggests that work into the use of FgCatL1G or 
component peptides as vaccine candidates is warranted.  Such work is currently being 
undertaken in our laboratory. 
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4.1 Introduction 
The ES of Fasciola has been shown to digest a variety of host substrates including collagen, 
immunoglobulin, haemoglobin and laminin (for examples, see references Chapman and 
Mitchell, 1982; Smith et al., 1993a; Dowd et al., 1995; Berasain et al., 1997; Wilson et al., 
1998; Berasain et al., 2000) supporting its proposed roles in the acquisition of nutrients, 
immune evasion and migration.  Cathepsin L-like proteases are predominantly responsible for 
the protease activity in adult fluke ES (Dalton and Heffernan, 1989; Dowd et al., 1992; 
Dalton et al., 1996a; Brady et al., 1999a; Tort et al., 1999), although their expression in 
juvenile life stages has also been reported (Tkalcevic et al., 1995; Cancela et al., 2008).  
However, the number of proteases expressed, and their high degree of identity means that the 
specific roles of the various cathepsin L-like proteases are unknown. 
Despite the vast array of Fasciola cathepsin L-like protease sequences deposited in public 
databases, enzymatic characterisation has been undertaken on only three recombinant 
enzymes (Dowd et al., 1997; Roche et al., 1997; Smooker et al., 2000).  FhCatL1 and 
FhCatL5, despite belonging to different evolutionary clades both possess Leu69 and show 
relatively high amino acid identity including along the active site cleft.  They appear to 
possess similar substrate specificities, with a preference for aliphatic residues at P2 and can 
cleave substrates possessing Phe at residue P2, but have difficulty accommodating Pro (Dowd 
et al., 1994; Roche et al., 1997; Smooker et al., 2000; Stack et al., 2008).  Characterisation of 
recombinant FhCatL2, with its ability to cleave synthetic substrates with Pro residues at P2 
(Dowd et al., 1994; Dowd et al., 1997; Smooker et al., 2000) has shown that Fasciola 
cathepsin L-like proteases can exhibit different substrate specificities despite high levels of 
identity.  This unusual ability of FhCatL2 was shown to be in part due to amino acid residue 
69 (aa69; FhCatL5 mature numbering).  This residue is important to S2 subsite architecture, 
and the presence of Tyr69 in FhCatL2 as opposed to Leu69, which is found in a majority of 
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Fasciola cathepsin L-like proteases, allows Pro to be accommodated more efficiently by the 
S2 subsite (Smooker et al., 2000). 
As mentioned in the previous chapter, analysis of codon usage in Fasciola cathepsin L-like 
proteases that were initially identified suggested that enzymes with alternate residues at aa69 
were likely to also be expressed, or were at some point during the flukes evolution.  
Subsequently cDNA’s encoding enzymes possessing Trp and Phe where identified in both 
Fasciola species.  The cathepsins containing Trp or Phe at aa69 have to date only been 
identified in immature fluke life stages and are evolutionarily divergent from the cathepsin L-
like proteases expressed by adult fluke (Irving et al., 2003).  While a Trp69 containing 
Fasciola cathepsin L-like protease has been previously expressed, it failed to be efficiently 
activated (Harmsen et al., 2004), and to date no Fasciola cathepsin possessing either Trp69 or 
Phe69 has been characterised.  Although for Trp69 Fasciola cathepsin L-like proteases, 
inference from another cathepsin containing Trp69 (Choi et al., 1999) combined with 
molecular modeling has been used to suggests that they would have a preference for a small 
non-polar hydrophobic sidechain such as Pro at P2 (Irving et al., 2003). 
The discrimination between F. hepatica cathepsin L-like proteases in terms of substrate 
specificity and identification of protein substrates that the enzymes digest will provide an 
insight into the specific roles the various Fasciola cathepsins undertake within the host 
environment.  The knowledge obtained on Fasciola cathepsin L-like proteases may also be 
extrapolated to other parasites expressing a large family of cathepsin L-like proteases, such as 
schistosomes and leishmania species. 
Three recombinant Fasciola cathepsin L-like proteases were expressed and characterised.  
These enzymes, FhCatL5, FhCatL2 and FgCatL1G possess Leu, Tyr and Trp at aa69 
respectively and belong to three separate evolutionary clades.  This is the first time a 
cathepsins L-like protease isolated from Fasciola metacercariae has been enzymatically 
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characterised and provides an overview of the range of activities achieved by the the Fasciola 
cathepsin L family not previously undertaken.  In addition, FhCatL5 with defined 
substitutions at aa69 described previously in chapter 3 and shown to be functionally active 
were also characterised.  This will allow for further elucidation of the role aa69 plays in S2 
subsite architecture.  A FhCatL2 Y69L mutant was also constructed to determine if the effects 
observed with the FhCatL5 L69Y mutation, which resulted in an increased acceptance of Pro 
at P2 by the enzyme (Smooker et al., 2000) could be reversed, leading to a decrease in Pro 
acceptance by FhCatL2.   
Molecular modeling will provide a structure-based interpretation of the enzyme properties, 
and facilitate predictions regarding substrate preferences and possible roles for as yet 
uncharacterised or undiscovered Fasciola cathepsins. 
4.2 Materials and methods 
4.2.1 YEpFLAG constructs for recombinant cathepsin expression in yeast 
The constructs used for expression of recombinant proteases were designed and constructed 
as described in section 3.2.1.   
4.2.2 Protein expression and initial IMAC purification 
Recombinant protein expression and an initial IMAC purification was undertaken as 
described in section 3.2.3. 
4.2.3 Protein processing 
Post IMAC purification, pooled fractions were dialysed against buffer A, pH 5.  Dialysis 
buffer was changed 4 times for all proteins, except FhCatL5 L69W and FgCatL1G proteins, 
where buffer was changed 5 and 6 times respectively.  After dialysis, samples were buffer 
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exchanged twice into buffer A and concentrated to 10% of their original volume using 
centricon centrifugal devices (Millipore).  The pH of buffer A used during the buffer 
exchange step was the pH at which the enzyme was to be autoprocessed.  The optimum pH 
for autoprocessing in buffer A was determined over a pH range of 4.0 to 5.5 as specified in 
Section 2.6.3.4.2.  For FhCatL5 and variants, processing was undertaken between pH 4.5 and 
5.0, while for FhCatL2 and –Y69L a pH of 5.5 was used.  The protein was then diluted to its 
original volume in buffer A, and then processed at 37°C for 2.5 h in the presence of 10 mM 
cysteine.  Processing was visualised on SDS-PAGE.  If the protein was to be purified by ion 
exchange chromatography the next day it was kept on ice, otherwise it was stored at −80ºC. 
Processing of rFgCatL1G did not occur within the buffer range of buffer A, as such after 
dialysis and concentration in buffer A pH 5.0, the enzyme was diluted in AMT pH 7.0, and 
processed at 37˚C for 2 h in the presence of 10 mM cysteine.  After processing, the enzyme 
was then buffer exchanged into buffer A, pH 5.0 for subsequent ion exchange purification.  
4.2.4 Cation exchange chromatography. 
Completely processed proteins were further purified by ion exchange chromatography as 
outlined in section 2.6.3.5.  When required, protein solutions had their pH adjusted to either 
4.9 or 5.0 by the addition of NaOH or HCl.  FhCatL5 variants and FgCatL1G proteins were 
purified with buffers at pH 5.  FhCatL2 variants did not bind efficiently to the column, so 
buffers with a pH of 4.9 were used to attempt to increase yields.  Bound protein was eluted 
with the addition of 500 nM NaCl.  Fractions were tested for activity against fluorescent 
substrate and also visualised on SDS-PAGE as stated in section 2.6.3.6.  Proteins were kept 
on ice during fraction analysis, after which a secondary IMAC purification was undertaken. 
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4.2.5 Secondary IMAC purification. 
A secondary IMAC purification of proteins was undertaken to separate the mature protein 
from any propeptide that may have been present after MonoS purification.  After pooling, 
MonoS fractions were concentrated to 1 mL using 10,000 MWCO centricons then diluted to 
10 mL in wash buffer containing imidazole.  Samples were then passed over a 1 mL IMAC 
column, washed with 10 CV of wash buffer and eluted with 10 CV of elution buffer.  Elution 
fractions of 1 mL were collected, and analysed by SDS-PAGE and fluorogenic assay.  All 
proteins were loaded and washed in the presence of 10 mM imidazole with the exception of 
FgCatL1G C-79Y, where 1 mM imidazole was used. 
Appropriate elution samples were concentrated and buffer exchanged into buffer A, with 
aliquots stored at −80ºC (2.6.4). 
4.2.6 Protease assays. 
4.2.6.1 Synthetic substrate assays. 
Active site molarities of the enzymes were determined by titration with the irreversible 
cysteine protease inhibitor, E-64 according to the method of Barrett et al., 1982) (2.6.5.2).  
Protease activity was determined with assays containing AMC releasing fluorogenic 
substrates (2.6.5.1), with an AMC standard curve (2.6.5.2.1) used to convert Arbitrary 
fluorescence units (AFU) into the amount of product released.  Graphpad Prism 3 was used to 
analyse data. 
4.2.6.1.1  Initial velocities against fluorogenic peptide substrates. 
Assays were performed in duplicate, in enzyme buffer, pH 5.5, with final substrate 
concentrations ranging from 1-200 µM in 4% (v/v) DMSO.  One hundred microlitres of 
substrate diluted in 8% (v/v) DMSO was added to 100 µl of diluted enzyme and assayed for 
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activity at 37°C according to Section 2.6.5.1.  Initial velocities were determined from the 
linear portion of the release of fluorescence, with product released determined using an AMC 
standard curve.   
Substrates assayed in this manner were Z-FR-AMC and Tosyl-GPR-AMC. 
4.2.6.1.2  Determination of kcat and Km values. 
The catalytic rate constant (kcat) and Michaelis-Menten constant (Km) were determined from 
initial velocities (v0) over a range of substrate concentrations [S] at a fixed enzyme 
concentration, obtained according to Section 4.2.6.1.1.  Non-linear regression was fitted 
according to Equation 4.1 using GraphPad Prism 3.   
Equation 4.1:      v0 ]S[
]S[ 
m
max
+
=
K
V
 
The kcat was then determined by incorporating the enzyme concentration [E] as determined in 
section 2.6.5.2 into Equation 4.2. 
Equation 4.2:      kcat ]E[
maxV
=  
4.2.6.1.3  Determination of kcat/Km values from progress curve kinetics. 
An estimate of kcat/Km was obtained by following substrate cleavage at concentrations at least 
10-fold lower than Km.  Assays were performed in enzyme buffer, pH 5.5, in the presence of 
4% DMSO at 37°C.  Enzyme was incubated with 0.05-2 µM of substrate.  The fluorescence 
was measured every 72 s, for 4 h.   
Chapter 4: Characterisation of recombinant Fasciola cathepsin L 
168 
Initial fluorescence (I0), maximal fluorescence intensity (Imax) and the first order rate constant 
(k) where estimated by fitting a non-linear regression line to the fluorescence intensity (INT) 
against time (t) according to Equation 4.3. 
Equation 4.3:      INT = I0 + Imax(1 – e-Ekt) 
When the initial substrate concentration is much less than the Km, k equals kcat/Km (Le 
Bonniec et al., 1996).  Since Km was not determined for all substrates, the concentration of 
substrates used for the progress curves was determined by reducing the substrate 
concentration until the difference between kcat/Km values was less than 10%.   
4.2.6.2  Enzyme stability. 
Enzyme at 20 nM was incubated in 20 µL AMT buffer containing 10 mM cysteine.  The 
enzymes were incubated for 0, 30, 60 and 120 minutes at different pH values and assayed 
simultaneously by the addition of 180 µL of 10 µM Z-FR-AMC or Tosyl-GPR-AMC in 
enzyme buffer, pH 5.5.  The pH of the assay buffer was not altered by the pH of the AMT 
buffer.  The natural log of the residual activity (AFU/min) was plotted against time (min) and 
the slope of the linear regression used to calculate the half life (t½) with the following 
equations (Dennison et al., 1992): 
Equation 4.4:      kobs = slope × 2.3 
Equation 4.5:      
obs
693.0
2
1
k
t =  
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4.2.6.3  pH profiles of activity against AMC releasing substrates. 
Enzymes were incubated in AMT buffers ranging in pH from 4.0 to 9.0, in the presence of 
10 mM cysteine and 10 µM of fluorogenic substrate at 37°C.  Fluorescence and initial 
velocity were measured as described previously. 
4.2.6.4 pH profile of FITC-casein digestion. 
Enzyme was incubated for 30 min at 37˚C in AMT buffers ranging from pH 4.0 to 9.0, 
containing 10 mM cysteine and 50 µg/ml of FITC-casein.  Then 60 µl of 5% (w/v) TCA was 
added to 10 µl of the digest and incubated for 5 min at RT.  The precipitate was collected by 
centrifugation at 10,000 × g for 10 min at RT.  Ten microlitres of the supernatant was 
removed to a 96 well plate and 190 µl of AMT buffer, pH 8.5, was added.  The fluorescence 
was read in duplicate at excitation and emission wavelengths of 485 nm and 520 nm 
respectively, on a Polarstar fluorescent microtitre plate reader.  Negative controls in the 
absence of enzyme were subjected to the same conditions, with values obtained for these 
fluorescence measurements subtracted from those of the digested samples.  
4.2.6.5 Molecular modeling 
Molecular modeling was undertaken as outlined in section 3.2.6.   
4.3 Results 
4.3.1 Modeling of the S2 active site 
The S2 subsite of papain-like cysteine proteases plays a major role in determining substrate 
specificity of the enzyme.  Mutagenesis performed on papain-like cysteine proteases has 
shown that one or two substitutions can alter the substrate specificity of the enzyme (Khouri 
et al., 1991; Hasnain et al., 1992; Bromme et al., 1994; Barlic-Maganja et al., 1998; Lecaille 
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et al., 2002a; Lecaille et al., 2007).  Smooker et al. (2000) showed that a single amino acid 
substitution, at aa69, situated within the S2 subsite, was able to alter the substrate specificity 
of FhCatL5. 
The active sites of the three Fasciola enzymes vary at several residues, not just aa69.  The 
release of the Fasciola cathepsin L1 three-dimensional structure (2o6x) allowed for direct 
analysis of a Fasciola cathepsin L active site and provided the template (along with several 
other cysteine proteases) for homology-based modeling of the enzymes utilised in this study.  
Other residues within the active sites of the enzymes used in this study that showed variation, 
and may influence subsite architecture and subsequently substrate binding within the S2 
subsite included those lining the ‘bottom’ and ‘right wall’ of the subsite.  These included 
aa209 and residues aa160, aa161 and aa163 (FhCatL5 mature protein numbering; Figure 4.1).  
Stack et al., (2008) recently showed that substitution of one of these residues, aa209, was 
capable of influencing the substrate preference of FhCatL1. 
Amongst the residues that line the S2 subsite of the Fasciola cathepsins, most variation is seen 
at aa69, where Leu, Tyr, Phe and Trp isoforms have been discovered, although other residues 
also show variation as outlined in Table 4.1. 
As all the recombinant enzymes were able to be processed and showed activity, the next step 
was to determine their substrate specificities.  Homology modeling (Figure 4.2) and 
characterisation of the FhCatL5 variants will help to determine the influence of the respective 
aa69 substitutions and their role in determining the substrate specificity of wildtype cathepins.  
It may also help explain the absence of Ser69 and Cys69 cathepsins within Fasciola.  
The characterisation of FhCatL2 and FgCatL1G, allow for not only comparison with FhCatL5 
and its variants, but also expand the knowledge of the capabilities of individual cathepsins 
within the Fasciola repertoire. 
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Figure 4.1:  Molecular models of Fasciola cathepsins.   
(A) S2 active site representation of FhCatL5, FhCatL2 and FgCatL1G.  Amino acids forming 
the S2 active site are represented as stick models and numbered.  (B,C and D) Surface 
representations of FhCatL5, FhCatL2 and FgCatL1G respectively.  Amino acids are coloured 
according to type (acidic, basic, polar, and non-polar).  A P2 phenylalanine residue is 
superimposed into the S2 active site cleft. 
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Table 4.1:  Residues lining the S2 subsite of Fasciola cathepsin L-like proteases 
Enzyme S2 subsite preferences S2 subsite amino acids 
  69* 70* 135* 160* 161 163* 209* 
FhCatL1 Aliphatic>Aromatic a Leu Met Ala Val Asn Ala Leu 
FhCatL5 Aliphatic>Aromatic b Leu Met Ala Leu Asn Gly Leu 
Clone 320A f Unknown Leu Met Ala Leu Asn Ala Met 
Clone 24.5A+ f Unknown Leu Met Ala Leu Asn Ala Leu 
FgCatL1H Unknown Phe Met Ala Leu Asn Ala Phe 
FhCatL2 Aliphatic>Aromatic, Proline a Tyr Met Ala Leu Thr Ala Leu 
FgCatL1G Aliphatic>Aromatic, Proline b Trp Met Ala Val Thr Ala Val 
HuCatL Aromatic>Aliphatic c Leu Met Ala Met Asp Gly Ala 
HuCatV Aromatic>Aliphatic c Phe Met Ala Leu Asp Gly Ala 
HuCatK Aliphatic>Aromatic, Proline c Tyr Met Ala Leu Asn Ala Leu 
HuCatS Aliphatic>Aromatic c Phe Met Gly Val Asn Gly Phe 
HuCatH Val>Phe  d Leu Pro Ala Val Asn Ala Cys 
HuCatF Aliphatic>Aromatic, Aspartic acid c Leu Pro Ala Ile Asp Ala Met 
Ginger Rhizome GP II Proline e Trp Met Thr Ala Asn Ala Phe 
Papain Val>Phe c Tyr Pro Val Val Asp Ala Ser 
Where * denotes residues whose sidechain extends into the subsite; a = Results obtained from Stack et al., 2008); b = Results obtained in this study; c = 
Results obtained from Choe et al., 2006); d = Results obtained from Vasiljeva et al., 2003) with HuCatH lacking mini chain; e = Results obtained from 
Choi et al., 1999); f= Clones isolated in this study (see Chapter 5) 
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(A) 
                    FhCatL5 
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                    FhCatL5 L69W 
                    FhCatL5 L69F 
(B) 
                    FhCatL5 
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                    FhCatL5 L69S 
 
 
 
Figure 4.2:  Molecular models of Fasciola cathepsins variants.  
Overlay of S2 active site representations of FhCatL5 and aa69 variants.  (A) FhCatL5 and 
L69Y, L69W and L69F; and (B) FhCatL5 and L69C and L69S.  Amino acids forming the S2 
active site are represented as stick models with residue numbers displayed (FhCatL5 mature 
region numbering). A P2 phenylalanine residue is superimposed into the S2 active site. 
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4.3.2 pH optima 
The pH profile of enzyme activity was assayed against three substrates; Z-FR-AMC, Tosyl-
GPR-AMC and FITC-casein (Figure 4.3).  AMT buffer across the pH range of 4.0-9.0 was 
used to maintain a constant ionic strength.  For all substrates, enzymes produced bell-shaped 
activity profiles with most activity at or near pH 7.0.  Substitutions introduced at aa69 in 
FhCatL2 and FhCatL5 did not result in altered pH profiles against any of substrates tested 
(data not shown).  Against Z-FR-AMC, all enzymes possessed similar pH profiles.  Relatively 
high (>70%) activity in the range of pH 5.5-8.0 was observed, with optimum activity 
exhibited in the region of pH 6.0-7.0.  The pH profiles for all proteases against Tosyl-GPR-
AMC showed optimum activity at pH 7.0, although FhCatL5, similar to the profile with the 
substrate Z-FR-AMC, maintained a relatively high activity at pH 8.0 compared to FhCatL2 
and FgCatL1G, while FgCatL1G activity dropped quickly in acidic pH conditions.  Optimal 
activity against FITC-casein was also observed at pH 7.0 for all enzymes. 
4.3.3 pH stability 
The stability of the enzymes across a pH range of 4.0 to 9.0 was evaluated by incubating in 
AMT buffer at 37ºC for different lengths of time, then measuring residual activity at pH 5.5 
against Z-FR-AMC or Tosyl-GPR-AMC.  FhCatL2, FhCatL5 and their variants were most 
stable around pH 7.0-8.0, with stability declining in increasingly acidic or basic conditions 
(Figure 4.4).  Alternatively, FgCatL1G was most stable in a slightly acidic environment, with 
optimum stability at pH 6.0, and relatively low stability at physiological pH.  While both 
FhCatL2 and FhCatL5 retained >90% activity after 4 hrs incubation at pH 7.5, the latter 
proved to be slightly more stable and retained about 40% activity after incubation for 24 hours 
(Figure 4.5).  No significant differences were seen in the stability profiles of the variants from 
either enzyme, all possessing high stability around neutral pH (data not shown).   
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Figure 4.3:  pH profiles of cathepsin activity.   
Assayed against (A) Z-Phe-Arg-AMC, (B) Tosyl-Gly-Pro-Arg-AMC and (C) FITC-casein. 
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Figure 4.4:  Stability profiles of enzymes at different pH.   
Residual enzyme activity of FhCatL5, FhCatL2 and FgCatL1G after 2 hours incubation at 
37ºC. 
 
 
 
 
 
 
 
Figure 4.5:  Stability of recombinant enzymes at pH 5.0 and 7.5 over 24 hours. 
Residual enzyme activity after incubation at 37ºC at pH 7.5 (and pH 5.0 inset). 
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4.3.4  Substrate specificity  
The kcat and Km values were ascertained for each enzyme against the substrates Z-FR-AMC 
and Tosyl-GPR-AMC in enzyme buffer, pH 5.5 in the presence of 10 mM cysteine.  Values 
were determined by assaying the initial velocity of substrate cleavage versus substrate 
concentration.  To determine the affinities and turnover rates of the proteases, Michaelis-
Menten plots (example shown in Figure 4.6) were undertaken to predict Km and kcat against Z-
FR-AMC and Tosyl-GPR-AMC.  These values are shown in Table 4.2. 
FhCatL5 has a clear preference for Z-FR-AMC over Tosyl-GPR-AMC.  The introduction of 
the Ser69 and Cys69 substitutions to FhCatL5 resulted in higher affinity for Z-FR-AMC, 
however the overall efficiency (kcat/Km) against Z-FR-AMC was greatly reduced.  The affinity 
for and efficiency against Tosyl-GPR-AMC were also diminished.   Alternatively the Phe69 
and Tyr69 subsitutions lead to a 2 to 3-fold increased efficiency towards Tosyl-GPR-AMC.  
The Trp69 substitution had poor affinity for both substrates, particularly against Z-FR-AMC, 
which contributed to a relatively low kcat/Km, however an efficiency against Tosyl-GPR-AMC 
comparable to FhCatL5 translated to a relatively high preference towards Tosyl-GPR-AMC 
compared to Z-FR-AMC (Figure 4.7). 
This study indicated that FhCatL2 has an almost equal preference for Z-FR-AMC and Tosyl-
GPR-AMC.  The introduction of the Leu69 substitution resulted in a reduced affinity to both 
substrates, with the overall efficiency reduced more significantly against Tosyl-GPR-AMC. 
The FgCatL1G protease, which possesses Trp69 possessed low activity when compared to the 
other enzymes, however it did show a clear preference for Tosyl-GPR-AMC over Z-FR-
AMC. 
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Figure 4.6:  Substrate concentration versus initial velocity plots. 
An example of substrate concentration versus initial velocity plots, determined from the slope 
of the increase in fluorescence at pH 5.5.  Here shown with FhCatL5.  A plot with the 
substrate, tosyl-GPR-AMC on a smaller scale is inset to the main graph.  
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Table 4.2:  Individual Km, kcat and kcat/Km values for FhCatL cleavage of peptide 
substrates 
Enzyme Substrate Km (µM) + kcat (s-1) + kcat/Km (M-1s-1) 
FhCatL5 Z-FR-AMC 24.81 3.73 17.89 1.19 721,262 
  tosyl-GPR-AMC 53.92 5.73 0.84 0.06 15,496 
FhCatL5 L69Y Z-FR-AMC 32.87 6.81 21.52 2.11 654,659 
  tosyl-GPR-AMC 63.46 5.49 2.54 0.09 40,002 
FhCatL5 L69W Z-FR-AMC 137.30 13.60 11.05 0.61 80,477 
  tosyl-GPR-AMC 78.60 4.79 1.34 0.04 17,045 
FhCatL5 L69C Z-FR-AMC 13.72 1.52 1.92 0.08 140,204 
  tosyl-GPR-AMC 76.74 11.50 0.19 0.01 2,503 
FhCatL5 L69S Z-FR-AMC 12.72 2.03 1.73 0.10 135,759 
  tosyl-GPR-AMC 126.90 16.06 0.27 0.02 2,101 
FhCatL5 L69F Z-FR-AMC 19.11 2.51 17.93 0.87 938,217 
  tosyl-GPR-AMC 51.93 5.47 1.78 0.07 34,366 
FhCatL2 Z-FR-AMC 22.57 4.51 5.17 0.50 229,119 
  tosyl-GPR-AMC 36.15 5.65 7.08 0.57 195,970 
FhCatL2 Y69L Z-FR-AMC 50.08 5.65 5.22 0.36 104,331 
  tosyl-GPR-AMC 54.71 7.57 2.19 0.13 40,079 
FgCatL1G Z-FR-AMC 74.69 17.76 0.51 0.08 6,777 
  tosyl-GPR-AMC 89.53 18.00 1.87 0.22 20,862 
Individual Km, kcat and kcat/Km values predicted from the non-linear regression fitting 
(according to Equation 4.1, Section 4.2.6.1.2) of Michaelis-Menten curves for cleavage of 
peptide substrates by cathepsins at pH 5.5. 
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Figure 4.7:  kcat/Km values calculated from individual Km and kcat values for 
recombinant Fasciola cathepsin L proteases against Z-FR-AMC and tosyl-GPR-AMC. 
Values calculated from data in Table 4.2 and expressed as the percentage of activity against 
Z-FR-AMC.  
%
 
o
f Z
-
FR
-
A
M
C 
k c
at
/K
m
 
Z-FR-AMC 
Tosyl-GPR-AMC 
Fh
Ca
tL
5 
Fh
Ca
tL
5 
L6
9Y
 
Fh
Ca
tL
5 
L6
9W
 
Fh
Ca
tL
5 
L6
9C
 
Fh
Ca
tL
5 
L6
9S
 
Fh
Ca
tL
5 
L6
9F
 
Fh
Ca
tL
2 
Fh
Ca
tL
2 
Y
69
L 
Fg
Ca
tL
1G
 
400 
300 
200 
100 
50 
0 
Chapter 4: Characterisation of recombinant Fasciola cathepsin L 
181 
4.3.5 Initial velocities 
The cleavage of di- and tri-peptide fluorogenic substrates was performed to compare substrate 
preferences with a more diverse range of substrates.  These included substrates with P2 Phe 
and Pro, as well as Leu and Val; while substrates with substitutions at residues P1 and P3 
provide insight into preferences at sites S1 and S3.  While not all the substrates were directly 
comparable, several inferences could be made.   
On the basis of initial velocity FhCatL5 has a relative preference for substrates with leucine 
residues at P2 when compared to phenylalanine.  A greater than 20-fold difference between Z-
FR-AMC and substrates with proline at P2 was also evident (Figure 4.8).  FhCatL5 appears to 
accept lysine in its S1 subsite more readily than arginine, with the initial velocity of Boc-
VLK-AMC slightly greater than that of D-VLR-AMC. 
Compared to FhCatL5, the initial velocities for FhCatL2 were more even between substrates.  
Compared to Z-FR-AMC the proline possessing P2 substrates ranged from about 20% to 
300%.  The preference for leucine at P2 was evident as with FhCatL5 although to a lesser 
degree, the initial velocity of D-VLR-AMC less than 2-fold greater than Boc-VPR-AMC 
(compared to 1000-fold with FhCatL5).  FhCatL2 also appears to prefer glycine at P3 over 
valine and aspartate.  A preference for lysine over arginine at P1 was also observed.  
Compared to FhCatL5, the initial velocities of PFR-AMC and Bz-FVR-AMC were greater 
and smaller respectively. 
The initial velocities for FgCatL1G showed its S2 subsite had a significant preference for 
proline at P2 compared to phenylalanine, with initial velocities at least 3-fold higher.  Similar 
to FhCatL2, the initial velocities also suggest the S3 subsite has a strong preference for 
glycine over valine and aspartate.  Unlike FhCatL2 and FhCatL5, the initial velocity for D-
VLR-AMC was greater than for Boc-VLK-AMC, indicating a preference for arginine over  
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Figure 4.8:  Initial velocities of recombinant Fasciola cathepsin L proteases.   
Initial velocities against various peptide substrates expressed as a percentage of initial 
velocity against Z-FR-AMC.  (A) FhCatL5, FhCatL2 and FgCatL1G; (B) FhCatL2 and 
variant; (C) FhCatL5 and variants.  Data derived from Table 4.3. 
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Table 4.3:  Initial velocities against various substrates 
 
 
 
 
 
 
Initial velocities determined from release of AMC from 1µM of fluorogenic substrates at pH 5.5 in enzyme buffer.  Expressed as a percentage of the 
initial velocity against Z-FR-AMC. 
 
 
Substrate 
FhCatL5 FhCatL5 
L69Y 
FhCatL5 
L69W 
FhCatL5 
L69C 
FhCatL5 
L69S 
FhCatL5 
L69F 
FhCatL2 FhCatL2 
Y69L 
FgCatL1G 
Z-FR-AMC 100 100 100 100 100 100 100 100 100 
PFR-AMC 36 138 258 148 154 85 83 25 240 
Boc-Bz-DPR-AMC 2.5 1.1 76 4.3 4.3 3.4 23 27 359 
Tos-GPR-AMC 3.7 14 94 9.2 5.2 6.7 307 178 12756 
Boc-AGPR-AMC 4.1 7.6 126 8.7 14 7.7 227 45 7514 
Boc-VPR-AMC 1.7 4.1 39 3.0 1.6 1.8 48 17 544 
D-VLR-AMC 1792 333 193 309 1034 203 77 986 1629 
Boc-VLK-AMC 1970 662 1840 2279 5798 1605 450 2237 444 
Bz-FVR-AMC 130 6 113 86 424 55 28 50 945 
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lysine at P1.  Despite the high initial velocities for Tosyl-GPR-AMC and Boc-AGPR-AMC, 
comparison of Boc-VPR-AMC and D-VLR-AMC showed a 4-fold higher initial velocity for 
the latter, indicating a preference for leucine at P2. 
The introduction of substitutions at aa69 in FhCatL2 and FhCatL5 resulted in slight variances 
to the initial velocities of the enzymes.  All substitutions in FhCatL5 resulted in higher initial 
velocities against PFR-AMC when compared to Z-FR-AMC.  This may be due to the 
variants’ ability to better accommodate for the backbone restraint caused by proline that could 
influence interaction with the S3 subsite.  Compared to FhCatL5, the relative preferences for 
D-VLR-AMC decreased in all variants, however an increase for Boc-VLK-AMC was 
observed with -L69C and -L69S.  The serine substitution also resulted in almost a 4-fold 
increased preference for Bz-FVR-AMC.  Alternatively, the tyrosine substitution resulted in an 
initial velocity for Bz-FVR-AMC that was considerably lower.  While the initial velocities 
against P2 proline containing substrates generally remained low, minor increases were 
observed in all FhCatL5 variants, most significantly in the Trp69 variant with the increase in 
initial velocity against Boc-AGPR-AMC most profound. 
The Y69L substitution introduced into FhCatL2 lessened the ability to accommodate proline 
at P2 when compared to FhCatL2.  The preference for PFR-AMC relative to Z-FR-AMC was 
also lowered, while the initial velocities of Bz-FVR-AMC and the P2 leucine substrates were 
higher than observed for FhCatL2. 
4.3.6 Progress curves 
As initial velocities only indicate relative preferences, progress curves were used to predict 
kcat/Km.  When substrate cleavage is followed at substrate concentrations at least 10-fold lower 
than Km the resultant curve can be used to estimate kcat/Km (Figure 4.9 for example curve).  
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These results compare well with both the initial velocity data and the individual estimate kcat 
and Km values.  The progress curve data indicated that FhCatL5 has a clear preference for 
leucine at P2, while phenylalanine is much more readily accepted than proline (Table 4.4; 
Figure 4.10).  The Tyr69, Phe69 and Trp69 substitutions all resulted in an increased 
preference for proline at P2, although levels were still several-fold lower than for 
phenylalanine.  The efficiency against the aliphatic P2 possessing substrates D-VLR-AMC, 
Boc-VLK-AMC and Bz-FVR-AMC all decreased.  Ser69 and Cys69 substitutions resulted in 
decreased efficiency against most substrates tested, although efficiency against substrates with 
leu at P2 remained comparable to FhCatL5, while efficiency against Bz-FVR-AMC was also 
relatively high for the Ser69 variant.  
Like FhCatL5, FhCatL2 has a preference for leucine over proline at P2, although to much a 
lesser degree, while the FhCatL2 efficiencies against proline and phenylalanine substrates 
overlap.  The introduction of Leu69 into FhCatL2 resulted in an increased efficiency against 
D-VLR-AMC, Boc-VLK-AMC and Bz-FVR-AMC, while the proline and phenylalanine P2 
substrates were less efficiently catalysed. 
As the earlier results showed, FgCatL1G has low efficiency compared to the other enzymes.  
The order in which this enzyme appears to prefer amino acids at P2 is Leu ≈ Pro > Phe. 
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Figure 4.9:  Typical progress curves for cleavage of fluorogenic substrates by FhCatL. 
The release of AMC from cleavage of 0.1-1 µM of fluorogenic substrate in the presence of 
FhCatL in enzyme buffer was followed over 4 hours at 37˚C.  The solid lines are the results of 
non-linear curve fitting as seen in Equation 4.3 (Section 4.2.6.1.3).  The values from the 
progress curves are seen in Table 4.4. 
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Table 4.4:  kcat/Km (M-1s-1) values determined from progress curves 
 
 
 
 
 
 
-
a
 below detection limit 
 
Substrate 
FhCatL5 FhCatL5 
L69Y 
FhCatL5 
L69W 
FhCatL5 
L69C 
FhCatL5 
L69S 
FhCatL5 
L69F 
FhCatL2 FhCatL2 
Y69L 
FgCatL1G 
Z-FR-AMC 4.74 x105 9.16 x105 1.52 x105 3.48 x105 2.22 x105 1.22 x106 1.84 x105 1.02 x105 -a  
PFR-AMC 1.49 x105 1.25 x106 2.11 x105 8.38 x105 2.87 x105 7.97 x105 5.85 x104 2.83 x104 -a  
Boc-Bz-DPR-AMC 1.01 x104 1.63 x104 7.52 x104 1.02 x104 1.77 x104 2.33 x104 2.87 x104 2.47 x104 1.13 x104 
Tos-GPR-AMC 2.44 x104 1.64 x105 8.43 x104 1.06 x104 8.42 x103 4.43 x104 1.46 x105 6.12 x104 3.85 x104 
Boc-AGPR-AMC 1.66 x104 1.61 x105 1.19 x105 8.93 x103 1.17 x104 3.56 x104 1.10 x105 4.55 x104 3.38 x104 
Boc-VPR-AMC 2.24 x104 1.65 x104 5.27 x104 4.48 x103 3.42 x103 1.68 x104 6.73 x104 4.45 x104 5.01 x103 
D-VLR-AMC 5.42 x106 1.28 x106 3.08 x105 1.40 x106 2.14 x106 9.12 x105 9.10 x104 1.62 x106 3.83 x104 
Boc-VLK-AMC 7.22 x106 1.33 x106 1.39 x106 6.24 x106 1.07 x107 5.05 x106 5.03 x105 1.78 x106 6.75 x103 
Bz-FVR-AMC 7.81 x105 4.24 x104 1.82 x105 2.26 x105 6.29 x105 3.72 x105 5.33 x104 1.16 x105 1.81 x104 
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Figure 4.10:  kcat/Km (M-1s-1) values determined from progress curves. 
Data derived from Table 4.4. 
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4.4 Discussion 
4.4.1 pH optima and stability 
The influence of pH on the activity and stability of the recombinant proteases provides an 
insight into their possible roles in their native environment.  While most mammalian 
lysosomal cathepsins have acidic pH optima and are quickly inactivated at neutral pH, 
helminth cathepsins tend to possess broad activity profiles and stability at neutral pH (Chung 
et al., 1995; Shin et al., 2001; and reviewed in Brady et al., 1999a; Sajid and McKerrow, 
2002).  While S. mansoni and S. japonica cathepsin L2, which are thought to have divergent 
functions have acidic pH optima (Day et al., 1995; Brady et al., 2000a), the Fasciola 
cathepsins in this study exhibited broad pH profiles, with optimal activity at pH 7.  This 
corresponds to other studies on Fasciola cathepsin L-like proteases which report broad 
activity, which is optimal at or near physiological pH (Wijffels et al., 1994a; Dowd et al., 
1997; Roche et al., 1997l; Stack et al., 2008).  Native Fasciola cathepsin L1 has been shown 
to be extremely stable at pH 7 (Dowd et al., 2000), and while the enzymes analysed in this 
study did not show quite the same level of stability, FhCatL5 and FhCatL2 were also most 
stable at physiological pH.  Interestingly, FgCatL1G was most stable at pH 6, with activity 
dropping markedly at pH 7.  The broad pH profiles and stability at physiological pH observed 
with FhCatL2 and FhCatL5 are consistent with other reports on Fasciola cathepsin L-like 
proteases and suggests these cathepsins perform functions external to the parasites gut, either 
once expelled into the surrounding host environment or possibly at other sites within the fluke 
such as the Mehlis gland.  The altered pH stability profile of FgCatL1G, combined with the 
need for a near neutral pH during its activation, as outlined in the previous chapter, may 
reflect its different expression profile compared to other Fasciola cathepsin L-like proteases, 
with the enzyme active in different environmental conditions to enzymes of other clades.  The 
pI of clade A cathepsins differ from their adult expressed counterparts which are generally 
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around 5.  The theoretical pI of native FgCatL1G is 6.98.  The pI of Fasciola cathepsins is 
discussed in more detail in chapter 5, however pI values near the pH of the surrounding 
environment are unusual due to issues with insolubility and stability, and the pI value of 
FgCatL1G may reflect its primary use in an environment distinct from the near neutral 
physiological host environment encountered by cathepsins in the ES of mature fluke.   
FgCatL1G and other clade A cathepsins have to date only been isolated from metacercariae or 
NEJ flukes (Harmsen et al., 2004;Cancela et al., 2008;Sobhon et al., unpublished) and are 
thus likely to encounter different environmental conditions and undertake different roles to 
cathepsins of mature flukes.  FgCatL1G cDNA has been isolated from metacercariae, as such 
it is probable that it is involved in excystment, with recent work supporting such a role 
(Cancela et al., 2008), although other possible roles may include migration and immune 
evasion during the fluke’s development.  The pH of the duodenum in humans is 6-6.5.  This 
pH would enable efficient processing of the zymogen and good stability for the mature 
activate enzyme.  Such conditions are also near optimal pH for FgCatL1G activity.   
With the primary roles of FgCatL1G possibly involving digestion of fluke structural proteins 
(excystment) or host structural proteins (migration), the shorter half-life of FgCatL1G at 
physiological pH may also ensure protease degradation before the enzyme is able to cause 
non-specific damage, either to the fluke itself or to the host once the fluke leaves the 
duodenum.   
4.4.2 Fasciola enzyme specifity. 
The S2 subsite exerts a dominant influence on the specificity of cysteine proteases, and in this 
study FhCatL5 showed a clear preference for leucine at P2.  Similar preferences of leucine 
over phenylalanine at the P2 position have also been reported for FhCatL1 and FhCatL2 
(Dowd et al., 1994; Stack et al., 2008), and have been observed in HuCatK and HuCatS, and 
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certain parasite cysteine proteases (Brady et al., 2000b; Lecaille et al., 2007).  The relatively 
high kcat/Km values for FhCatL5 obtained against Bz-FVR-AMC as compared to Z-FR-AMC 
suggest that the S2 subsite of FhCatL5 has a specific preference for aliphatic residues as also 
seen with FhCatL1 (Dowd et al., 1994; Stack et al., 2008), rather than just bulky hydrophobic 
residues.  These results contrast with the S2 subsite preference of HuCatL which more readily 
accommodates the aromatic phenylalanine over the aliphatic leucine.  Differences at residue 
209, leucine in the Fasciola cathepsins and alanine in HuCatL can cause such a dramatic shift 
in specificity (Lecaille et al., 2002a; Stack et al., 2008). 
The FhCatL2 enzyme also showed a preference for leucine at P2, although activity was 
considerably lower than observed with FhCatL5.  Activity against P2 phenylalanine was also 
diminished when compared to FhCatL5, although to a lesser degree.  The unusual ability to 
accommodate proline at P2 as reported on several previous occasions was also evident (Dowd 
et al., 1994; Smooker et al., 2000; Stack et al., 2008).  This ability has been partially 
attributed to the Tyr69 of FhCatL2.  Smooker and colleagues (2000) were able to show that 
substitution of L69Y in FhCatL5 resulted in an increased ability to accommodate Pro at P2.  
While substrate preferences were not completely altered at the S2 subsite, it did suggest that 
aa69 was important to subsite architecture and through that, substrate specificity and protein 
function.  A similar study by Lecaille et al. (2002a), was able to produce HuCatL-like activity 
in HuCatK, including a reduction in activity against proline by dual substitution of Y69L and 
L205A.  Similar studies changing just one or two amino acids in the S2 subsites of cysteine 
proteases, highlight the importance of these amino acids to the architecture of the S2 subsite 
and enzyme specificity (Khouri et al., 1991; Hasnain et al., 1993; Bromme et al., 1994; 
Barlic-Maganja et al., 1998; Chan et al., 1999; Lecaille et al., 2002a; Stack et al., 2008). 
The F.gigantica cathepsin L1G showed considerably lower activity than the other enzymes 
studied.  The substrates with leucine or proline at P2 were the most efficiently cleaved.  
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Cleavage of both P2 phenylalanine substrates was very poor, with levels too low for progress 
curve analysis to be undertaken.  The low affinity for these P2- S2 interactions was evident by 
the relatively high Km value obtained with Z-FR-AMC.  FgCatL1G has the large hydrophobic 
tryptophan at position 69.  The sidechain is expected to sit in a similar orientation to the 
corresponding tryptophan in GP-II (Choi et al., 1999).  Such an orientation leads to a smaller 
hydrophobic pocket, which cannot easily accommodate larger residues due to steric 
hindrances with the tryptophan.  This size exclusion would be expected to influence 
specificity away from phenylalanine, and towards proline.  Like other Fasciola cathepsins, it 
has aliphatic residues lining the far wall and base of the active site at aa160 and aa209.  At 
aa160 it possesses a valine rather than leucine like FhCatL5 and -L2.  A valine is also present 
at residue 209.  Typically in Fasciola cathepsins this residue is a leucine which extends from 
the base of the subsite.  The residue at aa160 has been proposed to act as a ‘gatekeeper’ in 
combination with aa69 (Stack et al., 2008), while aa209 is considered important to substrate 
specificity, with alterations at this site capable of substantially altering substrate specificity 
(Barlic-Maganja et al., 1998; Stack et al., 2008).  The similarity of valine and leucine 
suggests the influence of this substitution would be smaller than the leucine to alanine 
substitutions in the referred articles.  Valine is present in all clade A (W69) Fasciola 
cathepsins sequenced to date, and would not be expected to extend into the pocket as far as an 
equivalent leucine.  This minimises any possible disturbing influences of aa209 on the 
sidechain of Trp69 without dramatically extending the size of the active site (Figure 4.1).   
These amino acid differences to the S2 subsite make the specificity of FgCatL1G unique 
among Fasciola cathepsins, having relatively good activity against proline, while having very 
poor activity against phenylalanine.  The activity against substrates with leucine and proline at 
P2 were also similar.  This differs from the specificity observed for FhCatL2 which while able 
to accept proline, also accepts phenylalanine and has a preference for leucine at P2.  Other 
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cysteine proteases possessing tryptophan at the equivalent to aa69 that exhibit specificity for 
proline include GP-II (Choi et al., 1999) and crustapain (Aoki et al., 2003).   
4.4.3 Influence of aa69 substitutions. 
The sidechains of residues lining the S2 subsite determine cathepsin specificity, and 
mutagenesis studies have shown the importance a single amino acid can have on the subsite 
architecture and substrate specificity of an enzyme.  The enzyme kinetic results obtained in 
this study reinforce those obtained by Smooker et al., (2000) where a single mutation at aa69, 
can alter the substrate specificity of a cathepsin.  The tyrosine residue reduces the size of the 
active site, increasing the enzyme efficiency against P2 proline by allowing the pyrrolidine 
ring of the P2 proline to pack tightly against the phenolic ring of the Tyr69 sidechain.  Despite 
aa69 being the major S2 subsite difference between FhCatL2 and FhCatL5, the L69Y 
substitution did not produce complete FhCatL2-like specificity in FhCatL5.   
As enzyme specificity is likely to be determined by the complex interplay of amino acids, one 
of the more understated S2 subsite differences at aa161 and aa163, or substitutions removed 
from the S2 active site may also play important roles. 
This is highlighted by the results in a recent publication by Stack et al.(2008) where the L69Y 
substitution introduced into FhCatL1 did not result in a discernable change in substrate 
specificity.  While FhCatL1 and FhCatL5 share high amino acid identity, several S2 subsite 
forming residues are not conserved.  These residues which line the far wall of the S2 subsite 
may act in combination with aa69 to allow residues entry to the S2 subsite, thus limiting the 
influence of substitutions at aa69.  The greater similarity within these residues between 
FhCatL2 and FhCatL5 enable the influence of aa69 to be more easily identified. 
Comparable to the work undertaken by Smooker and colleagues (2000), a Y69L substitution 
was introduced into FhCatL2.  This resulted in a decrease in the enzyme’s ability to 
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accommodate Pro in comparison with the wildtype, both affinity and turnover being 
diminished.  Similar to the corresponding L69Y substitution in FhCatL5, the change in 
specificity was only partial, once again indicating the importance of other residues in 
determining S2 subsite specificity. 
A recent publication by Lecaille and colleagues (2007), who altered HuCatK and HuCatL 
introducing mirror Y/L69 and L/A209 substitutions, almost completely switched substrate 
specificities of the enzymes regarding leucine and phenylalanine, and to a lesser degree 
proline P2 residues. 
As mentioned previously, the aliphatic/aromatic preferences of FhCatL5 and HuCatL differ.  
A major reason for this appears to lie with aa209 which sits at the base of the S2 subsite, 
HuCatL possessing alanine rather than leucine in this position.  Stack et al, (2008) have 
shown that an L209A substitution in FhCatL1 increases the S2 subsites preference for 
aromatic residues (FWY) while diminishing preferences for aliphatic (LVI) residues.  Earlier 
work by Bromme et al. (1994), with mutagenesis work on human cathepsin S showed that 
residue 135, which lines the right wall of the S2 subsite, can also play a role in influencing the 
S2 subsites preference for aliphatic and aromatic residues.  While this residue is conserved 
amongst the Fasciola and most human cathepsins as alanine it does indicate that aa209 is not 
necessarily the only determining residue.  The human cathepsins –L and –V share similar S2 
active sites, with just two differences, L69F and M160L.  Both possess Ala135 and Ala209 at 
the floor and base of the S2 subsite.  The enzyme kinetics, more specifically the 
leucine/phenylalanine preferences of these similar enzymes, with HuCatL favouring 
phenylalanine and HuCatV showing an even preference, show that aa209 is not the only 
residue to influence this form of substrate recognition, with aa69 also possibly playing a role 
(Bromme et al., 1999). 
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The data in this study also suggests that aa69, while not possessing the same influence as 
aa209, also plays a role in the relative preference the S2 subsite has for aliphatic versus 
aromatic residues.  Along with an increase in the efficiency against proline, the L69Y 
substitution in FhCatL5 also altered the respective preference for aliphatic and aromatic P2 
residues.  FhCatL5 has a clear preference for leucine, and to a lesser degree valine over 
phenylalanine at P2.  The L69Y substitution resulted in a large drop in enzyme efficiency 
towards leucine and valine at the S2 subsite when compared to phenylalanine, thus producing 
a more even, FhCatL2-like specificity.  The alternate Y69L substitution in FhCatL2 resulted 
in the opposite scenario, with leucine and valine more readily accepted compared to 
phenylalanine, a more FhCatL5-like specificity.  However, in both cases the change in 
substrate specificity was only partial. 
The sidechain of phenylalanine is similar to tyrosine, the exception a lack of an –OH group.  
The L69F substitution to FhCatL5 had a similar influence to the L69Y substitution, although 
the increase in proline acceptance, and shifting of aromatic and aliphatic preferences was less 
dramatic than with the L69Y scenario.  While the sizes of the respective side chains are 
similar, the polar nature or tyrosine compared to the non-polar phenylalanine appears to be 
important to the S2-P2 interactions.   
Modeling work undertaken and described in Irving et al. (2003) extrapolated a proposed role 
for Trp69 in Fasciola cathepsins, producing a shallower hydrophobic pocket most accepting 
of small hydrophobic residues such as proline.  The current study showed that FgCatL1G 
naturally possessing Trp69 can, like the Tyr69 possessing FhCatL2, accommodate Pro at P2.  
The role of Trp69 in this ability was confirmed by the development of the FhCatL5 L69W 
variant.  This variant indeed showed an increase in preference for proline respective to other 
residues.  Similar to that observed in FgCatL1G, the L69W variant, with its small S2 pocket 
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resulted in a general decrease in activity against the other larger hydrophobic residues tested.  
This is most likely due to steric hindrances brought about by the tryptophan sidechain. 
As mentioned, FhCatL2 can also accept pro at P2.  The high levels of conservation among 
members of clades of Fasciola cathepsins suggest that other Tyr69 possessing (clade B) 
cathepsins, both in F. hepatica and F. gigantica would show similar substrate preference to 
FhCatL2, including the ability to accept proline.  The Phe69 possessing Fasciola cathepsins, 
appear to have evolved between the Tyr69 and the Leu69 clades.  While the Phe69 cathepsins 
would be expected to confer preferences similar to those possessing Tyr69, differences at 
other residues lining the S2 subsite, most noticeable Phe209 or Met209 in these cathepsins 
may themselves alter the substrate specificity.  HuCatS, itself possessing Phe69 also possesses 
a phenylalanine at aa209.  Crystal structures of Cathepsin S indicate that Phe209 does not 
extend into the active site like leucine and make the pocket smaller, nor does Met209 in 
HuCatF.  Mutagenesis studies involving HuCatS indicate that a F209A substitution does not 
change the aliphatic>aromatic preference (Bromme et al., 1994), however the apparently 
conservative G135A substitution causes a flip in this preference.  This is interesting as all 
Fasciola cathepsins possess Ala135, yet to date all prefer leucine over phenylalanine in the S2 
subsite.  In the native Fasciola cathepsins the presence of the large Phe69 sidechain reducing 
pocket size and interacting with the proline ring, in a manner similar to that proposed with 
Tyr69 would be expected to cleave substrates with P2 proline.  Furthermore, the lengthening 
of the S2 pocket produced by the presence of the Phe209 or Met209 may influence this 
preference marginally, allowing access to larger hydrophobic P2 residues, resulting in an 
increased preference towards aromatic compared to aliphatic residues. 
These results, as postulated by Irving and colleagues (2003) indicated that the ancestral 
Fasciola cathepsins possessing Trp69 were able to accommodate proline.  As the newer 
clades of enzymes evolved, slightly larger S2 subsites possessing Tyr69 and Phe69 retained 
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this ability, while larger hydrophobic residues such as phenylalanine were also more easily 
accommodated.  The more recently evolved Leu69 Fasciola cathepsins with their strong 
preference for aliphatic P2 residues and poor efficiency against proline are therefore more 
recent evolutionary developments. 
Prior to the commencement of this project, only Trp69, Leu69 and Tyr69 Fasciola cathepsins 
had been discovered.  As such a gap existed in the evolutionary process, as F69, C69 or S69 
cathepsins would be required to be produced between the mutation of alleles L69 and Y69 by 
virtue of codon usage.  While Phe69 homologous cysteine proteases had been discovered no 
C69 or S69 homologues where evident, suggesting a possible structural or functional 
compromise. 
The L69C and L69S variants produced in this study were able to be activated and could 
cleave synthetic peptides.  The smaller size of the side chains means they do not extend into 
the active site as far as the other amino acid variants trialled, creating a larger active site.  As 
such the ability to efficiently accommodate proline was very poor.  The affinity of their S2 
active sites for Z-FR-AMC was higher, Km values about half those of FhCatL5, however poor 
turnover meant the overall efficiency was reduced.  The preferences however were similar to 
those of FhCatL5, with a strong preference for aliphatic compared to aromatic P2 residues. 
The evolution of Fasciola cathepsins passed from Trp69 to Tyr69, then passed through Phe69 
on the way to Leu69.  The absence of Ser69 and Cys69 in Fasciola cathepsins, and among 
homologous cysteine proteases appears to be due to the fact that although functional these 
variants provided no alteration to the substrate preferences present with Leu69, at least in the 
conformation present in FhCatL5, and only offered diminished overall efficiency. 
The S2 subsite exerts a dominant influence on the specificity of cysteine proteases, thus 
studies on this region in several members of the papain superfamily has been undertaken.  
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Mutagenesis studies have shown the importance a single amino acid can have on the subsite 
architecture and substrate specificity of an enzyme.  The enzyme kinetic results obtained in 
this study reinforce those obtained by Smooker et al. (2000), where a single mutation at aa69, 
can alter the substrate specificity of FhCatL5.   
The interaction of amino acid side chains can influence other substitutions, and both size and 
properties of the substituted amino acid influence the effect on the active site.  At aa69, the 
introduction of large aromatic residues (YWF) increases proline P2 accessibility by reducing 
subsite size and generating subsequent interaction with the P2 substrate.  The preference for 
aromatic over aliphatic residues also increases, although this is countered by the smaller 
subsite, and steric hindrances caused by the size of the sidechain.  The presence of Leu69 
appears to increase the relative preference towards other aliphatic P2 residues, possibly 
through stabilising interactions in combination with those at aa209.  The presence of the 
smaller serine and cysteine residues open up the subsite, however without the stabilising 
interactions provided by the side-chains of the larger residues overall efficiency of the enzyme 
drops. 
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5.1 Introduction 
Numerous mammalian cysteine proteases classes have been identified, with most expressed in 
lysosomes.  They perform a variety of functions, with cathepsin L the most active (Barrett and 
Kirschke, 1981; Kominami et al., 1991).  Besides mammals, a variety of other organisms 
utilise cathepsin L-like cysteine proteases, including parasites and pathogens such as 
trematodes and protozoa (reviewed in McKerrow et al., 1993; Tort et al., 1999; Sajid and 
McKerrow, 2002). 
Fasciola spp. have an extensive repertoire of papain-like cysteine proteases.  There are over 
30 cathepsin L-like sequences contained in the non-redundant GenBank database, derived 
from parasite mRNA, as well as two genomic gene sequences.  A majority of sequences 
encode F. hepatica proteins. 
As mentioned in chapter 1, these proteases have been proposed to be involved in a variety of 
functions including immune evasion, immune modulation, migration and feeding. 
Phylogenetic analysis of Fasciola cathepsin L-like proteases has shown that they are related 
to mammalian cathepsin K, L and S, and that they belong to a monophyletic clade, arising 
from a single gene (Tort et al., 1999; Irving et al., 2003).   
The Fasciola cathepsin L monophyletic clade can be further subdivided into clades that share 
sequence similarity.  These clades are proposed to reflect subsite architecture and 
subsequently substrate specificity (Smooker et al., 2000; Irving et al., 2003).  All clades 
possess sequences that encode proteins from both F. hepatica and F. gigantica, and it has 
been shown that both species express a number of cathepsin L-like proteases simultaneously 
(Dalton and Heffernan, 1989; Heussler and Dobbelaere, 1994; Grams et al., 2001; Jefferies et 
al., 2001; Morphew et al., 2007). 
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Phylogenetic analysis of Fasciola cathepsin L-like proteases has been used, along with GST 
gene sequences to estimate the divergence of the two Fasciola species to 19 MYA (Irving et 
al., 2003).  This work also highlighted periods of gene duplication and evolution, which 
correspond with the time of divergence of host species, suggesting co-evolution of Fasciola 
with its host species.  
Since the phylogenetic analysis of Tort and colleagues (1999) and then Irving and colleagues 
(2003), the number of gene sequences added to public databases has continued to increase, 
resulting in the need for an update of the phylogenetic analysis of the Fasciola cathepsin L-
like proteases.   
This chapter will further the work already undertaken on the phylogenetic analysis of 
Fasciola cathepsin L-like proteases by including sequences newly added to public databases.  
A search of both the genome and mRNA sequences of F. gigantica isolates was also 
undertaken in an attempt to find novel gene sequences, which were also included in the 
phylogenetic analysis.  The number and variety of cathepsin L-like transcripts isolated also 
provides a clue to the relative expression levels amongst the cathepsin L-like proteases in 
adult F. gigantica. 
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5.2 Materials and Methods 
5.2.1 Template DNA and RNA 
DNA and RNA was extracted from F. gigantica flukes, stored at −80°C.  The flukes, kindly 
provided by Prof. Terry Spithill were field isolates obtained from cattle in Bogor, Indonesia.  
Genomic DNA was purified using the Wizard® genomic DNA purification kit as per the 
manufacturers’ protocol.  Template RNA was isolated using the RNAgents® total RNA 
isolation system (Promega). 
5.2.2 ITS2 analysis 
The second internal transcribed spacer (ITS2) of the nuclear ribosomal RNA cluster was 
amplified by PCR using the primers ITS2 F BamHI and ITS2 R EcoRI (Table 5.1).  Fluke 
genomic DNA was used as template at a concentration of 100 ng per reaction.  The PCR 
annealing temperature was 50°C, with a 2 min extension step repeated 35 times, in the 
presence of Pfu polymerase.   
Table 5.1:  ITS2 primers 
Name Sequence 5'-3' Description 
ITS2 F BamHI CGCGGATCCTATTGCGGCCATGGGTT Generation of ITS2 region 
ITS2 R EcoRI GCGGAATTCAGCGGGTAATCACGTC Generation of ITS2 region 
Restriction sites incorporated into primers are underlined. 
The PCR product was directly digested with a variety of restriction enzymes.  The fragments 
were separated by electrophoresis and visualised on a 4% agarose gel run at 60 V for 150 min 
and stained with ethidium bromide.   
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The PCR product was also cloned into pBluescript.  The PCR product was cleaned using the 
Wizard® PCR preps DNA purification kit.  The cleaned PCR product and isolated 
pBluescript, were digested with BamHI and EcoRI overnight at 37°C in Promega 1× 
MultiCore buffer in the presence of BSA.  The restriction enzymes were heat inactivated, and 
pBluescript dephosphorylated with alkaline phosphatase.  The samples were then ligated in 
the presence of 100 µM ATP.  The ligation product was cleaned, then electroporated into 
DH5α.  Colonies were subjected to blue-white screening.  Several white colonies were 
cultured overnight in LB broth containing ampicillin.  Plasmids were isolated from the 
cultures and inserts confirmed by digestion with BamHI and EcoRI overnight, then separation 
by electrophoresis on a 1% agarose gel.  The sequence of the amplified ITS2 region was 
confirmed by DNA sequencing from two clones.  ITS2 sequences were aligned using the 
program ClustalX (Thompson et al., 1997). 
5.2.3 Genome gene search 
5.2.3.1 PCR conditions 
5.2.3.1.1 Genomic DNA 
The cathepsin L genes were amplified by PCR with Taq polymerase using a variety of 
different primer combinations.  Standard PCR conditions are stated in Section 2.5.4.2.1, while 
the primers used are listed in Table 5.2.  For the genomic search, primers without restriction 
sites were used.  These included FCLF139 and FCLF384 as sense primers; and FCLR944 and 
FCLR981 as antisense primers.  The PCR annealing temperature was 51°C with an elongation 
step of 2.5 min over 35 cycles.  The genomic DNA for template was added to a final 
concentration of 100ng in a 25µL PCR reaction. 
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Table 5.2:  Fasciola gene search primers 
Name Sequence 5'-3' Description 
FCLF139 AATGYGAAACATATYSAAGA Denenerate forward primer, matching bp 139-158 cathepsin L gene 
FCLF385 TGYGGNTCNGGYTGGGCNTT Denenerate forward primer, matching bp 385-404 cathepsin L gene 
Reverse868 TRTTYTTNACNRTCCARTA Denenerate reverse primer, matching bp 850-868 cathepsin L gene 
Reverse905 CGNAWRTARCCNYNBTCNCC Denenerate reverse primer, matching bp 884-905 cathepsin L gene 
FCLR944 GAAGMAATTSCACACAT Denenerate reverse primer, matching bp 928-944 cathepsin L gene 
FCLR981 TCACGGRAATYGTKCCACC Denenerate reverse primer, matching bp 963-981 cathepsin L gene 
FCLF BamHI 139 CGCGGATCCAATGYGAAACATATYSAAGA Denenerate forward primer, matching bp 139-158 cathepsin L gene 
TFEEFK BamHI 226  CGCGGATCCACNTTYGARGARTT Denenerate forward primer, matching bp 226-239 cathepsin L gene 
FCLF BamHI 245 CGCGGATCCAAATATCTAAYRGAAT Denenerate forward primer, matching bp 245-263 cathepsin L gene 
CGCWAFS BamHI 384 TGYGGATCCGGYTGGGCNTT Denenerate forward primer, matching bp 394-404 cathepsin L gene 
Gtdywi BamHI R 857 CGCGGATCCARTARTCNGTNCC Denenerate reverse primer, matching bp 841-857 cathepsin L gene 
Knswg BamHI R 876 CGCGGATCCCCANSWRTTYTT Denenerate reverse primer, matching bp 862-876 cathepsin L gene 
Reverse BamHI 890 CGCGGATCCTCACCCCASBACDWTCCCCA Denenerate reverse primer, matching bp 871-890 cathepsin L gene 
Nmcgia BamHI R 941 CGCGGATCCGCDATNCCRCACATRTT Denenerate reverse primer, matching bp 925-941 cathepsin L gene 
Reverse BamHI 957 CGCGGATCCGASACTGGCCASMGAAG Denenerate reverse primer, matching bp 941-957 cathepsin L gene 
FCLR BamHI 981 CGCGGATCCTCACGGRAATYGTKCCACC Denenerate reverse primer, matching bp 963-981 cathepsin L gene 
PolyA BamHI CGCGGATCCTTTTTTTTTTTTTTT Primer for generation of poly A cDNA products 
Restriction sites incorporated into primers are underlined. 
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5.2.3.1.2 mRNA 
F. gigantica mRNA was initially amplified by reverse transcriptase using the PolyA BamHI 
primer (2.5.4.2.3).  One microlitre of reverse transcriptase product was used as template for 
the subsequent PCR using Pfu polymerase.  The annealing temperature was 50°C with an 
elongation step of 6 min over 35 cycles.  The PolyA BamHI primer was always used as the 
antisense primer, however either FCLF BamHI 139, TFEEFK BamHI 226, FCLF BamHI 245 
or CGCWAFS BamHI 384 were used as the sense primer.  All primers contained BamHI 
restriction sites, allowing for digestion and sticky-end ligation. 
The PCR for relative transcription levels was stopped after 25 cycles to make sure 
amplification had not reached a plateau, and ensured the semi-quantitative nature of the 
amplification.  Only primers CGCWAFS BamHI 384 and PolyA BamHI were used in this 
reaction.   
5.2.3.2 Cloning 
5.2.3.2.1 TA cloning 
F. gigantica genomic DNA amplified by PCR was inserted into pCR®2.1 according to the 
manufacturers protocol.  Briefly, PCR product was analysed by gel electrophoresis and the 
concentration estimated.  The PCR product (1 µg) was mixed with 50 ng pCR®2.1 vector, in 
1× Ligation Buffer with 3U T4 DNA ligase in a total volume of 10 µL.  The ligation was 
incubated overnight at 16°C.  The ligation was spun briefly by centrifugation, and then placed 
on ice.  Samples were either heat shock- or electro-transformed into competent cells (InvαF or 
TOP10F’). 
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5.2.3.2.2 mRNA derived cloning 
PCR amplified mRNA was cloned into pBluescript.  The PCR product was cleaned using the 
Wizard® PCR prep DNA purification kit.  pBluescript, previously isolated from DH5α using 
the alkaline lysis method and the purified PCR product were both digested overnight with 
10U BamHI.  Both samples were heat inactivated, and the digested plasmid was 
dephosphorylated with alkaline phosphatase.  The PCR product was then ligated into 
pBlusecript without further purification.  The ligation reaction was cleaned and electro-
transformed into competent DH5α cells.  Colonies were then screened for inserts.   
5.2.3.3 Screening 
5.2.3.3.1 Genomic DNA clone screening 
Colonies containing inserts were initially determined by blue-white screening.  After blue-
white screening, suitable isolated colonies were grown in LB + ampicillin and subcultured 
onto LB + ampicillin plates.  Plasmid DNA was isolated from broth cultures and the insert 
excised by digestion with EcoRI overnight in the presence of BSA.  The digested products 
were separated and visualised by agarose gel electrophoresis.  Plate cultures were used for 
colony hybridisation analysis.  Samples where chosen depending on insert size and probe 
specificity during colony hybridisation, and were sequenced using the M13-20 and M13 
Reverse primers.   
5.2.3.3.2 mRNA derived clone screening 
Blue-white screening was used to identify colonies containing an insert.  Isolated white 
colonies were grown in LB + ampicillin, shaking overnight at 37°C.  An aliquot of broth 
culture was diluted 1:30 with mH2O, 1µL of which was then used as template in a PCR using 
Taq polymerase, with the primers CGCWAFS BamHI 384 and PolyA BamHI.  An elongation 
time of 30 s, with 35 cycles and an annealing temperature of 52°C were used for the PCR.  
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The PCR products were visualised by agarose gel electrophoresis.  PCR products of the 
expected size (~670 bp) were digested with Sau3AI or NlaIII before again being visualised by 
agarose gel electrophoresis.  PCR using M13-20 and M13 Reverse primers on the 1:30 broth 
template was also undertaken to determine the overall size of inserts present. 
During a further search of mRNA derived clones (separate from that incorporating relative 
clone abundance), colonies were also subcultured onto LB+ ampicillin plates, which were 
subsequently used for colony hybridisation analysis.   
5.2.3.3.3 Colony hybridisation analysis 
Colony hybridisation analysis was undertaken using the DIG system for filter hybridisation 
(Boehringer Mannheim) according to the manufacturers’ user’s guide. 
5.2.3.3.3.1 Probe synthesis 
The cathepsin L probe was synthesised from clones produced as described in 3.2.1 
(YEpFLAGFhCatL5, YEpFLAGFhCatL2 and YEpFLAGFgCatL1G).  The PCR reaction 
mix, using Taq polymerase contained 4 mM MgCl2 and the primers CatL1GF and FCLR981 
(Table 3.2 and Table 5.2) in a volume of 50 µL.  The annealing temperature was 50ºC, with 
elongation steps lasting 1 min with 35 cycles.   
The PCR products underwent electrophoresis on agarose gels, were excised and cleaned using 
the GeneClean® kit. 
The probes were labelled using the random prime method using the standard random primed 
DNA labelling reaction.  Briefly, 3 µg of template DNA was diluted to 15 µL with mH20 and 
denatured at 100°C for 10 min, then chilled on ice.  The sample was then mixed into 1× dNTP 
labelling mixture, 1× hexanucleotide mixture and 2U of Klenow enzyme and incubated at 
37°C for 20 h.  The reaction was stopped by the addition of EDTA. 
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5.2.3.3.3.2 Estimating probe yield 
The concentration of the probe was determined by a spot test with DIG-labelled control DNA.  
The probe yield was estimated using the DIG System User’s Guide for Filter Hybridisation 
and diluted to approximately 1 ng/µL., then 10-fold serially diluted 5 times.  The DIG-
labelled control DNA was diluted in DNA dilution buffer to 1 ng/µL, then underwent serial 
10 fold dilutions producing standards ranging from 1 ng/µL to 0.01 pg/µL.  
A piece of Amersham Hybond™-N nylon membrane was spotted with 1 µL of the standards 
in one row, then with 1 µL of the experimental probe on a second row.  The membrane was 
then cross-linked under UV light for 5 min.  The membrane was washed briefly in Maleic 
acid wash buffer, then incubated for 30 min at RT in blocking solution. The membrane was 
then incubated in Anti-DIG Antibody solution for 30 min at room temperature.  Unbound 
antibody was removed by washing twice, for 15 min each, in Maleic acid wash buffer at RT.  
The membrane was incubated in detection buffer for 2 min, before colour developed in 
substrate solution.  Colour development was stopped by washing the membrane with dH2O.  
Experimental probe spot intensities were compared with the standard DIG-Labelled control 
DNA spots to determine the probe concentration. 
The three probes were then combined at an equal concentration, producing the cathepsin L 
probe used for all colony hybridisations.  The final concentration of each probe within the 
final cathepsin probe was 7 ng/mL, diluted in hybridisation solution. 
5.2.3.3.3.3 Colony lifts 
Colonies were hybridised directly onto a Hybond™-N nylon membrane. Briefly, white 
colonies identified by blue-white screening were inoculated onto LB plates containing 
ampicillin and grown at 37°C overnight, then cooled at 4°C for 30 min.  A membrane disc 
was carefully layered onto the surface of the plate, and left for 1 min before it was removed 
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and dried.  The membrane was then subjected to denaturation solution and neutralisation 
solution for 15 min each before 10 min with 2 x SSC.  The DNA was cross-linked to the 
membrane by UV irradiation for 5 min.  Membranes were incubated with 2 mg/mL Proteinase 
K dissolved in 2× SSC for 1 h at 37°C, before cellular debris was removed using filter paper. 
5.2.3.3.3.4 Hybridisation 
The membrane was pre-hybridised at 65°C in hybridisation solution for 1 h.  The probe was 
diluted in hybridisation solution and heated for 5 min at 100°C, cooled on ice, then added to 
the membrane and incubated overnight at 65°C.  The membrane was washed twice with 2× 
SSC wash buffer for 5 min at RT, then washed twice in 0.5× SSC wash buffer for 15 min at 
68°C.  Following the stringency washes, the membrane was equilibrated in Maleic acid wash 
buffer for 1 min, and then incubated in blocking solution for 1 h at RT.  Blocking solution 
was discarded and replaced with Anti-DIG Antibody Solution and incubated for 30 min at 
RT.  Unbound antibody was removed with two, 15 min washes in Maleic acid wash buffer at 
RT.  The membrane was equilibrated in detection buffer for 2 min.  Detection buffer was 
discarded and the membrane was incubated in substrate solution, in the dark until a coloured 
precipitate formed.  Colour development was stopped by washing in dH2O. 
5.2.3.4 Clone analysis 
Clones were analysed by pairwise analysis to determine if overlapping sequences could be 
combined and referred to as a single gene.  Several mRNA- and genomic DNA-derived clones 
were able to be combined to assemble single ‘consensus’ sequences.  While several genomic 
DNA-derived sequences encoded identical amino acid regions, often they possessed 
numerous differences in the intron regions and synonymous substitutions within the coding 
regions.  Due to the clone sequences covering only a part of the complete gene sequence it 
was impossible to determine whether they encoded the same gene or were just closely related.  
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As such, for intron analysis sequences were not combined, while for amino acid alignment 
and phylogenetic analysis sequences were combined to form a single consensus gene 
sequence and designated with a plus sign (+).  When combined consensus sequences (+) were 
used in an analysis the partial sequences used to produce the combined consensus sequences 
were considered redundant, and therefore excluded from that analysis.   
Many of the sequences identified from both genomic DNA- and mRNA-derived cloning 
possess only a few substitutions when compared to each other.  Several substitutions occur in 
the primer binding sites and appear to have been introduced by the use of degenerate primers, 
while errors introduced during PCR amplification cannot be completely discounted as 
discussed by Grams et al. (2001), when analysing these results. 
Nucleotide and encoded amino acid sequences for mRNA- and genomic DNA-derived clones 
can be found in Appendix 2 and Appendix 3.  Combined consensus sequences and associated 
alignments can be found in Appendix 4 and Appendix 5. 
5.2.4 Bioinformatics 
5.2.4.1 Database search 
The nucleotide and protein sequence of FhCatL5 (AF271385, AAF76330) was used to 
perform BLAST (Basic Local Alignment Search Tool; Altschul et al., 1997) searches of the 
NCBI non-redundant database (dated April 26, 2007) for other Fasciola cathepsin L-like 
proteases.  The BLASTN program search identified 37 sequences with expect values of 
5e-120 or above.  A search with the BLASTP program revealed further sequences.  Updates 
to the NCBI database were monitored weekly for any new cathepsin submissions derived 
from Fasciola. 
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Several sequences were also obtained from the preliminary F. hepatica EST database, which 
were produced by the F. hepatica sequencing group at the Sanger Institute and can be 
obtained from ftp://ftp.sanger.ac.uk/pub/pathogens/Fasciola/hepatica/ESTs/. 
5.2.4.2 Alignment 
Fasciola cathepsin L-like protease amino acid sequences were aligned using the program 
ClustalX with default parameters (Thompson et al., 1997).  The DNA sequences were aligned 
based on the amino acid alignment using the Codon Align program to ensure codon to codon 
correspondence. 
The numbering of residues in alignments and throughout this study starts at the valine residue, 
which aligns with residue 1 in mature Human Cathepsin L, and ensures numbering is 
consistent with most other studies.  While there is some disagreement in regard to the start 
site of the mature region of certain Fasciola cathepsin L proteases (Smith et al., 1993b; 
Yamasaki and Aoki, 1993; Wijffels et al., 1994a; Hawthorne et al., 2000), the putative start 
sites of the mature region is stated as starting 1 amino acid upstream of valine 1, and is 
designated ‘0’.  This seems to be the consensus start for most Fasciola cathepsin L proteases 
processed in vivo (Smith et al., 1993b; Dowd et al., 1994; Tkalcevic et al., 1995; Cornelissen 
et al., 1999; Harmsen et al., 2004).   
Outgroups used for phylogenetic analysis were also aligned with ClustalX.  These sequences 
were aligned against a “seed” sequence with site specific gap penalties based on the 
consensus secondary structure of human cathepsin L (1cjl) (Coulombe et al., 1996). 
5.2.4.3 Phylogenetic analysis 
Phylogenetic trees were constructed from DNA and protein alignments using both distance-
based and character-based methods including; (1) bootstrapped (1000-trial) neighbour-joining 
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method (MEGA v3.1, codon based modified Nei-Gojobori/Jukes-Cantor calculation for DNA, 
poisson-based calculation for protein (Kumar et al., 2004); (2) bootstrapped (1000-trial) 
minimum evolution method (MEGA ;Kumar et al., 2004); (3) maximum-parsimony algorithm 
(MEGA;Kumar et al., 2004); and (4) maximum-likelihood algorithm (DNAML, PROTML 
from PHYLIP v3.61 package; (Felsenstein, 1996). 
5.2.4.4 Outgroups 
DNA and protein cathepsin L-like sequences used as outgroups were those used in Irving et 
al. (2003).  These included Bombyx mori (S77508), Bos taurus (P25975; NM_174032), Canis 
familiaris (CAC08809; AJ279008), Cercopithecus aethiops (AF201700), Drosophila 
melanogaster (Q95029; BT016071), Homarus americanus (P25784; X63569) Homo sapiens 
(P07711; M20496), Mus musculus (P06797; J02583), Nephros norvegicus (CAA56915; 
X80990), Rattus norvegicus (P07154; Y00697), Sus scrofa (BAA07140; D37917) and papain 
from Carcaya papaya (P00784; M15203). 
5.2.4.5 Molecular modeling 
Homology modeling was undertaken as outlined in section 3.2.6. 
5.2.4.6 Protein characterisation 
The program Compute pI/MW (Bjellqvist et al., 1993; Bjellqvist et al., 1994; Gasteiger et al., 
2005) in the Expasy suite of programs (http://au.expasy.org/tools/) was used to compute the 
theoretical molecular weight and the isoelectric point of proteins (resolution: average). 
The NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/) was used to predict 
N-glycosylation sites (Gupta et al., 2004), while prediction of O-glycosylation (mucin-type) 
was undertaken with the program OGPET v1.0 (http://ogpet.utep.edu/index.php). 
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5.3 Results 
5.3.1 ITS2 analysis 
While taxonomically identified as F. gigantica, the species of fluke provide for use in this 
study was confirmed by ITS2 analysis due to the presence of interspecific cross-hybridisation 
amongst fluke in south-east Asia (Kendall, 1965; Agatsuma et al., 2000).   
The primers used for ITS2 PCR amplification were complementary to sections within the 
5.8S and 28S genes that flank ITS2, allowing amplification of the complete 362 bp ITS2 
region.   The resultant 458 bp PCR product was digested with NlaIII to check for restriction 
patterns suggestive of either F. gigantica and F. hepatica.  The restriction pattern observed 
was consistent with that of F. gigantica, with bands at the expected sizes of 158, 113, 88, 77 
and 22 bp (Figure 5.1).  The F. hepatica specific banding profile (235, 113, 89 and 22 bp) was 
not present.  A number of other digests with various restriction enzymes were also employed 
to determine if sequence polymorphisms were present among copies of the ITS2 array.  The 
banding profiles suggesting no polymorphisms were present within the flukes (Figure 5.1).   
Several clones containing the ITS2 insert were identified during screening.  The nucleotide 
sequences of two clones were obtained and found to be identical.  Alignment with several 
nucleotide sequences from publicly available databases allowed easy visualisation of the 
species specific sites (Figure 5.2), confirming the ITS2 sequence belonged to an F. gigantica 
fluke as expected. 
F. gigantica ITS2 species specific diagnostic sites present in this ITS2 sequence included 
cytosine at nucleotide numbers 207, 231; thymine at 270 and 276; adenine at nucleotide 
position 334, and also a deletion at residue 327 in relation to F. hepatica ITS2 nucleotide 
sequences. 
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(A)      1         2         3             (B)       1        2         3        4                (C)  1        2         3                 (D)              1          2         3 
 
 
 
 
 
 
 
 
 
Figure 5.1:  ITS2 cloning and characterisation.   
(A) ITS2 PCR product.  Lane 1, ITS2 PCR product; Lane 2, 100 bp marker; Lane 3, ITS2 PCR product digested with NlaIII.  (B) ITS2 restriction 
screening.  Lane 1, 100 bp marker; Lane 2, ITS2 digested with BamHI; Lane 3, ITS2 digested with KpnI; Lane 4, ITS2 digested with Sau3AI. (C) ITS2 
cloning.  Lane 1, λ-PstI; Lane 2, ITS2 PCR product digested with EcoRI and BamHI; Lane 3, pBSKII- digested with EcoRI and BamHI.  (D) ITS2 
clone screening.  Lane 1, λ-PstI; Lanes 2 and 3, ITS2 clones digested with EcoRI and BamHI.   
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Figure 5.2.  Nucleotide alignment of the ITS2 region of nuclear DNA from Fasciola species.   
The ITS2 region obtained in this study aligned against several published ITS2 sequences.  ITS2 nucleotide differences are highlighted light grey, 
species determinant nucleotides are inverted.  The proposed start and finish of the ITS2 region is marked with ► and ◄arrows respectively.  
Restriction sites for NlaIII, BamHI, KpnI and Sau3AI are indicated. 
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5.3.2 BLAST Search 
Protein and nucleotide based BLAST program searches identified 50 Fasciola cathepsin L-
like sequences.  In addition to the typical Fasciola cathepsin L-like proteases identified, a 
region of a Fasciola vitelline B sequence (accession M93025; FhCatL14) was identified as 
was a Fasciola cathepsin L-like proteases sequence with little nucleotide sequence similarity 
(accession Z22767; FhCatL17).  Several short N-terminal protein sequences and a synthetic 
construct were also identified, but have not been included in this study.  In total 35 
F. hepatica and 15 F. gigantica gene sequences were identified (Table 5.3). 
Cathepsin L homology to the vitelline B2 protein (M93025) appears to be brought about by 
an unusual mRNA splicing event.  The vitelline B2 mRNA transcript was isolated with an 
aberrant 3 prime untranslated region (3’ UTR) (Rice-Ficht et al., 1992).  This 3’ UTR is 
complementary to the 3’ coding region of Fasciola cathepsin L-like proteases, spanning the 
amino acid region from 104 to 219 (Fasciola mature protein numbering).  The designation 
FhCatL14 used in this study refers to only this 116 amino acid complementary region, rather 
than the encoded vitelline B2 protein. 
 
 
 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
217 
Table 5.3:  Fasciola cathepsin L protease clones referred to in this study 
Name DNA acc # Protein acc # Species Origin Stage Range Reference 
FhCatL1 U62288 AAB41670 F. hepatica Ireland Adult 1-326 Roche et al., 1997 
FhCatL2 U62289 AAC47721 F. hepatica Ireland Adult 1-326 Dowd et al., 1997 
FhCatL3 L33771 AAA29136 F. hepatica Australia Adult 1-326 Wijffels et al., 1994a 
FhCatL4 L33772 AAA29137 F. hepatica Australia Adult 1-326 Panaccio et al., unpublished 
FhCatL5 AF271385 AAF76330 F. hepatica Australia Adult 1-326 Smooker et al., 2000 
FhCatL6 AB009306 BAA23743 F. species* Japan Adult 1-326 Yamasaki and Aoki, 1993 
FhCatL7 Z22765 CAA80446 F. hepatica Switzerland Adult 1-326 Heussler and Dobbelaere, 1994 
FhCatL8 AJ279091 CAC12805 F. hepatica Netherlands NEJ 16-326 Harmsen et al., 2004 
FhCatL9 AJ279092 CAC12806 F. hepatica Netherlands Adult 16-326 Cornelissen et al., 2001 
FhCatL10 AJ279093 CAC12807 F. hepatica Netherlands NEJ 21-326 Harmsen et al., unpublished 
FhCatL11 AY029229 AAK38169 F. hepatica Argentina Adult 17-326 Carnevale et al., unpublished 
FhCatL12 Z22766 CAA80447 F. hepatica Switzerland Adult 126-291 Heussler and Dobbelaere, 1994 
FhCatL13 Z22769 CAA80450 F. hepatica Switzerland Adult 126-291 Heussler and Dobbelaere, 1994 
FhCatL14# M93025 AAA29144 F. hepatica USA Adult 210-326 Rice-Ficht et al., 1992 
FhCatL15 Z22764 CAA80445 F. hepatica Switzerland Adult 126-291 Heussler and Dobbelaere, 1994 
FhCatL16 Z22763 CAA80444 F. hepatica Switzerland Adult 126-291 Heussler and Dobbelaere, 1994 
FhCatL17 Z22767 CAA80448 F. hepatica Switzerland Adult 126-291 Heussler and Dobbelaere, 1994 
FhCatL20 AF490984 AAM11647 F. hepatica Peru Adult 16-326 Barrantes et al., unpublished 
FhCatL21 AY277628 AAP49831 F. hepatica Poland Adult 1-326 Kofta et al., 2000 
FhCatL22 AY519972 AAR99519 F. hepatica Portugal N/S 88-326 Castro et al., unpublished 
FhCatL23 AY519971 AAR99518 F. hepatica Portugal N/S 1-326 Castro et al., unpublished 
FhCatL26 AY573569 AAT76664 F. hepatica Turkey Adult 1-326 Kuk et al., 2005 
FhCatL29 EF407948 ABN50361 F. hepatica Poland N/S 1-326 Jaros et al., unpublished-a 
FhCatL30 DQ533986 ABG00260 F. hepatica Uruguay Adult 108-326 Rinaldi et al., unpublished 
FhCatL31 DQ533985 ABG00259 F. hepatica Uruguay Adult 108-326 Rinaldi et al., unpublished 
FhCatL32 DQ534446 ABF85681 F. hepatica Uruguay NEJ 24-249 Cancela et al., unpublished 
FhCatL33 DQ534447 ABF85682 F. hepatica Uruguay NEJ 24-249 Cancela et al., unpublished 
FhCatL34 EF611824 ABQ95351 F. hepatica Turkey N/S 1-326 Baspinar et al., unpublished 
FhCatL35 EU191984 ABW24657 F. hepatica Poland Metacerceriae 1-326 Jaros et al., unpublished-b 
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Table 4.3 continued:  Fasciola cathepsin L protease clones referred to in this study 
Name DNA acc # Protein acc # Species Origin Stage Range Reference 
FhCatL36 EU195859 ABW75768 F. hepatica Poland Metacerceriae 16-326 Jaros et al., unpublished-b 
FhCatL37 EU287914 ABZ80398 F. hepatica Uruguay NEJ 21-326 Corvo et al., unpublished 
FhCatL38 EU287915 ABZ80399 F. hepatica Uruguay NEJ 21-326 Corvo et al., unpublished 
FhCatL39 EU287916 ABZ80400 F. hepatica Uruguay NEJ 24-326 Corvo et al., unpublished 
FhCatL40 EU287917 ABZ80401 F. hepatica Uruguay NEJ 24-326 Corvo et al., unpublished 
FhCatL41 EU287918 ABZ80402 F. hepatica Uruguay NEJ 21-326 Corvo et al., unpublished 
        
FgCatL1A AF112566 AAD23996 F. gigantica Thailand Adult 1-326 Grams et al., 2001 
FgCatL1B AF239264 AAF44675 F. gigantica Thailand Adult 1-326 Grams et al., 2001 
FgCatL1C AF239265 AAF44676 F. gigantica Thailand Adult 1-326 Grams et al., 2001 
FgCatL1D AF239266 AAF44677 F. gigantica Thailand Adult 1-326 Grams et al., 2001 
FgCatL1E AF239267 AAF44678 F. gigantica Thailand Adult 108-326 Grams et al., 2001 
FgCatL1F AF239268 AAF44679 F. gigantica Thailand Adult 108-326 Grams et al., 2001 
FgCatL1G AF419329 AAL23917 F. gigantica Thailand Metacerceriae 1-326 Sobhon et al., unpublished 
FhCatL1H AY428949 AAR08900 F. gigantica Thailand NEJ 1-326 Meemon et al., unpublished 
FgCatL1I EF536899 ABQ01982 F. gigantica China N/S 1-326 Guo et al., unpublished 
FgCatL2 AF510856 AAM44832 F. gigantica Indonesia Adult 1-326 Irving et al., 2003 
FgCatLB7 AB010924 BAB86960 F. gigantica Japan Adult 1-326 Yamasaki et al., 2002 
FgCatLB22 AB010923 BAB86959 F. gigantica Japan Adult 1-326 Yamasaki et al., 2002 
FgCatL3 EU156178 ABV90500 F. gigantica Indonesia Adult 76-326 This study 
FgCatL1FA EU156179 ABV90501 F. gigantica Indonesia Adult 83-326 This study 
FgCatL4 EU156180 ABV90502 F. gigantica Indonesia Adult 47-326 This study 
N/S means ‘not stated’. 
* Notionally a Japanese strain of F. hepatica, however phylogenetic studies suggest actually F. gigantica (Irving et al., 2003). 
#
 FhCatL14 refers to only the 3’ UTR isolated with the F. hepatica vitelline B2 sequence. 
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5.3.3 Gene search 
5.3.3.1 Genomic DNA 
PCR reactions with genomic DNA as template amplified products of ranging size.  The 
presence of multiple bands was expected, as while there are only two genomic gene sequences 
on the public database, these were different sizes due to the presence of variable sized intron 
regions.  The banding profiles from genomic DNA ranged over several hundred bp (Figure 
5.3).   
5.3.3.2 mRNA 
The reverse transcripatse-PCR using the CGCWAFS BamHI 384 and PolyA primers resulted 
in the generation of a population of DNA fragments approximately 670 bp in length.  This 
corresponded to the expected size of an mRNA fragment possessing a 588 bp partial coding 
region and a 3’ UTR with polyA tail (Figure 5.4).   
The primers contained BamHI restriction sites, as these sites were absent from all published 
sequences within the region to be amplified.  This enabled sticky-end ligation during cloning. 
 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
220 
(A) 1      2        3       4         5                  (B) 1      2      3      4      5      6      7       8      9     10 
 
 
 
 
 
Figure 5.3:  Genomic DNA-derived clones.   
(A) PCR products derived from F. gigantica genomic DNA with different primer 
combinations.  Lanes 1-4, PCR products; Lane 5, λ-PstI marker.  (B) Genomic clone 
screening by insert visualisation after digestion with EcoRI.  Lanes 1 and 10, λ-PstI marker; 
Lanes 2-9, digested clones. 
                                                                    1            2 
 
 
 
 
 
Figure 5.4:  mRNA derived PCR product. 
Lane 1, 100bp marker; Lane 2, mRNA-derived PCR product. 
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5.3.3.3 Screening 
5.3.3.3.1 Genomic DNA-derived clone screening 
Miniprep isolation of plasmid DNA, and digestion with EcoRI identified clones with inserts 
ranging in size from a few hundred base pairs to over 2 kbp.  Colony hybridisation was 
undertaken to determine clones that were likely to contain cathepsin L-like genes.  A range of 
intensities were observed during colony hybridisation screening (data not shown).  Colonies 
were chosen from across the spectrum of detection intensities.  A number of colonies that 
tested negative were also analysed.  This was to minimise exclusion of divergent clones 
during this screening step. 
Plasmid DNA was isolated from chosen colonies, then digested with EcoRI and visualised by 
gel electrophoresis.  A sample of clones with inserts ranging in size from 1.1-1.9 kb were then 
sequenced, resulting in the generation of 19 genomic cathepsin L-like gene sequences.  The 
nucleotide and deduced amino acid sequences of the 19 clones can be found in Appendix 3. 
Pairwise alignment of the translated amino acid coding regions revealed up to 14 genes or 
alleles.  Multiple sequence alignment and phylogenetic analysis of the genes (minus their 
introns) placed them in the Fasciola cathepsin L monophyletic clade, and designating them as 
belonging specifically to clades A and D (detailed in section 5.3.4).  During the genomic 
DNA gene search, no genes were identified and sequenced that were found to belong to 
clades B or C.  An overview of the genomic DNA and mRNA derived genes isolated in this 
study is provided in Table 5.4. 
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Table 5.4:  F. gigantica cathepsin L-like genes/alleles isolated in this study 
Clone 
 
Source 
 
Amino acid 
sequence range 
GenBank 
accession 
number 
Clade 
 
Cathepsin with 
most identity 
F2 Genomic 47-326 - A FgCatL1G 
1.1+ Genomic 47-326 - D FgCatL1A 
2+ Genomic 47-326 - A FhCatL35 
2.1 Genomic 47-326 - D FhCatL22 
2.2 Genomic 47-314 - D FgCatL1A 
4.10+ Genomic 129-326 - D FgCatL2 
4.21 Genomic 129-314 - D FhCatL22 
4.30 Genomic 129-314 - D FhCatL22 
6.1+ Genomic 129-326 - D FgCatL2 
6.6 Genomic 129-326 - D FhCatL22 
6.25 Genomic 129-326 - D FgCatL1-B and -E 
6.26 Genomic 129-326 - D FhCatL22 
7.7+ Genomic 47-326 - D FgCatL1A 
13 Genomic 47-326 - D FhCatL22 
G13.8 mRNA 132-326 - D FgCatL1-B and -E 
24.5A+ mRNA 76-326 EU156178 E FhCatL16 
24.5B mRNA 76-326 - D FgCatL2 
24.8A mRNA 82-326 - D FhCatL22 
24.8B+ mRNA 85-326 - B FgCatL1D 
293A+ mRNA 132-326 - B FgCatL1D 
293B mRNA 132-326 - E FhCatL16 
303A mRNA 132-326 - D FgCatL2 
303B mRNA 132-236 - E FhCatL16 
306 mRNA 132-326 - D FgCatL2 
315+ mRNA 83-326 EU156179 C FgCatL1F 
319 mRNA 83-326 - D FgCatL2 
320A mRNA 47-326 EU156180 D FhCatL22 
320B+ mRNA 47-326 - D FgCatL2 
321+ mRNA 47-326 - D FgCatL1A 
325A mRNA 47-326 - D FhCatL22 
325B mRNA 47-326 - D FgCatL2 
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The intron-exon splicing regions for the genomic sequences were determined by alignment 
against public mRNA derived sequences as well as mRNA derived sequences isolated in this 
study.  All genomic cathepsin L-like gene constructs conformed to the structure previously 
outlined by Yamasaki and colleagues (2002) and consisted of four exons and three introns, 
each varying in length (Figure 5.5 and Figure 5.6).  The introns were also found to correspond 
to the positions specified in Yamasaki et al. (2002), with the breakpoints of introns 1 and 2 
interrupting the open reading frame between codons (type 0), while intron 3 interrupts the 
coding sequence after the second nucleotide of a codon (type 2).  The GT-AG rule 
(Breathnach and Chambon, 1981) was observed at all intron-exon splice sites, with the 
exception of clone 6.26 which possessed a deletion at the 3’end of intron 2 that extended into 
exon 3. 
Among the genomic clones isolated in this study, the first intron varied in length from 53 to 
63 bp.  While fairly conserved, gene specific variability due to nucleotide substitutions and 
small deletions/insertions were observed. 
Intron 2, 159-165 bp in length was also fairly well conserved.  Clones 2+ and F2, which show 
similarity to the FgCatL1G genes showed a degree of divergence when compared to other 
genes, with variability mainly through substitution rather than deletion or insertion events.   
Intron 3 was the largest of the introns, and also possessed the most variation.  The size of the 
intron ranged from 776 bp in clone 4.10 (FgCatL2 allele); to only 416 bp in clone 2+ 
(FgCatL1G allele).  The main difference was due to the presence of several indels, although 
two microsatellite repeats of varying lengths are also present.  The majority of sequences 
possessed intron 3 regions over 700 bp in length. 
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Figure 5.5:  Schematic diagram of F. gigantica cathepsin L-like protease gene exon and intron sites.   
Incorporates data from this study and Yamasaki et al. (2002). 
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Figure 5.6:  Nucleotide alignment of intron regions in genomic clones isolated in this study.  
(A) Intron 1; (B) intron 2 and; (C) intron 3.  Exon regions of nucleotide similarity shaded dark grey.  Intron regions of similarity shaded light grey.  
Numbering in exon regions corresponds to nucleotide numbering of FgCatL5 from the start of the prepropeptide.  (Part 1 of 2) 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
226 
(C) continued 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 concluded.  (Part 2 of 2) 
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5.3.3.3.2 mRNA derived clone screening 
The presence of mRNA derived fragments in transformed E. coli was determined by PCR 
using the primers CGCWAFS BamH1 384 and PolyA BamHI.  This screening method 
identified 39 clones expected to contain amplified F. gigantica cathepsin L-like DNA 
sequences.  The sequences from these clones were used to determine the relative abundance 
of each cathepsin obtained during cloning. 
The DNA inserts were subsequently amplified by PCR and digested with the restriction 
enzymes Sau3AI and NlaIII.  The Sau3AI digestion profile was not able to sufficiently 
separate the clones into defined groups (results not shown), however the restriction pattern 
produced by the NlaIII restriction enzyme was able to distinguish between all but a handful of 
the sequences deposited in the GenBank database (Table 5.5).  The initial NlaIII digestion 
analysis of the amplified DNA fragments resulted in five distinct restriction patterns (Figure 
5.7A).  The most common restriction profile was that belonging to FgCatL1D.  Other 
restriction profiles included those similar to FgCatL1A, FgCatL1F and also the FgCatL1-E, -I 
or FgCatL2 types.  Several samples possessed a restriction pattern not observed in any of the 
known F. gigantica cathepsin L-like sequences.  These were initially designated ‘unknown’. 
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Table 5.5:  Expected restriction patterns of F .gigantica cathepsin L-like proteases 
Clade Cathepsin Expected amplified 
PCR product size* 
Restriction pattern band sizes* 
  (bp) Sau3AI NlaIII 
A FgCatL1G 672 672 384,99,95,60,34 
B FgCatL1D 672 402,188,82 360,254,58 
C FgCatL1C 672 672 254,208,152,50 
 FgCatL1F 672 402,270 418,132,122 
D FgCatL1A 672 484,188 355,132,122,58,5 
 FgCatL1B 672 484,188 289,132,124,122,5 
 FgCatL1E 672 271,213,188 231,132,124,122,58,5 
 FgCatL1I 672 484,188 231,132,124,122,58,5 
 FgCatL2 672 484,188 231,132,129,122,49,9 
 FgCatLB22 666 337, 329 355,132,122,52,5 
F FgCatL1H 672 484,188 357,167,148 
Other FgCatLB7 672 439, 233 254,219,141,56 
* Unknown 3’UTR regions are assumed to be the same length and sequence as FgCatL2. 
(A) 1       2       3        4       5        6      7      (B)       1       2 
 
 
 
 
Figure 5.7:  NlaIII restriction mapping of cDNA derived clones.   
Samples visualised by agarose gel electrophoresis on a 4% gel run at 60 V for 180 min.  
(A) Restriction profiles observed during determination of relative clone abundance. Lane 1, 
100bp marker; Lane 2-6; Representative samples of the five different restriction profiles 
observed during restriction mapping; Lane7, 100bp marker. (B) Mixed restriction profiles 
from a single plasmid.  Lane 1, 100bp marker; Lane 2, Mixed profiles including 
representative sample of the ‘unknown 2’ (FgCatLB22-like) restriction profile and FgCatL2 
restriction profile.
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There were also several clones that possessed more that one F. gigantica gene insert (example 
in Figure 5.7B).  This made it difficult to quantify the exact number of restriction profiles 
present.  To determine the number of genes present in each clone, PCR was undertaken using 
M13-20 and M13 Reverse primers, which were situated outside the insert site.  The size of the 
subsequent PCR fragment was used to determine the number of subcloned mRNA derived 
products present per clones.  Clones that resulted in a band visualised at about 850 bp were 
deemed to possess only a single gene insert, while clones with a band visible at about 1.5 kb 
were deemed to possess two gene inserts (Figure 5.8).  Over 10% of plasmids were found to 
possess two inserts.  The presence of multiple inserts in several clones appears to be a result 
of the cloning method, possibly due to the use of only one restriction enzyme (BamHI) 
combined with the a high insert:plasmid ratio. 
At least one clone was sequenced from each distinctive restriction profile, while each clone 
possessing a mixed profile was also sequenced.  The results to determine the relative 
abundance amongst the clones was subsequently inclusive of 46 mRNA derived sequences 
and showed that FgCatL1D-like cathepsins were predominant (Table 5.6). 
An additional search for mRNA sequences, using primers specific to conserved regions in the 
proregion was undertaken in an attempt to identify different genes, and also to obtain the 
complete mature region of genes isolated earlier.  Clones were screened using colony 
hybridisation analysis (data not shown).  Subsequently, colonies were chosen from across the 
spectrum of detection intensities.  Restriction profiles with NlaIII were then analysed.  As 
well as identifying clones with restriction profiles similar to those already mentioned, an 
additional restriction profile was observed, similar to that expected for FgCatLB22, and 
termed unknown 2 (Figure 5.7B).  A further 13 clones were sequenced, resulting in a total of 
33 mRNA-derived nucleotide sequences generated. 
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Figure 5.8:  PCR amplification of transformation inserts to determine the number of 
inserts present per clone.   
PCR was undertaken with M13-20 and M13 Reverse primers using Taq polymerase.  Samples 
were visualised by agarose gel electrophoresis on a 1% gel run at 100V for 70 min.  Lane 
1, λ-PstI; Lanes 2 -6, PCR products amplified from clones. 
 
Table 5.6:  Restriction profile frequencies among mRNA-derived cathepsin L clones 
Restriction profile type No. sequences 
identified 
No. sequences 
characterised 
No. different 
alleles 
Total % of 
clones 
FgCatL1D 30 7 2 65% 
FgCatL1A 1 1 1 2% 
FgCatL1F 1 1 1 2% 
FgCatL1-E, -I or FgCatL2 4 4 3 9% 
Unknown type 10 7 3 22% 
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5.3.4 Bioinformatics 
The deduced amino acid sequences of all published F. hepatica and F. gigantica cathepsin L-
like sequences along with the sequences isolated in this study were aligned (Figure 5.9).  In 
total this included 47 published sequences, 14 genomic sequences and 17 mRNA-derived 
sequences.   
The cathepsin L sequences all contained the conserved Cys-His-Asn active site residues and 
all cysteines required for disulfide bond formation.  The exception was genomic DNA-derived 
clone 6.26, which had a predicted 5 amino acid deletion, removing C97 which is involved in a 
disulfide bond, and also affecting an intron-exon boundary.  Along with FhCatL6, the 
database sequence FgCatLB22 also contains an indel.  Two genomic DNA derived clones 
isolated in this study (1.1+ and 2.2) were found to contain premature stop codons. 
Several motifs have been identified in the proregion of cysteine proteases that show high 
degrees of conservation between species.  The ERF/WNIN motif (present as DRWNIN) 
(Karrer et al., 1993), is found in all Fasciola cathepsin L sequences published to date.  The 
Fasciola cathepsin L motif is slightly altered however, with the glutamate (E) replaced with 
aspartate (D).  Two proteins (FhCat6 and FgCatLB22) differ slightly at this point; both 
possessing a valine (V) residue.  The tripartite tryptophan (Kreusch et al., 2000) is also 
present, being completely conserved, while the GNFD motif (Vernet et al., 1995) is generally 
conserved, with only five sequences containing substitutions. 
Sequences that spanned the complete mature region were also used to construct an overall 
rooted phylogenetic tree of the Fasciola cathepsin L-like monophyletic clade (Figure 5.10).  
This included 37 of the published sequences, 11 mRNA derived sequences and 6 genomic 
DNA derived sequences (including one pseudogene). 
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Figure 5.9:  Amino acid alignment of deduced Fasciola cathepsin L-like sequences.   
Spans complete sequence of preproprotein.  Alignment is shaded by conservation.  Includes 
sequences (mRNA and genomic) from this study.  X represents stop codon.  Possible N- and 
O-linked glycosylation sites are coloured.  Several important proregion motifs are displayed 
above the alignment.  ► indicates start of mature region.  (Part 1 of 4)
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Figure 5.9 continued. (Part 2 of 4)
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Figure 5.9 continued. (Part 3 of 4)
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Figure 5.9 concluded. (Part 4 of 4)
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Figure 5.10:  Distance based bootstrapped neighbour-joining phylogenetic tree of 
Fasciola enzymes.   
Tree constructed using codon-based modified Nei-Gojobori/Jukes-Cantor calculation with 
distances based on non-synonymous mutations, using MEGA 3.1 from alignment of complete 
mature regions.  Numbers indicate bootstrap support at given node.  Sequences identified in 
this study are marked with a solid box ■ (genome-derived sequences) or circle ● (mRNA-
derived sequences).  Sequences characterised biochemically in this study are marked with a 
star    .  Outgroups are listed in materials and methods. 
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A number of tree building methods were utilised, including a neighbour-joining tree with 
protein data, minimum evolution, maximum parsimony and maximum likelihood.  Tree 
topology was fairly conserved.  Ultimately a bootstrapped neighbour-joining tree with 
distances based on the degree of non-synonymous mutations between sequences was used to 
resolve the data (Figure 5.10).  The tree agreed with previously published data on the Fasciola 
cathepsin L-like monophyletic clade (Irving et al., 2003), with the four previously described 
clades clearly differentiated.   
5.3.4.1 Cathepsin characteristics 
5.3.4.1.1 Isoelectric points (pI) 
Comparison of Fasciola cathepsin L-like proteases reveals most have acidic isoelectric points, 
generally between 4.54 and 5.77 (Table 5.7).  The exception is FhCatL3 and some clade A 
cathepsins which have higher, more neutral pI values.  Some cDNA derived clones isolated in 
this study predicted proteins with slightly higher, but still acidic pI values (5.75-6.18).  
FhCatL41, isolated from F. hepatica NEJ (Corvo et al., unpublished) possesses the highest 
theoretical isolelectric point, 8.79. 
Figure 5.11 shows that clades B, C and the ‘others’ all have low pI values, generally 5 and 
below, the exception being FhCatL41.  Clade D on the other hand has a spread of pI values 
ranging from about 5 to 7, though the majority are still well in the acidic range, from 5 to 
5.75.  Clade A seems to have a broad spread of pI values from the acidic through to the basic, 
with a clade A cathepsin from both F. hepatica and F. gigantica (this study) found with a pI 
above 7.0.  Fasciola cathepsin L proenzymes do not have the same broad range of pI values. 
All are acidic, generally between pH 5 and 6, the exception being FhCatL3 with a pI of 6.45. 
 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
238 
Table 5.7:  Isoelectric point of Fasciola cathepsin L-like proteases 
Clade Name Protein accession number  pI 
   mature pro-mature 
A FhCatL8 CAC12805 5.67 5.46 
 FhCatL10 CAC12807 7.70 NS 
 FhCatL35 ABW24657 6.98 5.56 
 FhCatL36 ABW75768 6.36 5.56 
 FhCatL37 ABZ80398 5.44 NS 
 FhCatL38 ABZ80399 8.19 NS 
 FgCatL1G AAL23917 6.98 5.68 
 F2 This study 7.70 NS 
 2+ This study 6.36 NS 
B FhCatL2 AAC47721 4.65 5.43 
 FhCatL7 CAA80446 4.54 5.33 
 FhCatL29 ABN50361 4.63 5.42 
 FhCatL31 ABG00259 5.12 NS 
 FhCatL34 ABQ95351 4.59 5.33 
 FgCatL1D AAF44677 4.76 5.32 
 24.8B+ This study 4.76 NS 
C FhCatL4 AAA29137 4.92 5.80 
 FhCatL5 AAF76330 4.75 5.44 
 FhCatL30 ABG00260 5.00 NS 
 FgCatL1C AAF44676 4.78 5.40 
 FgCatL1F AAF44679 5.00* NS 
 315+ This study; ABV90501 4.90 NS 
D FhCatL1 AAB41670 5.77 6.08 
 FhCatL3 AAA29136 6.93 6.45 
 FhCatL6 BAA23743 5.13 5.44 
 FhCatL9 CAC12806 5.14 5.34 
 FhCatL11 AAK38169 5.76 5.79* 
 FhCatL20 AAM11647 5.27 5.79 
 FhCatL21 AAP49831 5.11 5.33 
 FhCatL22 AAR99519 5.45 NS 
 FhCatL23 AAR99518 4.98 5.24 
 FhCatL26 AAT76664 5.66 6.00 
 FgCatL1A AAD23996 5.13 5.34 
 FgCatL1B AAF44675 5.13 5.34 
 FgCatL1E AAF44678 5.01* NS 
 FgCatL1I ABQ01982 5.13 5.44 
 FgCatL2 AAM44832 5.11 5.32 
 FgCatLB22 BAB86959 5.46 5.65 
 24.5B This study 5.13 NS 
 24.8A This study 6.18 NS 
 319 This study 5.13 NS 
 320A This study; ABV90502 6.18 NS 
 320B+ This study 5.13 NS 
 321+ This study 5.13 NS 
 325A This study 5.74 NS 
 325B This study 5.13 NS 
 2.1 This study 5.74 NS 
 13 This study 5.45 NS 
 7.7+ This study 4.99 NS 
E 24.5A+ This study; ABV90500 4.92 NS 
F FhCatL39 ABZ80400 4.68 NS 
 FhCatL40 ABZ80401 4.75 NS 
 FgCatL1H AAR08900 4.78 5.10 
G FhCatL41 ABZ80402 8.79 NS 
Other FgCatLB7 BAB86960 4.62 5.31 
The amino acid range for mature is 0-219, and pro-mature is -91 to 219.   
* = First amino acid of sequence missing. 
NS = Not suitable due to sequence covering insufficient amino acid range. 
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Figure 5.11:  The theoretical isoelectric points (pI) of Fasciola cathepsin L-like proteases.   
(A)  Theoretical pI values of mature Fasciola cathepsins separated into clades and species of origin.  The pI values of unactivated promature cathepsins 
are also included (this is less than the sum of all cathepsins as many sequences did not cover the proregion).  (B) Boxplot of the data represented in (A).  
Clade ‘Other’ includes cathepsins not assigned to clades A-D. 
pI 
F. hepatica 
F. gigantica 
F. gigantica (this study) 
pI 
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5.3.4.1.2 Glycosylation 
A number of Fasciola cathepsins possess asparagines (N) with the potential to be N-
glycosylated (Figure 5.9), including the F. hepatica clade A cathepsins at residue N44.  
FgCatL1H has two potential glycosylation sites, at residues N45 and N154, as do the F. 
hepatica orthologs FhCatL 39 and –L40, while FhCatL33 has a single site at N45.  A number 
of other Fasciola cathepsin L-like proteases also possess potential glycosylated asparagines at 
N45 including FgCatL1F and those designated clade E in this study (FhCatL16 and clones 
24.5A, 293B and 303B).  Despite FhCatL29 sharing greater than 95% amino acid identity 
with other F. hepatica clade B cathepsins, it is the only cathepsin in this clade with a potential 
N-glycosylated asparagine; situated at N55.  The divergent FhCatL17 also has three potential 
N-glycosylated sites, at residues N79, N100 and N116.  
Fasciola hepatica has been shown to possess ppGaNTase, enabling O-glycosylation of 
proteins (Casaravilla et al., 2003; Freire et al., 2003).  Potential sites for O-GalNac (mucin-
type) glycosylation were also observed in the cathepsin L-like proteases from both Fasciola 
species (Figure 5.9).  Serine residue 87 was found to be a potential site for this form of 
glycosylation in cathepsins belonging to clades E and F, as well as clade C (excluding 
FgCatL1F).  FhCatL9 also possessed this potential glycosylation site as did a number of 
cathepsins identified in this study, including those clones similar to 320A.  FhCatL17 
possessed two potential O-GalNac glycosylation sites at residues T128 and S153. 
Despite the presence of these potential glycosylation sites, to date no native Fasciola 
cathepsin L has been shown to be glycosylated. 
5.3.4.2 Genomic DNA derived and mRNA derived clones 
5.3.4.2.1 Clade A: W69 
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Along with the single F. gigantica and six F. hepatica genes that make up clade A, a 
F. hepatica partial sequence (FhCatL32) also belongs to this clade.   
During genomic screening, two clones (2+ and F2) were identified that were found to belong 
to clade A (Figure 5.10). They possessed similar nucleotide and deduced protein sequences to 
FgCatL1G and FhCatL35 (Figure 5.12 and Figure 5.13), possessing greater than 95% amino 
acid identity to both published sequences.  Despite being isolated from F. hepatica from a 
region where co-speciation has not been reported, indicating hybridisation is unlikely, 
FhCatL35 aligns with these F. gigantica clade A cathepsins rather than the F. hepatica clade 
A cathepsins (Figure 5.10). 
Clones 2+ and F2 possess similar coding regions, with only 7 amino acid differences in the 
mature region.  Introns 1 and 2 are fairly conserved however; intron 3 shows a high degree of 
divergence.  Intron 3 in clone 2+ contains several deletions within this region when compared 
to F2, resulting in intron sizes of 415 bp and 767 bp respectively. 
Clone F2 has higher identity with FgCatL1G while clone 2+ has higher identity with 
FhCatL35.  Differences between clones F2 and 2+ with FgCatL1G and FhCatL35 correspond 
to residues seen in other clade A cathepsins.  A grouping of 4 amino acid differences between 
residues 146 and 157 in clone 2+ and F2 is the only area in the mature protein where the 
mutations between these alleles are closely grouped.  This is also an area where previously 
published clade A proteases possess several amino acid differences.  Figure 5.14 shows the 
surface structure of FgCatL1G, highlighting differences with clones 2+ and F2. 
No mRNA clones were isolated that were found to belong to clade A, which was not 
unexpected, as to date clade A cathepsins have only been shown to be expressed by immature 
life stages of Fasciola, with these cathepsins isolated from NEJ or metacercariae (Harmsen et 
al., 2004; Cancela et al., 2008; Sobhon et al., unpublished). 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
242 
 
 
 
 
 
 
 
 
 
Figure 5.12:  Nucleotide alignment of genomic clones 2+ and F2 with FgCatL1G and FhCatL35.   
Areas of consensus are highlighted, exon regions dark grey and non-coding regions light grey.  Primer binding sites are underlined.  The proposed start 
of the mature coding region is indicated with an arrow (►). 
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Figure 5.13:  Amino acid alignment of clade A Fasciola cathepsin L proteases against 
genome-derived clones isolated in this study.   
Sites of positive selection (Irving et al., 2003) are shaded light grey, positively selected sites 
within the extended active site cleft are in bold, residues implicated in subsite interactions are 
shaded dark grey (Turk et al., 1998), catalytic triad residues are boxed, amino acid 69 is  
inverted on a black background, an arrow (►) indicates proposed cleavage site during 
processing.  Intron insertion positions are indicated by a down arrow (▼). PCR primer 
binding sites in clones are underlined.  The DRWNIN motif residues are designated with a 
solid circle ‘•’.  The GNFD region is shown by overline. 
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Figure 5.14:  Molecular models of FgCatL1G visualised with DeepView.  
(A) Surface and ribbon model of FgCatL1G showing residue types as acidic, basic, polar and 
non-polar.  (B) Surface and ribbon model of FgCatL1G showing the position of residues that 
show variation in clones 2+ and F2.  
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
245 
5.3.4.2.2 Clade B: Y69 
Along with the single F. gigantica gene, clade B is composed of 5 complete mature 
F. hepatica genes sequences.  The partial sequence of FhCatL15 shows a high amount of 
identity and also belongs to this clade, while phylogenetic analysis and sequence similarity 
suggests the partial sequence FhCatL31 also belongs to this clade. 
During genomic screening no clones were identified that were found to belong to clade B.  
However, 65% of the mRNA-derived clones possessed restriction profiles similar to that 
expected from FgCatL1D.  Sequence analysis of clones possessing FgCatL1D restriction 
profiles revealed that there were two FgCatL1D alleles present within the restriction profile 
type (24.8B+ and 293A+), with one amino acid difference between them at aa153 (Figure 
5.15).  A clone incorporating the complete mature region and part of the proregion, identical 
with allele 24.8B+ was also later identified. 
During the study of relative clone abundance eight nucleotide sequences were determined.  
Alleles encoding the same amino acid sequence as 24.8B+ were identified in four clones.  
Allele 293A+, which encodes a gene with only one amino acid difference, was identified in 
two clones.  Another two partial sequences could be attributed to either allele.  While allele 
24.8B+ showed 100% amino acid identity to FgCatL1D over the region it spans, of the clones 
that encoded this allele there was some variation, with synonymous substitutions present 
(Figure 5.16).  The sequences that make up allele 293A+ (293A and 308A) also possessed a 
synonymous substitution between themselves, and three to four substitutions when compared 
to FgCatL1D, only one of which resulted in an amino acid mutation (aa153). 
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Figure 5.15:  Amino acid alignment of clade B cathepsins against FgCatL1D.   
Sites of positive selection (Irving et al., 2003) are shaded light grey, positively selected sites 
within the extended active site cleft are in bold, residues implicated in subsite interactions are 
shaded dark grey (Turk et al., 1998), catalytic triad residues are boxed, amino acid 69 is  
inverted on a black background, an arrow (►) indicates the proposed start of the mature 
region.  PCR primer binding sites in clones are underlined. 
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Figure 5.16:  Nucleotide alignment of FgCatL1D, FhCatL27 and FgCatL1D-like clones 
isolated in this study.   
Nucleotide sequences encoding allele 24.8B+ are labelled blue, those encoding allele 293A+ 
are labelled red.  Nucleotides divergent from the FgCatL1D published sequence are 
highlighted light grey.  The amino acid sequence of FgCatL1D is aligned in blue below the 
nucleotide alignment.  Codons encoding mutations compared to FgCatL1D are boxed in blue, 
with stop codons boxed in red.  PCR primer binding sites are underlined.  The start of the 
mature region is indicated with an arrow (►).  The number of different clones with identical 
nucleotide sequences isolated when determining relative clone abundance are stated, ie. (x3). 
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The single mutation at residue 153 of a large acidic (E) to a large basic (K) residue occurs at 
the patch I region of positive selection (Irving et al., 2003), and is remote from the active site 
cleft (Figure 5.17).   
There are a number of species-specific differences between the clade B cathepsins.  A 
majority are surface exposed residues present at sites of positive selection.  The patch I region 
is well represented; with generally polar for polar substitutions, while the same is evident in 
the few altered residues that belong in patch II. 
A number of the amino acid differences are also expected to affect subsite architecture, with 
aa63 (H-Y) affecting the S3 subsite.  Residues 138 (V-A) and 186-7 (SS-TW) are also situated 
within the active site cleft, affecting the architecture of S1’ and >S3’, though the role they play 
in substrate specificity is not known.  The S2 subsites of the clade B cathepsins are composed 
of identical residues.  FhCatL31 is the exception, being relatively divergent from the other 
clade B cathepsins. 
FhCatL31 shows a high degree of identity with the other clade B cathepsins at its N-terminal 
region, however the C-terminal region shows high identity with certain clade D cathepsins 
(Figure 5.18).  The nucleotide sequence of FhCatL31 that encodes residue 1 to 133 shows 
high identity with the FhCatL2-like alleles, and is 100% identical with FhCatL34 if the N-
terminal primer binding site in FhCatL31 is excluded.  In contrast, the remaining sequence 
shows much lower nucleotide (<91%) and amino acid (84%) identity.  Alternatively, the 
nucleotide sequence encoding from amino acid 131 corresponds to FhCatL9,-11 and -22, 
possessing over 98% nucleotide and amino acid identity for each.  The 3’ UTR even shows 
similarity with the 3’UTR region of FhCatL22 (Figure 5.18).  A number of possibilities could 
account for this chimeric clone including gene fusion, alternative splicing or trans-splicing.  
The possible fusion/splicing site is indicated in Figure 5.18.   
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Figure 5.17:  Molecular models of FgCatL1D and FhCatL2 visualised with DeepView. 
Surface models of mature (A) FgCatL1D and (B) FhCatL2 showing residue types as acidic, 
basic, polar and non-polar.  The residue that shows variation with allele 293A+ is circled and 
labelled. 
E153K 
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Figure 5.18:  Alignment of FhCatL31 against select F. hepatica clade B and clade D 
cathepsins.   
(A) Amino acid alignment. (B) Nucleotide alignment of proposed splice site. (C) Nucleotide 
alignment of 3’ UTR.  Clade B genes are labelled black, while clade D genes are labelled 
grey.  Residues divergent from the FhCatL31 published sequence are highlighted light grey.  
The sequence of FhCatL31 encoding the clade B-like region is black, the region encoding the 
clade D-like portion is grey.  The proposed fusion/splice site is marked with a red down arrow 
(▼), Fasciola cathepsin L cis-splice sites are marked with a black down arrow (▼).  The 
proposed start of the mature region is indicated with an arrow (►).  The N-terminal PCR 
primer binding site for FhCatL31 is underlined.  The deduced amino acid sequence of 
FhCatL31 is aligned below the nucleotide sequences in blue.  Stop codons are boxed in red.   
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5.3.4.2.3 Clade C: L69 
Along with two F. gigantica cathepsins, four F. hepatica cathepsins make up clade C, 
including the partial sequences FhCatL12 and FhCatL30.  Four distinct genes appear in this 
clade; FhCatL5-like which includes FhCatL4 and FhCatL12, the F. gigantica ortholog 
FgCatL1C, as well as two divergent cathepsins, FhCatL30 and FgCatL1F. 
No genomic DNA-derived clones were identified that were found to belong to clade C.  
During analysis of relative clone abundance, a single mRNA-derived clone was identified that 
possessed an NlaIII restriction profile similar to that of FgCatL1F.  Nucleotide sequencing of 
the clone (23.12A) revealed the insert corresponded to the FgCatL1F database sequence with 
a synonymous SNP outside the primer binding sites.   
A clone (315A) encoding the complete mature region and 24 residues of the proregion was 
later isolated.  When compared to the published sequence of FgCatL1F it possessed two 
nucleotide substitutions, and encoded for a protease with a single deduced amino acid 
difference in the mature region at residue 4 (Figure 5.19). 
No clones were identified that showed high identity with the other F. gigantica clade C 
cathepsin FgCatL1C. 
There are a number of distinct genes in this clade, and the level of divergence between them 
means all five positive selection patches are well represented (Figure 5.20).  Some variations 
occur along the active site cleft that would be expected to affect the architecture of several 
subsites (Figure 5.21), though all enzymes would still be expected to have a preference for 
bulky non-polar residues at P2. 
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Figure 5.19:  Nucleotide alignment of FgCatL1F and FgCatL1F-like clones isolated in 
this study.   
Nucleotides divergent from the published FgCatL1F sequence are highlighted in light grey.  
The deduced amino acid sequence of clone 315A is aligned in blue below the nucleotide 
alignment.  The start of the mature region is indicated with an arrow (►).  Non-synonymous 
substitutions compared to the deduced amino acid sequence are boxed in blue and stop codons 
are boxed in red.  PCR primer binding sites are underlined. 
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Figure 5.20:  Amino acid alignment of clade C cathepsins against FhCatL5.  
Sites of positive selection (Irving et al., 2003) are shaded light grey, while positive selected 
sites within the extended active site cleft are in bold, residues implicated in subsite 
interactions are shaded dark grey (Turk et al., 1998), catalytic triad residues are boxed, amino 
acid 69 is  inverted on a black background.  PCR primer binding sites in the mRNA-derived 
clone are underlined.  Unknown amino acids are designated with ‘?’. 
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Figure 5.21:  Molecular models FhCatL5 and FgCatL1F visualised with DeepView. 
(A) Surface model of mature FhCatL5.  Amino acid residues lining the extended active site 
cleft that show variation in clade C are highlighted. (B) Surface models of mature FhCatL5 
and FgCatL1F showing residue types as acidic, basic, polar and non-polar. 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
255 
5.3.4.2.4 Clade D: L69 
Currently 16 complete mature database sequences make up clade D (Figure 5.10). An 
additional partial sequence, FhCatL13 shows significant similarity to suggest it also belongs 
to this clade, with greatest amino acid identity (92.2%) with FhCatL22.  The 3’UTR region of 
the vitelline B2 mRNA transcript that shows homology with Fasciola cathepsin L proteases 
(FhCatL14) also has highest identity with the clade D cathepsins. 
Analysis of the remaining genomic-derived clones suggested they belong to clade D (Figure 
5.10). The sequences were split into two types, those that showed similarity to 320A, and 
those with similarity to the ‘classical’ F. gigantica clade D cathepsin L genes.   
During the study of relative clone abundance, 11% of transcripts were identified that 
possessed restriction profiles similar to those expected for ‘classical’ F. gigantica clade D 
proteases.  Amino acid alignment of the genomic DNA and mRNA derived clones with 
published clade D F. gigantica sequences revealed a high degree of sequence similarity 
(Figure 5.22) and in total 8 mRNA-derived and six genomic DNA-derived sequences were 
identified as showing high levels of identity with these cathepsins.  Phylogenetic analysis of 
the clones and published sequences spanning C25 to P219 further revealed how these genes 
are evolutionarily related (Figure 5.23).   
Two of the genomic DNA-derived clones belonging to this clade, 1.1+ and 2.2 were found to 
contain premature stop codons after residues 199 and 95 respectively, and may be 
psuedogenes.  
The ‘classical’ F. gigantica clade D cathepsin L genes show a high degree of identity, but 
substitutions at residues 63 and 66 are expected to affect substrate specificity by changing S1 
and S3 subsite architecture.  .
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Figure 5.22:  Amino acid alignment of ‘classical’ F. gigantica clade D cathepsins with similar clones identified in this study.   
Residues are shaded as stated in previous figures.  Premature stop codons are signified with an X.  Sequence names are coloured to distinguish the 
most closely related alleles.  
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Figure 5.23:  Distance based bootstrapped neighbour-joining phylogenetic tree of 
Fasciola Clade D cathepsin L-like proteins.   
Tree constructed using codon-based modified Nei-Gojobori/Jukes-Cantor calculation with 
distances based on non-synonymous mutations.  Generated and visualised in MEGA 3.1, from 
alignment spanning C25 to P219.  Numbers indicated bootstrap support at given node.  
Sequences identified in this study are marked with a solid box ■ (genomic-derived sequences) 
or circle ● (mRNA-derived sequences) box.  Clones excluded because they did not cover the 
required range, but through pairwise analysis are proposed to belong to this clade include 
clones 4.21, 4.30 and 2.2, as well as FhCatL13 and FhCatL14.   
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5.3.4.2.4.1 FgCatL1A-like clones: 
When determining relative clone abundance, a single mRNA derived clone (321+) was 
identified that possessed an NlaIII restriction profile and nucleotide sequence similar to that of 
FgCatL1A.  Two genomic DNA-derived clones (7.7+ and 1.1+) also showed significant 
similarity to FgCatL1A, although like clone 321+ at least one amino acid difference was 
present (Figure 5.22).  As mentioned previously, clone 1.1+ has a premature stop codon.   
5.3.4.2.4.2 FgCatL1B-like and FgCatL2-like clones: 
During determination of relative clone abundance, three mRNA-derived clones (303A, 306 
and G13.8) produced restriction patterns identifying them as possible paralogs of FgCatL1E, 
FgCatL1I or FgCatL2, with each possessing a different nucleotide sequence.   
Along with clone G13.8, the genomic DNA-derived clone 6.25 had high identity with both 
FgCatL1-B and -E.  Clone G13.8 appears to be the transcript for genomic clone 6.25, as their 
nucleotide sequences are identical outside their respective primer binding sites.   
Clones 303A and 306 were very similar, with high identity to FgCatL2 in their coding 
regions.  The clones showed divergence from the FgCatL2 gene near the 3’ terminus, where 
they instead had identity with FgCatL1D.  This region of FgCatL1D similarity extended from 
nucleotide 928 (M203) into the mRNA 3’ UTR (Figure 5.24).  Similar to clone FhCatL31, 
several possibilities could account for these apparent chimeric clones.  The proposed 
fusion/splicing site is included in Figure 5.24. 
Several mRNA-derived clones spanning the complete mature region were also identified that 
resembled FgCatL1I and FgCatL2 as where two genomic DNA-derived clones.   
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Figure 5.24:  Nucleotide alignment of clones 303A and 306 against selected clade D and 
clade B cathepsins.   
The deduced amino acid sequence of 303A is aligned in blue below the nucleotide alignment.  
Divergent nucleotides are highlighted in light grey.  The region of the proposed 
fusion/splicing site is designated with a red overline.  Fasciola cathepsin L cis-splice sites are 
marked with a black down arrow (▼).  Stop codons are boxed in red. 
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5.3.4.2.4.3 Unknown 2 (320A-like) restriction profile type 
During analysis of relative clone abundance, 5 distinct restriction patterns were identified.  
When mRNA-derived clones were screened for complete mature regions, three clones were 
identified with a different restriction pattern.  This restriction pattern was similar to that 
expected from FgCatLB22 and was termed Unknown 2. 
Upon determining the nucleotide sequence of the clones, two (24.8A and 320A) showed high 
similarity, with just two non-synonymous substitutions between sequences.  The third gene 
(325A), while possessing the same restriction profile, possessed 19 distinct nucleotide 
substitutions in its coding region (Figure 5.25). This resulted in a protein with seven distinct 
amino acid differences, all in the second half of the mature region (Figure 5.27).  The only 
grouping of differences was between residues 120-128 (mature numbering) where 3 mutations 
were found in the positive selection region corresponding to patch III.  Residue 209 was the 
only amino acid in the active site cleft that showed variation, alternating between the 
hydrophobic M and the aliphatic L (Figure 5.26).   
The three mRNA-derived genes showed high identity with six genomic clones isolated in this 
study (up to 99%; Figure 5.27).  These genes, when analysed by pairwise analysis against 
published F. gigantica cathepsins showed highest amino acid identity with clade D 
cathepsins, but at no greater than 94%.  This is significantly lower than the 98.4-100% 
observed with many of the other cathepsin L-like genes identified in this study.  Phylogenetic 
analysis grouped these sequences with several F. hepatica clade D cathepsins that included 
FhCatL9 (Figure 5.10 and Figure 5.23), and they are referred to in this study as ‘320A-like’ 
proteases.  Thus, rather then being paralogous to the ‘classical’ F. gigantica clade D cathepsin 
L genes, they appear to be orthologs of the FhCatL9-like genes.   
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Figure 5.25:  Nucleotide alignment of mRNA-derived clones 320A, 325A and 24.8A.   
The deduced amino acid sequence of 320A is aligned in blue below the nucleotide sequences. 
Variable nucleotides are shaded light grey, non-synonymous substitutions are boxed in blue 
and stop codons in red. The proposed start of the mature region is indicated with an arrow 
(►).  PCR primer binding sites are underlined. 
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Figure 5.26:  Molecular models 320A and 325A visualised with DeepView. 
(A) Surface model of 325A, with amino acid residues that show variation with 320A coloured 
red.  The sections corresponding to the proposed chimeric regions are coloured different 
shades of grey.  (B) Surface models of mature 320A, 325A and FhCatL1 showing residue 
types as acidic, basic, polar and non-polar 
FhCatL1 
320A 325A 
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Figure 5.27:  Amino acid alignment of 320A-like clones 
Residues of positive selection and those implicated in subsite interactions are shaded as stated 
in previous figures.  An arrow (►) indicates the proposed start of the mature protein, intron 
insertion positions are indicated by down arrow (▼). PCR primer binding sites are 
underlined.   
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As mentioned previously, genomic DNA-derived clone 6.26 has a deletion at the end of intron 
2, extending into exon 3.  This mutation affects one of the critical cis-splicing signals and 
would have important consequences, interfering with the splicing process. This would result 
in either the intron failing to be removed or alternatively splicing occurring at a cryptic site 
upstream or downstream of the deletion.  In both cases the mRNA would be incorrectly 
processed, resulting in a mutant protein.   
Clone 325A showed greatest identity with the partial sequence, FhCatL14 (97.4%), and high 
identity (94.6%), with F. hepatica cathepsins FhCatL9, 11 and 22.  Alternatively clones 320A 
and 24.8A showed more identity with FhCatL9 than FhCatL14.  The genomic clones all 
showed greater identity to the 320A and 24.8A clones compared to clone 325A.   
The N-terminal region of 325A shows far higher nucleotide and amino acid identity with the 
homologous clones isolated in this study, when compared to the C-terminal region.  The fact 
almost all substitutions specific to 325A occur in one section of the gene suggest a chimeric 
clone, possibly as a result of a trans-splicing event.  A search of the preliminary F. hepatica 
EST database being constructed by The Sanger Institute with clones 320A and 325A 
identified several sequences that showed strong similarity to the mRNA-derived sequences as 
well as to FhCatL14.  Two EST sequences (HAN5020h10 and HAN5021h01) that showed 
similarity to FhCatL14 were aligned against the 320A-like mRNA-derived clones (Figure 
5.28).  It showed that substitutions between the F. hepatica and F. gigantica sequences are 
distributed throughout the genes.  Also 325A is similar to clones 24.8A and 320A until amino 
acid residue E119, after which point it shows similarity to the FhCatL14-like sequences, 
including in the 3’ UTR which is more similar to the EST sequences than either 320A or 
24.8A. 
Inclusion of the F. hepatica EST sequence in a phylogenetic analysis shows it groups with 
FhCatL9-like clones in clade D, despite showing only 92-94% amino acid identity.  
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Figure 5.28:  Alignment of clone 325A against 320A, 24.8A and selected FhCatL14-like 
EST sequences.   
(A) Amino acid alignment.  (B) Nucleotide alignment of the proposed fusion/splicing site.  
(C) Nucleotide alignment showing the 3’ UTR.  Clones similar to FhCatL14 (5020h10 and 
5021h01) were obtained from the preliminary F. hepatica EST database.  Residues divergent 
from 325A are highlighted light grey.  The proposed fusion/splicing site is marked with a red 
down arrow (▼), Fasciola cathepsin L cis-splice sites are marked with a black down arrow 
(▼).  The proposed start of the mature region is indicated with an arrow (►).  The deduced 
amino acid sequence of 325A is aligned in blue below the nucleotide alignment.  Stop codons 
are boxed in red.   
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Figure 5.29:  Distance based bootstrapped neighbour-joining phylogenetic tree of 
Fasciola Clade D cathepsin L-like proteins.   
Tree constructed using codon-based modified Nei-Gojobori/Jukes-Cantor calculation with 
distances based on non-synonymous mutations.  Generated and visualised in MEGA 3.1, from 
alignment spanning the complete mature region.  Numbers indicated bootstrap support at 
given node.  Sequences are identified by source with a solid box ■ (genomic-derived 
sequences), circle ● (mRNA-derived sequences), or triangle ▲ (F. hepatica preliminary EST 
database obtained) box.  Non-clade D Fasciola cathepsin L proteases that spanned the 
complete mature region were used as outgroups. 
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The observed amino acid and nucleotide identity between the C-terminal portion of 325A and 
the FhCatL14-like genes is very high (99%), and is greater than any identity observed 
between any F. gigantica and F. hepatica cathepsin L orthologs. 
5.3.4.2.5 Clade E (Unknown restriction profile type) 
During the determination of the relative clone abundance, an unknown restriction profile was 
obtained in over 20% of the clones.  Seven of these clones had their nucleotide sequences 
determined which revealed three alleles of the same gene.  The complete mature region of the 
gene was later obtained from an mRNA-derived clone designated 24.5A which encoded the 
most common of the alleles observed (24.5A+). 
During determination of relative clone abundance, 5 clones encoded deduced amino acid 
sequences with 100% identity to allele 24.5A+, however the clones were not all identical in 
regard to nucleotide sequence, with up to three synonymous mutations present between 
sequences.  Two other alleles (293B and 303B) were each encoded by a single clone, with the 
nucleotide sequences for alleles 293B and 303B also showing very high nucleotide identity to 
24.5A+ (Figure 5.30). 
The amino acid sequences of three alleles were almost identical, each possessing a single 
amino acid difference (Figure 5.31).  Clone 24.5A+ and 293B only differ at amino acid 
residue aa128 (V to M), which is a site of positive selection.  Clone 303B possesses a BamHI 
restriction site in the nucleotide sequence, consequently only a partial sequence encoding 105 
amino acids was obtained.  The presence of the BamHI restriction site resulted in a mutation 
at residue 129 from E to D.  Differences between the alleles are all remote from the active site 
cleft (Figure 5.32). 
The genes are fairly divergent when compared to other F. gigantica cathepsin L proteases.  
The highest amino acid identity was observed with FgCatL1C at just 71%.  Much greater 
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identity (93%) was observed against the F. hepatica cathepsin FhCatL16, with several of the 
observed differences situated in primer binding sites (Figure 5.31).  
Despite the fact that two clades already exist that possess L69 (C and D), the low level of 
amino acid identity and the phylogenetic analysis suggests that this group of clones may form 
a new clade, designated clade E, which diverged prior to the clade C and D split.  The active 
sites of the cathepsin L proteases belonging to the three clades possessing leucine at residue 
69 (C, D and E) are fairly similar.  The S2 subsites of each would be expected to 
accommodate bulky hydrophobic residues.  The main difference between 24.5A+ and 
cathepsins of clades C and D is the presence of charged (basic) polar residues at S3 (Figure 
5.32). 
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Figure 5.30:  Nucleotide alignment of mRNA-derived clade E alleles with FhCatL16.   
Nucleotide sequences encoding allele 24.5A+ are labelled blue, while those encoding the 
alleles 293B and 303B are labelled red and orange respectively.  The deduced amino acid 
sequence of 24.5A+ is aligned below the nucleotide sequences in blue.  Divergent nucleotides 
are highlighted in light grey.  Non-synonymous substitutions are boxed in blue.  Primer 
binding regions are underlined.  The stop codons are boxed in red. The proposed start of the 
mature region is indicated with an arrow (►).   
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Figure 5.31:  Amino acid alignment of clones 24.5A+, 293B, 303B and FhCatL16  
Sites of positive selection (Irving et al., 2003) are shaded light grey, positive selected sites 
within the extended active site cleft are in bold, residues implicated in subsite interactions are 
shaded dark grey (Turk et al., 1998) , catalytic triad residues are boxed, amino acid 69 is  
inverted on a black background, an arrow (►) indicates the proposed start of the mature 
protein.  PCR primer binding sites are underlined. 
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Figure 5.32:  Molecular models of clone 24.5A+ visualised with DeepView.  
(A) Surface model of 24.5A+ showing the position of residues that show variation in alleles 
293B, 303B and with the ortholog FhCatL16. (B) Surface models of mature 24.5A+, FhCatL1 
and FhCatL5; showing residue types as acidic, basic, polar and non-polar. 
24.5A+ 
FhCatL1 FhCatL5 
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5.3.4.2.6 Others 
FgCatL1H forms its own clade, designated clade F.  This clade is proposed to also include the 
the partial sequence FhCatL33, which shares 91% amino acid identity. The recently published 
sequences FhCatL39 and FhCatL40 also belong to this clade (Cancela et al., 2008).  These 
genes all encode phenylalanine (F) at amino acid 69.  Like clade A, genes belonging to this 
clade seem to only be expressed during the immature life stages of flukes; all mRNA’s have 
been isolated from NEJ.  The separation of this clade from other clades is supported by the 
proposed difference in active site architecture due to the amino acid at position 69, the level of 
divergence in identity from genes in other clades, as well as the difference in expression of 
life stages. 
The published genomic DNA-derived FgCatLB7, possesses F69 and appears to have diverged 
later than the clade F split.  To date, it has not been shown to be expressed however, it has 
only been specifically searched for in adult F. gigantica (Yamasaki et al., 2002), and like the 
other Fasciola cathepsins that possess F69, it may only be expressed in immature life stages.  
No known F. hepatica orthologs have been published.   
Along with the clade A and clade F cathepsins recently isolated from F. hepatica NEJ, a G69 
cathepsin transcript was also isolated (FhCatL41) (Cancela et al., 2008).  This is the only 
Fasciola cathepsin L to possess such a variation, and it does not show significant similarity to 
any other isolated Fasciola gene (all less than 80% amino acid identity).  As such this gene 
appears to form its own singleton clade.   
Neither genomic DNA- or mRNA-derived clones were isolated in this study that were found 
with similarity to FgCatL1H, FgCatLB7 or FhCatL41. 
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5.4 Discussion 
5.4.1 ITS2 analysis 
As mentioned in chapter 1, molecular techniques are increasingly being used to distinguish 
between Fasciola species.  The internal transcribed spacer region of ribosomal DNA has 
almost become the default region of choice for molecular approaches for recognition of 
trematodes (reviewed in Nolan and Cribb, 2005).  
The second internal transcribed spacer (ITS2) is a highly variable region within ribosomal 
DNA, that in Fasciola species is flanked by the highly conserved 5.8s and 28s genes.  The 
ITS2 region generally contains fewer variable sites than ITS1, and is known for relatively 
high sequence conservation at species level (Nolan and Cribb, 2005).   
It has previously been reported that the variations in the nucleotide sequence of the ITS2 
region allow differentiation between F. hepatica and F. gigantica with several species-
specific single nucleotide polymorphisms identified (Adlard et al., 1993; Hashimoto et al., 
1997; Itagaki and Tsutsumi, 1998; Agatsuma et al., 2000; Mas-Coma et al., 2001; Huang et 
al., 2004).   
There has also been some intraspecific variation observed between flukes, particularly those 
from different geographical locations.  Fasciola species from Japan and Korea have been 
shown to possess both F. gigantica and F. hepatica-like ITS2 regions, and ITS2 
polymorphisms have been isolated from a single worm, leading to suggestions that natural 
hybridisation occurs between F. hepatica and F. gigantica in some areas (Itagaki and 
Tsutsumi, 1998; Agatsuma et al., 2000). 
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The restriction digests of the ITS2 PCR product resulted in banding patterns signifying that 
only one type of ITS2 nucleotide region was present after PCR amplification, which 
suggested that no polymorphisms were present in the fluke analysed in this study.   
The ITS2 nucleotide sequence obtained in this study corresponded to typical F. gigantica 
ITS2 regions, and was identical with several Asian derived F. gigantica ITS2 nucleotide 
sequences. 
The majority of ITS2 nucleotide sequences that are available come from F. gigantica obtained 
in Asia.  In generating the F. gigantica ITS2 consensus sequence, the African derived 
F. gigantica were most divergent.  Several F. gigantica sequences from isolates in Egypt 
(DQ385828 and DQ385829) were excluded due to the large amount of divergence seen 
between these sequences and other publicly availably F. gigantica ITS2 nucleotide sequences.  
Another Egyptian isolate (DQ383512) was divergent at the 5’ end of the ITS2 nucleotide 
sequence, but otherwise almost completely identical to other published F. gigantica ITS2 
sequences.  It should also be noted that the African isolates possessed a mutation typically 
considered to be an F. hepatica-like polymorphisms, namely a thymine at base 207.  A 
Zambian derived fluke ITS2 sequence (Acc # AB010975) also possessed F. hepatica-like 
nucleotides at bp 270, 276, 333.  
The published nucleotide sequences of the F. hepatica ITS2 regions were fairly well 
conserved with generally only one or two substitutions between sequences, most at either the 
start or end of the sequences and possibly resulting from sequencing errors. 
The ITS2 sequence obtained in this study possessed all the F. gigantica characteristic 
nucleotides at the designated species differentiation points, namely at bp 207, 231, 270, 276, 
327, 334.  This and the absence of more than one type of ITS2 region confirmed the species 
of the fluke used as belonging to F. gigantica.  The fluke was obtained from Indonesia, and as 
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would be expected, the nucleotide sequences were most similar with ITS2 regions from 
F. gigantica obtained from Asia   
5.4.2 pI variation among Fasciola cathepsin L-like proteases 
Cathepsins L-like proteases expressed by adult Fasciola appear to activate in the acidic gut of 
the parasite (Collins et al., 2004), with the pI of the majority of these proenzymes around 5.4.  
The gut lumen of flukes is estimated to have a pH of about 5.5 or lower (Halton, 1997).  Once 
activated the pI of most of the cathepsins is around 5, as such they would be expected to 
possess little net electrical charge.  However, once expelled into the surrounding 
physiological environment (pH~7.4), the proteins would take on a much greater net negative 
charge.  A few cathepsins, predominantly the clade A cathepsins and FhCatL41 which are 
expressed by immature flukes, possess a higher pI up to 8.8.  These proteins appear to be 
active in the duodenum (Cancela et al., 2008) the pH of which in humans is 6-6.5, meaning 
they would possess a net positive charge. 
Analysis of adult F. hepatica ES with 2D-gel electophoresis has identified cathepsin L 
proteases across a range of isoelectric points (Wijffels et al., 1994a; Jefferies et al., 2001; 
Morphew et al., 2007).  All three studies identified dominant cathepsin L species with pI 
values between 4 and 5.5, each also identified cathepsin L-like proteases with a pI at or above 
6.5.  This corresponds to the theoretical work undertaken in this study, which shows the pI of 
mature cathepsins belonging to clades B, C and D generally ranging from 4.5 to 5.5, while 
FhCatL3 has a pI of 6.93. 
Two of the groups also putatively identified the same cathepsin protein at several pI values 
(Jefferies et al., 2001; Morphew et al., 2007).  This variation could be due to minor amino 
acid differences among similar alleles, or alternatively some proline may be modified to 3-
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hydroxyproline derivatives (Wijffels et al., 1994a), which would account for some of the 
variation seen. 
The effect and role pI plays with Fasciola cathepsins if any, is not known, though proteins are 
most insoluble, least reactive and unstable in pH close to their pI (Arakawa and Timasheff, 
1985).  Thus it would be unusual for proteins to have pI values near the pH of the 
environment in which they are thought to be active.  This would further hint at several of the 
Fasciola cathepsins being functional in the host environment, at or near physiological pH.   
The median pI of the proenzymes is 5.4 resulting in the proenzymes having little net charge in 
the gut lumen and would be the point at which they have least intermolecular repulsions.  This 
may help facilitate trans-processing by permitting the enzymes close proximity to one another 
to cleave proregions.   
Certain clade A cathepsins produced by immature developmental stages in both Fasciola 
species and FhCatL41 were the only cathepsins that were found to possess basic pI’s.  There 
was a broad spread of pI values among the clade A proteins and closely related genes did not 
necessarily possess a similar pI, for example FhCatL8 and FhCatL10 have pI values of 5.7 
and 7.7 respectively.  The spread of pI values amongst clade A cathepsins may reflect the 
needs of these proteases to perform a variety of functions in a range of environments.  It may 
also suggest that the environment in which these cathepsins function is different to the one 
encountered by those expressed in mature fluke. 
5.4.3 Potential glycosylation of cathepsins 
Glycosylation of proteins serves various functions.  N-linked glycosylation is important for 
correct folding of some proteins and conferring stability as well as protein targeting, while O-
linked glycosylation is involved in cell-cell adhesion and acts as a component of mucosal 
secretions.  It can also be involved in targeting of certain proteins (Atiya-Nasagi et al., 2005). 
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Mammalian cathepsin L proteases are glycosylated, with the N-linked glycosylation sites 
thought to target cathepsins into lysosomes via the mannose 6-phosphate receptor pathway.  
Fasciola possess a range of glycolipids and glycoproteins, but the originally identified 
secreted Fasciola cathepsin L proteases were found to be non-glycosylated, with no potential 
glycosylation sites and a signal sequence directing them to the secretion pathway (reviewed in 
Dalton et al., 2003b).  Since then several Fasciola cathepsin L-like proteases have been 
identified with possible N-glycosylation sites, predominantly those expressed during the 
immature life stages.  However, for FhCatL8 at least, while the potential sites are glycosylated 
when expressed by recombinant yeast, the native protein is not glycosylated (Van Milligen et 
al., 2000; Harmsen et al., 2004).  Cancela and colleagues (2008) also found that a F. hepatica 
clade A protease was not glycosylated in vivo despite the presence of possible glycosylation 
sites.  Whether this holds true for all Fasciola cathepsin L-like proteases is not known, with a 
number of different potential glycosylation sites identified. 
While in situ hybridisation (Grams et al., 2001) and immunolocalisation studies (Yamasaki et 
al., 1992; Smith et al., 1993b; Collins et al., 2004) have shown that a majority of cathepsin L 
localises in secretory granules in the cells lining the parasite’s gut, F. hepatica have been 
shown to produce a greater range of cysteine proteases than are secreted (Dalton and 
Heffernan, 1989).  Some cathepsin L localisation has been observed in other cells including 
those associated with reproduction (Wijffels et al., 1994b).  With glycosylation able to 
mediate sorting of proteins in cells and different glycosylation types important in different cell 
types, it may be that intracellularly retained cathepsins, undertaking different functions to 
their secreted counterparts are those that would be glycosylated. 
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5.4.4 Phylogenetic analysis 
5.4.4.1 Gene search 
It has been known for years that Fasciola utilise proteolytic enzymes, with dominant activity 
ascribed to cathepsin L-like proteases.  In this study F. gigantica cathepsin L genes were 
identified from genomic DNA and mRNA including at least 6 distinct genes, several of which 
were novel.  All adult specific clades (B, C and D) were represented by mRNA-derived 
clones, as was the newly designated clade E.  Genomic DNA-derived clones predominantly 
encoded clade D genes and encoded proteins homologous to several of the mRNA derived 
sequences.  Some genomic clones were also identified that belong to clade A, although none 
were found that belong to any other clades.  No attempt was made to quantify cathepsin L-like 
genes present, thus whether the relative abundance of the genome-derived clade D genes is a 
result of their predominance within the F. gigantica genome, or whether the PCR 
amplification and subsequent screening process was biased towards the clade D genes was not 
determined. 
A pair of clade A paralogs were identified (F2 and 2+) from genomic-DNA, with both 
matching published sequences.  Identical mRNA derived clones were not isolated to confirm 
their expression, but as these proteins have only been found to be expressed in immature 
flukes this was expected.   
Several of the published sequences differ in only a few amino acids, and are likely due to 
regional differences reflecting genetic diversity among different Fasciola strains (Heussler 
and Dobbelaere, 1994; Panaccio and Trudgett, 1999).  Several of the genes isolated in this 
study, either from mRNA or genomic DNA also differed in only one to a few predicted amino 
acids in their respective sequences.  While mutations introduced during PCR amplification 
cannot be completely discounted, these sequences are likely to be alleles of the same gene, 
with the substitutions observed representing real sequence polymorphisms.  A high degree of 
Chapter 5: Phylogenetic analysis of Fasciola cathepsin L 
279 
variation has been confirmed in several Fasciola proteins, with mRNA clones rarely totally 
identical (reviewed in Panaccio and Trudgett, 1999).  The variation reflects genetic diversity 
within the population, rather than the presence of different genes.  The presence of isoforms 
and heterogenicity among the Fasciola ES cathepsin L-like proteases has been reported 
previously (Heussler and Dobbelaere, 1994; Wijffels et al., 1994a; Jefferies et al., 2001; 
Morphew et al., 2007), and this appears to be the case with the sequences in this study. 
A similar phenomenon was observed in the non-coding regions, with several of the genes 
encoding the same protein showing variation within intron regions (Figure 5.6; Appendix 4).  
However, in these cases all the coding region was not characterised, therefore coding 
variations may have been missed. 
The number of Fasciola cathepsin L-like proteases and diversity seen amongst them is greater 
than those of most other organisms.  The two fluke species diverged about 19 MYA (Irving et 
al., 2003) with the gene duplication events in a common ancestor and species differentiation 
leading to the genes observed today.  As such almost all F. gigantica cathepsin L genes have 
F. hepatica orthologs, including the novel genes isolated in this study. 
Grams and colleagues (2001) estimated that the F. gigantica genome consisted of about 10 
closely related cathepsin L genes.  This may not take into account the more recently isolated 
divergent members of the gene family such as FgCatL1G and 24.5A+, or more divergent as 
yet unidentified cathepsin L genes.  The reason for the development of such a large number of 
multiple genes has not been completely resolved, owing to difficulties in determining 
temporal expression and localisation due to sequence similarities, although some progress has 
been made.  While cathepsin L production predominantly occurs during the fluke’s adult 
stage, cathepsin L proteases are expressed or processed in a developmentally regulated 
manner (Dalton and Heffernan, 1989; Heussler and Dobbelaere, 1994; Cancela et al., 2008) 
and to date two clades of enzymes have been shown to be expressed at alternate life stages.  
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Clade A cDNA’s and their expressed proteins have to date only been isolated from 
metacercariae or NEJ, while clade F cDNA’s have only been obtained from NEJ, as has 
FhCatL41.  This would appear to validate the suggestion that the Fasciola cathepsins L have 
diverse biological functions at different developmental stages. 
Functional diversity in different tissues, specialised cells or external environments also 
appears to be a basis for the large number of genes.  A majority of the cathepsin L proteases 
are secreted, with several different proteases identified in ES (Dalton and Heffernan, 1989; 
Jefferies et al., 2001; Morphew et al., 2007), where they are believed to be involved in a 
range of functions from nutrition to the more specialised roles of migration, immune evasion 
and immune modulation (reviewed in Tort et al., 1999; Mulcahy and Dalton, 2001; Dzik, 
2006).  Fasciola are capable of infecting a range of host species (reviewed in Spithill et al., 
1999a; Torgerson and Claxton, 1999).  The combination of redundancy and diversity seen 
within the Fasciola cathepsin L family may facilitate this ability, both through functional 
diversity, and through antigenic variability, with several closely related Fasciola cathepsin L 
genes showing variability removed from the active site cleft. 
While cathepsin L-like proteases have been localised to secretory vesicles of cells lining the 
gut (Dowd et al., 1992; Yamasaki et al., 1992; Smith et al., 1993b; Grams et al., 2001; 
Collins et al., 2004), localisation to other cell types, specifically reproductive organs has been 
reported (Wijffels et al., 1994b; Panaccio and Trudgett, 1999; Panaccio et al., unpublished).  
The localisation of cathepsin L expression to reproductive organs hints at their role in the egg 
production pathway (Wijffels et al., 1994b).  Decreased egg output and viability has been 
observed when purified native protein was used in vaccinations (Wijffels et al., 1994b; Dalton 
et al., 1996b; Piacenza et al., 1999).  Use of cysteine protease inhibitors also had a similar 
effect (Alcala-Canto et al., 2007), while unpublished histochemical studies indicates their 
presence in vitelline cells and oocytes along with gut association (cited in Wijffels et al., 
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1994b).  Other cathepsin L proteases may also be involved, with the GenBank entry for 
FhCatL4 stating its localisation to the Mehlis’ gland and gut related cells (Panaccio et al., 
unpublished).  The isolation of the partial sequence of FhCatL14 paired with a vitelline 
eggshell precursor protein (Rice-Ficht et al., 1992) also hints at its localisation in vitelline 
cells.  As discussed in Heussler and Dobbelaere (1994), and Roche et al. (1997) the Fasciola 
cathepsin L proteases are also likely to play roles in normal cellular processes similar to their 
mammalian counterparts such as activation or turnover of proteins, while a presentation at the 
2006 ASP & ARC/NHMRC Research Network for Parasitology Annual Conference linked a 
F. hepatica cathepsin L with neuropeptide signal termination in nerve cells (McGonigle et al., 
2006).   
5.4.4.1.1 Cathepsin L gene features 
While no genome gene sequence (including introns) from F. hepatica has been published, 
Yamasaki et al., 2002) has published the gene sequence for a F. gigantica clade D cathepsin 
(FgCatLB22) and also determined a second gene sequence (FgCatLB7).  The genome-derived 
clones isolated in this study showed a much larger range of intron variation than was 
exhibited between FgCatLB22 and FgCatLB7, with the clade A genes possessing the most 
divergence when compared to other genes.  This is an expected result considering the 
divergence also associated with the coding regions of these genes.  Among the genes, most 
variation was in intron 3, by far the largest of the introns.  Deletions within intron 3 lead to 
large variation in intron length between closely related genes. 
While genomic clones 2.1 and 13 (320A-like) and also the clade A clones (2+ and F2) had 
mutations affecting residues leading into the 5’ splice site in introns 1 and 3 respectively, the 
only obvious cis-splicing site affected by mutations was that of clone 6.26.  The 3’ splice site 
AG acceptor of intron 2 was interrupted by the presence of a 16 bp deletion.  The result of this 
alteration at a critical splicing signal would have important consequences, interfering with the 
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splicing mechanism.  This would result in an incorrectly processed mRNA and mutant 
protein, due either to the intron failing to be spliced, or splicing occurring at an alternate 
cryptic site. 
The 3’ extension of several mRNA sequences was also obtained in this study, with most 
possessing an AATAAA signal 32 bp downstream of the stop codon.  Exceptions were clones 
320A and 24.8A which both have an AATGAA signal.  Several published sequences also 
have variations in this region, including FhCatL3, -L38 and –L41.  The AATAAA or closely 
related signal sequences are considered necessary for polyA tail addition to transcripts, and 
the presence of polyA tails on the transcripts isolated in this study suggests that the alternate 
signal sequence is also functional, though whether polyA tail addition is downregulated was 
not explored. 
5.4.4.1.2 Pseudogenes 
While the deletion in clone 6.26 results in a transcript that does not appear to be able to be 
spliced correctly and may encode a pseudogene, two other genomic-DNA derived clones 
(1.1+ and 2.2) were found with premature stop codons.  Clone 1.1+ contains a premature stop 
codon after amino acid residue 199, while clone 2.2 encodes a stop codon after residue 95.  
Clone 1.1+ has high identity with FgCatL1A-like genes in both exon and intron regions.  
Clone 2.2 is slightly more divergent than clone 1.1+, but still has high identity to other 
F. gigantica ‘classical’ clade D genes in exon and intron regions, the major difference a large 
deletion in intron 3.  While the presence of the premature stop codons maybe due to an 
artefact introduced by Taq polymerase, it appears probable that these two pseudogenes were 
brought about by relatively recent duplication events.  While several cathepsin L pseudogenes 
have been isolated from humans (Bryce et al., 1994; Rossi et al., 2004), this is the first report 
of the presence of a cathepsin L pseudogene in Fasciola.  
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5.4.4.1.3 Cathepsin L structural features 
Several structural motifs in the proregion of cathepsin L genes from various species have been 
described.  The ERFNIN motif stabilises the globular structure of the proregion, influencing 
transport and processing of cathepsin L proteases (Coulombe et al., 1996; Groves et al., 1996; 
Wiederanders, 2000).  In Fasciola it is present as a DRWNIN motif however, the amino acid 
differences would not be expected to drastically alter the function of the motif.   
The tripartite tryptophan which is important for maintenance of prodomain structure and its 
stability (Kreusch et al., 2000) was completely conserved in all the Fasciola cathepsin L 
proteases (Figure 5.9). 
The GNFD motif which has been shown to be involved in processing of papain-like cysteine 
protease (Vernet et al., 1995) including Fasciola cathepsin L (Collins et al., 2004), is well 
conserved, with only five sequences possessing substitutions, all of which are conservative.  
The G-42 - L-41 bond, which has been identified as an intermediate cleavage site in FhCatL1 
processing (Collins et al., 2004) is preserved in all Fasciola cathepsin L proteases.   
The fact these prodomain motifs are conserved suggests the roles these regions play in 
mammalian cathepsin proteases are conserved in the Fasciola cathepsins, including their 
importance in transport, stability and processing. 
The overall structure of mature Fasciola cathepsin L-like proteases is highly conserved with 
the other papain-like proteases.  They possess 2 conserved domains, the left largely helical 
and the right predominantly beta-sheet with the active site cleft lying between the two. 
The six cysteine residues involved in disulphide bond formation were completely conserved 
amongst the Fasciola cathepsin L-like genes, the exception was with the possible pseudogene, 
clone 6.26, where the C97 residue was deleted. 
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Like other cathepsin L proteases the S2 subsite determines protease specificity.  The 
specificity at this pocket appears to be largely determined by residue 69 (Smooker et al., 
2000), with several variations at this residue observed in Fasciola cathepsin L-like proteases 
in a clade specific manner (Irving et al., 2003).  Residue 209 is also important to S2 subsite 
architecture and specificity in cathepsin L genes (Bromme et al., 1994; Lecaille et al., 2001; 
Lecaille et al., 2002a; Sajid and McKerrow, 2002), with some variation also observed 
amongst the Fasciola cathepsin L genes.  A number of variable surface patches, determined 
through positive selection have also been observed in Fasciola cathepsin L genes, with 
suggested roles including antigenic variability, inter-protein interactions and higher order 
substrate binding (Irving et al., 2003). 
5.4.4.1.4 Cathepsin L clades 
5.4.4.1.4.1 Clade A 
Phylogenetic analysis in this study showed FhCatL35 grouped with the F. gigantica clade A 
cathepsins rather than with the F. hepatica orthologs, and appears to be an allele of clone 2+ 
isolated in this study.  This suggests an ancestor of the F. hepatica strain that FhCatL35 was 
isolated from has somehow obtained F. gigantica genomic DNA, resulting in expression of a 
gene originally from F. gigantica.  This is discussed in more detail in section 5.4.7. 
There are several substitutions between the two F. gigantica paralogs, with many of the 
substitutions present in FhCatL35/clone 2+ present in the F. hepatica clade A alleles.  The 
mutations in the mature region are surface exposed amino acids, with the exception of S180, 
while aa19 is the only one present in the vicinity of the active site cleft, possibly playing a 
role in P2’ interactions.  The surface exposed mutations are clustered within or near the region 
of positive selection classified as patch I (aa146-157) where they may interact with substrates 
removed from the active site or play a role in the interaction with immune effector molecules, 
providing epitope variability (Irving et al., 2003).   
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The F. hepatica clade A paralogs possess slightly more differences between themselves than 
their F. gigantica counterparts and like their F. gigantica homologues a majority of the 
differences are with surface exposed amino acids.  The mutations are predominantly clustered 
in patch I and patch III, while residues 30 and 134 line, but face away from the active site, and 
thus would not be expected to affect the active site architecture to any great extent.  Thus, like 
the F. gigantica clade A cathepsins, the differences do not directly affect the active site. 
Between the species in clade A there is only a single residue (aa66) that differs within the 
respective active sites.  The S66 found in F. gigantica is replaced with G66 in F. hepatica.  
These residues form part of the architecture of the S1 and S3 subsites and their substitution 
may account for substrate specificity differences at P1 and P3, with the serine producing a 
more polar environment.  FhCatL8 and -L37 differ from the other cathepsins at residue 159, 
possessing a serine rather than an arginine.  While this residue lines the S2 pocket, its side-
chain faces away from subsite so the effect of any mutations on subsite architecture would be 
expected to be minimal. 
The active site of the clade A cathepsins is significantly different from cathepsins belonging 
to other clades, with a tryptophan residue present at aa69.  These cathepsins are all proposed 
to have a preference for proline, similar to that shown for FgCatL1G, with recent work on 
juvenile F. hepatica cathepsins supporting this (Cancela et al., 2008). 
5.4.4.1.4.2 Clade B 
Among the clade B cathepsins are three distinct genes; FgCatL1D, the F. hepatica ortholog 
FhCatL2 and the divergent paralog FhCatL31.  These proteases are all characterised by Y69.   
Two alleles of FgCatL1D were identified in this study, one identical to the published 
sequence, the other with just a single substitution. 
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Four sequences have been identified that are similar to FhCatL2, with each possessing greater 
than 95% amino acid identity.  None of the differences are expected to affect substrate 
specificity, and are probably the result of natural allelic variation among fluke strains.  
Interestingly though, a region of nucleotide variability occurs at the proposed trans-splicing 
site in the FhCatL31 gene.  These nucleotides encode residues 130-132 which are buried, and 
not surface exposed.  The reason for the nucleotide variability seen in FhCatL-7 and -11 may 
be to alter the donor and acceptor splice residues respectively, prohibiting a trans-splicing 
event like that proposed for FhCatL31.  
As a result of the proposed trans-splicing event to produce FhCatL31, the majority of the 
differences seen in FhCatL31 when compared to the F. hepatica clade B cathepsins run along 
one wall of the active site cleft, as such affecting predominantly the S2 and S1’subsites.  How 
much this would affect the subsite architecture and substrate binding is uncertain with side-
chain of the residues affected facing away from the S2 subsite, though S1’ subsite architecture 
would likely be altered.   
5.4.4.1.4.3 Clade C 
This clade encompasses quite a diverse group of cathepsins.  Due to their level of divergence, 
substitutions appear throughout the proteases, with all the positive selection patches referred 
to by Irving and colleagues (2003) represented.  Like the other clades mentioned so far, a 
majority of the variable residues appear to be surface exposed, probably playing a role in 
antigenic variability.  However, unlike the other clades previously mentioned several variable 
residues would influence substrate architecture.  Active sites S1 through to S3 as well as S1’ all 
possess at least one residue that varies between proteases of the clade, suggesting they may 
represent functionally different proteins.  Interestingly the GenBank annotation for FhCatL4, 
stated it was localised to the Mehlis’ gland and gut microvilli (Panaccio et al., unpublished), 
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suggesting that as well as secretion into the gut, these cathepsins may play a role in 
reproduction.   
FgCatL1F and FhCatL30 appear to have diverged soon after the split with the Clade D genes 
and have no closely related proteins, only sharing 82% amino acid identity.  These cathepsins 
are likely to have orthologs, and a search of the preliminary F. hepatica EST database against 
FgCatL1F revealed several transcripts that had maximum amino acid identity of about 90%.  
This is higher than the similarity with the most closely related published sequences (FhCatL5 
and FgCatL1C have 85% amino acid identity), and is about the same identity displayed 
between other apparent Fasciola cathepsin L orthologs.   
Interestingly the FgCatL1F sequence isolated in this study (315+) shows a high level of 
variation in the C-terminal region of the prodomain when compared to other Fasciola 
cathepsins.  Residue differences are present at the autocatalytic cleavage site, including those 
proposed to sit in the S1 to S3 subsites (Stack et al., 2007), with the leucine proposed to be at 
P2 replaced with a tyrosine.  This may reflect differences in the substrate preference of 
FgCatL1F. 
The active sites of the clade C and D cathepsins are fairly similar, with their architecture and 
specificities discussed in the previous chapters, specifically FhCatL1 and FhCatL5.  The 
major difference in FgCatL1F compared to FhCatL5 at the S2 subsite appears to be a L209M 
substitution which may influence binding of aromatic/aliphatic P2 residues.  FgCatL1F also 
appears to have a charged S1 subsite. 
5.4.4.1.4.4 Clade D 
Clade D is the most recent Fasciola cathepsin L clade to have diverged and it is also the 
largest clade.  The cathepsins of this clade are secreted, and have been shown to be integral 
members of adult Fasciola ES (Smith et al., 1993b), with multiple isoforms identified 
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(Jefferies et al., 2001; Morphew et al., 2007), although their relative expression levels appear 
to vary between different studies.   
A number of the clones isolated in this study, both genomic and mRNA derived, were found 
to be grouped in this clade.  Generally F. hepatica genes in this clade are designated simply as 
FhCatL1, however despite the phylogenetic relationship amongst all the genes not being clear, 
there is a distinct separation into FhCatL1-like and FhCatL9-like genes, with F. gigantica 
classical clade D and 320A-like genes orthologs to each subgroup respectively.   
Published sequences from both species show a high degree of sequence identity, with many 
sequences only possessing one or two variable amino acids.  As such, despite the large 
number of sequences, each of the subgroups mentioned within this clade is fairly shallow 
evolutionarily and little sequence divergence is present.  While such a relationship may 
represent allelic variation amongst fluke, recent gene duplication and evolution of this group 
of enzymes and simultaneous gene expression is also possible.  Variability between the 
subgroupings tends to focus around the patch I region, particularly residues 156-160.  These 
residues sit off to one side of the active site cleft next to the S2 subsite.  While not 
traditionally found in one of the residue-discerning subsites, they may still interact with 
substrates, and form a functional basis to the phylogenetic divisions.  The staggered timing of 
gene duplication events within the Fasciola cathepsin L family have been proposed to occur 
with host species expansion, which suggested co-adaption and co-speciation (Irving et al., 
2003).  The recent gene duplication and evolution observed in the clade D proteases may 
reflect this adaption, as fluke are introduced to new geographical locations and interact with 
new host species.   
Previously, Grams et al. (2001) identified three near identical genes FgCatL1-A, -B and –E, 
while FgCatL2 identified by Irving et al. (2003) also showed very high identity.  For each of 
these genes, almost identical genome- and mRNA-derived sequences were isolated in this 
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study, suggesting that the subtle polymorphisms observed are part of the natural population 
expressed by F. gigantica.  The division of these paralogous sequences into three distinct 
groups (FgCat-L1A-like, L1B-like and L2-like) may represent functional separation brought 
about by substitutions at residues lining the active site cleft resulting in minor substrate 
specificity differences; or alternatively may result from the need for antigenic variability.  The 
variation observed at residue 66 may affect protease interaction with cystatins (Irving et al., 
2003).  Alleles to the more divergent, but still closely related FgCatLB22 were not observed 
in this study. 
The 320A-like genes are novel, being first described in this study.  Three mRNA-derived 
clones were identified, along with 6 genomic clones with amino acid identity of 92-99%.  
While the presence of mRNA transcripts suggests they are expressed, none were identified 
during the analysis of relative clone abundance undertaken in this study. 
Phylogenetically, these genes were grouped with the FhCatL9-like clade D cathepins, which 
have been shown to be secreted in ES (Jefferies et al., 2001; Morphew et al., 2007).  Protein 
expression levels have varied in different studies.  Morphew et al. (2007) putatively identifed 
proteins similar to FhCatL11 (FhCatL9-like) at several locations, Heussler and Dobbelaere 
(1994) suggested FhCatL13 (FhCatL9-like) transcripts were rare, while Jefferies et al. (2001) 
identifed several possible clade D proteins, although the one identified as FhCatL9 was at 
relatively low expression levels.   
Two of the mRNA-derived clones were almost identical, however the third, 325A showed 
some divergence.  The genome-derived clones all showed higher amiono acid identity with 
clones 320A and 24.8A (<99%) compared to clone 325A (<97%).  The F. hepatica partial 
clone FhCatL14 isolated as a 3’ UTR with a vitelline protein (Rice-Ficht et al., 1992) showed 
significantly higher amino acid identity with clone 325A (>97%), than it did with the 320A-
like homologous genomic DNA- and mRNA-derived clones (<93%).  It is proposed that the 
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genomic clones encode genes 320A and 24.5A or similar alleles and clone 325A is actually a 
spliced gene.  Interestingly the 3’ trans-spliced region of 325A shows very high identity with 
sequences from F. hepatica, far more so than any F. gigantica genes.  Either this region of the 
gene is an undiscovered F. gigantica homolog to FhCatL14 which shows very high identity, 
or the F. gigantica used in this study possess a gene that originated in F. hepatica, similar to 
the discovery of FhCatL6 in F. gigantica species (Irving et al., 2003).   
It appears that the detection of the partial FhCatL14 sequence as a 3’ UTR extension to the 
vitelline B2 transcript may itself be a situation where mispairing of separately trans-spliced 
sequences has occurred.  As this would be expected to occur where both transcripts are 
generated, it may suggest a function for FhCatL14-like genes in vitelline specific tissues and 
organs, and hints at a possible role in the egg production pathway for this cathepsin. 
5.4.4.1.4.5 Others 
Besides the three previously described clades, a further three clades where identified during 
the phylogenetic analysis.  While these clades did not receive high bootstrap support, 
resulting in uncertaintly to their exact position, no tree building methods placed the sequences 
that compose these clades into any of the existing 4 clades. 
Clade E is composed of three mRNA-derived sequences isolated in this study and the 
apparent ortholog FhCatL16.  This group of cathepsins, like the clade C and D cathepsins 
possess L69, and have similar S2 subsite architecture to cathepsins of the aforementioned 
clades.  However, there is some variability in the residues that form the other subsites and the 
level of amino acid diversity among the genes and phylogenetic analysis suggests they belong 
to a distinct clade. 
Clade F consists of FgCatL1H and FhCatL33, -L39 and -L40.  All possess F69 and were 
isolated from NEJ.  FgCatLB7, while also possessing F69 is not situated within clade F, and 
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does not appear to be closely related to FgCatL1H, rather showing more identity to the L69 
cathepsins in clades C and D.  FgCatLB7 is a genomic DNA-derived clone which has yet to 
be shown to be expressed, and thus may be a pseudogene, although it has only been 
specifically searched for in adult fluke (Yamasaki et al., 2002).  To date no FgCatLB7 like 
sequences have been isolated from F. hepatica. 
The recently published FhCatL41 phylogenetically forms its own singleton clade.  Isolated 
from NEJ, the cathepsin diverged early during fluke evolution similar to the other juvenile 
specific cathepsins.  The protein is expected to have a distinct substrate specificity with 
variation at several residues lining the S2 subsite.  It is the only Fasciola cathepsin to possess 
G69, and also has M160.  The protein also possesses A209 which has been associated with a 
preference for P2 aromatic residues compared to aliphatic residues as outlined in Chapter 5. 
5.4.5 Relative clone abundance 
During analysis of mRNA-derived clones, the frequency with which each cathepsin was 
identified was determined relative to the total number of clones.  While biases in the methods 
used preclude this from being a quantitative determination of protein expression levels, it can 
be used as an indirect method to provide an estimation of relative transcription levels, the 
results of which can be used as an initial indication subsequent to further studies involving a 
semi-quantitative approach.  Such an approach to detect gene-specific mRNAs will require 
short, gene-specific probes.  The methods utilised in this study attempted to minimise any 
inherent bias caused by this approach; including stopping the PCR prior to the amplification 
plateau, the use of a single primer set complementary to all sequences and the lack of clone 
screening selectivity.   
While some Fasciola cathepsin L proteases are undoubtedly involved in normal cellular 
processes, cathepsins have been predominantly localised to secretory vesicles in the parasites 
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gut for secretion into the gut lumen.  Thus it would be expected that transcripts for these 
abundant secreted proteases would be among the more predominant sequences isolated in the 
study of relative clone abundance. 
Cathepsin L proteases are the main proteins present in adult F. hepatica ES (Dalton and 
Heffernan, 1989; Dowd et al., 1994; Jefferies et al., 2001; Morphew et al., 2007), with 
FhCatL1 and FhCatL2, or similar isoforms, estimated to represent >80% of F. hepatica ES 
(Smith et al., 1993b; Dowd et al., 1994) and also act as the immunodominant antigens 
(Cordova et al., 1997; Morphew et al., 2007).   
However, reports of heterogenicity and identification of numerous cathepsin L proteases in 
F. hepatica ES across a range of pI values (Wijffels et al., 1994a; Jefferies et al., 2001; 
Morphew et al., 2007), along with the large number of genes isolated in the gene family to 
date indicate that several other cathepsin L proteases are important for fluke survival.   
Stage-specific expression levels (Dalton and Heffernan, 1989; Van Milligen et al., 2000; 
Cancela et al., 2008), varying relative proportions in different secretion samples (Wijffels et 
al., 1994a), and incubation conditions affecting types and levels of cathepsins expressed 
(Morphew et al., 2007) indicates that Fasciola possess a diverse and complex cathepsin L 
expression pattern. 
Analysis of the relative frequency of specific sequences among the mRNA-derived clones 
showed that for F. gigantica the clade B cathepsin FgCatL1D was predominant, representing 
over half of all clones recovered.  Two isoenzymes of this gene were discovered in the study, 
with one transcribed to a greater (two-thirds) extent.   
While relative clone abundance is an indirect and qualitative estimate of protein expression 
levels, the high level of FgCatL1D transcripts observed in F. gigantica in this study compares 
to several F. hepatica studies, where clade B transcripts or proteins have been identified as 
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being abundant (Dowd et al., 1994; Heussler and Dobbelaere, 1994; Cordova et al., 1997; 
Jefferies et al., 2001; Morphew et al., 2007; Robinson et al., 2008b).  
The presence of more than one allele was not unexpected, with Heussler and Dobbelaere 
(1994) indicating through Southern blot analysis that there may be multiple FhCatL7-like 
genes present.  Morphew et al. (2007) identified two different clade B-like cathepsins by 2D-
gel electrophoresis, and putative FhCatL7 proteases have been identified at various pI values 
(Jefferies et al., 2001; Robinson et al., 2008b) however, whether these were isoforms or 
alternatively, slightly different alleles is not known. 
FhCatL2 has been shown to possess the unusual ability to accommodate synthetic substrates 
with proline at position P2, and can cleave fibrinogen to produce a fibrin clot (Dowd et al., 
1994; Dowd et al., 1995; Dowd et al., 1997).  No substrate specificity studies have been 
performed with FgCatL1D, however it possesses an identical S2 pocket and overall the active 
site cleft is very similar to FhCatL2, thus it would also be expected to have similar substrate 
preferences. 
Several roles have been proposed for cathepsins secreted into the ES, including general 
nutrition, migration and immune evasion and modulation.  Specifically, FhCL2 is able to 
degrade extracellular matrix and basement membrane molecules, including fibronectin, 
laminin and collagen (Berasain et al., 1997), and the ability of FhCatL2 to cleave 
immunoglobulins (Berasain et al., 2000) and cleave fibrinogen to produce a fibrin clot (Dowd 
et al., 1995; Dowd et al., 1997) has also hinted at a possible role in immune evasion.  
FhCatL2 may also have a role in the egg production pathway, vaccination studies 
incorporating native purified FhCatL2 resulting in reduced egg production and viability 
(Dalton et al., 1996b; McManus and Dalton, 2006), although this may be due to 
immunological cross-reactivity.  However, to date FgCatL1D has only been observed in ES, 
and the use of a purified FgCatL vaccine failed to protect or significantly reduce egg 
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production or viability (Estuningsih et al., 1997).  Whether this was due to the differences 
between the Fasciola species or different vaccine strategies, specifically the use of adjuvants, 
is unknown (reviewed in Spithill et al., 1997; Spithill et al., 1999a). 
Most studies identify FhCatL1 and FhCatL2 as the main F. hepatica ES proteases, thus also 
identifying clade D cathepsins as being dominant ES products.  In this study, sequences very 
similar to those identified by Grams et al. (2001) were isolated (classical F.gigantica clade 
D), though at far lower levels (11%) than FgCatL1D.  A number of different alleles were 
identified, with almost every clone encoding a slightly different amino acid sequence.  A 
majority of the genome-derived clones and several other mRNA-derived clones isolated at a 
later stage were also similar to these genes. 
The presence of both genome- and mRNA-derived clones for each of FgCatL-1A, -1B and -2, 
suggests that the observed subtle differences first noted with these closely related genes by 
Grams et al. (2001) are real existing sequence polymorphisms.  It is possible that F. gigantica 
expresses several of these paralogous genes simultaneously, potentially with each expressed 
at a relatively low level, which when combined give the impression of a predominant clade D 
protein.   
The clone abundance observed for the classical F. gigantica clade D paralogs in this study 
was relatively low.  This may be a result of biases present in the methods used in this study, 
as the FhCatL1-like clade D cathepsins have been reported to be dominant ES cathepsin L 
protease in F. hepatica (Smith et al., 1993b; Dowd et al., 1994; Cordova et al., 1997; 
Robinson et al., 2008b), while FgCatLB22 was reported as the dominant cathepsin L in adult 
F. gigantica ES (Yamasaki et al., 2002).  However Heussler and Dobbelaere (1994) did not 
identify any FhCatL1-like transcripts, while an in vivo study by Morphew et al. (2007) only 
identified low levels of FhCatL1-like clade D cathepsins in F.hepatica ES. 
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Several factors may be responsible for expression variances in those studies.  These can 
simply be species or strain specific differences, while time of sampling (Carmona et al., 1993; 
Wijffels et al., 1994a) and incubation environment (Lee et al., 1992a; Morphew et al., 2007) 
can also be factors.   
Alternatively, FhCatL9-like and FhCatL1-like proteases may not have been distinguished in 
earlier studies, with the first 15 N-terminal residues of the mature proteases identical in almost 
all the clade D cathepsins, making it difficult to positively identify the proteases by this 
method, while the high degree of similarity between the genes in each species also makes it 
difficult to determine exact types when using MALDI-TOF, with both Jefferies et al. (2001) 
and Morphew et al. (2007) discussing the limitations of the method. 
The 24.5A-like proteases were encoded by almost a quarter (22%) of clones sampled, the 
second most commonly isolated group of clones in this study.  This relatively high level of 
clone abundance makes it curious as to why these sequences were novel, having not been 
identified in F. gigantica before.  Three alleles of the gene were identified, with the most 
common allele encoded by over 70% of clones.  FhCatL16 appears to be the F. hepatica 
ortholog.  Heussler and Dobbelaere (1994) identified FhCatL16 transcripts as being abundant 
and possibly present in multiple genes as determined by southern blot.  No other studies have 
reported the presence of similar transcripts or identified proteins with high similarity.   
N-terminal sequencing may not distinguish FhCatL16 due to similarity with other cathepsins 
in this region, while divergence of clade E genes at nucleotide (<84%) and amino acid 
(≤77%) level may have hindered identification by in situ hybridisation or immunolocalisation 
studies.  However, the high amino acid diverence suggests methods such as MALDI-TOF 
should distinguish them from other cathepsin L proteases.   
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Expression only under certain conditions or lack of secretion, with expression directed to 
specific organelles or tissues and protein retained intracellularly may also have hindered 
identification.  The clade E genes all possess O- and N-linked glycosylation sequons, with 
both forms of glycosylation involved in intracellular targeting of certain proteins (Atiya-
Nasagi et al., 2005).   
The other gene identified when analysing relative clone abundance was an isoenzyme of 
FgCatL1F, with only a single clone identified.  No clones were identified for the other 
F. gigantica clade C cathepsin FgCatL1C.  As with the other cathepsins, expression levels 
vary in different studies, Morphew et al. (2007) and Robinson et al. (2008) both identifying 
low levels of FhCatL5 in F. hepatica ES, while Heussler and Dobbelaere (1994) suggested 
FhCatL12 was abundant. 
Overall, transcripts encoding FgCatL1D alleles were by far the most common identified 
among the clones.  This was consistent with other protein and mRNA studies in Fasciola 
species, which have consistently identified clade B cathepsins as one of, if not the 
predominant cathepsin L in adult ES, to which a majority of cathepsin L expression appears to 
be directed.  The relative clone abundancies of the other cathepsins identified were slightly 
surprising, and may highlight the bias in the methods used.  The clade D clone abundancies 
were relatively low considering that FhCatL1 is considered one of the two main ES proteins 
in F. hepatica, and the identification of a novel gene in almost a quarter of clones was 
unexpected.  These preliminary results need to be quantified by further study due to inherent 
bias in the methods used.  The variation observed among other studies could be due to a 
number of possibilities, with species specific differences between F. gigantica and 
F. hepatica the most obvious cause.  However, fluke development or times of sampling are 
also possible explanations, with overall cathepsin L-like activity shown to vary daily in 
specific developmental stages (Carmona et al., 1993), while relative levels of expression in 
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ES fluctuate (Wijffels et al., 1994a).  The incubation environment has also been shown to 
alter the levels and types of cathepsins expressed (Morphew et al., 2007).  It is interesting that 
the only study to identify another clade E cathepsin (FhCatL16) also analysed mRNA 
transcripts using degenerate primers (Heussler and Dobbelaere, 1994), rather than protein 
analysis in ES.  It may be that these cathepsins are not secreted into the ES, but rather retained 
within the fluke, and localised to specific tissues or organs for an as yet unknown function, 
thereby leading to their lack of identification in ES related protein studies.  
5.4.6 RNA processing  
Most eukaryotic transcripts undergo cis-splicing events, removing intron regions to produce 
mature mRNA.  Classical splice leader (SL) trans-splicing involves the addition of a 5’ UTR 
leader sequence to mRNA transcripts.  SL trans-splicing has been reported in Fasciola (Davis 
et al., 1994; reviewed in Panaccio and Trudgett, 1999), and is proposed to be a common 
mechanisms within Fasciola and other trematodes (Davis et al., 1995), although it has not 
been reported with Fasciola cathepsin L-like genes (Yamasaki et al., 2002).  While cis- and 
SL trans-splicing are similar with comparable splice boundary regions, other forms of trans-
splicing distinct from SL trans-splicing have been reported, with some forms not requiring the 
canonical GT-AG consensus splice sites (Davis et al., 1995; reviewed in Blumenthal, 1995; 
Mayer and Floeter-Winter, 2005) 
Previous studies have revealed a distribution of substitutions throughout Fasciola cathepsin 
sequences that was consistent with multiple genes rather than alternatively spliced variants 
(Yamasaki et al., 2002; Irving et al., 2003).  However, pairwise comparisons undertaken in 
this study showed several sequences possessed an accumulation of substitutions in the 3’ 
region of the gene, while maintaining identity throughout the rest of the sequence.  This 
hinted at the prospect of trans-splicing, processing events which accurately join sequences 
derived from distinctly transcribed RNAs (reviewed in Mayer and Floeter-Winter, 2005).  The 
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fact that closely linked trans-spliced genes tend to be expressed at lower frequencies than 
their cis-spliced counterparts may explain why so few have been identified to date (Mayer and 
Floeter-Winter, 2005).  
Three sequences isolated in this study and a published sequence all possessed C-terminal 
regions that showed similarity with separate genes extending from the coding region into the 
3’ UTR.  These proposed trans-splicing events appear to have occurred within exon regions, 
and with the exception of one proposed trans-splice site, do not appear to require the 
canonical GT-AG boundary splice sites. 
FhCatL31, a clade B cathepsin appears to have spliced with a clade D gene, the proposed 
splicing site occurring between codons 129-133 (mature numbering).  This resulted in a fairly 
divergent protein, that compared to other clade B cathepsins has several surface exposed 
variations, including to active site residues. 
Clones 303A and 306 are almost identical clones that were isolated during the relative clone 
abundance study.  They appear as FgCatL2-like genes (clade D) that have spliced with a clade 
B gene.  The splice site is far closer to the C-terminus than that observed with FhCatL31, 
occurring somewhere between codons encoding M203 and S211.  As a result of the position 
of the proposed splice site, the event only produced a single substitution to the deduced 
protein sequence when compared to other FgCatL2-like sequences. 
The final example of a splicing event occurred with clone 325A.  It appears to diverge from 
the closely related genome- and mRNA-clones after residue E119.  Interestingly it then shows 
significant identity (both nucleotide and amino acid) with the F. hepatica clone, FhCatL14.  
The partial sequence of FhCatL14 shows fairly high identity to the 320A-like genes, but 
FhCatL14 was itself not isolated as a cathepsin, but instead as a 3’ UTR to another protein 
(Rice-Ficht et al., 1992).   
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The sequence of FhCatL14 starts less than 20 amino acids prior to the proposed trans-splicing 
site, thus it was difficult to confirm the level of sequence identity across the gene and if a 
splicing event had actually occurred.  A search of the preliminary F. hepatica EST database 
being constructed by The Sanger Institute, identified several sequences with similarity to 
FhCatL14.  Firstly, this showed that FhCatL14-like clones are expressed by F. hepatica, and 
appear to be closely related, possible paralogs to FhCatL9-like genes, with about 93% amino 
acid identity.  Secondly it allowed pairwise comparison across a much larger region of the 
gene sequences.  While the other proposed trans-splicing events occurred between cathepsins 
from different clades, this event appears to be a splice with a far more closely related gene, 
thus even though almost half the gene was altered by the proposed splice event the number of 
amino acid variations were relatively small and only the M209L substitution affected the 
active sites.   
Trans-splicing can be difficult to demonstrate, requiring the absence of DNA recombination 
and determination of putative splice sites.  It is made harder with some forms of trans-splicing 
not requiring the presence of GT-AG boundary splice sites.  The mRNA processing events 
were not specifically looked for in this study, as such experimental results were not obtained 
to support the pairwise analysis, while the lack of the complete genomic data also makes it 
difficult to exclude other mRNA processing events or genomic recombination, such as 
alternative splicing of long transcripts from tandemly arrayed genes or gene fusion. 
However, Fasciola appears to possess several compact cathepsin L genes, spanning 2 kb in 
F. gigantica (Grams et al., 2001; Yamasaki et al., 2002).  While not all cathepsin L genes 
have been isolated from genomic DNA, those that have show conservation of introns within 
and between clades.  The F. gigantica cathepsin L genes are similar to cathepsin L genes from 
other species, and while they have fewer introns than their mammalian counterparts, several 
intron sites are conserved among various species (Yamasaki et al., 2002), and none appear at 
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the proposed splice sites specified for the chimeric clones.  When isolating the FgCatLB22 
gene, (Yamasaki et al., 2002) found only a single cathepsin L gene in a 16 kb region, 
suggesting this cathepsin L gene is not present in a tandem array. 
Further evidence to support the proposed trans-splicing event are that the genes contained a 
section that diverged from closely related genes, and showed similarity to less related 
sequences, which extended into the 3’ UTR.  Also for the sequences isolated in this study, 
genome-derived clones were isolated that were similar to the closely related genes, but not to 
the spliced sequences; although specific primers for amplification of such recombined genes 
were not constructed during the relevant experimental section.   
Although it is difficult to assign a function to trans-splicing, it appears to be another way to 
generate variability, although as mentioned, the level of variability seen varied amongst the 
different sequences.  Almost no variability was observed in the coding region of the 303A and 
306 clones when compared to FgCatL2-like genes, thus it may be that regulation through 
different 3’ UTR may have been the primary function for at least these sequences, with the 3’ 
UTR known to affect transcript stability, localisation and translation efficiency. 
5.4.7 Species origin of genes. 
The duplication events that lead to Fasciola cathepsin L-like genes occurred prior to 
speciation which has been estimated at 19 MYA through cathepsin L and GST gene analysis 
(Irving et al., 2003).  Recently several clones have been identified that appear to have 
diverged much more recently.  Initially the only gene where this was observed was with 
FhCatL6, which appears to have diverged from FgCatL2 only 2.8 MYA (Irving et al., 2003).  
Irving et al. (2003) noted that the gene was obtained from a Japanese Fasciola species, which 
are difficult to identify morphologically (Hashimoto et al., 1997; Itagaki and Tsutsumi, 1998) 
and may have been miscategorised, or alternatively natural hybridisation may have occurred, 
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with Japanese fluke possessing ITS2 sequences specific to both F. gigantica and F. hepatica 
(Itagaki and Tsutsumi, 1998).  Molecular evidence for natural hybridisation between 
F. hepatica and F. gigantica has been reported in Korean flukes (Agatsuma et al., 2000), with 
the apparent hybrids showing little morphological variation.   
F. gigantica located in Indonesia have been shown to be closely related to Japanese and 
Korean flukes (Itagaki et al., 2005b).  While the F. gigantica in this study did not show ITS2 
polymorphisms consistent with F. hepatica, as mentioned previously, 325A appears to encode 
the partial sequence of a F. hepatica protein.  While the presence of this F. hepatica gene 
cannot be confirmed until the complete gene sequence is obtained, the region trans-spliced as 
the C-terminal portion of 325A appears to show enough amino acid and nucleotide identity 
(99%) with FhCatL14, and constructs from the preliminary F. hepatica EST database to 
suggest it is a F. hepatica gene, rather than a closely related F. gigantica ortholog.  If this is 
the case, it appears that natural hybridisation has occurred in an ancestor of at least one fluke 
used in this study, resulting in it obtaining a gene of F. hepatica origin.  The similarity 
between clone 2+ and FhCatL35 also suggests one fluke is expressing a gene that originated 
from the other species.  However, with the phylogenetic analysis placing both genes with 
other F. gigantica clade A cathepsins, it appears that the F. hepatica is expressing a gene of 
F. gigantica origin.   
Fletcher et al., 2004) has proposed that facultative gynogenesis is widespread among 
Fasciola, not just in Asia, and it may be that natural hybridisation may be more widespread 
than reported, with several regions supporting the co-existance of both fluke species.  This 
would indicate that in the future more genes are likely to be obtained from fluke which appear 
to have originated in the alternate species. 
The Fasciola cathepsin L family has been shown to be a good model of expansion and 
evolution through the large number of closely related genes, their stage specific expression 
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and staggered timing of divergence.  Although a lot of work has been undertaken and progress 
has been made in elucidating the substrate specificities and location of several members of the 
Fasciola cathepsin L family, it is clear that further work still needs to be undertaken.  While 
novel genes were isolated in this study, it appears that several more genes await discovery, 
possibly including some very divergent genes, such as FhCatL17.  This is supported by the 
recent publication of several F. hepatica juvenile specific cathepsins, noticeably FhCatL41.  
The F. hepatica EST database currently being constructed by the Sanger Institute should offer 
a wealth of information on the adult expressed cathepsin L genes upon its completion, not 
only in regard to F. hepatica, but also for directing research in F. gigantica.  However, the 
stage specific expression of this family within Fasciola means that a number of genes are 
likely to be excluded.  While adult expressed cathepsin L proteases to date have been shown 
to be good vaccine candidates (reviewed in Spithill et al., 1999b; Dalton et al., 2003a; Dalton 
et al., 2003b), the cathepsins expressed in juvenile stages appear as equally important 
vaccines candidates (Harmsen et al., 2004) and should not be ignored. 
 
 
 
 
  
 
Chapter 6                     
General discussion 
 
Chapter 6: General discussion 
304 
Fasciola causes considerable economic costs in the agriculture industry (Spithill et al., 1999a) 
and is emerging as an important human parasitic disease (Mas-Coma et al., 2005).  With no 
commercial vaccine currently available, and drug resistance to the most widely used drugs 
having emerged in recent years (Fairweather, 2005), the need to understand the mechanisms 
the parasite uses to invade and survive within the host is becoming increasingly important. 
Some of the most abundant proteins present in the ES material of the fluke are the cathepsin 
L-like proteases (Jefferies et al., 2001), which are believed to be involved in a variety of roles 
(Dalton et al., 2003b).  Vaccine studies with native and recombinant versions of several of 
these proteases have given promising results and further elucidation of this large family of 
proteases may provide a means to develop a way to combat this parasite. 
The enzymatic specificity differences observed between FhCatL1 and FhCatL2 (Dowd et al., 
1994), which translated into the latter’s ability to form fibrin clots (Dowd et al., 1995) and 
degrade collagen within the triple helices (Stack et al., 2008), combined with the observation 
that the introduction of a L69Y substitution into FhCatL5 provided the protease with an 
increased ability to accommodate P2 proline (Smooker et al., 2000) led to the proposal that the 
phylogenetic separation of Fasciola cathepsin L-like proteases into clades corresponds to 
functional diversity.  This is at least partially attributed to variations at aa69 which lines the S2 
subsite (Irving et al., 2003).  Differentiation based on differential expression between adult 
specific and juvenile specific cathepsins is also evident. 
This study focused on the substrate specificity of FhCatL5, -L2 and FgCatL1G, while 
determining the influence of specific aa69 substitutions on said specificity.  The processing 
and activation of these proteases were also analysed.  This data was incorporated into the 
phylogenetic analysis of the Fasciola cathepsin L-like family along with the identification of 
novel transcripts in an attempt to elucidate the role several of these cathepsins play in parasite 
invasion and survival. 
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Along with the expanding repertoire of cathepsin L-like proteases being discovered in 
Fasciola, it appears that alternate splicing to produce further variation within fluke cathepsins 
is also able to take place as evidenced by the discovery of several mRNA transcripts in this 
study.  Two pseudogenes were also characterised in this study, and combined with natural 
polymorphisms, regional variances and natural hybridisation, this results in a large and 
complex family of proteins expressed at diverse life stages.  Understanding the functions of 
these enzymes, and how they interact individually and in combination with the host is 
important to developing control measures against these parasites. 
Transcripts obtained in this study produced results that matched previous analysis indicating 
that clade B and D cathepsins are predominantly expressed by adult F. hepatica and 
F. gigantica.  A clade of previously unidentified cathepsins (Clade E) were also identified at 
high levels among clones, further highlighting the variety of cathepsin L-like proteases 
expressed by Fasciola.  A previous lack of identification of this clade hints at low levels in ES 
or lack of stability, while a possible role within fluke tissues is also possible as is expression 
only under certain conditions. 
The substitution of Y69L in FhCatL2 leads to a reduction in the enzyme’s ability to cleave 
substrates with P2 proline.  This combined with results first obtained by Smooker et al., 2000) 
where a L69Y substitution in FhCatL5 resulted in an increased ability to accommodate P2 
proline suggests an important role for aa69 in determining substrate specificity.  This residue, 
along with aa209 appears to be the major determinant of substrate specificity in cathepsins, 
although it has recently been reported that the effect of aa69 substitutions may be influenced 
by the residue at aa157, which acts as a gatekeeper to the S2 subsite (Stack et al., 2008). 
While FhCatL2 is known to cleave collagen (Stack et al., 2008) and fibrin (Dowd et al., 1995) 
along with several other blood constituents (Berasain et al., 1997; Berasain et al., 2000) the 
activities of FhCatL5 and FgCatL1G are untested.  Time constraints did not permit analysis 
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during this study.  The ability of FhCatL5 and FgCatL1G to degrade a range of host 
substrates, including extracellular matrix proteins, immune effectors and general blood 
constituents may provide an indication of the specific roles these Fasciola cathepsin L-like 
proteases undertake in vivo.  Analysis of the FhCatL5 aa69 variants’ ability to degrade said 
substrates may also reveal the influence of the S2 subsite on such functionality and may 
provide clues to roles for cathepsins in other clades, specifically the F69 variant with the clade 
F cathepsins.  
With its similar primary sequence and substrate specificity to FhCatL1, FhCatL5 would be 
expected to show overlap with FhCatL1 in regard to host substrate degradation, while the 
localisation of the closely related FhCatL4 to the mehlis gland as well as to ES, suggests 
FhCatL5 may also perform a function in the reproductive process. 
The ability to accept P2 proline has been shown to be vital to the ability of FhCatL2 to cleave 
collagen within the triple helices (Stack et al., 2008).  Thus FgCatL1G may also have the 
ability to cleave collagen within the triple helices which, combined with its expression in 
metacercariae and NEJ, supports proposed roles in excystment and migration through 
degradation of structural proteins.  However, care must be taken when inferring protein 
function based on substrate specificity, as altering substrate specificity does not always lead to 
changes in protein functions as observed with collagen degradation by HuCatK and HuCatL 
variants (Lecaille et al., 2007). 
Initial phylogenetic analysis of the Fasciola cathepsins differentiated the proteases into 4 
distinct clades (Irving et al., 2003) (designated A-D in this study).  By virtue of codon usage it 
was suggested that Fasciola cathepsins with F69, C69 or S69 would have evolved during the 
evolution of the gene family.  Transcripts for several F69 cathepsin L-like proteases have 
since been isolated from both Fasciola species.  These cathepsins form their own clade (F) 
and appear to be juvenile specific.  The L69F substitution in FhCatL5 produced in this study, 
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resulted in an increase in proline acceptance at the S2 subsite, although not to the degree 
observed with the L69Y variant, while overall general activity was comparable to FhCatL5.  
This suggests the clade F cathepsins are also likely to be able to accept P2 proline.  Combined 
with the enzymatic preferences for FgCatL1G, this supports the proposal by Irving et al., 
2003) that in the context of the phylogenetic tree, the “ancestral” enzyme had the ability to 
accept proline, and the reduction in such activity observed with FhCatL1 and FhCatL5 is a 
recent occurrence.   
While functionally stable the FhCatL5 L69C and -L69S proteases had low overall efficiency 
(kcat/Km) against most of the substrates analysed.  These results may explain the lack of any 
such variants amongst the Fasciola cathepsin L-like proteases as there would be no functional 
advantages to expressing these proteases. 
The FhCatL5 L69W variant allowed comparison with FgCatL1G and determination of the 
influence of tryptophan at aa69.  The FhCatL5 L69W variant showed an increased ability to 
cleave substrates with P2 proline, along with a decrease in the ability to cleave substrates with 
P2 valine, leucine and phenylalanine.  This indicated that the preference for proline observed 
by FgCatL1G was predominantly influenced by W69, while other amino acid variations 
contribute to its distinct specificity profile.   
Fasciola show stage specific expression profiles, with the cathepsins expressed by juvenile 
flukes distinct from those expressed by the adult (Cancela et al., 2008).  While the work 
undertaken on Fasciola cathepsin L-like proteases has focused predominantly on the adult 
expressed cathepsins, recent efforts are increasingly focusing on the cathepsins expressed by 
juvenile fluke (Harmsen et al., 2004; Cancela et al., 2008; McGonigle et al., 2008).  These 
proteases will be relevant targets for vaccines and chemotherapy design as disease pathology 
occurs during liver migration and migrating flukes are exposed to protective immune 
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responses.  Determination of their role in fluke invasion will allow design of targeted 
treatments against infection.   
FgCatL1G is unique amongst the Fasciola cathepsins studied to date.  The transcript was 
isolated from metacercaiae, and putative orthologs identified in NEJ (Harmsen et al., 2004; 
Cancela et al., 2008) have been shown to be expressed as the predominant cathepsin L during 
in vitro excystment and early NEJ development (Cancela et al., 2008). 
FhCatL2 and FhCatL5 exhibited similar in vitro processing to FhCatL1, which in vivo 
processes and activates following secretion of the proenzyme into the fluke gut (Collins et al., 
2004).  The processing of FgCatL1G differed considerably however, perhaps not surprisingly 
considering its differential expression in fluke and hence the environment to which this 
enzymes is exposed.  A lack of processing with the ortholog rFhCatL8 when expressed in 
yeast (Harmsen et al., 2004) also indicates an alternate mechanism to the adult expressed 
Fasciola cathepsin L-like proteases. 
FgCatL1G requires two distinct processing environments in vitro.  Firstly an acidic pH, 
before processing continues at neutral pH.  This differs from the adult expressed cathepsins 
which process best between pH 4.5-5.5 which corresponds to the proposed pH in the adult 
fluke gut. 
Recenty, a F. hepatica ortholog has been shown to be the major cathepsin L present during 
excystment and in NEJ (Cancela et al., 2008), while McGonigle et al., 2008) has shown that 
cathepsin L is highly expressed in the NEJ gut of F. hepatica.  Assuming the metacercarial 
and NEJ gut has a similar pH to the adult this would provide a suitable environment for the 
first phase of FgCatL1G processing.  Once expelled, the influence of the surrounding 
environment, the duodenum of the host, which is generally pH 6-6.5 in humans would 
provide suitable conditions for processing and activation to complete.  The activation of 
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FgCatL1G may also be initiated by other proteases, possibly an asparaginyl endopeptidase 
which is present in NEJ somatic extracts and ES (Tkalcevic et al., 1995; Cancela et al., 2008). 
Proteolytic activity in NEJ also favours cleavage of the substrate TGPR over FR (Cancela et 
al., 2008), which matches FgCatL1G activity preferences.  These results indicate that the 
clade A cathepsins appear to be responsible for the majority of cathepsin L-like proteolytic 
activity seen during early fluke develop and appear to be involved in excystment and invasion 
with McGonigle et al., 2008) showing downregulation of both cathepsin L and B-like 
proteases reduces the ability of juvenile flukes to penetrate the intestinal wall. 
The other cathepsins expressed by juvenile flukes, those belonging to clade F, appear to be 
expressed at a much lower level than their clade A counterparts (Cancela et al., 2008).  The 
substrate specificity of FhCatL5 L69F suggest these cathepsins can also accommodate P2 
proline as well as accept larger hydrophobic residues such as leucine and phenylalanine, 
although the influence of F209 within the clade F cathepsins may alter the relative preference 
for aromatic and aliphatic residues compared to FhCatL5. 
The work undertaken in this study further elucidates the substrate specificity of cathepsin L-
like proteases from several different clades, including a juvenile specific cathepsin and 
provides clues to specificities of other cathepsins through subsite mutagenesis.  It also 
identified new cathepsin transcripts and the possible presence of trans-splicing in generating 
variance.  However, further work including host substrate degradation, inhibitor studies, 
immunolocalisation, RNAi work, combinational library screening, as well as transcription 
studies including RNA-splicing analysis and determination of relative transcript levels, are all 
areas that can be undertaken to further understand how, when and where these cathepsins 
function which can ultimately help in the design of targeted agents to combat Fasciola 
infection. 
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(A)         (B) 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1 DNA ladders 
(A) Lambda DNA digested with PstI.  PstI digested λ-DNA separated by agarose gel 
electrophoresis with size and quantity of individual DNA fragments specified.  Reproduced 
from Lambda DNA/PstI marker certificate of analysis (Fermentas).  (B) 100 bp DNA ladder  
Reproduced from 100 bp DNA marker product guide (Promega) 
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Figure A1.2 Protein standards 
(A) SeeBlue® Plus2 pre-stained protein standard.  Reproduced from SeeBlue® Plus2 pre-
stained protein standard product specifications sheet (Invitrogen).  (B) Mark12™ unstained 
protein marker.  Reproduced from Mark12™ unstained standard product specifications sheet 
(Invitrogen). 
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Appendix 2   mRNA-derived clones 
Nucleotide sequences of all mRNA-derived clones, with amino acid sequences aligned below 
the relevant nucleotides.  Primer binding sites are underlined.  Nucleotides in the 3’ UTR are 
in lower case.   
23.12A 
   1  GGCTGGGCTT TCTCAACAAC CGGTACTATG GAGGGACAGT TTATGAAGAA TATAGGATTC 
        g  w  a   f  s  t   t  g  t  m   e  g  q   f  m  k   n  i  g  f 
  61  AATGTTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGCA GTGATTTTGG GAATAATGGT 
        n  v  s   f  s  e   q  q  l  v   d  c  s   s  d  f   g  n  n  g 
 121  TGCCGTGGTG GACTGATGGA AATTGCTTAC GAATATTTGA GACGATTCGG ATTGGAAATC 
        c  r  g   g  l  m   e  i  a  y   e  y  l   r  r  f   g  l  e  i 
 181  GAGAGCACTT ATCCGTACAG GGCTGTGGAG GGACCGTGTC GATACGACAG GCGGTTGGGA 
        e  s  t   y  p  y   r  a  v  e   g  p  c   r  y  d   r  r  l  g 
 241  GTTGCCAAAG TGACTGGATA CTATATTGTA CATTCTGGCG ATGAGGTAGA ATTGCAAAAT 
        v  a  k   v  t  g   y  y  i  v   h  s  g   d  e  v   e  l  q  n 
 301  CTAGTCGGTA TCGAAGGGCC TGCTGCGGTC GCTTTGGATG TGGAATCTGA CTTCGTAATG 
        l  v  g   i  e  g   p  a  a  v   a  l  d   v  e  s   d  f  v  m 
 361  TACAGGAGTG GTATTTATCA GAGCCAAACT TGTTCACCGG ATCGTTTGAA CCATGGAGTG 
        y  r  s   g  i  y   q  s  q  t   c  s  p   d  r  l   n  h  g  v 
 421  TTGGCCGTCG GTTATGGAAC ACAGAGTGGT ACTGACTATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  q  s  g   t  d  y   w  i  v   k  n  s  w 
 481  GGGACGTGGT GGGGTGAGGG CGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT 
        g  t  w   w  g  e   g  g  y  i   r  m  v   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGATGGCCAG TCTCCCGATG GTGGCACGAT TTCCGTGAta cgtttctgtt 
        g  i  a   s  m  a   s  l  p  m   v  a  r   f  p  *    
 601  attatgaaaa cacactgaac aataaatttc attccgcttt aaaaaaaaaa aaaaaaaa 
23.16A 
   1  GGTTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCGAAACT TGTTTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  e  t   c  l  p   d  r  l   t  h  a  v 
 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTAGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaaa aaaaaaaa 
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24.5A 
   1  ACCTTTGAGG AATTCAAAGC CAAATATCTG TCCGAAATGC CACGCGCGTC TGCATTTCTC 
        t  f  e   e  f  k   a  k  y  l   s  e  m   p  r  a   s  a  f  l 
  61  TCACATGGCA TGCCGTATAG GGCGAAAAAT CGTGCCGTAC CCACGAGCAT TGACTGGCGT 
        s  h  g   m  p  y   r  a  k  n   r  a  v   p  t  s   i  d  w  r 
 121  GAATCTGGTT ATGTGACGGA GGTGAAAGAT CAGGGAGGCT GCGGCTCTTG TTGGGCTTTC 
        e  s  g   y  v  t   e  v  k  d   q  g  g   c  g  s   c  w  a  f 
 181  TCAACAACGG GTGCTATGGA AGGACAGTAC ATGAAAAGCC AGAGGATTAA TATTTCATTC 
        s  t  t   g  a  m   e  g  q  y   m  k  s   q  r  i   n  i  s  f 
 241  TCTGAACAAC AACTGGTCGA TTGTAGTGGT GATTTTGGTA ATCATGGTTG TAGTGGTGGA 
        s  e  q   q  l  v   d  c  s  g   d  f  g   n  h  g   c  s  g  g 
 301  TTAATGGAAA AGGCTTACGA ATATTTGCGA CATTTTGGAT TGGAAACGGA GTCCTCCTAT 
        l  m  e   k  a  y   e  y  l  r   h  f  g   l  e  t   e  s  s  y 
 361  CCGTACAGGG CTGATGAAGG TCCGTGTCAA TACGACAAGC AGCTGGGAGT TGCCCAATTG 
        p  y  r   a  d  e   g  p  c  q   y  d  k   q  l  g   v  a  q  l 
 421  TCTGACTATT ATATTGTGCA TTCTCAAGAT GAGGTGGCAT TAAAGAATCT AATCGGTGTG 
        s  d  y   y  i  v   h  s  q  d   e  v  a   l  k  n   l  i  g  v 
 481  GAAGGACCTG CTGCAGTCGC TTTGGATGTG AATATTGACT TTATGATGTA CAAGAGTGGT 
        e  g  p   a  a  v   a  l  d  v   n  i  d   f  m  m   y  k  s  g 
 541  ATTTATCAGG ACGAAATTTG TTCATCACGA TATTTGAATC ATGCACTGTT GGCTGTCGGT 
        i  y  q   d  e  i   c  s  s  r   y  l  n   h  a  l   l  a  v  g 
 601  TACGGAACAG AGGATGGTAC TGAATATTGG ATTGTGAAAA ACAGTTGGGG ATCGCGATGG 
        y  g  t   e  d  g   t  e  y  w   i  v  k   n  s  w   g  s  r  w 
 661  GGTGAGCATG GTTATATTCG ATTGGCTAGG AACCGAGATA ATATGTGTGG AATAGCTACA 
        g  e  h   g  y  i   r  l  a  r   n  r  d   n  m  c   g  i  a  t 
 721  CTGGCCAGTC TCCCAATAGT GAAACGTTTT CCGTGAaatt ctgctgtcag tatgaaaacg 
        l  a  s   l  p  i   v  k  r  f   p  *   
 781  cactgaacaa taaatttcat ccagctttgc aaaaaaaaaa aaaaa 
24.5B 
   1  ACATTTGAGG AATTCAAGGC CAAATATCTA ACAGAAATGC CACGCGCGTC CGATATACTC 
        t  f  e   e  f  k   a  k  y  l   t  e  m   p  r  a   s  d  i  l 
  61  TCACACGGTA TCCCGTATGA GGCGAACAAT CGTGCCGTAC CCGACAAAAT TGACTGGCGT 
        s  h  g   i  p  y   e  a  n  n   r  a  v   p  d  k   i  d  w  r 
 121  GAATCTGGTT ATGTGACGGA GGTGAAAGAT CAGGGAAATT GTGGTTCATG TTGGGCATTC 
        e  s  g   y  v  t   e  v  k  d   q  g  n   c  g  s   c  w  a  f 
 181  TCAACAACCG GTACTATGGA AGGACAGTAT ATGAAAAACG AAAGAACTAG TATTTCATTC 
        s  t  t   g  t  m   e  g  q  y   m  k  n   e  r  t   s  i  s  f 
 241  TCTGAGCAAC AACTGGTCGA TTGTAGCGGT CCTTGGGGAA ATATGGGTTG CATGGGCGGA 
        s  e  q   q  l  v   d  c  s  g   p  w  g   n  m  g   c  m  g  g 
 301  TTGATGGAAA ATGTTTACGA ATATTTGAAA CAATTTGGAT TGGAAACCGA ATCCTCTTAT 
        l  m  e   n  v  y   e  y  l  k   q  f  g   l  e  t   e  s  s  y 
 361  CCGTACACGG CTGTGGAAGG TCAGTGTCGA TACAATAGGC AGTTGGGAGT TGCCAAAGTG 
        p  y  t   a  v  e   g  q  c  r   y  n  r   q  l  g   v  a  k  v 
 421  ACGGACTACT ATACTGTGCA TTCTGGCAGT GAGGTAGAAT TGAAAAATCT AGTCGGTGCC 
        t  d  y   y  t  v   h  s  g  s   e  v  e   l  k  n   l  v  g  a 
 481  GAAGGACCTG CTGCGGTCGC TGTGGATGTG GAATCTGACT TCATGATGTA CAGTGGTGGT 
        e  g  p   a  a  v   a  v  d  v   e  s  d   f  m  m   y  s  g  g 
 541  ATTTATCAGA GCCGAACTTG TTCATCGCTT CGTGTGAATC ATGCAGTCTT GGCTGTCGGT 
        i  y  q   s  r  t   c  s  s  l   r  v  n   h  a  v   l  a  v  g 
 601  TATGGAACAC AGGGTGGTAC TGACTATTGG ATTGTGAAAA ATAGTTGGGG ATCGTCCTGG 
        y  g  t   q  g  g   t  d  y  w   i  v  k   n  s  w   g  s  s  w 
 661  GGTGAGCGTG GTTACATTCG AATGGTTAGG AACCGAGGTA ACATGTGTGG AATTGCTTCG 
        g  e  r   g  y  i   r  m  v  r   n  r  g   n  m  c   g  i  a  s 
 721  CTGGCCAGTC TCCCGATGGT GGCACGATTT CCGTGAtacg tttctgtcat tatgaaaacg 
        l  a  s   l  p  m   v  a  r  f   p  *   
 781  cactgaacaa taaatttcat tccgctttaa aaaaaaaaaa aaaaaa 
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46 
   1  GGTTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCGAAACT TGTTTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  e  t   c  l  p   d  r  l   t  h  a  v 
 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA GAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTGGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaaa aaaaaaa 
61 
   1  GGTTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTAATGGA AAAGGCTTAC GAATATTTGC GACATTTTGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTGGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   v  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *    
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gcaaaaaaaa aaaaaaa 
127A 
   1  GGTTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTAATGGA AAAGGCTTAC GAATATTTGC GACATTTTGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTAGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   v  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
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 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *   
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gaaaaaaaaa aaaaaaaa 
127B 
   1  GGCTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CA... 
        y  a  k   v  t  d   y  y  t  v  ... 
234A 
   1  GGTTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCGAAACT TGTTTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  e  t   c  l  p   d  r  l   t  h  a  v 
 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTAGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaaa aaaaaaaa 
289A 
   1  GGTTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTGATGGA AAAGGCTTAC GAATATTTGC GACATTTCGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTAGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   v  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
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 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *    
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gcaaaaaaaa aaaaaaaaa 
289B 
   1  GGTTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTAATGGA AAAGGCTTAC GAATATTTGC GACATTTTGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTGGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   v  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *    
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gcaaaaaaaa aaaaaaaaaa 
291A 
   1  GGTTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCGAAACT TGTTTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  e  t   c  l  p   d  r  l   t  h  a  v 
 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTAGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaaa aaaaaaaa 
293A 
   1  GGCTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
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  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCAAAACT TGTCTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  k  t   c  l  p   d  r  l   t  h  a  v 
 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTGGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gaaaaaaaaa aaaaa 
293B 
   1  GGCTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTGATGGA AAAGGCTTAC GAATATTTGC GACATTTCGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTAGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTA TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   m  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *   
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gcaaaaaaaa aaaaaaaaaa 
303A 
   1  GGCTGGGCTT TCTCAACAAC CGGTACTATG GAAGGACAGT ATATGAAAAA CGAAAGAACT 
        g  w  a   f  s  t   t  g  t  m   e  g  q   y  m  k   n  e  r  t 
  61  AGTATTTCAT TCTCTGAGCA ACAACTGGTC GATTGTAGCG GTCCTTGGGG AAATATGGGT 
        s  i  s   f  s  e   q  q  l  v   d  c  s   g  p  w   g  n  m  g 
 121  TGCATGGGCG GATTGATGGA AAATGCTTAC GAATATTTGA AACAATTTGG ATTGGAAACC 
        c  m  g   g  l  m   e  n  a  y   e  y  l   k  q  f   g  l  e  t 
 181  GAATCCTCTT ATCCGTACAC GGCTGTGGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA 
        e  s  s   y  p  y   t  a  v  e   g  q  c   r  y  n   r  q  l  g 
 241  GTTGCCAAAG TGACGGACTA CTATACTGTG CATTCTGGCA GTGAGGTAGA ATTGAAAAAT 
        v  a  k   v  t  d   y  y  t  v   h  s  g   s  e  v   e  l  k  n 
 301  CTAGTCGGTG CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG 
        l  v  g   a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m 
 361  TACAGTGGTG GTATTTATCA GAGCCGAACT TGTTCATCGC TTCGTGTGAA TCATGCAGTC 
        y  s  g   g  i  y   q  s  r  t   c  s  s   l  r  v   n  h  a  v 
 421  TTGGCTGTCG GTTATGGAAC ACAGGGTGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   t  q  g  g   t  d  y   w  i  v   k  n  s  w 
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 481  GGATCGTCCT GGGGTGAGCG TGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT 
        g  s  s   w  g  e   r  g  y  i   r  m  v   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTGGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaa 
303B 
   1  GGTTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTAATGGA AAAGGCTTAC GAATATTTGC GACATTTTGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTAGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGATCC 
        l  i  g   v  d 
306A 
   1  GGTTGGGCTT TCTCAACAAC CGGTACTATG GAAGGACAGT ATATGAAAAA CGAAAGAACT 
        g  w  a   f  s  t   t  g  t  m   e  g  q   y  m  k   n  e  r  t 
  61  AGTATTTCAT TCTCTGAGCA ACAACTGGTC GATTGTAGCG GTCCTTGGGG AAATATGGGT 
        s  i  s   f  s  e   q  q  l  v   d  c  s   g  p  w   g  n  m  g 
 121  TGCATGGGCG GATTGATGGA AAATGCTTAC GAATATTTGA AACAATTTGG ATTGGAAACC 
        c  m  g   g  l  m   e  n  a  y   e  y  l   k  q  f   g  l  e  t 
 181  GAATCCTCTT ATCCGTACAC GGCTGTGGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA 
        e  s  s   y  p  y   t  a  v  e   g  q  c   r  y  n   r  q  l  g 
 241  GTTGCCAAAG TGACGGACTA CTATACTGTG CATTCTGGCA GTGAGGTAGA ATTGAAAAAT 
        v  a  k   v  t  d   y  y  t  v   h  s  g   s  e  v   e  l  k  n 
 301  CTAGTCGGTG CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG 
        l  v  g   a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m 
 361  TACAGTGGTG GTATTTATCA GAGCCGAACT TGTTCATCGC TTCGTGTGAA TCATGCAGTC 
        y  s  g   g  i  y   q  s  r  t   c  s  s   l  r  v   n  h  a  v 
 421  TTGGCTGTCG GTTATGGAAC ACAGGGTGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   t  q  g  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGCG TGGTTACATT CGAATAGTTA GGAACCGAGG TAACATGTGT 
        g  s  s   w  g  e   r  g  y  i   r  i  v   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTAGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *   
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcataaaaaa aaaaaaaaaa 
308A 
   1  GGCTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAAAGAAT 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l  k  n 
 301  TTGGTCGGTA CCGAAGGACC TGCGGCGGTC GCTTTGGATG TGGATTATGA CTTCATGATG 
        l  v  g   t  e  g   p  a  a  v   a  l  d   v  d  y   d  f  m  m 
 361  TACGAGAGTG GTATTTATCA CAGCAAAACT TGTCTACCGG ATCGCTTGAC TCATGCAGTC 
        y  e  s   g  i  y   h  s  k  t   c  l  p   d  r  l   t  h  a  v 
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 421  TTGGCTGTCG GTTATGGAGC ACAAGATGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   a  q  d  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGAA AGGTTACATT CGGTTTGCCA GGAACCGAGG TAATATGTGT 
        g  s  s   w  g  e   k  g  y  i   r  f  a   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TGTCCCGATG GTAGCACGAT TTCCGTGAta ctttgctgtc 
        g  i  a   s  l  a   s  v  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcaatgaac aataaatctc actcggcctt gcaaaaaaaa aaaaaaaaaa 
315A 
   1  ATTGACTGGC GTGATTCTGG TTATGTGACA AAGGTGAAAG ATCAGGAAGA CTGCGGTTCC 
        i  d  w   r  d  s   g  y  v  t   k  v  k   d  q  e   d  c  g  s 
  61  TGTTGGGCTT TCTCAACAAC CGGTACTATG GAGGGACAGT TTATGAAGAA TATAGGATTC 
        c  w  a   f  s  t   t  g  t  m   e  g  q   f  m  k   n  i  g  f 
 121  AATGTTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGCA GTGATTTTGG GAATAATGGT 
        n  v  s   f  s  e   q  q  l  v   d  c  s   s  d  f   g  n  n  g 
 181  TGCCGTGGTG GACTGATGGA AATTGCTTAC GAATATTTGA GACGATTCGG ATTGGAAATC 
        c  r  g   g  l  m   e  i  a  y   e  y  l   r  r  f   g  l  e  i 
 241  GAGAGCACTT ATCCGTACAG GGCTGTGGAG GGACCGTGTC GATACGACAG GCGGTTGGGA 
        e  s  t   y  p  y   r  a  v  e   g  p  c   r  y  d   r  r  l  g 
 301  GTTGCCAAAG TGACTGGATA CTATATTGTA CATTCTGGCG ATGAGGTAGA ATTGCAAAAT 
        v  a  k   v  t  g   y  y  i  v   h  s  g   d  e  v   e  l  q  n 
 361  CTAGTCGGTA TCGAAGGGCC TGCTGCGGTC GCTTTGGATG TGGAATCTGA CTTCGTGATG 
        l  v  g   i  e  g   p  a  a  v   a  l  d   v  e  s   d  f  v  m 
 421  TACAGGAGTG GTATTTATCA GAGCCAAACT TGTTCACCGG ATCGTTTGAA CCATGGAGTG 
        y  r  s   g  i  y   q  s  q  t   c  s  p   d  r  l   n  h  g  v 
 481  TTGGCCGTCG GTTATGGAAC ACAGAGTGGT ACTGACTATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  q  s  g   t  d  y   w  i  v   k  n  s  w 
 541  GGGACGTGGT GGGGTGAGGG CGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT 
        g  t  w   w  g  e   g  g  y  i   r  m  v   r  n  r   g  n  m  c 
 601  GGAATTGCTT CGATGGCCAG TCTCCCGATG GTGGCACGAT TTCCGTGAta cgtttctgtt 
        g  i  a   s  m  a   s  l  p  m   v  a  r   f  p  *    
 661  attatgaaaa cacactgaac aataaatttc attccgcttt aaaaaaaaaa aaaaaaaa 
318A 
   1  AAATATCTAA CAGAAATGCC ACGCGCGTCC GATATACTCT CACACGGTAT CCCGTATGAG 
        k  y  l   t  e  m   p  r  a  s   d  i  l   s  h  g   i  p  y  e 
  61  GCGAACAATC GTGCCGTACC CGACAAAATT GACTGGCGTG AATCTGGTTA TGTGACGGAG 
        a  n  n   r  a  v   p  d  k  i   d  w  r   e  s  g   y  v  t  e 
 121  GTGAAAGATC AGGGAAATTG TGGTTCATGT TGGGCATTCT CAACAACCGG TACTATGGAA 
        v  k  d   q  g  n   c  g  s  c   w  a  f   s  t  t   g  t  m  e 
 181  GGACAGTATA TGAAAAACGA AAGAACTAGT ATTTCATTCT CTGAGCAACA ACTGGTCGAT 
        g  q  y   m  k  n   e  r  t  s   i  s  f   s  e  q   q  l  v  d 
 241  TGTAGCGGTC CTTGGGGAAA TATGGGTTGC ATGGGCGGAT TGATGGAAAA TGCTTACGAA 
        c  s  g   p  w  g   n  m  g  c   m  g  g   l  m  e   n  a  y  e 
 301  TATTTGAAAC AATTTGGATT GGAAACCGAA TCCTCTTATC CGTACACGGC TGTGGAAGGT 
        y  l  k   q  f  g   l  e  t  e   s  s  y   p  y  t   a  v  e  g 
 361  CAGTGTCGAT ACAATAGGCA GTTGGGAGTT GCCAAAGTGA CGGACTACTA TACTGTGCAT 
        q  c  r   y  n  r   q  l  g  v   a  k  v   t  d  y   y  t  v  h 
 421  TCTGGCAGTG AGGTAGAATT GAAAAATCTA GTCGGTGCCG AAGGACCTGC TGCGGTCGCT 
        s  g  s   e  v  e   l  k  n  l   v  g  a   e  g  p   a  a  v  a 
 481  GTGGATGTGG AATCTGACTT CATGATGTAC AGTGGTGGTA TTTATCAGAG CCGAACTTGT 
        v  d  v   e  s  d   f  m  m  y   s  g  g   i  y  q   s  r  t  c 
 541  TCATCGCTTC GTGTGAATCA TGCAGTCTTG GCTGTCGGTT ATGGAACACA GGGTGGTACT 
        s  s  l   r  v  n   h  a  v  l   a  v  g   y  g  t   q  g  g  t 
 601  GACTATTGGA TTGTGAAAAA TAGTTGGGGA TCGTCCTGGG GTGAGCGTGG TTACATTCGA 
        d  y  w   i  v  k   n  s  w  g   s  s  w   g  e  r   g  y  i  r 
 661  ATGGTTAGGA ACCGAGGTAA CATGTGTGGA ATTGCTTCGC TGGCCAGTCT CCCGATGGTG 
        m  v  r   n  r  g   n  m  c  g   i  a  s   l  a  s   l  p  m  v 
 721  GCACGATTTC CGTGAtacgt ttctgtcatt atgaaaacgc actgaacaat aaatttcatt 
        a  r  f   p  *   
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 781  ctgctttgct tcaaaaaaaa aaaaaaaaaa 
319 
   1  AAATATCTAA CAGAAATGCC ACGCGCGTCC GATATACTCT CACACGGTAT CCCGTATGAG 
        k  y  l   t  e  m   p  r  a  s   d  i  l   s  h  g   i  p  y  e 
  61  GCGAACAATC GTGCCGTACC CGACAAAATT GACTGGCGTG AATCTGGTTA TGTGACGGAG 
        a  n  n   r  a  v   p  d  k  i   d  w  r   e  s  g   y  v  t  e 
 121  GTGAAAGATC AGGGAAATTG TGGTTCATGT TGGGCATTCT CAACAACCGG TACTATGGAA 
        v  k  d   q  g  n   c  g  s  c   w  a  f   s  t  t   g  t  m  e 
 181  GGACAGTATA TGAAAAACGA AAGAACTAGT ATTTCATTCT CTGAGCAACA ACTGGTCGAT 
        g  q  y   m  k  n   e  r  t  s   i  s  f   s  e  q   q  l  v  d 
 241  TGTAGCGGTC CTTGGGGAAA TATGGGTTGC ATGGGCGGAT TGATGGAAAA TGCTTACGAA 
        c  s  g   p  w  g   n  m  g  c   m  g  g   l  m  e   n  a  y  e 
 301  TATTTGAAAC AATTTGGATT GGAAACCGAA TCCTCTTATC CGTACACGGC TGTGGAAGGT 
        y  l  k   q  f  g   l  e  t  e   s  s  y   p  y  t   a  v  e  g 
 361  CAGTGTCGAT ACAATAGGCA GTTGGGAGTT GCCAAAGTGA CGGACTACTA TACTGTGCAT 
        q  c  r   y  n  r   q  l  g  v   a  k  v   t  d  y   y  t  v  h 
 421  TCTGGCAGTG AGGTAGAATT GAAAAATCTA GTCGGTGCCG AAGGACCTGC TGCGGTCGCT 
        s  g  s   e  v  e   l  k  n  l   v  g  a   e  g  p   a  a  v  a 
 481  GTGGATGTGG AATCTGACTT CATGATGTAC AGTGGTGGTA TTTATCAGAG CCGAACTTGT 
        v  d  v   e  s  d   f  m  m  y   s  g  g   i  y  q   s  r  t  c 
 541  TCATCGCTTC GTGTGAATCA TGCAGTCTTG GCTGTCGGTT ATGGAACACA GGGTGGTACT 
        s  s  l   r  v  n   h  a  v  l   a  v  g   y  g  t   q  g  g  t 
 601  GACTATTGGA TTGTGAAAAA TAGTTGGGGA TCGTCCTGGG GTGAGCGTGG TTACATTCGA 
        d  y  w   i  v  k   n  s  w  g   s  s  w   g  e  r   g  y  i  r 
 661  ATGGTTAGGA ACCGAGGTAA CATGTGTGGA ATTGCTTCGC TGGCCAGTCT CCCGATGGTG 
        m  v  r   n  r  g   n  m  c  g   i  a  s   l  a  s   l  p  m  v 
 721  GCACGAATTC CGTGAtacgt ttctgtcatt atgaaaacac actgaacaat aaatttcatt 
        a  r  i   p  *   
 781  ctgctttgct tcaaaaaaaa aaaaaaaaa 
320A 
   1  AATGCGAAAC ATATCCAAGA ACACAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
        n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGCATCC CGTATGAGGC GAACAACCGT 
        e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTACG TGACGGGGGT GAAAGACCAA 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  g   v  k  d  q 
 241  GGAAACTGTG GTTCTTGTTG GGCTTTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACCAAA GAACCAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCC 
        k  n  q   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAG TGGTGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   s  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACAGGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  r  a   v  e  g   q  c  r  y 
 481  AATAGGCAGT TGGGAGTTGT CAAAGTGACT GGCTACTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   v  k  v  t   g  y  y   t  v  h   s  g  s  e 
 541  GTAGGATTGA AAAATCTAGT CGGTGCCGAA GGACCTGCTG CGGTCGCTGT GGATGTGGAA 
        v  g  l   k  n  l   v  g  a  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG GAGTGGTATT TATCAGAGCC AAACTTGTTC ACCGTTTGGT 
        s  d  f   m  m  y   r  s  g  i   y  q  s   q  t  c   s  p  f  g 
 661  TTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT 
        l  n  h   a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATC GTCCTGGGGT GAGCGCGGTT ACATTCGAAT GGTTAGGAAC 
        v  k  n   s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCAATG GCCAGTCTTC CGATGGTGGC ACGATTTCCG 
        r  g  n   m  c  g   i  a  s  m   a  s  l   p  m  v   a  r  f  p 
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 841  TGAtacgttt ctgttattat gaacatgcac taaacaatga atttcattca gcaaaaaaaa 
        *   
 901  aaaaaaa 
320B 
   1  AATGTGAAAC ATATCCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
        n  v  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
        e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
 241  GGAAATTGTG GTTCATGTTG GGCATTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACGAAA GAACTAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCT 
        k  n  e   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAT GGGCGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   m  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACACGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  t  a   v  e  g   q  c  r  y 
 481  AATAGGCAGT TGGGAGTTGC CAAAGTGACG GACTACTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   a  k  v  t   d  y  y   t  v  h   s  g  s  e 
 541  GTAGAATTGA AAAATCTAGT CGGTGCCGAA GGACCTGCTG CGGTCGCTGT GGATGTGGAA 
        v  e  l   k  n  l   v  g  a  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG TGGTGGTATT TATCAGAGCC GAACTTGTTC ATCGCTTCGT 
        s  d  f   m  m  y   s  g  g  i   y  q  s   r  t  c   s  s  l  r 
 661  GTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT 
        v  n  h   a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATC GTCCTGGGGT GAGCGTGGTT ACATTCGAAT GGTTAGGAAC 
        v  k  n   s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCGCTG GCCAGTCTCC CGATGGTGGC ACGATTTCCG 
        r  g  n   m  c  g   i  a  s  l   a  s  l   p  m  v   a  r  f  p 
 841  TGATACGTTT CTGTCATTAT GAAAACGCAC TGAacaataa atttcattct gctttgcttc 
        *  y  v   s  v  i   m  k  t  h   *   
 901  aaaaaaaaaa aaaaa 
321A 
   1  AATGTGAAAC ATATTCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
        n  v  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
        e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
 241  GGAAATTGTG GTTCATGTTG GGCATTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACGAAA GAACTAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCT 
        k  n  e   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAG TGGTGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   s  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACACGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  t  a   v  e  g   q  c  r  y 
 481  AATAGGCAGT TGGGAGTTGC CAAAGTGACG GACTACTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   a  k  v  t   d  y  y   t  v  h   s  g  s  e 
 541  GTAGAATTGA AAAATCTAGT CGGTGCCGAA GGACCTGCTG CGGTCGCTGT GGATGTGGAA 
        v  e  l   k  n  l   v  g  a  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG TGGTGGTATT TATCAGAGCC GAACTTGTTC ATCGCTTCGT 
        s  d  f   m  m  y   s  g  g  i   y  q  s   r  t  c   s  s  l  r 
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361 
 661  GTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT 
        v  n  h   a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATC GTCCTGGGGT GAGCGTGGTT ACATTCGAAT GGTTAGGAAC 
        v  k  n   s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCGCTG GCCAGTCTCC CGATGGTGGC ACGATTTCCG 
        r  g  n   m  c  g   i  a  s  l   a  s  l   p  m  v   a  r  f  p 
 841  TGAtacgttt ctgtcattat gaaaacgcac tgaacaataa atttcattct gctttgcttc 
        *   
 901  aaaaaaaaaa aaaaaaaaaa 
325A 
   1  AATGCGAAAC ATATTCAAGA ACACAACCTA CGCCACGATC TCGGCCTCGT CACCTACACA 
        n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  CTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAACCGT 
        e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTACG TGACGGGGGT GAAAGACCAA 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  g   v  k  d  q 
 241  GGAAACTGTG GTTCTTGTTG GGCTTTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACCAAA GAACCAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCT 
        k  n  q   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAG TGGTGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   s  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACAGGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  r  a   v  e  g   q  c  r  y 
 481  AATAGGCAAT TGGGAGTTGC CAAAGTGACT GGCTATTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   a  k  v  t   g  y  y   t  v  h   s  g  s  e 
 541  GCAGGATTGA AAAGTTTAGT CGGTTCCGAA GGACCTGCTG CGGTCGCTGT GGATGTTGAA 
        a  g  l   k  s  l   v  g  s  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG GAGTGGTATT TATCAGAGCC AAACTTGTTC ACCGCTTGGT 
        s  d  f   m  m  y   r  s  g  i   y  q  s   q  t  c   s  p  l  g 
 661  TTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG ATGGTACTGA CTATTGGATT 
        l  n  h   a  v  l   a  v  g  y   g  t  q   d  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATT GTCGTGGGGT GAGCGCGGTT ACATTCGAAT GGCTAGGAAC 
        v  k  n   s  w  g   l  s  w  g   e  r  g   y  i  r   m  a  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCGCTG GCCAGTCTCC CGATGGTGGC ACGATTCCCG 
        r  g  n   m  c  g   i  a  s  l   a  s  l   p  m  v   a  r  f  p 
 841  TGAtacgttt ctgttattat gaaaacgcac taaacaataa atttcattca gctttgaaaa 
        *  
 901  aaaaaaaaaa aaaaa 
325B 
   1  AATGCGAAAC ATATTCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
        n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCCA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
        e  m  p   r  a  s   h  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTACG TGACGGAGGT GAAAGATCAG 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
 241  GGAAATTGTG GTTCATGTTG GGCATTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACGAAA GAACTAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCT 
        k  n  e   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAT GGGCGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   m  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACACGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  t  a   v  e  g   q  c  r  y 
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 481  AATAGGCAGT TGGGAGTTGC CAAAGTGACG GACTACTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   a  k  v  t   d  y  y   t  v  h   s  g  s  e 
 541  GTAGAATTGA AAAATCTAGT CGGTGCCGAA GGACCTGCTG CGGTCGCTGT GGATGTGGAA 
        v  e  l   k  n  l   v  g  a  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG TGGTGGTATT TATCAGAGCC GAACTTGTTC ATCGCTTCGT 
        s  d  f   m  m  y   s  g  g  i   y  q  s   r  t  c   s  s  l  r 
 661  GTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT 
        v  n  h   a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATC GTCCTGGGGT GAGCGTGGTT ACATTCGAAT GGTTAGGAAC 
        v  k  n   s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCGCTG GCCAGTCTCC CGATGGTGGC ACGATTTCCG 
        r  g  n   m  c  g   i  a  s  l   a  s  l   p  m  v   a  r  f  p 
 841  TGAtacgttt ctgtcattat gaaaacgcac tgaacaataa atttcattct gctttgcttc 
        *   
 901  aaaaaaaaaa aaaaaa 
327A 
   1  AATGCGAAAC ATATTCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
        n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
  61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
        l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
 121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
        e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
 181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
        a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
 241  GGAAATTGTG GTTCATGTTG GGCATTCTCA ACAACCGGTA CTATGGAAGG ACAGTATATG 
        g  n  c   g  s  c   w  a  f  s   t  t  g   t  m  e   g  q  y  m 
 301  AAAAACGAAA GAACTAGTAT TTCATTCTCT GAGCAACAAC TGGTCGATTG TAGCGGTCCT 
        k  n  e   r  t  s   i  s  f  s   e  q  q   l  v  d   c  s  g  p 
 361  TGGGGAAATA TGGGTTGCAT GGGCGGATTG ATGGAAAATG CTTACGAATA TTTGAAACAA 
        w  g  n   m  g  c   m  g  g  l   m  e  n   a  y  e   y  l  k  q 
 421  TTTGGATTGG AAACCGAATC CTCTTATCCG TACACGGCTG TGGAAGGTCA GTGTCGATAC 
        f  g  l   e  t  e   s  s  y  p   y  t  a   v  e  g   q  c  r  y 
 481  AATAGGCAGT TGGGAGTTGC CAAAGTGACG GACTACTATA CTGTGCATTC TGGCAGTGAG 
        n  r  q   l  g  v   a  k  v  t   d  y  y   t  v  h   s  g  s  e 
 541  GTAGAATTGA AAAATCTAGT CGGTGCCGAA GGACCTGCTG CGGTCGCTGT GGATGTGGAA 
        v  e  l   k  n  l   v  g  a  e   g  p  a   a  v  a   v  d  v  e 
 601  TCTGACTTCA TGATGTACAG TGGTGGTATT TATCAGAGCC GAACTTGTTC ATCGCTTCGT 
        s  d  f   m  m  y   s  g  g  i   y  q  s   r  t  c   s  s  l  r 
 661  GTGAATCATG CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT 
        v  n  h   a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i 
 721  GTGAAAAATA GTTGGGGATC GTCCTGGGGT GAGCGTGGTT ACATTCGAAT GGTTAGGAAC 
        v  k  n   s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n 
 781  CGAGGTAACA TGTGTGGAAT TGCTTCGCTG GCCAGTCTCC CGATGGTGGC ACGATTTCCG 
        r  g  n   m  c  g   i  a  s  l   a  s  l   p  m  v   a  r  f  p 
 841  TGAtacgttt ctgtcattat gaaaacgcac tgaacaataa atttcattct gctttgctta 
        *   
 901  aaaaaaaaaa aaaa 
G13.8A 
   1  GGTTGGGCAT TCTCAACAAC CGGTACTATG GAAGGACAGT ATATGAAAAA CGAAAGAACT 
        g  w  a   f  s  t   t  g  t  m   e  g  q   y  m  k   n  e  r  t 
  61  AGTATTTCAT TCTCTGAGCA ACAACTGGTC GATTGTAGCG GTCCTTGGGG AAATTATGGT 
        s  i  s   f  s  e   q  q  l  v   d  c  s   g  p  w   g  n  y  g 
 121  TGCATGGGCG GATTGATGGA AAATGCTTAC GAATATTTGA AACAATTTGG ATTGGAAACC 
        c  m  g   g  l  m   e  n  a  y   e  y  l   k  q  f   g  l  e  t 
 181  GAATCCTCTT ATCCGTACAC GGCTGTGGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA 
        e  s  s   y  p  y   t  a  v  e   g  q  c   r  y  n   r  q  l  g 
 241  GTTGCCAAAG TGACGGACTA CTATACTGTG CATTCTGGCA GTGAGGTAGA ATTGAAAAAT 
        v  a  k   v  t  d   y  y  t  v   h  s  g   s  e  v   e  l  k  n 
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 301  CTAGTCGGTG CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG 
        l  v  g   a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m 
 361  TACAGTGGTG GTATTTATCA GAGCCGAACT TGTTCATCGC TTCGTGTGAA TCATGCAGTC 
        y  s  g   g  i  y   q  s  r  t   c  s  s   l  r  v   n  h  a  v 
 421  TTGGCTGTCG GTTATGGAAC ACAGGGTGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   t  q  g  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGCG TGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT 
        g  s  s   w  g  e   r  g  y  i   r  m  v   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TCTCCCGATG GTGGCACGAT TTCCGTGAta cgtttctgtc 
        g  i  a   s  l  a   s  l  p  m   v  a  r   f  p  *    
 601  attatgaaaa cgcactgaac aataaatttc attctgcttt gcttcaaaaa aaaaaaaaaa 
G14.1A 
   1  GGTTGGGCAT TCTCAACAAC CGGTACTATG GAAGGACAGT ATATGAAAAA CGAAAGAACT 
        g  w  a   f  s  t   t  g  t  m   e  g  q   y  m  k   n  e  r  t 
  61  AGTATTTCAT TCTCTGAGCA ACAACTGGTC GATTGTAGCG GTCCTTGGGG AAATATGGGT 
        s  i  s   f  s  e   q  q  l  v   d  c  s   g  p  w   g  n  m  g 
 121  TGCAGTGGTG GATTGATGGA AAATGCTTAC GAATATTTGA AACAATTTGG ATTGGAAACC 
        c  s  g   g  l  m   e  n  a  y   e  y  l   k  q  f   g  l  e  t 
 181  GAATCCTCTT ATCCGTACAC GGCTGTGGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA 
        e  s  s   y  p  y   t  a  v  e   g  q  c   r  y  n   r  q  l  g 
 241  GTTGCCAAAG TGACGGACTA CTATACTGTG CATTCTGGCA GTGAGGTAGA ATTGAAAAAT 
        v  a  k   v  t  d   y  y  t  v   h  s  g   s  e  v   e  l  k  n 
 301  CTAGTCGGTG CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG 
        l  v  g   a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m 
 361  TACAGTGGTG GTATTTATCA GAGCCGAACT TGTTCATCGC TTCGTGTGAA TCATGCAGTC 
        y  s  g   g  i  y   q  s  r  t   c  s  s   l  r  v   n  h  a  v 
 421  TTGGCTGTCG GTTATGGAAC ACAGGGTGGT ACTGACTATT GGATTGTGAA AAATAGTTGG 
        l  a  v   g  y  g   t  q  g  g   t  d  y   w  i  v   k  n  s  w 
 481  GGATCGTCCT GGGGTGAGCG TGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT 
        g  s  s   w  g  e   r  g  y  i   r  m  v   r  n  r   g  n  m  c 
 541  GGAATTGCTT CGCTGGCCAG TCTCCCGATG GTGGCACGAT TTCCGTGAta cgtttctgtc 
        g  i  a   s  l  a   s  l  p  m   v  a  r   f  p  *  
 601  attatgaaaa cgcactgaac aataaatttc attctgcttt gcttcaaaaa aaaaaaaaaa 
H14.6A 
   1  GGCTGGGCTT TCTCAACAAC GGGTGCTATG GAAGGACAGT ACATGAAAAG CCAGAGGATT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   y  m  k   s  q  r  i 
  61  AATATTTCAT TCTCTGAACA ACAACTGGTC GATTGTAGTG GTGATTTTGG TAATCATGGT 
        n  i  s   f  s  e   q  q  l  v   d  c  s   g  d  f   g  n  h  g 
 121  TGTAGTGGTG GATTAATGGA AAAGGCTTAC GAATATTTGC GACATTTTGG ATTGGAAACG 
        c  s  g   g  l  m   e  k  a  y   e  y  l   r  h  f   g  l  e  t 
 181  GAGTCCTCCT ATCCGTACAG GGCTGATGAA GGTCCGTGTC AATACGACAA GCAGCTGGGA 
        e  s  s   y  p  y   r  a  d  e   g  p  c   q  y  d   k  q  l  g 
 241  GTTGCCCAAT TGTCTGACTA TTATATTGTG CATTCTCAAG ATGAGGTGGC ATTAAAGAAT 
        v  a  q   l  s  d   y  y  i  v   h  s  q   d  e  v   a  l  k  n 
 301  CTAATCGGTG TGGAAGGACC TGCTGCAGTC GCTTTGGATG TGAATATTGA CTTTATGATG 
        l  i  g   v  e  g   p  a  a  v   a  l  d   v  n  i   d  f  m  m 
 361  TACAAGAGTG GTATTTATCA GGACGAAATT TGTTCATCAC GATATTTGAA TCATGCACTG 
        y  k  s   g  i  y   q  d  e  i   c  s  s   r  y  l   n  h  a  l 
 421  TTGGCTGTCG GTTACGGAAC AGAGGATGGT ACTGAATATT GGATTGTGAA AAACAGTTGG 
        l  a  v   g  y  g   t  e  d  g   t  e  y   w  i  v   k  n  s  w 
 481  GGATCGCGAT GGGGTGAGCA TGGTTATATT CGATTGGCTA GGAACCGAGA TAATATGTGT 
        g  s  r   w  g  e   h  g  y  i   r  l  a   r  n  r   d  n  m  c 
 541  GGAATAGCTA CACTGGCCAG TCTCCCAATA GTGAAACGTT TTCCGTGAaa ttctgctgtc 
        g  i  a   t  l  a   s  l  p  i   v  k  r   f  p  *    
 601  agtatgaaaa cgcactgaac aataaatttc atccagcttt gcaaaaaaaa aaaaaaaaaa 
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H14.6B 
   1  GGCTGGGCTT TCTCAACAAC CGGTGCTATG GAGGGACAGT TTAGGAAGAA CGAAAGAGCT 
        g  w  a   f  s  t   t  g  a  m   e  g  q   f  r  k   n  e  r  a 
  61  AGTGCTTCAT TCTCTGAGCA ACAACTGGTC GATTGTACTC GTAATTTTGG AAATCACGGT 
        s  a  s   f  s  e   q  q  l  v   d  c  t   r  n  f   g  n  h  g 
 121  TGCGGTGGTG GATATATGGA AAACGCTTAT GAATATTTGA AACACAGCGG ATTGGAAACT 
        c  g  g   g  y  m   e  n  a  y   e  y  l   k  h  s   g  l  e  t 
 181  GATTCCTATT ATCCGTACCA GGCTGTGGAA GGTCCGTGTC AATACGATGG GCGGTTGGCA 
        d  s  y   y  p  y   q  a  v  e   g  p  c   q  y  d   g  r  l  a 
 241  TATGCCAAAG TGACTGACTA CTATACTGTG CATTCTGGCG ATGAGGTAGA ATTAA... 
        y  a  k   v  t  d   y  y  t  v   h  s  g   d  e  v   e  l... 
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F2 
    1  AATGTGAAAC ATATCCAAGA ACACAACCTG CGTCACGATC TCGGTCTCGT CACTTACACG 
         n  v  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGACCTGACG TTTGAGGAAT TCAAGGCCAA ATATCTAATA 
         l  g  l   n  q  f   t  d  l  t   f  e  e   f  k  a   k  y  l  i 
  121  GAAATGTCAC CGGAGTCCGA ATCACTCTCA GACGGCATTT CATATGAGGC CGAAGGCAAT 
         e  m  s   p  e  s   e  s  l  s   d  g  i   s  y  e   a  e  g  n 
  181  GACGTACCGG CCAGTATAGA TTGGCGTCAA TATGGTTATG TGACGGAGGT GAAAAATCAG 
         d  v  p   a  s  i   d  w  r  q   y  g  y   v  t  e   v  k  n  q 
  241  gttagtatag attgtgaaca cttaataata atcctatgat gatttgattt gaacagGGAC 
                      G  
  301  AATGTGGTTC CTGTTGGGCT TTTTCAGCCG TCGGTGCAAT AGAGGGACAG TATGTCAAAA 
        q  c  g   s  c  w  a   f  s  a   v  g  a   i  e  g  q   y  v  k 
  361  AGTTTCAAAA CCGAATGTTA TTCTCCGAGC AACAGTTGGT CGATTGTACC AAACGATTTG 
        k  f  q   n  r  m  l   f  s  e   q  q  l   v  d  c  t   k  r  f 
  421  GCAACCACGG ATGTAGCGGT GGTTGGATGG AGAACGCTTA TAGATATTTG AAAGACAGCG 
        g  n  h   g  c  s  g   g  w  m   e  n  a   y  r  y  l   k  d  s 
  481  GATTGGAAAC GGCATCCTAT TACCCGTATC AGGCTTGGgt gagtattgtg aatgtttgtg 
        g  l  e   t  a  s  y   y  p  y   q  a  w   
  541  ctcttctctc gagttatcct gtattctaat gcccaccatt ttacctcttc ccatctcata 
  601  caactctcat ctgaaaaacg attgatacag ctaccatgaa ctatcatact taaccgaatt 
  661  gtgttcttgt ccccatttca gGAATATCAA TGTCAATACA GGAGAGAGCT TGGAGTAGCC 
                                e  y  q   c  q  y   r  r  e   l  g  v  a 
  721  AAAGTGACTG GTGCCTATAC GGTGCATTCT GGTGATGAGA TGAGGTTGAT GCAAATGGTC 
         k  v  t   g  a  y   t  v  h  s   g  d  e   m  r  l   m  q  m  v 
  781  GGTAGAGAAG GACCTGCTGC GGTCGCTGTG GATGCTCAAT CTGACTTCTA TATGTATAAg 
         g  r  e   g  p  a   a  v  a  v   d  a  q   s  d  f   y  m  y    
  841  tacgtgcatt cgtgtgattt ggatgataca cagaatgagc taagtagatg gagagtaagt 
  901  gagaaacaaa gagagagaga gagagagaga catggacagg gagaaaaatt aggtattgtg 
  961  agacaaatgg ttaagagttt ctcaattacc agttccattc ttgacattcc tcaccatcaa 
 1021  tccttgtgcg atgtactagc ttacttgtat gcataataac tggtttgctg aattccatgt 
 1081  ggttcgttgt ttgtttatta ggacaagctg atacttatgt gcccatctta ttgaatgcaa 
 1141  tgtccattgg atttggtctc gtgtattttt agcaagacag cctgaacttg tgtttcgtgg 
 1201  ttaacaagtt ggttcaataa acaacattcc tttcacaatt tgcacaagca atccaccttc 
 1261  agtgttacac gagaacaggt gtagatgtga ttgtaattgc tgaccaaata tttagtccat 
 1321  tgtcaaacaa caaacgtatt acctgggatt tatgctcgct cgggtcctca tgaatatcca 
 1381  tttgggaaaa gtatggtttg atcggttcac ttcgaataag cccaatcaaa cacatatcgt 
 1441  gctcaacagt tctcagttga gcattacttt tatttccggt tcacacagcg aaagttccgg 
 1501  ctctctgtca atcctctctt tttcaattca ttataagcac atattcgtct ccaatcttgc 
 1561  gttctcatat tcctatttat attgttgttt tttatttatt caaacagGAG TGGTATTTTC 
                                                          k   s  g  i  f 
 1621  ATGAGCCAAG TTTGTACAAC GCAACGTGTG ACTCATGCAG TGTTGGCTGT TGGTTATGGA 
         m  s  q   v  c  t   t  q  r  v   t  h  a   v  l  a   v  g  y  g 
 1681  ACAGAGAGTG GTACTGACTA TTGGATTTTG AAAAACAGTT GGGGAAAGTG GTGGGGTGAG 
         t  e  s   g  t  d   y  w  i  l   k  n  s   w  g  k   w  w  g  e 
 1741  GACGGTTACA TGCGGTTTGC CAGGAACCGA AACAATATGT GTGCAATTGC TTCGGTGGCC 
         d  g  y   m  r  f   a  r  n  r   n  n  m   c  a  i   a  s  v  a 
 1801  AGTGTCCCCA TGGTGGCACA ATTTCCGTGA 
         s  v  p   m  v  a   q  f  p  * 
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1.1 
    1  AATGCGAAAC ATATTCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
         n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
         l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
  121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
         e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
  181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
         a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
  241  gtgagtatag attgtgaaca cccaataatc tgatgatgat ttgatttgaa aagGGAAATT 
                                                                   q  n 
  301  GTGGTTCATG TTGGGCATTC TCAACAACCG GTACTATGGA AGGACAGTAT ATGAAAAACG 
        c  g  s   c  w  a  f   s  t  t   g  t  m   e  g  q  y   m  k  n 
  361  AAAGAACTAG TATTTCATTC TCTGAGCAAC AACTGGTCGA TTGTAGCGGT CCTTGGGGAA 
        e  r  t   s  i  s  f   s  e  q   q  l  v   d  c  s  g   p  w  g  
  421  ATATGGGTTG CAGTGGTGGA TTGATGGAAA ATGCTTACGA ATATTTGAAA CAATTTGGAT 
        n  m  g   c  s  g  g   l  m  e   n  a  y   e  y  l  k   q  f  g 
  481  TGGAAACCGA ATCCTCTTAT CCGTACACGG CTGTGgtgag tactgtttgt ctgtgtgcta 
        L  e  t   e  s  s  y   p  y  t   a  v    
  541  ttcctccgag tcattttgct taaacctccg caaattttac ctcccaccac atgacaccta 
  601  tttgacctta caaaaattcc ttctcttgtt atcaactact tcactcagtt cacttattac 
  661  ttgatcccat ttcagGAAGG TCAGTGTCGA TACAATAGGC AGTTGGGAGT TGCCAAAGTG 
                         e   g  q  c  r   y  n  r   q  l  g   v  a  k  v 
  721  ACGGACTACT ATACTGTGCA TTCTGGCAGT GAGGTAGAAT TGAAAAATCT AGTCGGTGCC 
         t  d  y   y  t  v   h  s  g  s   e  v  e   l  k  n   l  v  g  a 
  781  GAAGGACCTG CTGCGGTCGC TGTGGATGTG GAATCTGACT TCATGATGTA CAGgtacgtg 
         e  g  p   a  a  v   a  v  d  v   e  s  d   f  m  m   y 
  841  cttttatgtc attcggacga gacagatgat aaacgaagta gggagagaga gagagagaga 
  901  gagagagaat gaatgaggga gagaatgtgt gagacaatta ggttataaat tttcaattat 
  961  cagtttaccg ttcgacgttc ctcgtcatcg atgcatgtgt gatgtactaa cctactcgta 
 1021  tgtatgacat ctggtttgct agattccata cagttgctcg ctagattatt caaaccaaat 
 1081  gatgcttaga ttctctccct atggagtatg atattcatca aattcggttt catttagttt 
 1141  tgatcaaaca gtttgaacgt gcgtttcacg ggtaacaaat gggctcagta gatcacattg 
 1201  gttttacaat tcgcacagac aatcaatctt cagtgttaca gtagcacagt tgtaattgca 
 1261  attataacta ctgatcatgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtggta 
 1321  tattgtcaaa taacacatgt agtatttggg atttatgctc gcccgcatcc cggtcccgag 
 1381  tcagtttggg agaagtatga tttgaattgc ctatttcgaa tacgtcctat ttcacgcagt 
 1441  tcgcggtaag tagttcacag tggaacaggc tttttgtttc caattcgcat agcataaatg 
 1501  ttcgctctct ttcgtttcta tctattttca atcattctaa gcaccattcc atttccgaac 
 1561  cggtgttgtc atattcatat gtatattgtt aatttctgtt caaacagAGG TGGTATTTAT 
                                                          r   g  g  i  y 
 1621  CAGAGCCGAA CTTGTTCATC GCTTCGTGTG AATCATGCAG TCTTGGCTGT CGGTTATGGA 
         q  s  r   t  c  s   s  l  r  v   n  h  a   v  l  a   v  g  y  g 
 1681  ACACAGGGTG GTACTGACTA TTGGATTGTG AAAAATAGTT GGGGATCGTC CTGGGGTGAG 
         t  q  g   g  t  d   y  w  i  v   k  n  s   w  g  s   s  w  g  e 
 1741  CGTGGTTACA TTCGAATGGT TAGGAACTGA GGTAACATGT GTGGAATTGC TTCGCTGGCC 
         r  g  y   i  r  m   v  r  n  *   g  n  m   c  g  i   a  s  l  a 
 1801  AGTCTCCCGA TGGTGGCACG ATTCCCGTGA 
         s  l  p   m  v  a   r  f  p  * 
2.1 
    1  AATGCGAAAC ATATTGAAGA ACACAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
         n  a  k   h  i  e   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
         l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
  121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGCATCC CGTATGAGGC GAACAACCGT 
         e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
  181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTACG TGACGGGGGT GAAAGACCAA 
         a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  g   v  k  d  q 
  241  gtgagtatag attgtgaaca cccaataatc cgatgatgat ctgatttgat ttgatttgaa 
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  301  aagGGAAACT GTGGTTCTTG TTGGGCTTTC TCAACAACCG GTACTATGGA AGGACAGTAT 
            g  n   c  g  s   c  w  a  f   s  t  t   g  t  m   e  g  q  y 
  361  ATGAAAAACC AAAGAACCAG TATTTCATTC TCTGAGCAAC AACTGGTCGA TTGTAGCGGT 
         m  k  n   q  r  t   s  i  s  f   s  e  q   q  l  v   d  c  s  g 
  421  CCCTGGGGAA ATATGGGTTG CAGTGGTGGA TTGATGGAAA ATGCTTACGA ATATTTGAAA 
         p  w  g   n  m  g   c  s  g  g   l  m  e   n  a  y   e  y  l  k 
  481  CAATTTGGAT TGGAAACCGA ATCCTCTTAT CCGTACAGGG CTGTGgtgag tactgcatgt 
         q  f  g   l  e  t   e  s  s  y   p  y  r   a  v   
  541  atgcgcgccc ttcctccgat ttattttgct tacacctccc gtcgttttac ctcttaccat 
  601  gttgcaccaa tatgatctca caaaaaattg cctctgttat tatcaactac tttacccaat 
  661  tcacttatta tttgatccca ttttagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG 
                                     e   g  q  c   r  y  n  r   q  l  g 
  721  TTGCCAAAGT GACTGGCTAC TATACTGTGC ATTCTGGCAG TGAGGTAGGA TTGAAAAATC 
        v  a  k   v  t  g  y   y  t  v   h  s  g   s  e  v  g   l  k  n 
  781  TAGTCGGTGC CGAAGGACCT GCTGCGGTCG CTGTGGGTGT GGAATCTGAC TTCATGATGT 
        l  v  g   a  e  g  p   a  a  v   a  v  g   v  e  s  d   f  m  m  
  841  ACAGgtacgc gcttttatgt cattcggacg agacaaatga taaactaagt cgagagggag 
        y 
  901  ggagggagag agagaaggag aagagaatga aagagggaga gaatatgtta gacagatagg 
  961  ttatagatct tcaattatca gtttgatgtt cgactttcct cgtcatcgat acatgtgtga 
 1021  tgtattagct tactcgtatg catgcttgct ggatttctgg attccacaca attgctcact 
 1081  ttactgttca ggccgaatga cacttgtgtt ctctccctat ggagtaatat attcatcaaa 
 1141  tttggtttca ttcagttttg atcaaacagt ttgaacgtgc gtttcacggg tatcaaatgg 
 1201  gcctaataga aaacatttgt tttttaattg gcacaggcaa tctatcttca gtgtgacact 
 1261  ggcacagttg taattgtaat tgtaaccgct gatcatgtgt gtgtggtata ttgtcaaata 
 1321  acacatgtag tactttggat ttatgctcgc ccgcatcccg gtcacaattc gttttgggag 
 1381  atatattact ttaattgccc attttgacta aattcacttg cacgcacatc gcggtaagta 
 1441  cttctcaatt gaacaggctt tttgttttcg ctcgctctct ttcattcctc tgtactttca 
 1501  gtcattcgaa gcaccattcc atttccaaac ttgcgttgtc atatccatat ttatattgtt 
 1561  gtttttgtcc aaacagGAGT GGTATTTATC AGAGCCAAAC TTGTTCACCG TTTGGTTTGA 
                        r  s   g  i  y   q  s  q   t  c  s  p   f  g  l  
 1621  ATCATGCAGT CTTGGCTGTC GGTTATGGAA CACAGGGTGG TACTGACTAT TGGATTGTGA 
        n  h  a   v  l  a  v   g  y  g   t  q  g   g  t  d  y   w  i  v 
 1681  AAAATAGTTG GGGATCGTCC TGGGGTGAGC GCGGTTACAT TCGAATGGTT AGGAACCGAG 
        k  n  s   w  g  s  s   w  g  e   r  g  y   i  r  m  v   r  n  r  
 1741  GTAACATGTG TGGAATTGCT TCAATGGCCA GTCTTCCGAT GGTGGAACAA TTCCCGTGA 
        g  n  m   c  g  i  a   s  m  a   s  l  p   m  v  e  q   f  p  * 
2.2 
    1  AATGCGAAAC ATATCGAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
         n  a  k   h  i  e   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
         l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
  121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAATCGT 
         e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
  181  GTCGTACCCG ACAAAATTGA CCGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
         v  v  p   d  k  i   d  r  r  e   s  g  y   v  t  e   v  k  d  q 
  241  gtgagtatag attgtgaaca cccaataatc tgatgatgat ttgatttgaa aagGGAAATT 
                                                                   g  n  
  301  GTGGTTCATG TTGGGCATTC TCAACAACCG GTACTATGGA AGGACAGTAT ATGAAAAACG 
        c  g  s   c  w  a  f   s  t  t   g  t  m   e  g  q  y   m  k  n 
  361  AAAGAACTAG TATTTCATTC TCTGAGCAAC AACTGGTCGA TTGTAGCGGT CCTTGGGGAA 
        e  r  t   s  i  s  f   s  e  q   q  l  v   d  c  s  g   p  w  g 
  421  ATTATGGTTG CAGTGGTGGA TTGATGGAAA ATGCTTACGA ATATTTGAAA CAATTTGGAT 
        n  y  g   c  s  g  g   l  m  e   n  a  y   e  y  l  k   q  f  g 
  481  TGGAAACCGA ATCCTCTTAT CCGTACACGG CTGTGgtgag tactgtttgt ctgtgtgctc 
        l  e  t   e  s  s  y   p  y  t   a  v   
  541  ttcctccgag tcattttgct cacacctcca cacattttac ctcccatcac atggcaccaa 
  601  tttgatctca caaaaattcc ttctcttgtt atcaactact tcactcagtt cacttattac 
  661  ttgatcccat ttcagGAAGG TTAGTGTCGA TACAATAGGC AGTTGGGAGT TGCCAAAGTG 
                         e   g  *  c  r   y  n  r   q  l  g   v  a  k  v 
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  721  ACGGACTACT ATACTGTGCA TTCTGGCAGT GAGGTAGAAT TGAAAAATCT AGTCGGTGCC 
         t  d  y   y  t  v   h  s  g  s   e  v  e   l  k  n   l  v  g  a 
  781  GAAGGACCTG CTGCGGTCGC TGTGGATGTG GAATCTGACT TCATGATGTA CAGgtacgtg 
         e  g  p   a  a  v   a  v  d  v   e  s  d   f  m  m   y    
  841  cttttatgtc attcggacga gacagatgat aaacgaagtg gagagagaga gagagagaga 
  901  gagaatgaat gagggagaga atgtgtgaga caattaggtt ataaattttc aattatcagt 
  961  ttaccgttcg acgttcctcg tcatcgatgc atgtgtgatg tactaaccta ctcgtatgta 
 1021  tgacatctgg tttgctagat tccatacagt tgctcgctag attattcaaa ccgaatgatg 
 1081  cttagattct ctccctatgg agtatgatat tcatcaaatt cggtttcatt tagttttgat 
 1141  caaacagttt gaacgtgcgt ttcacgggta acaaatgggc tcagtagatc acattcgttt 
 1201  tataattcgc acagacaatc tatcttcagt gttacactag cacagttgta attgcaatta 
 1261  taactcatat gtttattgtt attttctgtt caaacagTGG TGGTATTTAT CAGAGCCGAA 
                                               s   g  g  i  y   q  s  r  
 1321  CTTGTTCATC GCTTCGTGTG AATCATGCAG TCTTGGCTGT CGGTTATGGA ACACAGGGTG 
        t  c  s   s  l  r  v   n  h  a   v  l  a   v  g  y  g   t  q  g  
 1381  GTACTGACTA TTGGATTGTG AAAAATAGTT GGGGATCGTC CTGGGGTGAG CGTGGTTACA 
        g  t  d   y  w  i  v   k  n  s   w  g  s   s  w  g  e   r  g  y 
 1441  TTCGAATGGT TAGGAACCGA GGTAACATGT GTGCAATTGC TTC 
        i  r  m   v  r  n  r   g  n  m   c  a  i   a 
2 
    1  AATGCGAAAC ATATTGAAGA ACACAACCTG CGTCACGATC TCGGTCTCGT CACTTACACG 
         n  a  k   h  i  e   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGACCTGACG TTTGAGGAAT TCAAGGCCAA ATATCTAATG 
         l  g  l   n  q  f   t  d  l  t   f  e  e   f  k  a   k  y  l  m 
  121  GAAATTTCAC CGGAGTCCGA ATCACTCTCA GATGGCATTT CATATGAGGC CGAAGGCAAT 
         e  i  s   p  e  s   e  s  l  s   d  g  i   s  y  e   a  e  g  n 
  181  GACGTACCGG CCAGTATAGA TTGGCGTCAA TATGGTTATG TGACGGAGGT GAAAGATCAG 
         d  v  p   a  s  i   d  w  r  q   y  g  y   v  t  e   v  k  d  q 
  241  gttagtatag attgtgaaca cttattaata atcctatgat aatttgattt gaacagGGAC 
                                                                      g 
  301  AATGTGGTTC CTGTTGGGCT TTTTCAGCCG TCGGTGCAAT AGAGGGACAG TATGTCAAAA 
        q  c  g   s  c  w  a   f  s  a   v  g  a   i  e  g  q   y  v  k 
  361  AGTTTCGAAA CCGAATGTTA TTCTCCGAGC AACAGTTGGT CGATTGTACC AAACGATTTG 
        k  f  r   n  r  m  l   f  s  e   q  q  l   v  d  c  t   k  r  f 
  421  GCAACCACGG ATGTAGCGGT GGTTGGATGG AGAACGCTTA TAGATATTTG AAAGACAGCG 
        g  n  h   g  c  s  g   g  w  m   e  n  a   y  r  y  l   k  d  s 
  481  GATTGGAAAC GGCATCCTAT TACCCGTATC AGGCTTGGgt gagtattgtg aatgtttgtg 
        g  l  e   t  a  s  y   y  p  y   q  a  w    
  541  ctcttctctc gagttatcct gtattctaat gcccaccatt ttacctcttc ccatctcata 
  601  caactctcat ctgacaaacg attgatacag ctaccatgaa ctatcatact taaccgaatt 
  661  gtgttcttgt ccccatttca gGAATATCAA TGTCAATACA GGAGAGAGCT TGGAGTAGCC 
                                e  y  q   c  q  y   r  r  e   l  g  v  a 
  721  AAAGTGACTG GTGCCTATAC TGTGCATTCT GGTGATGAGA TGAGGTTGAT GCAAATGGTC 
         k  v  t   g  a  y   t  v  h  s   g  d  e   m  r  l   m  q  m  v 
  781  GGTAGAGAAG GACCTGCTGC GGTCGCTGTT GATGCTCAAT CTGACTTCTA TATGTATCAg 
         g  r  e   g  p  a   a  v  a  v   d  a  q   s  d  f   y  m  y    
  841  tacgtgaatt gttatgattt gaatgataca gaggatcaga taagtagatg gagaggaaat 
  901  gagatggaaa cagataggga cagattgaaa gagatggata atgtgagaca gatggtttag 
  961  agtttctcgt ttaccagttc catgtttgaa attcctcacc atcaagcctt gtgtaatgtt 
 1021  ctagcttact tttatgcatg aaaactgact tgctggattc catgtggttt gttgtttgaa 
 1081  taataggatc ggacgatacg tatatgtcgt tcttgttcaa tgcaatgtcc attggatctg 
 1141  gtttcgtgta tttttaagca gacagcctct ctttttcaat tcattctaag cacatattta 
 1201  tctccaatct tgtattgtca tattcatatt tatattgttg tttttgtcca aacagGAGTG 
                                                                   q  s  
 1261  GCATCTTTCA GAGCCAAACT TGTACATCGC AACGTGTGAC TCATGCAGTG TTGGCTGTTG 
        g  i  f   q  s  q  t   c  t  s   q  r  v   t  h  a  v   l  a  v  
 1321  GTTATGGAAC AGAGAGTGGT ACTGACTATT GGATTTTGAA AAACAGTTGG GGAAAGTGGT 
        g  y  g   t  e  s  g   t  d  y   w  i  l   k  n  s  w   g  k  w 
 1381  GGGGTGAGGA CGGTTACATG CGGTTTGCCA GGAACCGAAA CAATATGTGT GCAATTGCTT 
        w  g  e   d  g  y  m   r  f  a   r  n  r   n  n  m  c   a  i  a 
 1441  C 
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4.10 
    1  TGTGGATCGG GTTGGGCGTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  GAAAGAACTA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCTTGGGGA 
         e  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCATGGGCGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  m  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACACG GCTGTGgtga gtactgtttg tctgtgtgct 
         l  e  t   e  s  s   y  p  y  t   a  v 
  241  attcctccga gttattttgc ttaaacctcc acctatttta catcccacca catggcacca 
  301  atttgatctc acaaaaattc cttctctgtt tatcaactac ttcactcagt tcacttatta 
  361  cttgatccca tttcagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG TTGCCAAAGT 
                          e   g  q  c   r  y  n  r   q  l  g   v  a  k   
  421  GACGGACTAC TATACTGTGC ATTCTGGCAG TGAGGTAGAA TTGAAAAATC TAGTCGGTGC 
       v  t  d  y   y  t  v   h  s  g   s  e  v  e   l  k  n   l  v  g   
  481  CGAAGGACCT GCTGCGGTCG CTGTGGATGT GGAATCTGAC TTCATGATGT ACAGgtacgt 
       a  e  g  p   a  a  v   a  v  d   v  e  s  d   f  m  m   y   
  541  gcttttatgt cattcggacg agacagatga taaacgaagt agagagagag agagagagag 
  601  agagagagag agagagaatg aatgagggag agaatgtgtg agacaattag gttataaatt 
  661  ttcaattatc agtttaccgt tcgacgttcc tcgtcatcga tgcatgtgtg atgtactaac 
  721  ctactcgtat gtatgacatc tggtttgcta gattccatac agttgctcgc tagattattc 
  781  aaaccaaatg atgcttagat tctctcccta tggagtatga tattcatcaa attcggtttc 
  841  atttagtttt gatcaaacag tttgaacgtg cgtttcacgg gtaacaaatg ggctcagtag 
  901  atcacattgg ttttacaatt cgcacagaca atctatcttc agtgttacag tagcacagtt 
  961  gtaattgcaa ttataactac tgatcatgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 
 1021  gtatattgtc aaataacaca tgtagtattt gggatttatg ctcgccggca tcccggtccc 
 1081  gagtcagttt gggagaagta tgatttgtat tgcctatttc gaatacgtcc tatttcacgc 
 1141  agttcgcggt aagtagttca cagtggaaca ggctttttgt ttccaattcg catagcataa 
 1201  atgttcgctc tctttcgttt ctatctattt tcaatcattc taagcaccat tccatttccg 
 1261  aaccggtgtt gtcatattca tatgtatatt gttaatttct gttcaaacag TGGTGGTATT 
                                                              s  g  g  i 
 1321  TATCAGAGCC GAACTTGTTC ATCGCTTCGT GTGAATCATG CAGTCTTGGC TGTCGGTTAT 
         y  q  s   r  t  c   s  s  l  r   v  n  h   a  v  l   a  v  g  y 
 1381  GGAACACAGG GTGGTACTGA CTATTGGATT GTGAAAAATA GTTGGGGATC GTCCTGGGGT 
         g  t  q   g  g  t   d  y  w  i   v  k  n   s  w  g   s  s  w  g 
 1441  GAGCGTGGTT ACATTCGAAT GGTTAGGAAC CGAGGTAACA TGTGTGGAAT TGCTTC 
         e  r  g   y  i  r   m  v  r  n   r  g  n   m  c  g   i  a 
4.20 
    1  TGTGGCTCGG GTTGGGCATT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  GAAAGAACTA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCTTGGGGA 
         e  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCATGGGCGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  m  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACACG GCTGTGgtga gtactgttcg tctgtgtgct 
         l  e  t   e  s  s   y  p  y  t   a  v 
  241  cttcctccga gttattttgc tcacacctcc acaaatttta cctcccacca catggcacct 
  301  atttgacctc acaaaaattc cttctcttgt tatcaactac ttcattcagt tcacttatta 
  361  cttgatccca tttcagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG TTGCCAAAGT 
                          e   g  q  c   r  y  n  r   q  l  g   v  a  k   
  421  GACGGACTAC TATACTGTGC ATTCTGGCAG TGAGGTAGAA TTGAAAAATC TAGTCGGTGC 
       v  t  d  y   y  t  v   h  s  g   s  e  v  e   l  k  n   l  v  g   
  481  CGAAGGACCT GCTGCGGTCG CTGTGGATGT GGAATCTGAC TTCATGATGT ACAGgtacgt 
       a  e  g  p   a  a  v   a  v  d   v  e  s  d   f  m  m   y   
  541  gcttttatgt cattcggacg agacagatga taaacgaagt agagagagag agagagagag 
  601  agagagagag agaatgaatg agggagagaa tgtgtgagac aattaggtta taaattttca 
  661  attatcagtt taccgttcga cgttcctcgt catcgatgca tgtgtgatgt actaacctac 
  721  tcgtatgtat gacatctggt ttgctagatt ccatacagtt gctcgctaga ttattcaaac 
  781  cgaatgatgc ttagattctc tccctatgga gtatgatatt catcaaattc ggtttcattt 
  841  agttttgatc aaacagtttg aacgtgcgtt tcacgggtaa caaatgggct cagtagatca 
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  901  cattcgtttt acaattcgca cagacaatct atcttcagtg ttacagtagc acagttgcaa 
  961  ttgcaattat aactactgat catgtgtgtg tgtgtgtgtg tgtgtgtgtg ttgtatattg 
 1021  tcaaataaca catgtagtat ttgggattta tgctcgccca catcccggtc ccgagtcagt 
 1081  ttgggagaag tatgatttga attgcctatt tcgaatacgt cctatttcac gcagttcgcg 
 1141  gaaagtagtt cacagtggaa caggcttttt gtttccaatt cgcatagcat aaatgttcgc 
 1201  tctctttcgt tcctatctat tttcaatcat tctaagcacc attccatttc cgaaccggtg 
 1261  ttgtcatatt catatgtata ttgttatttt ctgttcaaac agTGGTGGTA TTTATCAGAG 
                                                     s  g  g   i  y  q   
 1321  CCGAACTTGT TCATCGCTTC GTGTGAATCA TGCAGTCTTG GCTGTCGGTT ATGGAACACA 
       s  r  t  c   s  s  l   r  v  n   h  a  v  l   a  v  g   y  g  t   
 1381  GGGTGGTACT GACTATTGGA TTGTGAAAAA TAGTTGGGGA TCGTCCTGGG GTGAGCGTGG 
       q  g  g  t   d  y  w   i  v  k   n  s  w  g   s  s  w   g  e  r   
1441  TTACATTCGA ATGGTTAGGA ACCGAGGTAA CATGTGTGGA ATTGCTTC 
      g  y  i  r   m  v  r   n  r  g   n  m  c  g   i  a 
4.21 
    1  TGTGGTTCAG GTTGGGCTTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  CAAAGAACCA GGATTTCATT CTCTGAGCAA CAACTGGCCG ATTGTAGCGG TCCCTGGGGA 
         q  r  t   r  i  s   f  s  e  q   q  l  a   d  c  s   g  p  w  g 
  121  AATATGGGTT GCAGTGGTGG ATTGATGGAG AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  s  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTTTTA TCCGTACAGG GCTGTGgtga gtactgcatg tatgcgcgcc 
         l  e  t   e  s  f   y  p  y  r   a  v 
  241  cttcctccga tttattttgc ttacacctcc cgtcgtttta cctcttacca tgttgcacca 
  301  atatgatctc acaaaaaatt gcctctgtta tcaccaacta ctttacccaa ttcacttatt 
  361  atttgatccc attttagGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA GTTGCCAAAG 
                           e   g  q  c   r  y  n   r  q  l  g   v  a  k  
  421  TGACTGGCTA CTATACTGTG CATTCTGGCA GTGAGGTAGG ATTGAAAAAT CTAGTCGGTG 
        v  t  g   y  y  t  v   h  s  g   s  e  v   g  l  k  n   l  v  g  
  481  CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG TACAGgtacg 
        a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m   y   
  541  cgcttttatg tcattcggac gagacaaatg ataaactaag tcgagaggga gggagagaga 
  601  gagagagaga aggagaagag aatgagagag ggagagaata tgtgagacag ataggctata 
  661  gatcttcaat tatcagtttg atgttcgact ttcctcgtca tcgatacatg tgtgatgtat 
  721  tagctaactc gtatgcatgc ttgctggatt tctggattcc acacaattgc tcactttact 
  781  gttcaggccg aatgacactt gtgttctctc cctatggagt aatatattca tcaaatttgg 
  841  tttcattcag ttttgatcaa acagtttgaa cgtgcgtttc acgggtatca aatgggccta 
  901  atagaaaaca tttgtttttt aattggcaca ggcaatctat cttcagtgtg acactggcac 
  961  agttgtaatt gtaattgtaa ccgctgatca tgtgtgtgtg gtatattgtc aaataacaca 
 1021  tgtagtactt tggatttatg ctcgcccgca tcccggtcac aattcgtttt gggagatata 
 1081  tgactttaat tgcccatttt gaataagtcc acttgcacgc acatcgcggt aagtacttct 
 1141  caattgaaca ggctttttgt tttcgctcgc tctctttcat tcctctgtac tttcagtcat 
 1201  tcgaagcacc attccatttc caaacttgcg ttgtcatatt catatttata ttgttgtttt 
 1261  tgtccaaaaa gGAGTGGTTT TCATCAGAGC CAAACTTGTT CACCGTTAGG TTTGAATCAT 
                   r  s  g   f  h  q  s   q  t  c   s  p  l   g  l  n  h 
 1321  GCAGTCTTGG CTGTCGGTTA TGGAACACAG GGTGGTACTG ACTATTTGAT TGTGAAAAAT 
         a  v  l   a  v  g   y  g  t  q   g  g  t   d  y  l   i  v  k  n 
 1381  AGTTGGGGAT TGTCGTGGGG TGAGCGCGGT TACATTCGAA TGGCTAGGAA CCGAGGTAAC 
         s  w  g   l  s  w   g  e  r  g   y  i  r   m  a  r   n  r  g  n 
 1441  ATGTGTGCAA TTGCTTC 
         m  c  a   i  a 
4.30 
    1  TGTGGTTCGG GTTGGGCGTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  CAAAGAACCA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCCTGGGGA 
         q  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCAGTGGTGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  s  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
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  181  TTGGAAACCG AATCCTCTTA TCCGTACAGG GCTGTGgtga gtactgcatg tatgcgcgcc 
         l  e  t   e  s  s   y  p  y  r   a  v 
  241  ctccctccga tttattttgc ttacacctcc cgtcgtttta cctcttacca tgttgcacca 
  301  atatgatctc acaaaaaatt gcctctgtta ttatcaacta ctttacccaa ttcacttatt 
  361  atttgatccc attttagGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA GTTGCCAAAG 
                           e   g  q  c   r  y  n   r  q  l  g   v  a  k  
  421  TGACTGGCTA CTATACTGTG CATTCTGGCA GTGGGGTAGG ATTGAAAAAT CTAGTCGGTG 
        v  t  g   y  y  t  v   h  s  g   s  g  v   g  l  k  n   l  v  g 
  481  CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG TACAGggtacg 
        a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m   y   
  541  cgcttttatg tcattcggac gagacaaatg ataaactaag tcgagaggga gggagggaga 
  601  gagagagaag gagaagagaa tgaagggagg gagagaatat gtgagacaga taggttatag 
  661  atcttcagtt atcagtttga tatccgactt tcctcatcat cgatacatgt gtgatgtatt 
  721  agcttactcg tatgcatgct tgctggattt ctggattcca cacaattgct cactttactg 
  781  ttcaggccga atgacactta tgttctctcc ctatggagta atatattcat caaatttggt 
  841  ttcattcagt tttgatcaaa cagtttgaac gtgcgtttca cgggtatcaa atgggcctaa 
  901  tagaaaacat tcgtttttta attggcacag gcaatctatc ttcagtgtga cactggcaca 
  961  gttgtaattg taattgtaac cgctgatcat gtgtgtgtgg tatattgtca aataacacat 
 1021  gtagtacttt ggatttatgc tcgcccgcat cccggtcaca attcgttttg ggagatatat 
 1081  tactttaatt gcccattttg aataaattca cttgcacgca catcgcggta agtacttctc 
 1141  aattgaacag gctttttgtt ttcgctcgct ctcttttatt cctctgtact ttcagtcatt 
 1201  cgaagcacca ttccatttcc aaacttgcgt tgtcatactc atatttatat tgttgttttt 
 1261  gtccaaacag GAGTGGTATT TATCAGAGCC AAACTTGTTC ACCGTTTGGT TTGAATCATG 
                  r  s  g  i   y  q  s   q  t  c   s  p  f  g   l  n  h 
 1321  CAGTCTTGGC TGTCGGTTAT GGAACACAGG GTGGTACTGA CTATTGGATT GTGAAAAATA 
        a  v  l   a  v  g  y   g  t  q   g  g  t   d  y  w  i   v  k  n 
 1381  GTTGGGGATC GTCCTGGGGT GAGCGCGGTT ACATTCGAAT GGTTAGGAAC CGAGGTAACA 
        s  w  g   s  s  w  g   e  r  g   y  i  r   m  v  r  n   r  g  n 
 1441  TGTGTGCAAT TGCTTC 
        m  c  a   i  a 
6.1 
    1  TGTGGTTCTG GTTGGGCGTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  GAAAGAACTA GAATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCTTGGGGA 
         e  r  t   r  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCATGGGCGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  m  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACACG GCTGTGgtga gtactgtttg tctgtgtgct 
         l  e  t   e  s  s   y  p  y  t   a  v  
  241  attcctccga gttattttgc tcacacctcc acacatttta cctcccacca catggcacca 
  301  atttgatctc acaaaatatt ccttctcttg ttatcaacta cttcactcag ttcacttatt 
  361  acttgatccc atttcagGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA GTTGCCAAAG 
                           e   g  q  c   r  y  n   r  q  l  g   v  a  k 
  421  TGACGGACTA CTATACTGTG CATTCTGGCA GTGAGGTAGA ATTGAAAAAT CTAGTCGGTG 
        v  t  d   y  y  t  v   h  s  g   s  e  v   e  l  k  n   l  v  g  
  481  CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG TACAGgtacg 
        a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m   y   
  541  tgcttttatg tcattcggac gagacggatg ataaacgaag aagggagaga gagagagaaa 
  601  gagggaatga atgagggaga gaatgtgtga gacaattagg ttataaattt tcaattatca 
  661  gtttaccgtt cgacgttcct cgtcatcgat gcatgtgtga tgtactaacc tactcgtatg 
  721  tatgacatct ggtttgctag attccataca gtagctcgct agattattca aaccaaatga 
  781  tgcttagatt ctctccctat ggagtatgat attcatcaaa ttcggtttca tttagttttg 
  841  atcaaacagt atgaacgtgt gtttcacggg taacaaatgg gctcagtaga tcacattggt 
  901  tttacaattc gcacagacaa tctatcttca gtgttacact agctcagttg taattgcagt 
  961  tataactact gatcatgtgt gtgtgtgtgt gtgtgtatgt gtgtggtata ttgtcaaata 
 1021  acacatgtag tatttgggat ttatgctcgc ccgcatcccg gtcccgagtc agtttgggag 
 1081  aagtatgatt tgaattgccc atttcgtata ggtcctattt cacgcagttc gcggtaagta 
 1141  gttcacagtg gaacaggctt tttgtttcca attcgcatag cataaatgtt cgctctcttt 
 1201  cgtttctatc tattttcaat cattctaagc accattccat ttccgaaccg gtgttgtcat 
 1261  attcatatgt atattgttaa tttctgttca aacagTGGTG GTATTTATCA GAGCCGAACT 
                                             s  g   g  i  y   q  s  r  t 
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 1321  TGTTCATCGC TTCGTGTGAA TCATGCAGTC TTGGCTGTCG GTTATGGAAC ACAGGGTGGT 
         c  s  s   l  r  v   n  h  a  v   l  a  v   g  y  g   t  q  g  g 
 1381  ACTGACTATT GGATTGTGAA AAATAGTTGG GGATCGTCCT GGGGTGAGCG TGGTTACATT 
         t  d  y   w  i  v   k  n  s  w   g  s  s   w  g  e   r  g  y  i 
 1441  CGAATGGTTA GGAACCGAGG TAACATGTGT GGAATTGCTT CGCTGGCCAG TCTCCCGATG 
         r  m  v   r  n  r   g  n  m  c   g  i  a   s  l  a   s  l  p  m 
 1501  GTGGCACAAT TCCCGTGA 
         v  a  q   f  p  * 
6.6 
    1  TGTGGTTCTG GTTGGGCTTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  CAAAGAACCA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCCTGGGGA 
         q  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCAGTGGTGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  s  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACAGG GCTGTGgtga gtactgcatg tatgcgcgcc 
         l  e  t   e  s  s   y  p  y  r   a  v   
  241  cttcctccga tttattttgc ttacacctcc cgtcgtttta cctcttacca tgttgcacca 
  301  atatgatctc acaaaaaatt gcctctgtta ttaccaacta ctttacccaa ttcacttatt 
  361  atttgatccc attttagGAA GGTCAGTGTC GATACAATAG GCAGTTGGGA GTTGCCAAAG 
                           e   g  q  c   r  y  n   r  q  l  g   v  a  k  
  421  TGACTGGCTA CTATACTGTG CATTCTGGCA GTGAGGTAGG ATTGAAAAAT CTAGTCGGTG 
        v  t  g   y  y  t  v   h  s  g   s  e  v   g  l  k  n   l  v  g 
  481  CCGAAGGACC TGCTGCGGTC GCTGTGGATG TGGAATCTGA CTTCATGATG TACAGgtacg 
        a  e  g   p  a  a  v   a  v  d   v  e  s   d  f  m  m   y   
  541  cgcttttatg tcattcggac gagacaaatg ataaactaag tcgagaggga gggagggaga 
  601  gagagaagga gaagagaatg aaagagggag agaatatgtt agacagatag gttatagatc 
  661  ttcaattatc agtttgatgt tcgactttcc tcgtcatcga tacatgtgtg atgtattagc 
  721  ttactcgtat gcatgcttgc tggatttctg gattccacac aattgctcac tttactgttc 
  781  aggccgaatg acacttgtgt tctctcccta tggagtaata tattcatcaa atttggtttc 
  841  attcagtttt gatcaaacag tttgaacgtg cgtttcacgg gtatcaaatg ggcctaatag 
  901  aaaacatttg ttttttaatt ggcacaggca atctatcttc agtgtgacac tggcacagtt 
  961  gtaattgtaa ttgtaaccgc tgatcatgtg tgtgtggtat attgtcaaat aacacatgta 
 1021  gtactttgga tttatgctcg cccgcatccc ggtcacaatt cgttttggga gatatattac 
 1081  tttaattgcc cattttgaat aaattcactt gcacgcacat cgcggtaagt acttctcaaa 
 1141  tgaacaggct ttttgttttc gctcgctctc tttcattcct ctgtactttc agtcattcga 
 1201  agcaccattc catttccaaa cttgcgttgt catattcata tttatattgt tgtttttgtc 
 1261  caaacagGAG TGGTATTTAT CAGAGCCAAA CTTGTTCACC GTTTGGTTTG AATCATGCAG 
              r   s  g  i  y   q  s  q   t  c  s   p  f  g  l   n  h  a  
 1321  TCTTGGCTGT CGGTTATGGA ACACAGGGTG GTACTGACTA TTGGATTGTG AAAAATAGTT 
        v  l  a   v  g  y  g   t  q  g   g  t  d   y  w  i  v   k  n  s  
 1381  GGGGATCGTC CTGGGGTGAG CGCGGTTACA TTCGAATGGT TAGGAACCGA GGTAACATGT 
        w  g  s   s  w  g  e   r  g  y   i  r  m   v  r  n  r   g  n  m  
 1441  GTGGAATTGC TTCAATGGCC AGTCTTCCGA TGGTGGCACA ATTCCCGTGA 
        c  g  i   a  s  m  a   s  l  p   m  v  a   q  f  p  * 
6.14 
    1  agtactgttt gtctgtgtgc tcttcctccg agttattttg ctcacacctc cacacatttt 
   61  acctcccacc acatggcacc aatttgatct cacaaaatat tccttctctt gttatcaact 
  121  acttcactca gttcacttat tacttgatcc catttcagGA AGGTCAGTGT CGATACAATA 
                                                   e  g  q  c   r  y  n 
  181  GGCAGTTGGG AGTTGCCAAA GTGACGGACT ACTATACTGT GCATTCTGGC AGTGAGGTAG 
        r  q  l   g  v  a  k   v  t  d   y  y  t   v  h  s  g   s  e  v 
  241  AATTGAAAAA TCTAGTCGGT GCCGAAGGAC CTGCTGCGGT CGCTGTGGAT GTGGAATCTG 
        e  l  k   n  l  v  g   a  e  g   p  a  a   v  a  v  d   v  e  s  
  301  ACTTCATGAT GTACAGgtac gtgcttttat gtcattcgga cgagacggat gataaacgaa 
        d  f  m   m  y   
  361  gaagggagag agagagagaa agagggaatg aatgagggag agaatgtgtg agacaattag 
  421  gttataaatt ttcaattatc agtttaccgt tcgacgttcc tcgtcatcga tgcatgtgtg 
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  481  atgtactaac ctactcgtat gtatgacatc tggtttgcta gattccatac agttgctcgc 
  541  tagattattc aaaccaaatg atgcttagat tctctcccta tggagtatga tattcatcaa 
  601  attcggtttc atttagtttt gatcaaacag tatgaacgtg tgtttcacgg gtaacaaatg 
  661  ggctcagtag atcacattgg ttttacaatt cgcacagaca atctatcttc agtgttacac 
  721  tagcacagtt gtaattgcag ttataactac tgatcatgtg tgtgtgtgtg tgtgtgtggt 
  781  atattgtcaa ataacacatg tagtatttgg gatttatgct cgcccgcatc ccggtcccga 
  841  gtcagtttgg gagaagtatg atttgaattg cccatttcgt atacgtctta tttcacgcag 
  901  ttcgcggaaa gtagttcaca gtggaacagg ctttttgttt ccaattcgca tagcataaat 
  961  gttcgctctc tttcgttcct atctattttc aatcattcta agtaccattc catttccgaa 
 1021  ccggtgttgt catattcata tgtatattgt tattttctgt tcaaacagTG GTGGTATTTA 
                                                           s   g  g  i   
 1081  TCAGAGCCGA ACTTGTTCAT CGCTTCGTGT GAATCATGCA GTCTTGGCTG TCGGTTATGG 
       y  q  s  r   t  c  s   s  l  r   v  n  h  a   v  l  a   v  g  y   
 1141  AACACAGGGT GGTACTGACT ATTGGATTGT GAAAAATAGT TGGGGATCGT CCTGGGGTGA 
       g  t  q  g   g  t  d   y  w  i   v  k  n  s   w  g  s   s  w  g   
 1201  GCGTGGTTAC ATTCGAATGG TTAGGAACCG AGGTAACATG TGTGGAATTG CCTCGCTGGC 
       e  r  g  y   i  r  m   v  r  n   r  g  n  m   c  g  i   a  s  l   
 1261  CAGTCTCCCG ATGGTGGCAC GATTCCCGTG A  
       a  s  l  p   m  v  a   r  f  p   * 
6.16 
    1  TGTGGGTCAG GTTGGGCGTT TTCAGCCGTC GGTGCAATAG AGGGACAGTA TGTCAAAAAG 
         c  g  s   g  w  a   f  s  a  v   g  a  i   e  g  q   y  v  k  k 
   61  TTTCGAAACC GAATGTTATT CTCCGAGCAA CAGTTGGTCG ATTGTACCAA ACGATTTGGC 
         f  r  n   r  m  l   f  s  e  q   q  l  v   d  c  t   k  r  f  g 
  121  AACCACGGAT GTAGCGGTGG TTGGATGGAG AACGCTTATA GATATTTGAA AGACAGCGGA 
         n  h  g   c  s  g   g  w  m  e   n  a  y   r  y  l   k  d  s  g 
  181  TTGGAAACGG CATCCTATTA CCCGTATCAG GCTTGGgtga gtattgtgaa tgtttgtgct 
         l  e  t   a  s  y   y  p  y  q   a  w 
  241  cttctctcga gttatcctgt attctaatgc ccaccatttt acctcttccc atctcataca 
  301  actctcatct gacaaacgat tgatacagct accatgaact atcatactta accgaattgt 
  361  gttcttgtcc ccatttcagG AATATCAATG TCAATACAGG AGAGAGCTTG GAGTAGCCAA 
                              e  y  q   c  q  y  r   r  e  l   g  v  a   
  421  AGTGACTGGT GCCTATACTG TGCATTCTGG TGATGAGATG AGGTTGATGC AAATGGTCGG 
       k  v  t  g   a  y  t   v  h  s   g  d  e  m   r  l  m   q  m  v   
  481  TAGAGAAGGA CCTGCTGCGG TCGCTGTTGA TGCTCAATCT GACTTCTATA TGTATCAgta 
       g  r  e  g   p  a  a   v  a  v   d  a  q  s   d  f  y   m  y      
  541  cgtgaattgt tatgatttga atgatacaga ggatcagata agtagatgga gaggaaatga 
  601  gatggaaaca gatagggaca gattgaaaga gatggataat gtgagacaga tggtttagag 
  661  tttctcgatt accagttcca tgtttgaaat tcctcaccat caagccttgt gtaatgttct 
  721  agcttacttt tatgcatgaa aactgacttg ctggattcca tgtagtttgt tgtttgaata 
  781  ataggatcgg acgatacgta tatgtcgttc ttgttcaatg caatgtccat tagatctggt 
  841  ttcgtgtatt tttaagcaga cagcctctct ttttcaattc attctaagca catatttatc 
  901  tccaatcttg tattgtcata ttcatattta tattgttgtt tttgtccaaa cagGAGTGGC 
                                                                 q  s  g 
  961  ATCTTTCAGA GCCAAACTTG TACATCGCAA CGTGTGACTC ATGCAGTGTT GGCTGTTGGT 
         i  f  q   s  q  t   c  t  s  q   r  v  t   h  a  v   l  a  v  g 
 1021  TATGGAACAG AGAGTGGTAC TGACTATTGG ATTTTGAAAA ACAGTTGGGG AAAGTGGTGG 
         y  g  t   e  s  g   t  d  y  w   i  l  k   n  s  w   g  k  w  w 
 1081  GGTGAGGACG GTTACATGCG GTTTGCCAGG AACCGAAACA ATATGTGTGC AATTGCTTCG 
         g  e  d   g  y  m   r  f  a  r   n  r  n   n  m  c   a  i  a  s 
 1141  GTAGCCAGTG TCCCGATGGT GGAACAATTC CCGTGA 
         v  a  s   v  p  m   v  e  q  f   p  * 
6.22 
    1  TGTGGTTCAG GCTGGGCGTT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  GAAAGAACTA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCTTGGGGA 
         e  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCAGTGGTGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
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         n  m  g   c  s  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACACG GCTGTGgtga gtactgtttg tctgcgtgct 
         l  e  t   e  s  s   y  p  y  t   a  v   
  241  attcctccga gtcattttgc ttaaacctcc gcaaatttta cctcccacca cgtggcacct 
  301  atttgacctc acaaaaattc cttctcttgt tatcaactac ttcactcagt tcacttatta 
  361  cttgatccca tttcagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG TTGCCAAAGT 
                          e   g  q  c   r  y  n  r   q  l  g   v  a  k   
  421  GACGGACTAC TATACTGTGC ATTCTGGCAG TGAGGTAGAA TTGAAAAATC TAGTCGGTGC 
       v  t  d  y   y  t  v   h  s  g   s  e  v  e   l  k  n   l  v  g   
  481  CGAAGGACCT GCTGCGGTCG CTGTGGATGT GGAATCTGAC TTCATGATGT ACAGgtacgt 
       a  e  g  p   a  a  v   a  v  d   v  e  s  d   f  m  m   y 
  541  gcttttatgt cattcggacg agacagatga taaacgaagt agagagagag agagagagag 
  601  agagagagag agaatgaatg agggagagaa tgtgtgagac aattaggtta taaattttca 
  661  attatcagtt taccgttcga cgttcctcgt catcgatgca tgtgtgatgt actaacctac 
  721  tcgtatgtat gacatctggt ttgctagatt ccaaacagtt gctcgctaga ttattcaaac 
  781  caaacgatgc ttagattctc tccctatgga gtatgatatt catcaaattc ggtttcattt 
  841  agttttgatc aaacagtttg aacgtgcgtt tcacgggtaa caaatgggct cagtagatca 
  901  cattggtttt acaattcgca cagacaatct atcttcagtg ttacactagc acagttgcaa 
  961  ttgcaattat aactactgat catgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 
 1021  gtatattgtc aaataacaca tgtagtattt gggatttatg ctcgcccaca tcccggtcct 
 1081  gagtcagttt gggagaagta tgatttgaat tgcctatttc gaatacgtcc tatttcacgc 
 1141  agttcgcgga aagtagttca cagtggaaca ggctttttgt ttccaattcg catagcataa 
 1201  atgttcgctc tctttcgttc ctatctattt tcaatcattc taagcaccat tccatttccg 
 1261  aaccggtgtt gtcatattca tatgtatatt gttaatttct g 
6.23 
    1  AAGGTCAGTG TCGATACAAT AGGCAGTTGG GAGTTGCCAA AGTGACGGAC TACTATACTG 
           g  q   c  r  y  n   r  q  l   g  v  a   k  v  t  d   y  y  t 
   61  TGCATTCTGG CAGTGAGGTA GAATTGAAAA ATCTAGTCGG TGCCGAAGGA CCTGCTGCGG 
        v  h  s   g  s  e  v   e  l  k   n  l  v   g  a  e  g   p  a  a  
  121  TCGCTGTGGA TGTGGAATCT GACTTCATGA TGTACAGgta cgtgctttta tgtcattcgg 
        v  a  v   d  v  e  s   d  f  m   m  y   
  181  acgagacaga tgataaacga agtagagaga gagagagaga gagagaatga atgagggaga 
  241  gaatgtgtga gacaattagg ttataaattt tcaattatca gtttaccgtt cgacgttcct 
  301  cgtcatcgat gcatgtgtga tgtactaacc tactcgtatg tatgacatct ggtttgctag 
  361  attccataca gttgctcgct agattattca aaccaaatga tgcttagatt ctctccctat 
  421  ggagtatgat attcatcaaa ttcggtttca tttagttttg atcaaacagt ttgaacgtgt 
  481  gtttcacggg taacaaatgg gctcagtaga tcacattcgt tttgcaattc gcacagacaa 
  541  tctatcttca gtgttacagt agcacagttg taattgcaat tataactact gatcatgtgt 
  601  gtgtgtgtgt gtgtgtgtgt gtgtgtgtgg tatattgtca aataacacat gtagtatttg 
  661  ggatttatgc tcgcccgcat cccggtcccg agtcagtttg ggagaagtat gatttgattt 
  721  gcccatttcg tataggtcct atttcacgca attcgcggta agtagttcac agtggaacag 
  781  gctttttgtt tccaattcgc atagcataaa tgttcgctct ctttcgtttc tatctatttt 
  841  caatcattct aagcaccatt ccatttccga accggtgttg tcatattcat atgtatattg 
  901  ttaatttctg ttcaaacagT GGTGGTATTT ATCAGAGCCG AACTTGTTCA TCGCTTCGTG 
                           s   g  g  i   y  q  s   r  t  c  s   s  l  r 
  961  TGAATCATGC AGTCTTGGCT GTCGGTTATG GAACACAGGG TGGTACTGAC TATTGGATTG 
        v  n  h   a  v  l  a   v  g  y   g  t  q   g  g  t  d   y  w  i  
 1021  TGAAAAATAG TTGGGGATCG TCCTGGGGTG AGCGTGGTTA CATTCGAATG GTTAGGAACC 
        v  k  n   s  w  g  s   s  w  g   e  r  g   y  i  r  m   v  r  n  
 1081  GAGGTAACAT GTGTGGAATT GCTTCGCTGG CCAGTCTCCC GATGGTGGCA CAATTCCCGT 
        r  g  n   m  c  g  i   a  s  l   a  s  l   p  m  v  a   q  f  p  
 1141  GA 
        * 
6.25 
    1  TGTGGGTCCG GTTGGGCATT CTCAACAACC GGTACTATGG AAGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  GAAAGAACTA GTATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCTTGGGGA 
         e  r  t   s  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
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  121  AATTATGGTT GCATGGGCGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  y  g   c  m  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  TTGGAAACCG AATCCTCTTA TCCGTACACG GCTGTGgtga gtactgtttg tctgtgtgct 
         l  e  t   e  s  s   y  p  y  t   a  v   
  241  attcctccga gtcattttgc ttaaacctcc gcaaatttta cctcccacca catggcacct 
  301  atttgacctc acaaaaattc cttctcttgt tatcaactac ttcactcagt tcacttatta 
  361  cttgatccca tttcagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG TTGCCAAAGT 
                          e   g  q  c   r  y  n  r   q  l  g   v  a  k   
  421  GACGGACTAC TATACTGTGC ATTCTGGCAG TGAGGTAGAA TTGAAAAATC TAGTCGGTGC 
       v  t  d  y   y  t  v   h  s  g   s  e  v  e   l  k  n   l  v  g 
  481  CGAAGGACCT GCTGCGGTCG CTGTGGATGT GGAATCTGAC TTCATGATGT ACAGgtacgt 
       a  e  g  p   a  a  v   a  v  d   v  e  s  d   f  m  m   y   
  541  gcttttatgt cattcggacg agacagatga taaacgaagt agagagagag agagagagag 
  601  agagaatgaa tgagggagag aatgtgtgag acaattaggt tataaatttt caattatcag 
  661  tttaccgttc gacgttcctc gtcatcgatg catgtgtgat gtactaacct actcgtatgt 
  721  atgacatctg gtttgctaga ttccatacag ttgctcgcta gattattcaa accaaatgat 
  781  gcttagattc tctccctatg gagtgtgata ttcatcaaat tcggtttcat ttagttttga 
  841  tcaaacagtt tgaacgtgcg tttaacgggt aacaaatggg ctcagtagat cacattcgtt 
  901  ttacaattcg cacagacaat ctatcttcag tgttacagta gcacagttgt aatcgcagtt 
  961  ataactactg atcatgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtggtat attgtcaaat 
 1021  aacacatgta gtatttggga tttatgctcg cccgcatccc ggtcccgagt cagtttggga 
 1081  gaagtatgat ttgaattgcc catttcgtat aggtcctatt tcacgcagtt cgcggtaagt 
 1141  agttcacagt ggaacaggct ttttgtttcc aattcgcata gcataaatgt tcgctctctt 
 1201  tcgtttctat ctattttcaa tcattctaag caccattcca tttccgaacc ggtgttgtca 
 1261  tattcatatg tatattgtta ttttctgttc aaacagTGGT GGTATTTATC AGAGCCGAAC 
                                              s  g   g  i  y   q  s  r   
 1321  TTGTTCATCG CTTCGTGTGA ATCATGCAGT CTTGGCTGTC GGTTATGGAA CACAGGGTGG 
       t  c  s  s   l  r  v   n  h  a   v  l  a  v   g  y  g   t  q  g   
 1381  TACTGACTAT TGGATTGTGA AAAATAGTTG GGGATCGTCC TGGGGTGAGC GTGGTTACAT 
       g  t  d  y   w  i  v   k  n  s   w  g  s  s   w  g  e   r  g  y   
 1441  TCGAATGGTT AGGAACCGAG GTAACATGTG TGGAATTGCT TCGCTGGCCA GTCTCCCGAT 
       i  r  m  v   r  n  r   g  n  m   c  g  i  a   s  l  a   s  l  p   
 1501  GGTGGAACAA TTCCCGTGA 
       m  v  e  q   f  p  * 
6.26 
    1  TGCGGGTCTG GTTGGGCTTT CTCAACAACA GGTACTATGG AGGGACAGTA TATGAAAAAC 
         c  g  s   g  w  a   f  s  t  t   g  t  m   e  g  q   y  m  k  n 
   61  CAAAGAACCA GGATTTCATT CTCTGAGCAA CAACTGGTCG ATTGTAGCGG TCCCTGGGGA 
         q  r  t   r  i  s   f  s  e  q   q  l  v   d  c  s   g  p  w  g 
  121  AATATGGGTT GCAGTGGTGG ATTGATGGAA AATGCTTACG AATATTTGAA ACAATTTGGA 
         n  m  g   c  s  g   g  l  m  e   n  a  y   e  y  l   k  q  f  g 
  181  CTGGAAACCG AATCCTCTTA TCTGTACAGG GCTGTGgtga gtattgcatg tatgcgcgcc 
         l  e  t   e  s  s   y  l  y  r   a  v 
  241  cttgctccga tatattttgc ttacacctcc cgtcgtttta cctcttacca tgttgcacca 
  301  atatgatctc aaaaaaatcg tttctattat tatcaactac ttcactcgat tcacttacta 
  361  cttgatccca tttcaTACAA TAGGCAGTTG GGAGTTGCCA AAGTTACTGG CTACTATATT 
                         y   n  r  q  l   g  v  a   k  v  t   g  y  y  i 
  421  GTGCATTCTG GCAGTGAGGT AGGATTGAAA AATCTAGTCG GTGCCGAAGG ACCTGCTGCG 
         v  h  s   g  s  e   v  g  l  k   n  l  v   g  a  e   g  p  a  a 
  481  GTCGCTGTGG ATGTGGAATC TGACTTCATG ATGTACAGgt acgtgcttta atgtcattcg 
         v  a  v   d  v  e   s  d  f  m   m  y   
  541  gacgagacga atgataaact tagtcgagag agagaaggag agagagagaa agagaaaaga 
  601  atgagagatg gagaggatat gtgagacaga taggttacag atttttaatt atcagttaaa 
  661  cgtttgattt tcctcgtcat cgatagatgt gtgatgtact ggcccactcc tatgtatgat 
  721  tgctggattt ttggattcca cacaattgct cactgtactg ttcaggccaa atgacacttg 
  781  tgctctctcc ctatggagta caatattcat caaatttggt ttcattcagt tttgaccaaa 
  841  cagtttgaac gtgcgtttca cgggtatcaa atgggctcaa tagacattcg ttttttaatt 
  901  ggcacaggca atctatcttc agtgttacac tagcacagtt gtaattgtaa atgtgtgtgg 
  961  tatattgtca aataacacac gtagtacttg ggatttatgc tcgcccgcat cccgttcaca 
 1021  agttggtttg ggagatacat gatttgaatt gcccatttcg aatacgtcca atagcacgca 
 1081  catctcggta agtagttctc agttgaacag gctttttgtt ttcgattcac atagtgtaag 
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 1141  tgctcgctct ctttcattcc tatgtacttt caaccattct aagcaccatt ccatttccaa 
 1201  acttgcgttg tcatattcat atttatattg ttgctttttg ttcaaacagG AGTGGTATTT 
                                                            r   s  g  i 
 1261  ATCAGAGCCA AACTTGTTCA CCACTTGGTT TGAATCATGC AGTCTTGGCT GTCGGTTATG 
        y  q  s   q  t  c  s   p  l  g   l  n  h   a  v  l  a   v  g  y 
 1321  GAACACAGGG TGGTACTGAC TATTGGATTG TGAAAAATAG TTGGGGATTG TCGTGGGGTG 
        g  t  q   g  g  t  d   y  w  i   v  k  n   s  w  g  l   s  w  g  
 1381  AGCGCGGTTA CATTCGAATG GTTAGGAACC GAGGTAACAT GTGTGGAATT GCTTCAATGG 
        e  r  g   y  i  r  m   v  r  n   r  g  n   m  c  g  i   a  s  m 
 1441  CCAGTCTCCC GATGGTGGCA CGATTCCCGT GA 
        a  s  l   p  m  v  a   r  f  p   * 
7.7 
    1  AATGCGAAAC ATATCCAAGA ACATAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
         n  a  k   h  i  q   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
         l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
  121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CGCGGTATCC CGTATGAGGC GAACAATCGT 
         e  m  p   r  a  s   d  i  l  s   r  g  i   p  y  e   a  n  n  r 
  181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTATG TGACGGAGGT GAAAGATCAG 
         a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  e   v  k  d  q 
  241  gtgagtatag attgtgaaca cccaataatc tgatgatgat ttgatttgaa aagGGAAATT 
                                                                   g  n  
  301  GTGGTTCATG TTGGGCATTC TCAACAACCG GTACTATGGA AGGACAGTAT ATGAAAAACG 
        c  g  s   c  w  a  f   s  t  t   g  t  m   e  g  q  y   m  k  n 
  361  AAAGAACTAG TATTTCATTC TCTGAGCAAC AACTGGTCGA TTGTAGCGGT CCTTGGGGAA 
        e  r  t   s  i  s  f   s  e  q   q  l  v   d  c  s  g   p  w  g 
  421  ATATGGGTTG CAGTGGTGGA TTGATGGAAA ATGCTTACGA ATATTTGAAA CAATTTGGAT 
        n  m  g   c  s  g  g   l  m  e   n  a  y   e  y  l  k   q  f  g 
  481  TGGAAACCGA ATCCTCTTAT CCGTACACGG CTGTGgtgag tactgtttgt ctgtgtgcta 
        l  e  t   e  s  s  y   p  y  t   a  v   
  541  ttcctccgag ttattttgct taaacctcca cctattttac atcccaccac atgacaccta 
  601  ttaaatctca caaaaattcc ttctcttgtt atcaactact tcactcagtt cacttattac 
  661  ttgatcccat ttcagGAAGG TCAGTGTCGA TACAATAGGC AGTTGGGAGT TGCCAAAGTG 
                         e   g  q  c  r   y  n  r   q  l  g   v  a  k  v 
  721  ACGGACTACT ATACTGTGCA TTCTGGCAGT GAGGTAGAAT TGAAAAATCT AGTCGGTGCC 
         t  d  y   y  t  v   h  s  g  s   e  v  e   l  k  n   l  v  g  a 
  781  GAAGGACCTG CTGCGGTCGC TGTGGATGTG GAATCTGACT TCATGATGTA CAGgtacgtg 
         e  g  p   a  a  v   a  v  d  v   e  s  d   f  m  m   y   
  841  cttttatgtc attcggacga gacagatgat aaacgaagta gagagagaga gagagagaga 
  901  gagagaatga atgagggaga gaatgtgtga gacaattagg ttataaattt tcaattatca 
  961  gtttaccgtt cgacgttcct cgtcatcgat gcatgtgtga tgtactaacc tactcgtatg 
 1021  tatgacatct ggtttgctag attccataca gttgctcgct agattattca aaccaaatga 
 1081  tgcttagatt ctctccctat ggagtatgat attcatcaaa ttcggtttca tttagttttg 
 1141  atcaaacagt ttgaacgtgc gtttcacggg taacaaatgg gctcagtaga tcacattcgt 
 1201  tttacaattc gcacagacaa tctatcttca gtgttacagt agcacagttg taattgcaat 
 1261  tataactact gatcatgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtggtata 
 1321  ttgtcaaata acacatgtag tatttgggat ttatgctcgc ccgcatcctg gtcccgagtc 
 1381  agtttgggag aagtatgatt tgaatcgcct atttcgaata cgtcctattt cacgcagttc 
 1441  gcggtaagta gttcacagtg gaacaggctt tttgtttcca attcgcatag cataaatgtt 
 1501  cgctctcttt cgtttctatc tattttcaat cattctaagc accattccat ttccgaaccg 
 1561  gtgttgtcat attcatatgt atattgttat tttctgttca aacagTGGTG GTATTTATCA 
                                                        s  g   g  i  y   
 1621  GAGCCGAACT TGTTCATCGC TTCGTGTGAA TCATGCAGTC TTGGCTGTCG GTTATGGAAC 
       q  s  r  t   c  s  s   l  r  v   n  h  a  v   l  a  v   g  y  g   
 1681  ACAGGGTGGT ACTGACTATT GGATTGTGAA AAATAGTTGG GGATCGTCCT GGGGTGAGCG 
       t  q  g  g   t  d  y   w  i  v   k  n  s  w   g  s  s   w  g  e   
 1741  TGGTTACATT CGAATGGTTA GGAACCGAGG TAACATGTGT GGAATTGCTT CGCTGGCCAG 
       r  g  y  i   r  m  v   r  n  r   g  n  m  c   g  i  a   s  l  a   
 1801  TCTCCCGATG GTGGCACAAT TCCCGTGA 
       s  l   p   m  v  a  q  f  p  * 
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    1  AATGCGAAAC ATATCGAAGA ACACAACCTA CGTCACGATC TCGGCCTCGT CACCTACACA 
         n  a  k   h  i  e   e  h  n  l   r  h  d   l  g  l   v  t  y  t 
   61  TTGGGATTGA ACCAATTCAC TGATATGACA TTCGAGGAAT TCAAGGCCAA ATATCTAACA 
         l  g  l   n  q  f   t  d  m  t   f  e  e   f  k  a   k  y  l  t 
  121  GAAATGCCAC GCGCGTCCGA TATACTCTCA CACGGTATCC CGTATGAGGC GAACAACCGT 
         e  m  p   r  a  s   d  i  l  s   h  g  i   p  y  e   a  n  n  r 
  181  GCCGTACCCG ACAAAATTGA CTGGCGTGAA TCTGGTTACG TGACGGGGGT GAAAGACCAA 
         a  v  p   d  k  i   d  w  r  e   s  g  y   v  t  g   v  k  d  q 
  241  gtgagtatag attgtgaaca cccaataatc cgatgatgat ctgatttgat ttgatttgaa 
  301  aagGGAAACT GTGGTTCTTG TTGGGCTTTC TCAACAACCG GTACTATGGA AGGACAGTAT 
            g  n   c  g  s   c  w  a  f   s  t  t   g  t  m   e  g  q  y 
  361  ATGAAAAACC AAAGAACCAG TATTTCATTC TCTGAGCAAC AACTGGTCGA TTGTAGCGGT 
         m  k  n   q  r  t   s  i  s  f   s  e  q   q  l  v   d  c  s  g 
  421  CCCTGGGGAA ATATGGGTTG CAGTGGTGGA TTGATGGAAA ATGCTTACGA ATATTTGAAA 
         p  w  g   n  m  g   c  s  g  g   l  m  e   n  a  y   e  y  l  k 
  481  CAATTTGGAT TGGAAACCGA ATCCTCTTAT CCGTACAGGG CTGTGgtgag tattgcatgt 
         q  f  g   l  e  t   e  s  s  y   p  y  r   a  v 
  541  attcgcgccc ttcctccgat ttattttgct tacacctccc gtcgttttac ctcttaccat 
  601  gttgcaccaa tatgatctca caaaaaattg cctctgttat tatcaactac tttacccaat 
  661  tcacttatta tttgatccca ttttagGAAG GTCAGTGTCG ATACAATAGG CAGTTGGGAG 
                                     e   g  q  c   r  y  n  r   q  l  g 
  721  TTGCCAAAGT GACTGGCTAC TATACTGTGC ATTCTGGCAG TGAGGTAGGA TTGAAAAATC 
        v  a  k   v  t  g  y   y  t  v   h  s  g   s  e  v  g   l  k  n  
  781  TAGTCGGTTC CGAAGGACCT GCTGCAGTCG CTGTGGATGT GGAATCTGAC TTCATGATGT 
        l  v  g   s  e  g  p   a  a  v   a  v  d   v  e  s  d   f  m  m  
  841  ACAGgtacgc gcttttatgt cattcggaca agacaaatga taaactaagt cgagagggag 
        y    
  901  ggagggagag agagagaagg agaagagaat gaggggaggg agagaatatg tgagacagat 
  961  aggttataga tcttcaatta tcagtttgat gttcgacttt cctcgtcatc gatacatgtg 
 1021  tgatgtatta gcttactcgt atgcatgctt gctggatttc tggattccac acagttgctc 
 1081  actttactgt tcaggccgaa tgacacttgt gttctctccc tatggagtaa tatattcatc 
 1141  aaatttggtt tcattcagtt ttgatcaaac agtttgaact tgcgtttcac gggaatcaaa 
 1201  tgggcctaat agaaaacatt tgttttttaa ttggcacagg caatctatct tcaatgtgac 
 1261  actggcacag ttgtaattgt aattgtaacc gctgatcacg tgtgtgtggt atattgtcaa 
 1321  ataacacatg tagtactttg gatttatgct cgcccgcatc ccggtcacaa ttcgttttgg 
 1381  gagatatatg actttaattg cccattttga ataagtccac ttgcacgcac atcgcggtaa 
 1441  gtacttctca attgaacagg ctttttgttt tcgctcgctc tcttttattc cccggtactt 
 1501  tcagtcattc gaagcaccat tccatttcca aacttgcgtt gtcatattca tatttatatt 
 1561  gttgttttta tccaaacagG AGTGGTATTT ATCAGAGCCA AACTTGTTCA CCGTTTGGTT 
                           r   s  g  i   y  q  s   q  t  c  s   p  f  g 
 1621  TGAATCATGC AGTCTTGGCT GTCGGTTATG GAACACAGGG TGGTACTGAC TATTGGATTG 
        l  n  h   a  v  l  a   v  g  y   g  t  q   g  g  t  d   y  w  i 
 1681  TGAAAAATAG TTGGGGATTG TCCTGGGGTG AGCGCGGTTA CATTCGAATG GTTAGGAACC 
        v  k  n   s  w  g   l  s  w  g   e  r  g   y  i  r   m  v  r  n 
 1741  GAGGTAACAT GTGTGGAATT GCTTCAATGG CCAGTCTTCC GATGGTGGAA CAATTCCCGT 
        r  g  n   m  c  g   i  a  s  m   a  s  l   p  m  v   e  q  f  p 
 1801  GA 
        * 
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Appendix 4   Combined genomic DNA-derived clones 
Clones 4.10 and 4.20 which encoded identical deduced amino acid sequences were combined 
and labelled clone 4.10+.  Two synonymous SNPs were identified in the coding region, both 
in the primer binding sites.  The intron regions contained 12 nucleotide differences in intron 
2, and 18 in intron 3 (Figure 5.6).  Clone 6.14 also encoded the same amino acid sequence and 
contained only one synonymous mutation at a primer binding site and was incorporated into 
clone 4.10+. 
Clones 7.7 and 6.22 possess 3 nucleotide differences in the coding region, all in primer 
binding sites.  Clone 6.14 has two synonymous substitutions when compared to those 
sequences, one of which is in a primer bind site.  There are about 50 nucleotide differences in 
the intron regions of the three clones (Figure 5.6).  Despite this the deduced amino acid 
sequences of the sequences are identical outside the primer binding sites, so the clones were 
combined and subsequently referred to as 7.7+. 
Clone 6.23 possesses an identical nucleotide sequence to clones 7.7+ and 6.1.  Clone 6.23 
consists of only 126 deduced amino acids, spanning the range of 202-326 and so it is not 
possibly to determine if it encodes the same gene as any of these clones.  There are several 
nucleotide differences between the clones in their intron regions, with 6.23 possessing 20 
nucleotide differences to both clones.  As such the clones are referred to as 7.7+ and 6.1+. 
Clone 6.22 also only contains nucleotide substitutions with clone 1.1 in primer binding sites 
and in intron regions, the combined clone is referred to as 1.1+. 
Clones 2 and 6.16 encoded identical amino acid sequences with no mutations observed in 
their nucleotide sequences, and only 3 mutations were observed in the intron regions.  The 
sequences were combined and referred to as 2+. 
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Figure A4.1:  Combined clone 4.10+ 
Exon regions showing homology are shaded light grey, primer binding regions are shaded 
dark grey, differences in nucleotide sequences are inverted on a black background.  The 
deduced amino acid sequence is displayed below the nucleotide alignment.  
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Figure A4.2:  Combined clone 7.7+  
Exon regions showing homology are shaded light grey, primer binding regions are shaded 
dark grey, differences in nucleotide sequences are inverted on a black background.  The 
deduced amino acid sequence is displayed below the nucleotide alignment.  
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Figure A4.3:  Combined clone 6.1+ 
Exon regions are shaded light grey, primer binding regions are shaded dark grey, differences 
in nucleotide sequences are inverted on a black background.  The deduced amino acid 
sequence is displayed below the nucleotide alignment.  
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Figure A4.4:  Combined clone 2+ 
Exon regions are shaded light grey, primer binding regions are shaded dark grey, differences 
in nucleotide sequences are inverted on a black background.  The deduced amino acid 
sequence is displayed below the nucleotide alignment.  
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Figure A4.5:  Combined clone 1.1+ 
Exon regions are shaded light grey, primer binding regions are shaded dark grey, differences 
in nucleotide sequences are inverted on a black background.  The deduced amino acid 
sequence is displayed below the nucleotide alignment.  
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Appendix 5   Combined mRNA-derived clones 
Several mRNA-derived clones when transcribed would result in the production of identical 
amino acid sequences.  These sequences were combined and the resulting sequence 
designated with a plus ‘+’ sign.  Alignments found in this appendices show the clone 
sequences combined to form these designated sequences. 
 
 
 
 
 
 
 
 
Figure A5.1:  Combined clone 293A+ 
Incorporates clones 293A, 308A, 127B and H14.6B.  Divergent nucleotides are highlighted in 
light grey. The deduced amino acid sequence of 293A+ is aligned under the nucleotide 
sequence.  Primer binding regions are underlined and the stop codons are boxed in red. The 
start of the mature region is indicated with an arrow (►).   
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Figure A5.2:  Combined clone 24.5A+ 
Incorporates clones 24.5A, 61, 127A, 289A, 289B and H14.6A.  Divergent nucleotides are 
highlighted in light grey. The deduced amino acid sequence of 24.5A+ is aligned under the 
nucleotide sequence.  Primer binding regions are underlined. The start of the mature region is 
indicated with an arrow (►).   
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Figure A5.3:  Combined clone 24.8B+ 
Incorporates clones 24.8B, 46, 127B, 234, 291A, H14.6B and 23.16A.  Divergent nucleotides 
are highlighted in light grey. The deduced amino acid sequence of 24.8B+ is aligned under 
the nucleotide sequence.  Primer binding regions are underlined. The start of the mature 
region is indicated with an arrow (►).   
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Figure A5.4:  Combined clone 315+ 
Incorporates clones 315A and 23.12A.  Divergent nucleotides are highlighted in light grey. 
The deduced amino acid sequence of 315+ is aligned under the nucleotide sequence.  Primer 
binding regions are underlined. The start of the mature region is indicated with an arrow (►).  
Proposed start of the mature coding region indicated with arrow (►). 
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Figure A5.5:  Combined clone 320B+ 
Incorporates clones 320B, 327A and 318A.  Divergent nucleotides are highlighted in light 
grey. The deduced amino acid sequence of 320B+ is aligned under the nucleotide sequence.  
Primer binding regions are underlined. The start of the mature region is indicated with an 
arrow (►).   
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Figure A5.6:  Combined clone 321+ 
Incorporates clones 321A nand H14.1A.  Divergent nucleotides are highlighted in light grey. 
The deduced amino acid sequence of 321+ is aligned under the nucleotide sequence.  Primer 
binding regions are underlined. The start of the mature region is indicated with an arrow (►).  
Proposed start of the mature coding region indicated with arrow (►). 
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Appendix 6   Amino acid (AA) identity 
Table A6.1:  Amino acid identity among Fasciola cathepsin L-like proteases (Part 1 of 4). 
Values (expressed as %) are based on identical amino acid residues across the complete 
protein (includes signal peptide and proregion).   
 FgCatL1A FgCatL1B FgCatL1C FgCatL1D FgCatL1E* FgCatL1F* FgCatL1G FgCatL1H FgCatL1I FgCatL2 FgCatLB22 FgCatLB7 
FgCatL1B 98.2            
FgCatL1C 85.6 85.0           
FgCatL1D 78.5 79.1 79.8          
FgCatL1E* 98.2 99.1 83.6 76.7         
FgCatL1F* 79.9 80.4 84.9 75.3 79.9        
FgCatL1G 70.6 69.9 72.1 73.0 67.1 64.8       
FgCatL1H 78.5 77.9 77.0 72.1 73.1 71.2 66.6      
FgCatL1I 98.2 97.5 85.3 77.9 98.6 80.8 70.2 77.6     
FgCatL2 99.1 98.5 85.9 78.5 98.6 79.9 70.2 78.5 98.5    
FgCatLB22 94.5 93.9 83.7 77.0 94.1 79.9 69.3 75.8 93.9 94.2   
FgCatLB7 81.3 81.3 79.1 77.9 80.8 75.8 69.3 72.4 80.7 81.3 79.1  
FhCatL1 94.5 94.5 86.5 78.5 94.1 81.7 70.9 76.4 93.6 94.5 92.3 81.3 
FhCatL2 77.3 78.2 80.1 92.3 75.3 76.7 73.0 71.2 76.7 77.3 76.7 77.9 
FhCatL3 94.5 93.6 86.2 77.3 93.2 81.3 71.2 77.0 93.3 94.2 92.6 80.4 
FhCatL4 85.3 85.0 89.9 78.8 85.4 83.6 69.6 74.8 85.0 85.3 84.0 79.1 
FhCatL5 85.9 85.6 91.7 80.1 85.8 84.9 70.9 75.5 85.6 85.9 84.7 80.4 
FhCatL6 98.2 98.2 85.0 77.9 99.1 79.9 69.6 77.6 97.5 98.5 95.1 80.7 
FhCatL7 76.7 77.3 80.1 92.3 74.4 76.3 72.7 70.9 76.4 76.7 76.1 77.9 
FhCatL8* 70.4 70.7 72.3 73.3 69.4 66.7 88.4 65.9 70.4 70.7 68.8 69.1 
FhCatL9* 92.6 92.3 87.1 78.5 89.0 81.3 70.7 78.1 92.0 92.6 92.9 80.4 
FhCatL10* 69.3 69.6 70.6 71.6 66.2 63.9 86.9 65.4 69.3 69.3 68.0 69.0 
FhCatL11* 93.5 93.2 86.8 78.7 90.9 80.4 71.0 77.7 92.9 93.5 93.9 81.3 
FhCatL12* 83.1 83.1 90.4 76.5 83.1 82.5 65.7 70.5 83.1 82.5 84.3 74.1 
FhCatL13* 84.9 84.3 81.9 73.5 84.3 75.3 63.9 67.5 84.9 84.9 86.7 75.3 
FhCatL14* 87.1 86.2 83.6 78.4 87.1 83.6 69.0 72.4 86.2 87.1 88.8 80.2 
FhCatL15* 72.3 72.3 76.5 89.8 72.3 74.1 66.9 64.5 72.3 71.7 73.5 70.5 
FhCatL16* 73.5 72.3 77.1 70.5 72.3 74.1 62.7 69.3 72.9 72.9 72.9 68.7 
FhCatL17* 50.0 50.0 49.4 45.8 50.0 47.6 44.0 44.6 50.0 50.0 47.6 48.8 
FhCatL20* 94.2 93.9 87.8 78.8 93.2 80.8 72.3 77.5 93.6 93.9 92.3 82.0 
FhCatL21 92.0 92.0 82.8 75.2 91.3 78.5 68.1 74.8 90.8 91.7 90.2 77.9 
FhCatL22* 92.5 92.1 84.1 74.9 91.8 81.3 66.1 72.8 92.1 92.5 94.6 77.8 
FhCatL23 95.4 94.5 86.2 77.3 94.1 81.7 70.9 77.0 94.2 95.4 92.9 80.4 
FhCatL26 93.9 93.3 85.9 77.6 92.7 80.8 69.9 75.8 92.9 94.2 92.3 80.7 
FhCatL29 74.8 75.5 78.2 90.5 71.7 73.5 71.8 69.9 74.2 74.8 74.2 76.1 
FhCatL30* 83.0 83.0 84.4 77.1 83.0 81.7 65.6 68.8 83.5 83.0 82.1 78.0 
FhCatL31* 77.2 77.6 78.5 87.7 77.6 76.7 67.6 69.4 77.6 77.6 79.9 72.6 
FhCatL32* 70.4 70.8 71.7 73.0 65.5 61.3 90.3 67.3 69.9 70.8 69.0 71.7 
FhCatL33* 79.2 79.6 79.6 73.9 72.5 72.5 68.6 90.7 78.8 79.6 76.5 74.3 
FhCatL34 77.9 78.8 81.3 93.9 75.8 77.6 73.9 72.1 77.3 77.9 77.3 78.8 
FhCatL35 70.9 70.6 71.2 72.1 69.4 66.7 92.9 66.3 70.6 70.6 70.2 68.7 
FhCatL36* 71.1 71.4 72.3 73.3 68.5 66.2 90.0 66.9 71.1 71.1 70.1 70.7 
FhCatL37* 70.6 70.9 72.5 72.2 67.1 64.4 88.9 66.0 70.6 70.9 69.6 69.3 
FhCatL38* 70.6 70.9 72.9 73.5 67.1 66.2 92.5 65.7 70.6 70.6 69.6 70.6 
FhCatL39* 75.6 75.9 76.2 70.3 71.2 70.8 64.4 89.4 75.2 75.9 73.6 71.3 
FhCatL40* 77.2 77.6 76.9 71.6 72.1 70.8 65.7 91.4 76.9 77.6 75.2 72.6 
FhCatL41* 74.5 74.8 73.2 71.2 72.1 68.9 74.5 69.3 73.9 74.5 73.9 70.3 
24.5A+* 76.5 76.1 76.9 71.7 75.3 73.5 62.9 72.5 76.5 76.5 74.9 71.7 
24.5B* 98.8 98.8 84.5 75.7 98.6 79.9 66.1 74.9 99.2 99.2 94.4 80.1 
24.8A* 93.9 93.1 86.5 73.9 92.2 83.1 66.1 74.7 93.5 93.9 93.5 79.2 
24.8B+* 75.2 75.2 76.9 100.0 76.7 75.3 68.2 67.4 75.6 75.2 74.8 74.4 
293A+* 77.4 76.9 77.9 99.5 76.9 75.9 68.7 66.2 77.4 76.9 76.9 72.8 
293B* 74.9 73.8 75.9 72.3 73.8 73.3 62.1 70.8 74.4 74.4 73.3 68.2 
303A* 99.0 98.5 84.1 77.9 98.5 79.5 66.7 71.8 99.0 99.0 93.8 80.5 
303B* 74.3 73.3 77.1 69.5 72.4 73.3 59.0 68.6 73.3 73.3 74.3 64.8 
306* 98.5 97.9 83.6 77.9 97.9 79.0 66.7 71.3 98.5 98.5 93.3 80.5 
315+* 79.5 80.0 85.6 75.8 79.5 100.0 65.1 71.6 80.5 79.5 79.5 76.3 
319* 98.8 98.8 84.0 75.4 98.6 79.9 65.2 74.2 99.2 99.2 94.3 79.5 
320A* 94.3 93.6 87.5 76.4 92.2 82.6 69.3 77.1 93.2 94.3 92.5 80.4 
320B+* 99.3 99.3 86.4 78.2 99.1 80.4 69.6 77.5 98.9 99.6 94.6 81.8 
321+* 99.6 98.9 86.4 78.2 98.6 80.4 70.0 77.9 98.6 99.3 95.0 81.8 
325A* 93.2 92.5 87.1 76.8 90.9 81.3 70.0 77.9 92.5 93.2 92.9 80.7 
325B* 98.6 98.6 85.7 77.9 99.1 80.4 69.3 76.8 98.2 98.9 93.9 81.4 
G13.8* 99.0 99.5 83.6 77.4 99.5 80.0 66.2 72.3 99.0 99.0 94.9 80.0 
1.1+* 98.6 97.9 86.1 77.5 97.7 80.4 69.3 77.5 97.5 98.2 94.6 81.4 
2+* 70.0 70.0 71.1 72.1 68.9 66.2 95.7 65.7 69.6 69.6 68.6 67.9 
2.1* 93.2 92.5 86.4 75.4 91.3 81.7 68.9 77.1 92.1 93.2 91.4 79.6 
2.2* 97.0 97.0 84.3 75.7 97.6 78.7 68.7 76.5 95.9 96.6 92.9 79.9 
4.10+* 99.5 99.0 83.8 77.8 99.0 80.3 66.7 72.7 99.5 99.5 94.4 79.8 
4.21* 89.8 88.2 82.8 73.1 88.2 79.0 67.2 71.0 88.7 89.2 90.3 75.3 
4.30* 93.0 91.4 86.0 75.3 91.4 81.2 67.2 73.1 91.9 92.5 91.4 77.4 
6.1+* 98.5 98.0 82.8 76.8 98.0 79.8 66.7 72.7 98.5 98.5 93.4 79.3 
6.6* 93.4 91.9 86.4 76.3 91.9 82.8 67.2 73.7 92.4 92.9 91.9 78.8 
6.25* 98.0 98.5 82.8 76.8 98.5 79.3 66.7 73.2 98.0 98.0 93.9 78.8 
6.26* 89.4 87.9 83.3 72.7 88.4 80.8 65.2 70.7 88.4 88.9 88.9 77.8 
7.7+* 98.6 97.9 85.4 77.9 98.2 79.9 69.3 77.1 97.5 98.2 93.9 80.7 
13* 92.9 92.1 86.8 75.4 90.9 82.2 69.3 77.1 91.8 92.9 91.8 79.3 
F2* 69.6 69.6 71.1 72.1 67.1 65.3 98.2 65.0 69.3 69.3 68.6 68.6 
* Only partial sequence information available for calculation. 
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Table A6.1:  Amino acid identity among Fasciola cathepsin L-like proteases (Part 2of 4). 
 FhCL1 FhCL2 FhCL3 FhCL4 FhCL5 FhCL6 FhCL7 FhCL8* FhCL9* FhCL10* FhCL11* FhCL12* FhCL13* FhCL14* FhCL15* FhCL16* FhCL17* FhCL20* FhCL21 FhCL22* FhCL23 FhCL26 FhCL29 FhCL30* FhCL31* FhCL32* FhCL33* FhCL34 FhCL35 FhCL36* FhCL37* FhCL38*FhCL39* FhCL40* FhCL41* 
FhCL2 78.5                                   
FhCL3 97.2 77.9                                  
FhCL4 85.3 80.4 86.8                                 
FhCL5 86.5 81.9 86.2 97.5                                
FhCL6 93.9 77.0 93.6 85.0 85.6                               
FhCL7 77.9 96.9 77.6 80.7 81.9 76.4                              
FhCL8* 73.0 73.6 72.0 70.1 71.4 69.8 73.6                             
FhCL9* 92.6 79.1 92.6 88.1 87.8 91.6 78.5 70.7                            
FhCL10* 70.9 71.6 70.3 69.6 70.6 68.6 71.6 92.8 69.3                           
FhCL11* 94.2 78.7 95.5 88.1 87.1 92.6 78.4 70.3 96.5 69.3                          
FhCL12* 85.5 78.9 86.1 93.4 95.8 83.7 78.3 67.5 84.9 64.5 84.9                         
FhCL13* 89.8 74.7 88.0 82.5 84.9 84.9 72.9 66.9 89.8 62.7 91.6 83.7                        
FhCL14* 91.4 80.2 89.7 81.0 82.8 86.2 77.6 72.4 89.7 68.1 89.7 81.5 85.2                       
FhCL15* 74.7 96.4 73.5 77.1 78.9 72.9 99.4 69.3 74.7 64.5 74.1 78.3 72.9 74.1                      
FhCL16* 71.7 69.9 72.3 74.1 76.5 72.9 68.7 62.7 72.9 60.2 72.9 77.1 71.1 70.4 69.3                     
FhCL17* 48.2 47.6 48.2 48.8 49.4 50.0 46.4 46.4 47.6 44.6 47.6 50.0 47.6 44.4 46.4 47.0                    
FhCL20* 97.1 78.8 98.1 87.5 88.1 93.2 78.1 72.7 92.9 70.6 94.5 86.1 89.8 88.8 74.7 74.1 48.2                   
FhCL21 95.1 75.2 94.8 82.5 83.1 91.1 74.8 69.8 91.3 68.0 92.6 84.9 88.6 87.1 73.5 72.9 48.2 95.2                  
FhCL22* 94.6 74.5 94.6 84.5 84.5 92.1 74.1 67.4 96.2 64.4 97.9 83.7 92.2 92.2 74.1 73.5 47.6 94.1 92.9                 
FhCL23 96.9 77.3 96.6 85.9 86.2 94.5 76.7 72.0 94.5 69.6 95.5 84.9 90.4 93.1 73.5 73.5 48.2 96.1 95.1 95.8                
FhCL26 95.7 77.9 95.4 85.3 85.3 93.6 77.6 71.1 92.6 69.3 93.5 85.5 86.7 91.4 74.1 72.3 47.0 94.2 92.0 93.7 95.1               
FhCL29 76.1 95.7 75.5 78.8 80.4 74.5 95.7 72.3 76.8 70.3 76.5 78.3 73.5 75.0 96.4 69.3 46.4 76.5 77.3 71.5 74.8 75.5              
FhCL30* 85.8 78.9 84.4 86.7 87.6 83.0 78.9 67.9 83.5 65.1 83.9 85.5 83.0 80.0 78.8 72.7 48.5 85.3 82.6 83.9 84.9 83.9 76.1             
FhCL31* 80.4 90.0 78.5 77.2 79.0 77.6 90.0 70.8 81.7 67.1 82.2 80.1 79.5 88.8 92.2 71.7 46.4 79.0 77.2 82.2 79.9 79.5 87.2 79.4            
FhCL32* 72.1 72.1 70.4 70.8 72.6 69.9 72.1 94.2 70.4 95.1 69.9 65.3 62.9 69.2 66.1 59.7 44.4 71.2 69.9 63.0 70.8 70.4 72.6 64.1 67.6           
FhCL33* 77.4 74.8 77.4 77.9 78.8 78.8 73.9 68.6 80.1 68.1 77.9 71.8 65.3 69.2 68.5 71.0 45.2 78.3 77.4 72.8 78.3 77.4 74.3 71.1 69.0 69.9          
FhCL34 79.1 98.5 78.5 81.6 83.1 77.6 98.5 74.9 79.7 72.9 79.4 79.5 74.7 80.2 97.6 70.5 47.6 79.4 75.8 75.3 77.9 78.5 96.6 79.4 91.3 73.9 75.7         
FhCL35 70.9 72.7 70.9 69.9 71.2 70.2 73.0 92.6 71.1 91.2 71.3 67.5 65.7 71.6 69.3 63.9 45.8 72.3 68.4 67.8 70.9 69.6 71.5 67.0 69.4 93.8 69.0 74.2        
FhCL36* 72.7 73.6 71.7 71.1 72.3 70.7 73.6 95.8 70.7 96.4 70.3 66.9 65.1 72.4 68.1 62.7 45.8 72.3 69.8 66.1 71.4 71.1 72.3 67.0 69.4 98.7 69.5 74.9 94.9       
FhCL37* 72.5 73.2 71.6 70.3 71.6 70.3 73.2 95.1 70.9 93.1 70.6 65.7 65.1 71.6 66.9 61.4 47.0 72.2 69.3 65.7 71.6 71.6 71.9 66.1 68.5 96.5 69.0 74.5 92.8 96.1      
FhCL38* 71.6 74.2 70.6 70.6 71.9 70.3 74.2 90.8 70.3 89.2 70.3 66.3 63.9 69.8 68.1 62.0 46.4 71.2 68.6 65.3 70.6 69.9 72.9 67.0 68.9 93.4 69.5 75.5 92.5 92.8 92.2     
FhCL39* 73.3 70.3 73.9 75.2 75.2 75.2 69.6 64.4 75.2 63.7 74.6 72.3 66.3 69.0 65.1 70.5 47.6 74.9 72.9 70.7 74.3 73.6 69.3 68.8 68.9 65.5 92.9 71.0 64.4 65.0 64.7 64.4    
FhCL40* 74.9 71.6 75.6 75.6 75.9 76.9 71.0 65.3 76.9 65.0 76.2 71.7 66.9 69.8 65.7 71.1 47.0 76.6 74.6 71.5 75.6 74.9 70.6 68.8 69.4 66.8 95.1 72.3 65.7 66.3 65.7 65.3 96.7   
FhCL41* 74.8 71.6 74.5 72.2 73.5 74.2 70.9 75.5 73.2 75.8 73.2 68.7 67.5 73.3 65.1 66.9 47.0 74.2 73.2 69.5 74.2 73.9 69.9 66.1 69.9 78.8 69.9 72.2 77.5 77.2 74.9 74.3 67.7 69.0  
24.5A+* 74.5 69.3 75.3 74.9 76.5 76.1 69.3 63.7 75.3 62.2 75.3 74.1 69.9 69.8 67.5 92.8 44.6 76.1 74.1 74.1 74.9 74.5 68.1 71.1 70.3 62.1 74.1 70.5 63.7 63.7 62.9 62.5 71.3 71.7 67.7 
24.5B* 94.0 74.1 93.2 85.3 85.7 98.8 73.7 67.3 90.4 65.3 92.0 82.5 84.3 87.1 71.7 72.3 50.0 93.2 91.2 92.1 93.6 93.6 71.3 83.0 77.2 64.4 75.3 74.9 68.1 67.3 66.1 66.1 72.9 73.7 70.9 
24.8A* 93.5 73.9 92.7 86.1 87.3 93.1 73.5 67.3 93.9 64.5 93.9 86.7 88.6 93.1 73.5 76.5 48.8 92.2 91.0 95.0 93.9 94.3 71.0 83.9 79.5 63.7 75.0 74.7 67.8 66.5 65.7 65.3 72.2 72.7 70.6 
24.8B+* 74.8 91.3 73.6 77.3 78.5 75.2 91.7 69.8 74.8 67.4 75.2 76.5 73.5 78.4 89.8 70.5 45.8 75.2 71.5 74.9 73.6 74.0 89.3 77.1 87.7 67.3 69.7 93.0 69.0 69.4 67.8 69.0 67.8 68.2 66.1 
293A+* 77.4 90.8 75.9 77.4 79.0 76.9 90.3 71.3 76.9 67.7 76.9 76.3 73.1 78.4 90.0 69.4 44.4 77.9 73.8 77.4 76.4 75.9 87.7 78.9 88.7 67.8 67.8 91.8 69.7 70.3 68.7 69.2 66.2 66.7 66.7 
293B* 72.3 69.7 73.3 72.3 74.4 73.8 68.7 62.6 73.3 60.5 72.8 74.4 70.0 69.8 67.5 93.1 43.8 74.4 72.3 73.3 73.3 72.3 67.7 70.6 71.3 59.3 71.2 70.3 62.6 62.6 61.5 61.0 69.2 69.7 67.2 
303A* 93.3 76.4 92.3 85.1 85.6 98.5 74.9 68.2 88.2 65.1 89.7 83.8 85.6 86.2 72.5 73.1 49.4 93.3 90.3 91.3 93.3 92.3 72.3 84.5 79.0 62.7 71.2 76.4 68.7 67.7 66.2 66.2 70.8 71.8 70.8 
303B* 70.5 66.7 73.3 74.3 76.2 73.3 67.6 58.1 73.3 56.2 72.4 75.2 69.5 46.2 67.6 93.3 41.0 73.3 72.4 72.4 72.4 71.4 65.7 71.4 67.6 57.1 70.5 67.6 59.0 57.1 56.2 57.1 68.6 68.6 61.0 
306* 92.8 76.4 91.8 84.6 85.1 97.9 74.9 68.2 87.7 65.1 89.2 83.8 85.6 85.3 72.5 73.1 49.4 92.8 89.7 90.8 92.8 91.8 72.3 84.0 78.5 62.7 71.2 76.4 68.7 67.7 66.2 66.2 70.3 71.3 70.3 
315+* 81.4 77.2 80.9 83.7 85.1 79.5 76.7 67.0 80.9 64.2 80.0 82.5 75.3 83.6 74.1 74.1 47.6 80.5 78.1 80.9 81.4 80.5 74.0 83.2 78.1 61.6 73.2 78.1 60.0 59.5 57.7 59.5 65.1 65.1 62.3 
319* 93.9 73.4 93.0 84.8 85.2 98.8 73.0 66.8 90.2 64.3 91.8 83.1 84.9 86.2 72.3 72.9 50.0 93.0 91.4 92.1 93.4 93.4 70.9 83.5 77.2 63.5 74.9 74.2 67.2 66.4 65.2 65.2 72.1 73.0 70.1 
320A* 93.2 75.7 92.9 86.8 87.9 93.2 75.0 68.9 93.6 67.1 93.6 86.1 88.0 91.4 72.9 75.9 49.4 92.9 91.1 94.1 93.6 93.2 73.2 83.5 78.5 67.0 77.3 76.4 69.6 68.6 67.9 68.6 75.4 76.1 72.5 
320B+* 95.0 76.4 94.3 86.8 87.1 98.9 75.7 69.6 91.8 67.5 93.2 83.1 84.9 87.1 72.3 72.9 50.0 94.3 92.5 92.5 94.6 93.9 73.9 83.5 77.6 68.0 78.3 77.1 70.4 69.6 68.6 69.6 75.4 76.4 73.2 
321+* 95.0 76.4 94.6 86.8 87.1 98.6 75.7 69.6 92.1 67.5 93.6 83.1 84.9 87.1 72.3 73.5 50.0 94.6 92.9 92.9 95.0 93.9 73.9 83.5 77.6 68.0 78.3 77.1 70.7 69.6 68.6 69.6 75.4 76.4 73.2 
325A* 92.9 76.8 92.9 86.8 87.5 92.1 76.1 69.6 94.6 67.9 94.6 85.5 88.0 97.4 73.5 75.9 49.4 93.2 91.4 94.6 93.9 92.9 74.3 83.5 79.9 67.5 77.8 77.5 70.4 69.3 68.6 69.3 75.4 76.1 72.1 
325B* 94.3 76.1 93.6 86.4 86.8 98.2 75.4 69.3 91.1 67.9 92.5 83.1 84.9 87.1 72.3 72.9 50.0 93.6 91.8 92.1 93.9 93.2 73.6 83.5 77.6 67.5 77.3 76.8 70.0 69.3 68.2 69.3 74.6 75.7 72.9 
G13.8* 93.8 76.4 92.8 85.1 85.6 99.5 74.9 67.7 88.7 64.6 90.3 84.4 85.6 87.1 73.1 73.1 49.4 92.8 90.8 91.8 93.8 92.8 72.3 84.0 80.0 62.7 71.2 76.4 68.2 67.2 65.6 65.6 70.3 71.3 71.3 
1.1+* 94.6 75.7 94.3 86.4 86.8 97.5 75.0 68.9 91.8 67.5 93.2 83.7 85.5 87.1 72.3 74.1 49.4 94.3 92.5 92.9 94.6 93.6 73.2 83.5 77.6 67.5 77.8 76.4 70.4 69.3 68.2 69.3 75.4 76.4 73.2 
2+* 70.4 72.9 70.4 69.6 70.7 69.3 72.9 91.1 69.3 89.3 69.6 67.5 65.7 70.7 69.3 63.9 45.8 71.1 68.9 66.9 70.0 68.9 71.8 67.4 68.9 92.1 68.5 74.3 97.9 92.5 91.1 93.6 64.3 65.0 75.0 
2.1* 92.1 74.6 91.8 86.4 87.5 92.1 73.9 69.3 92.9 67.5 92.5 86.1 88.0 89.7 72.9 75.9 48.8 91.8 90.7 93.3 92.5 92.1 72.9 83.5 77.6 67.5 76.8 75.4 70.0 68.9 68.2 68.2 74.6 75.4 72.9 
2.2* 92.5 74.3 92.2 85.1 85.4 96.6 73.5 69.0 89.6 67.5 91.0 81.8 83.1 84.6 70.8 71.4 46.1 92.9 92.5 90.7 92.5 91.4 73.9 83.0 75.8 64.9 74.9 75.0 70.5 69.4 68.3 69.0 75.0 76.1 72.8 
4.10+* 93.9 76.3 92.9 84.8 85.4 99.0 74.7 68.2 88.9 65.2 90.4 83.4 85.3 85.6 72.4 73.0 49.7 92.9 90.9 91.9 93.9 92.9 72.2 84.3 79.8 63.6 71.9 76.3 66.7 65.6 64.0 64.0 68.8 69.9 69.9 
4.21* 89.8 73.7 89.8 82.8 84.4 88.2 72.0 67.7 88.7 64.0 89.2 83.4 84.7 91.3 70.6 73.6 46.0 90.3 91.4 90.9 90.9 89.2 72.6 82.2 78.5 63.6 71.1 73.7 68.8 66.7 65.6 65.1 69.4 69.9 70.4 
4.30* 91.9 75.3 91.4 86.0 87.6 91.4 73.7 68.3 90.9 64.5 91.4 86.5 88.3 90.4 73.0 76.1 47.9 92.5 92.5 93.0 93.0 91.4 74.2 85.4 80.1 63.6 71.9 75.3 68.8 67.2 66.1 65.6 71.5 72.0 71.5 
6.1+* 92.9 75.3 91.9 84.8 85.4 98.0 73.7 67.7 87.9 64.6 89.4 82.8 84.7 86.2 71.8 73.0 49.7 91.9 90.4 90.9 92.9 91.9 71.7 84.3 78.8 63.6 71.9 75.3 68.7 67.2 65.7 65.7 70.7 71.7 71.7 
6.6* 92.4 76.3 91.9 86.9 88.4 91.9 74.7 68.2 91.4 64.6 91.9 87.1 89.0 91.4 73.6 76.7 48.5 91.9 90.4 93.4 93.4 91.9 72.7 85.8 81.3 64.5 72.7 76.3 68.7 67.2 66.2 65.7 71.2 71.7 71.7 
6.25* 92.9 75.8 91.9 85.4 85.9 98.5 74.2 68.2 87.9 65.2 89.4 84.0 85.3 85.3 73.0 73.0 49.7 91.9 90.9 90.9 92.9 91.9 72.7 84.3 79.3 63.6 71.9 75.8 68.7 67.7 66.2 66.2 71.2 72.2 71.7 
6.26* 89.4 73.2 88.4 81.8 83.3 87.9 71.7 65.7 87.4 62.1 87.9 81.6 82.8 93.1 69.3 74.8 46.6 87.9 86.9 89.4 90.4 89.4 69.2 81.2 78.3 59.5 69.4 73.2 69.7 67.7 66.7 66.7 71.7 72.2 72.7 
7.7+* 93.9 76.1 93.6 86.4 86.8 97.5 75.4 68.9 91.1 67.5 92.5 83.1 84.9 86.2 72.3 73.5 50.0 93.6 92.1 92.1 93.9 92.9 73.9 83.9 77.2 67.5 77.3 76.8 70.0 68.9 67.9 68.9 74.6 75.7 72.5 
13* 92.5 75.0 91.8 86.8 87.5 91.8 74.3 69.6 93.6 67.9 93.6 86.1 89.2 92.2 73.5 76.5 48.8 91.4 91.1 94.6 93.6 92.5 73.2 83.9 78.5 68.0 77.3 75.7 70.4 69.3 68.6 68.6 74.6 75.4 72.9 
F2* 70.4 72.9 70.4 70.0 70.7 68.9 72.1 89.6 69.6 87.5 69.6 65.7 63.9 69.8 66.9 62.0 44.6 71.1 68.6 66.1 70.0 68.9 71.4 66.5 67.6 92.1 68.5 73.6 95.4 91.4 89.6 93.9 63.6 64.3 73.6 
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Table A6.1: Amino acid identity among Fasciola cathepsin L-like proteases (Part 3of 4). 
 24.5A+* 24.5B* 24.8A* 24.8B+* 293A+* 293B* 303A* 303B* 306* 315+* 319* 320A* 320B+* 321+* 325A* 325B* G13.8* 
24.5B* 76.1                 
24.8A* 75.9 93.5                
24.8B+* 71.1 75.2 74.0               
293A+* 71.8 76.9 75.9 99.5              
293B* 99.5 73.8 74.9 72.3 71.8             
303A* 73.8 99.0 92.3 77.9 77.9 73.8            
303B* 99.0 72.4 75.2 69.5 69.5 98.1 73.3           
306* 73.8 98.5 91.8 77.9 77.9 73.8 99.5 73.3          
315+* 74.0 79.5 82.8 75.8 75.9 73.3 79.5 73.3 79.0         
319* 75.4 99.2 93.4 75.2 76.9 73.8 99.0 73.3 98.5 79.5        
320A* 76.5 93.6 99.2 74.0 75.9 74.9 92.3 74.3 91.8 82.3 93.4       
320B+* 76.5 99.6 93.9 75.6 77.4 74.4 99.5 73.3 99.0 80.0 99.6 94.3      
321+* 76.9 99.2 94.3 75.6 77.4 74.9 99.0 74.3 98.5 80.0 99.2 94.6 99.6     
325A* 76.9 92.4 97.1 74.4 76.4 75.4 90.8 73.3 90.3 80.9 92.2 96.8 93.2 93.6    
325B* 76.5 99.2 93.5 75.6 77.4 74.4 99.5 73.3 99.0 80.0 99.2 94.3 99.3 98.9 93.2   
G13.8* 74.4 99.0 92.3 77.4 77.4 74.4 99.0 73.3 98.5 80.0 99.0 92.3 99.5 99.0 90.8 99.5  
1.1+* 76.5 98.4 94.3 75.2 76.9 74.4 97.9 74.3 97.4 80.0 98.4 95.0 98.6 98.9 93.9 98.6 97.9 
2+* 62.9 67.3 66.9 69.0 69.2 62.1 68.2 59.0 68.2 66.5 66.4 70.0 70.0 70.4 70.7 70.4 67.7 
2.1* 76.1 92.8 98.4 73.1 74.9 74.4 91.3 75.2 90.8 81.4 92.6 98.2 93.2 93.6 95.7 93.2 91.3 
2.2* 75.7 97.1 92.3 73.5 76.0 74.3 97.8 71.0 97.3 78.3 97.4 92.9 97.0 97.4 91.4 97.0 98.4 
4.10+* 74.7 99.5 92.9 77.8 77.4 74.4 99.5 73.3 99.0 80.3 99.5 92.9 100.0 99.5 91.4 100.0 99.5 
4.21* 73.1 88.7 95.2 73.1 72.7 72.7 89.1 73.3 88.5 79.0 89.2 94.1 89.2 89.8 94.1 89.2 88.5 
4.30* 75.3 91.9 98.4 75.3 74.9 74.9 92.3 74.3 91.8 81.2 92.5 98.4 92.5 93.0 95.2 92.5 91.8 
6.1+* 74.2 98.5 91.9 76.8 76.4 73.8 98.5 73.3 97.9 79.8 98.5 91.9 99.0 98.5 90.4 99.0 98.5 
6.6* 75.3 92.4 99.0 76.3 75.9 74.9 92.3 75.2 91.8 82.8 92.4 99.0 92.9 93.4 95.5 92.9 92.3 
6.25* 74.2 98.0 91.4 76.8 76.4 73.8 97.9 73.3 97.4 79.3 98.0 91.4 98.5 98.0 89.9 98.5 99.0 
6.26* 73.2 88.4 94.9 72.7 72.3 72.8 88.2 71.4 87.7 80.8 88.4 93.9 88.9 89.4 92.4 88.9 88.2 
7.7+* 76.1 98.4 93.5 75.6 76.9 74.4 98.5 74.3 97.9 79.5 98.4 94.3 98.6 98.9 93.2 98.6 98.5 
13* 76.1 92.4 98.8 73.1 74.9 74.4 90.8 75.2 90.3 81.9 92.2 97.9 92.9 93.2 96.8 92.9 90.8 
F2* 62.2 66.1 66.1 68.2 68.7 61.0 66.7 58.1 66.7 65.6 65.2 69.3 69.6 70.0 70.0 69.3 66.2 
 
Table A6.1: Amino acid identity among Fasciola cathepsin L-like proteases (Part 4of 4). 
 1.1+* 2+* 2.1* 2.2* 4.10+* 4.21* 4.30* 6.1+* 6.6* 6.25* 6.26* 7.7+* 13* 
2+* 70.4             
2.1* 93.9 71.1            
2.2* 97.0 70.9 93.3           
4.10+* 98.5 68.2 91.9 97.8          
4.21* 89.8 68.8 94.1 88.5 89.2         
4.30* 93.0 68.8 98.4 92.0 92.5 94.6        
6.1+* 97.5 69.2 91.9 97.3 98.9 89.8 91.9       
6.6* 93.4 69.2 99.0 92.5 92.9 94.6 98.9 92.9      
6.25* 97.0 69.2 92.4 98.4 98.5 88.7 91.9 98.5 92.4     
6.26* 89.4 66.2 92.9 88.2 88.9 91.9 93.0 88.9 93.9 87.4    
7.7+* 98.6 71.1 93.9 97.4 99.0 89.8 93.0 99.0 93.9 98.5 88.9   
13* 93.6 71.4 98.9 92.9 91.4 94.6 97.8 91.4 98.5 91.9 93.4 93.6  
F2* 69.3 96.1 68.9 68.7 66.7 67.2 67.2 67.7 68.2 66.7 65.2 70.0 69.3 
 
